[
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGN, HA, CERE, HOLI - Hawaiian Holdings  ( NASDAQ:HA ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36443672/shareholder-investigation-halper-sadeh-llc-investigates-imgn-ha-cere-holi",
    "time_published": "20240101T141956",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ImmunoGen, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.08342,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.094766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HA",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.094766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMGN",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.094766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.094766",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.154927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOLI",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.088661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today",
    "url": "https://www.zacks.com/stock/news/2204045/heres-how-much-a-1000-investment-in-abbvie-made-10-years-ago-would-be-worth-today",
    "time_published": "20240101T133004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default28.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.172591,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.693171",
        "ticker_sentiment_score": "0.288933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.033051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2204026/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20240101T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.235866,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.208908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar",
    "url": "https://www.fool.com/investing/2024/01/01/3-top-etfs-im-planning-to-buy-hand-over-fist-in-20/",
    "time_published": "20240101T111700",
    "authors": [
      "CFP\u00ae",
      "Matthew Frankel"
    ],
    "summary": "I'm adding some ETFs to my retirement portfolio in 2024. here are the three I'm starting with.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759690/stock-trader-2022.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.341417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AVGO",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMT",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCI",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.089924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.006707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Biotech Stocks You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/01/02/2-biotech-stocks-you-can-buy-and-hold-for-the-next/",
    "time_published": "20240102T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The types of innovative drugs these companies develop are always in high demand.",
    "banner_image": "https://g.foolcdn.com/editorial/images/758457/patient-talking-with-a-physician.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      }
    ],
    "overall_sentiment_score": 0.220647,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.15094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.474763",
        "ticker_sentiment_score": "0.424548",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "-0.095077",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants USA - English - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/collplant-biotechnologies-begins-preclinical-trial-with-commercial-size-regenerative-breast-implants-302024360.html",
    "time_published": "20240102T120000",
    "authors": [],
    "summary": "CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants USA - English PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172874,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.110973",
        "ticker_sentiment_score": "0.091758",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Growth Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/01/02/3-top-dividend-growth-stocks-to-buy-in-2024/",
    "time_published": "20240102T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Income investors should love these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/759630/hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.433769,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.276491",
        "ticker_sentiment_score": "0.370944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.520773",
        "ticker_sentiment_score": "0.447609",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2205271/abbvie-abbv-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240103T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default326.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.17505,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.584328",
        "ticker_sentiment_score": "0.212656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CVS Caremark accelerates biosimilars adoption through formulary changes",
    "url": "https://www.prnewswire.com/news-releases/cvs-caremark-accelerates-biosimilars-adoption-through-formulary-changes-302025679.html",
    "time_published": "20240103T220000",
    "authors": [
      "CVS Health"
    ],
    "summary": "WOONSOCKET, R.I., Jan. 3, 2024 /PRNewswire/ -- Today CVS Caremark\u00ae, a CVS Health\u00ae ( NYSE: CVS ) company, announced the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira\u00ae will be removed from our major national commercial template formularies and Humira ...",
    "banner_image": "https://mma.prnewswire.com/media/487051/CVS_Health_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.386116,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.575123",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.149196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceutical Drug Delivery Market Set For Robust Growth: Market Size To Reach $2337 Billion By 2028 As Per The Business Research Company's Pharmaceutical Drug Delivery Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36473207/pharmaceutical-drug-delivery-market-set-for-robust-growth-market-size-to-reach-2337-billion-by-202",
    "time_published": "20240103T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's pharmaceutical drug delivery global market report 2024, the global pharmaceutical drug delivery market has exhibited robust growth, expanding from $1711.47 billion in 2023 to an estimated $1816.05 billion in 2024, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.332912,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04882",
        "ticker_sentiment_score": "0.091119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Concerning Trend for AbbVie Investors to Keep an Eye On",
    "url": "https://www.fool.com/investing/2024/01/03/1-concerning-trend-for-abbvie-investors-to-keep-an/",
    "time_published": "20240103T133000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Is AbbVie a good stock for dividend investors to own?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759502%2Fabbvie-chart-showing-its-dividend-growth-rate-by-year.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.122768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.220688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.678673",
        "ticker_sentiment_score": "0.139579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.061072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc.  ( Nasdaq - ICVX ) , Rain Oncology, Inc.  ( Nasdaq - RAIN ) , Consolidated Communications Holdings, Inc.  ( Nasdaq - CNSL ) , Cerevel Therapeutics Holdings, Inc.  ( Nasdaq - CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36493927/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-icosavax-inc-",
    "time_published": "20240104T162228",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.228424,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RAIN",
        "relevance_score": "0.284696",
        "ticker_sentiment_score": "0.284328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.234287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.064631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.237772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CNSL",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.131303",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICVX",
        "relevance_score": "0.215574",
        "ticker_sentiment_score": "0.21893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "PRISM MarketView Launches Emerging Women's Health Index",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36493710/prism-marketview-launches-emerging-womens-health-index",
    "time_published": "20240104T161457",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Global women's health market projected to reach $67.07 billion by 2031 Private equity investment in women's health exceeded $3 billion in 2022 NEW YORK, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.193475,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AGRX",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.080022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWH",
        "relevance_score": "0.125134",
        "ticker_sentiment_score": "0.004792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.062761",
        "ticker_sentiment_score": "0.029029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTRS",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.055967",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jnana Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36488133/jnana-therapeutics-to-present-at-42nd-annual-j-p-morgan-healthcare-conference",
    "time_published": "20240104T130045",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.246204,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.200545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.200545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets",
    "time_published": "20240104T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.287429,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMNM",
        "relevance_score": "0.039745",
        "ticker_sentiment_score": "0.095935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.04959",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.079392",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Reverse Goldilocks - why this bank is souring on stocks, for now",
    "url": "https://www.marketwatch.com/story/reverse-goldilocks-why-this-bank-is-souring-on-stocks-for-now-a109f4ba",
    "time_published": "20240104T114700",
    "authors": [
      "Steve Goldstein"
    ],
    "summary": "This bank is raising dry powder as they see a tough period for stocks as well as riskier corporate bonds ...",
    "banner_image": "https://images.mktw.net/im-01461765?width=700&height=609",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.029505,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.086919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.113951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "-0.20928",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.039824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CURV",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.039824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "-0.232413",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.09347",
        "ticker_sentiment_score": "0.093576",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CVS Partially Dropping Top-Selling Drug Humira In Favor Of Cheaper Biosimilars",
    "url": "https://www.forbes.com/sites/antoniopequenoiv/2024/01/03/cvs-partially-dropping-top-selling-drug-humira-in-favor-of-cheaper-biosimilars/",
    "time_published": "20240104T001409",
    "authors": [
      "Antonio Peque\u00f1o IV"
    ],
    "summary": "CVS Caremark, the pharmaceutical subsidiary of CVS Health, announced Wednesday it will replace AbbVie's Humira from its list of covered drugs with cheaper alternatives for some customers-a move that's sure to take a chunk out of eye-popping Humira sales that have generated hundreds of billions ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6595f7eecc8c440fc46bcfe5/0x0.jpg?format=jpg&crop=2000,1124,x0,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.049294,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.651499",
        "ticker_sentiment_score": "0.151807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.162953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/pharmaceutical-contract-manufacturing-market-to-grow-by-usd-58-billion-from-2022-to-2027-north-america-to-account-for-41-of-market-growth---technavio-302026185.html",
    "time_published": "20240105T223500",
    "authors": [],
    "summary": "Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMO",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.107545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRFS",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRL",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LH",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-is-to-grow-by-usd-86-47-billion-from-2023-to-2028--asia-to-account-for-52-of-market-growth---technavio-302026179.html",
    "time_published": "20240105T220100",
    "authors": [],
    "summary": "Active Pharmaceutical Ingredients Market is to grow by USD 86.47 billion from 2023 to 2028, Asia to account for 52% of ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.292851,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TMO",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.168128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.055405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.278179",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big Players' Recent Trades in ABBV Options - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36515720/big-players-recent-trades-in-abbv-options",
    "time_published": "20240105T191557",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.184443,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.183975",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.702807",
        "ticker_sentiment_score": "0.401106",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Will AbbVie  ( ABBV )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2206449/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20240105T171011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default3.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.302803,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.420083",
        "ticker_sentiment_score": "0.441597",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals",
    "url": "https://www.zacks.com/stock/news/2206363/pharma-stock-roundup-llys-new-digital-pharmacy-nvo-abbvs-fresh-rd-deals",
    "time_published": "20240105T152500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.143344,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.076649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.240803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.154026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.125188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "-0.119302",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/",
    "time_published": "20240105T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.12567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.069333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.037838",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IONS",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.084592",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARWR",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.150269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.153696",
        "ticker_sentiment_score": "0.053027",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.006781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.079056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTLA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.008781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHVN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.001871",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.017905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CPRX",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BEAM",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.057997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLNN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.020246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.08972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMPH",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.14181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.011896",
        "ticker_sentiment_score": "-0.115274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "0.067127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.02379",
        "ticker_sentiment_score": "-0.042606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.035679",
        "ticker_sentiment_score": "0.064761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.059429",
        "ticker_sentiment_score": "0.106048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAVD, CSTR, CERE - CapStar Finl Hldgs  ( NASDAQ:CSTR ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36508096/shareholder-investigation-halper-sadeh-llc-investigates-wavd-cstr-cere",
    "time_published": "20240105T124404",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.069199,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WAVD",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTR",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.142785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.096645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ONB",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.142785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.096645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent High-Yield Dividend Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/01/06/3-high-yield-dividend-stocks-to-buy-in-2024/",
    "time_published": "20240106T125000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "There's more than meets the eye with all three of these dividend stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760180/hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      }
    ],
    "overall_sentiment_score": 0.225967,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.236907",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.117644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.246757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.041264",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference - Molecular Partners  ( NASDAQ:MOLN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36526484/molecular-partners-provides-updates-at-42nd-annual-j-p-morgan-healthcare-conference",
    "time_published": "20240107T210000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy ( RDT ) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline. first data on DLL3 as lead ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.165974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MOLN",
        "relevance_score": "0.080548",
        "ticker_sentiment_score": "0.025378",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.02689",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/01/07/2805018/0/en/Molecular-Partners-Provides-Updates-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html",
    "time_published": "20240107T210000",
    "authors": [
      "Molecular Partners"
    ],
    "summary": "ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 07, 2024 ( GLOBE NEWSWIRE ) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( SIX: MOLN. NASDAQ: MOLN ) , a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.175822,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MOLN",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.108931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025901",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Boneheaded Investing Mistakes I Pledge Not to Make  ( Again )  in 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/01/07/3-boneheaded-investing-mistakes-i-pledge-not-to/",
    "time_published": "20240107T133000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "You should do your best to avoid making similar mistakes too.",
    "banner_image": "https://g.foolcdn.com/editorial/images/760229/stressed-investor-sitting-in-dark-at-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.090658,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INMD",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.074795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.235201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:SHIB",
        "relevance_score": "0.128592",
        "ticker_sentiment_score": "0.018468",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/01/07/is-abbvie-stock-a-buy-now/",
    "time_published": "20240107T123300",
    "authors": [
      "Justin Pope"
    ],
    "summary": "The company is grappling with losing Humira's patent protection in 2023.",
    "banner_image": "https://media.ycharts.com/charts/9342a2e450bd0ca7b1f165dc475d88fa.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.1171,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "-0.072189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.68039",
        "ticker_sentiment_score": "0.234714",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers",
    "url": "https://www.forbes.com/sites/brettowens/2024/01/07/dogs-of-the-dow-2024-10-blue-chip-dividend-payers/",
    "time_published": "20240107T121500",
    "authors": [
      "Brett Owens"
    ],
    "summary": "The 2024 Dogs of the Dow are particularly homely hounds-which means we're talking big dividends. This year's Dogs yield more than three-times the broader market's paltry payout. So, should we hold our noses and buy? Let's grab some peanut butter treats and investigate.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5e0e14c60bf81b00072e5836/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.882182"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.195231,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CSCO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "0.156862",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.073793",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.077156",
        "ticker_sentiment_score": "-0.095558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.106898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.003278",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.087575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.155125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.1006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPLK",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.25476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.068065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.096361",
        "ticker_sentiment_score": "0.107227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.038623",
        "ticker_sentiment_score": "0.106423",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Now Trades Above Golden Cross: Time to Buy?",
    "url": "https://www.zacks.com/stock/news/2207004/abbvie-abbv-now-trades-above-golden-cross-time-to-buy",
    "time_published": "20240108T145503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.320634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.512846",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion",
    "url": "https://www.cnbc.com/2024/01/08/jj-to-acquire-ambrx-biopharma-a-cancer-drug-developer.html",
    "time_published": "20240108T140931",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106974803-1636726862899-gettyimages-1164570932-AFP_1JU2A3.jpeg?v=1704721945&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.031525,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.076968",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.154455",
        "ticker_sentiment_score": "-0.076968",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things' - Bitfarms  ( NASDAQ:BITF ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36528274/cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-th",
    "time_published": "20240108T135311",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said he likes Realty Income O and recommends staying with it. \"It's a very steady story,\" he noted. When asked about ImmunoGen, Inc. IMGN, he said, \"That's AbbVie's ABBV property now, let's move on.\" Cramer said he is not a buyer of Ramaco ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/jim_cramer_nyse_shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.192744,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "METC",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.269521",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BITF",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.232595",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CAG",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GEHC",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "-0.00194",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMGN",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TKO",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.315376",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.206875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.261679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARM",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.339075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "O",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.233442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California USA - English - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/collplants-ceo-to-present-at-the-octane-aesthetic-tech-forum-conference-in-newport-beach-california-302028441.html",
    "time_published": "20240108T121800",
    "authors": [],
    "summary": "CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California USA - English PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.176735,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.096674",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is SPDR S&P Dividend ETF  ( SDY )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2206733/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now",
    "time_published": "20240108T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999974"
      }
    ],
    "overall_sentiment_score": 0.22825,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MMM",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.056325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STT",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.086935",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.056325",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2207896/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20240109T232159",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default189.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.217735,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.132664",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Ascends While Market Falls: Some Facts to Note",
    "url": "https://www.zacks.com/stock/news/2207785/abbvie-abbv-ascends-while-market-falls-some-facts-to-note",
    "time_published": "20240109T224518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $162.31, representing a +0.55% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      }
    ],
    "overall_sentiment_score": 0.186176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.225897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/24/01/36565408/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-3-300-today",
    "time_published": "20240109T210027",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.42% on an annualized basis producing an average annual return of 12.35%. Currently, AbbVie has a market capitalization of $286.32 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.983605",
        "ticker_sentiment_score": "0.387251",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Cytokinetics  ( CYTK )  Rises on Reports of Buyout by Novartis",
    "url": "https://www.zacks.com/stock/news/2207655/cytokinetics-cytk-rises-on-reports-of-buyout-by-novartis",
    "time_published": "20240109T181700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.225645,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CYTK",
        "relevance_score": "0.373378",
        "ticker_sentiment_score": "0.351949",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "KDNY",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.069052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.16427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.16427",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "-0.01124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "-0.014005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRTX",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.205434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biotech ETFs Stage Solid Comeback at the Start of 2024",
    "url": "https://www.zacks.com/stock/news/2207551/biotech-etfs-stage-solid-comeback-at-the-start-of-2024",
    "time_published": "20240109T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.147642,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RYZB",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.06769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRCL",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.058856",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.084886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.162037",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.071668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OMGA",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.140918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Simple Tricks That Every Investor Should Use  ( but Most Don't ) ",
    "url": "https://www.fool.com/investing/2024/01/09/3-simple-tricks-that-every-investor-should-use-but/",
    "time_published": "20240109T151500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Having a few tricks up your sleeve can increase your returns over time.",
    "banner_image": "https://media.ycharts.com/charts/48e06246cfdd0fa2187cc0683cfa221e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.233827,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128363",
        "ticker_sentiment_score": "0.032509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085782",
        "ticker_sentiment_score": "0.123385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "-0.026863",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024",
    "url": "https://www.globenewswire.com/news-release/2024/01/09/2806274/0/en/NEXGEL-Subsidiary-CG-Converting-and-Packaging-Begins-12-000-Square-Foot-Expansion-of-Texas-Facility-to-Support-the-Expected-Growth-in-Product-Demand-in-2024.html",
    "time_published": "20240109T133000",
    "authors": [
      "INC.",
      "NEXGEL"
    ],
    "summary": "LANGHORNE, Pa., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- NEXGEL, Inc. ( \"NEXGEL\" or the \"Company\" ) ( NASDAQ: NXGL ) , a leading provider of medical and over-the-counter ( OTC ) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0e76fff8-7aee-4b60-ba26-62dda9975939",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.211368,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.207811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NXGL",
        "relevance_score": "0.511734",
        "ticker_sentiment_score": "0.47961",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  to Strengthen Cancer Pipeline With Harpoon Buyout",
    "url": "https://www.zacks.com/stock/news/2207372/merck-mrk-to-strengthen-cancer-pipeline-with-harpoon-buyout",
    "time_published": "20240109T123400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.181898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRTX",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.1235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "-0.145006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "-0.145006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRTX",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.1235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "0.094519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.235748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ConcertAI Highlights 2024 Partnerships, Strategy, Business Results, and AI Roadmap at 42nd Annual J.P. Morgan Healthcare Conference",
    "url": "https://www.benzinga.com/pressreleases/24/01/n36600691/concertai-highlights-2024-partnerships-strategy-business-results-and-ai-roadmap-at-42nd-annual-j-p",
    "time_published": "20240111T200000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "Introduced CARA\u2122, the predictive and generative AI Platform powered by multi-modal Real-World Data, enabling precision oncology, accelerating clinical trials, increasing patient access, driving improved patient outcomes.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303869,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NEO",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.093173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "0.263908",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.296265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RSSS",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.125649",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2208771/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
    "time_published": "20240111T135006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.351131,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.330876",
        "ticker_sentiment_score": "0.345292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.282262",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/01/11/2-ultra-reliable-dividend-stocks-to-buy-in-2024-an/",
    "time_published": "20240111T103900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760816%2Fcouple-at-home-with-device-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.205181,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MDT",
        "relevance_score": "0.402941",
        "ticker_sentiment_score": "0.333402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.308246",
        "ticker_sentiment_score": "0.206293",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.124609",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/options/24/01/36615734/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20240112T184540",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on AbbVie ABBV, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.124926,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.340669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm",
    "url": "https://www.prnewswire.com/news-releases/kuehn-law-encourages-pxd-imgn-ha-and-icvx-investors-to-contact-law-firm-302033722.html",
    "time_published": "20240112T161000",
    "authors": [
      "PLLC",
      "Kuehn Law"
    ],
    "summary": "NEW YORK, Jan. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://mma.prnewswire.com/media/2309909/Kuehn_Law_PLLC.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.410079,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALK",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.332547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.297822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.232738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HA",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.332547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.300223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PXD",
        "relevance_score": "0.268294",
        "ticker_sentiment_score": "0.367654",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ICVX",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.297822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It",
    "url": "https://www.investors.com/news/technology/biotech-stocks-forge-a-paradigm-shift-in-immunology-and-big-pharma-pays-handsomely-for-it/",
    "time_published": "20240112T140000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "There's A Paradigm Shift In Immunology. And Big Pharma Is Paying Richly For It Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-Merck-02-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.130928,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.146266",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "0.208731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ROIV",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.00099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.023838",
        "ticker_sentiment_score": "-0.000896",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.047654",
        "ticker_sentiment_score": "-0.155656",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.118764",
        "ticker_sentiment_score": "-0.008046",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More",
    "url": "https://www.zacks.com/stock/news/2209354/pharma-stock-roundup-mrk-to-buy-harpoon-jnj-to-acquire-ambrx-biopharma-more",
    "time_published": "20240112T124800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.115606,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "-0.052005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "-0.037533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HARP",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.116703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.325208",
        "ticker_sentiment_score": "0.242886",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today",
    "url": "https://www.fool.com/investing/2024/01/14/heres-the-average-amount-investors-have-in-stocks/",
    "time_published": "20240114T141000",
    "authors": [
      "Bradley Guichard"
    ],
    "summary": "Curious as to how your portfolio stacks up? Take a look.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F760474%2Fstatistic_id270034_share-of-americans-investing-money-in-the-stock-market-1999-2023.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999355"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.273133,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EXPE",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.021746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.29792",
        "ticker_sentiment_score": "0.150166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "-0.024974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.173022",
        "ticker_sentiment_score": "0.202716",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.173022",
        "ticker_sentiment_score": "0.106374",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Stocks to Buy for 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/01/14/3-high-yield-stocks-to-buy-for-2024-and-beyond/",
    "time_published": "20240114T121400",
    "authors": [
      "Tyler Crowe",
      "and Jason Hall",
      "Matthew DiLallo"
    ],
    "summary": "These investments will generate lots of income for their investors in the coming years.",
    "banner_image": "https://media.ycharts.com/charts/e469000a3a6aee16ad2bf56a0a4cc314.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.2599,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.158731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PK",
        "relevance_score": "0.175539",
        "ticker_sentiment_score": "0.177897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.088309",
        "ticker_sentiment_score": "0.16669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.158731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EPR",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.353329",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Registers a Bigger Fall Than the Market: Important Facts to Note",
    "url": "https://www.zacks.com/stock/news/2211061/abbvie-abbv-registers-a-bigger-fall-than-the-market-important-facts-to-note",
    "time_published": "20240116T224521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default212.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      }
    ],
    "overall_sentiment_score": 0.103704,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.610329",
        "ticker_sentiment_score": "0.07138",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "REGENXBIO Announces Positive Interim Data from Phase II AAVIATE\u00ae Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery",
    "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-positive-interim-data-from-phase-ii-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery-302036184.html",
    "time_published": "20240116T194700",
    "authors": [
      "REGENXBIO Inc."
    ],
    "summary": "REGENXBIO Announces Positive Interim Data from Phase II AAVIATE\u00ae Trial of ABBV-RGX-314 for the Treatment of ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/684531/RGNX_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.066821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.424317",
        "ticker_sentiment_score": "0.135482",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.629492",
        "ticker_sentiment_score": "0.068912",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLSD",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.075996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.029765",
        "ticker_sentiment_score": "0.097855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Q4 Earnings Season Scorecard and Analyst Reports for Apple, AbbVie & Toyota",
    "url": "https://www.zacks.com/research-daily/2210770/q4-earnings-season-scorecard-and-analyst-reports-for-apple-abbvie-toyota",
    "time_published": "20240116T184800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on Apple (AAPL), AbbVie (ABBV), Toyota Motor (TM) and others.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0e/57351.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995973"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.118941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.251032",
        "ticker_sentiment_score": "0.20916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.18967",
        "ticker_sentiment_score": "0.1623",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.111085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "-0.111085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.063763",
        "ticker_sentiment_score": "0.143148",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Charts turn bullish on health-care stocks as sector takes early lead in 2024",
    "url": "https://www.marketwatch.com/story/charts-turn-bullish-on-health-care-stocks-as-sector-takes-early-lead-in-2024-12272495",
    "time_published": "20240116T162900",
    "authors": [
      "Joseph Adinolfi"
    ],
    "summary": "Health-care stocks are off to a strong start in 2024, and Wall Street analysts are taking notice.",
    "banner_image": "https://images.mktw.net/im-735118/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.342773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCK",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.294849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zylo Unveils Usage Connect, Setting New Standard in Enterprise SaaS Management Visibility",
    "url": "https://www.prnewswire.com/news-releases/zylo-unveils-usage-connect-setting-new-standard-in-enterprise-saas-management-visibility-302034144.html",
    "time_published": "20240116T140000",
    "authors": [
      "Zylo"
    ],
    "summary": "Industry-first feature enables no-code connection into usage data for any app, unlocking thousands of applications and expanding the depth and breadth of integrations",
    "banner_image": "https://mma.prnewswire.com/media/2079393/Zylo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.211543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "APG",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.156284",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.176451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.176451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DASH",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.176451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' - Crown Castle  ( NYSE:CCI ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36634562/uber-abbott-laboratories-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades",
    "time_published": "20240116T135155",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. CCI as her final trade. Crown Castle, last month, announced a comprehensive review of its Fiber business and the addition of two new independent directors to the company's board.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/16/trader_shutter2.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.33101,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CCI",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.491599",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MPC",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.386326",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.626508",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.151775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.573213",
        "ticker_sentiment_score": "0.687844",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is First Trust Value Line Dividend ETF  ( FVD )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2210512/is-first-trust-value-line-dividend-etf-fvd-a-strong-etf-right-now",
    "time_published": "20240116T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      }
    ],
    "overall_sentiment_score": 0.301355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VALU",
        "relevance_score": "0.276491",
        "ticker_sentiment_score": "0.29534",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ERIE",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.05392",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.05392",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Growth Stock: Abbott vs. AbbVie",
    "url": "https://www.fool.com/investing/2024/01/16/better-growth-stock-abbott-vs-abbvie/",
    "time_published": "20240116T100000",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These healthcare giants also offer investors the promise of increasing passive income.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761326%2Fgettyimages-two-researchers-work-in-a-lab.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999355"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.334975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.511864",
        "ticker_sentiment_score": "0.515043",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "0.243918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Halozyme Announces Roche Receives European Commission Approval of Tecentriq\u00ae SC with ENHANZE\u00ae Representing the EU's First Subcutaneous PD- ( L ) 1 Cancer Immunotherapy for Multiple Cancer Types",
    "url": "https://www.prnewswire.com/news-releases/halozyme-announces-roche-receives-european-commission-approval-of-tecentriq-sc-with-enhanze-representing-the-eus-first-subcutaneous-pd-l1-cancer-immunotherapy-for-multiple-cancer-types-302035190.html",
    "time_published": "20240116T061500",
    "authors": [
      "Halozyme Therapeutics",
      "Inc."
    ],
    "summary": "Halozyme Announces Roche Receives European Commission Approval of Tecentriq\u00ae SC with ENHANZE ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.10062,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.007116",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.181965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.080944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Regenxbio Stock Trading Lower Today? - Regenxbio  ( NASDAQ:RGNX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36667270/ocular-gene-therapy-regenxbio-data-shows-consistent-preservation-of-visual-acuity-r",
    "time_published": "20240117T202842",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Regenxbio Inc RGNX released Tuesday, Jan. 16, interim data from the Phase 2 AAVIATE trial of ABBV-RGX-314 for wet age-related macular degeneration ( wet AMD ) using suprachoroidal delivery. Investigational ABBV-RGX-314 using suprachoroidal delivery is designed as a one-time, in-office treatment.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/bz-pharma-briefs_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.090528,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.282091",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "-0.038909",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.655824",
        "ticker_sentiment_score": "-0.29614",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Biologics Contract Manufacturing Market on a Tear $14.4 Billion in 2022, Poised to Double by 2033, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36663729/biologics-contract-manufacturing-market-on-a-tear-14-4-billion-in-2022-poised-to-double-by-2033-pe",
    "time_published": "20240117T165000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- The dynamic and rapidly expanding field of biologics contract manufacturing, also referred to as the biopharmaceutical CMO market, is witnessing substantial investments in research and development by numerous players.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.290797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.021013",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBS",
        "relevance_score": "0.021013",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.042011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OUSZF",
        "relevance_score": "0.125569",
        "ticker_sentiment_score": "0.204848",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.042011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WXXWY",
        "relevance_score": "0.021013",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042011",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AJINY",
        "relevance_score": "0.021013",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3%| Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36658710/protein-therapeutics-market-size-to-be-worth-usd-549-4-billion-by-2031-at-a-cagr-of-6-3-transparen",
    "time_published": "20240117T133000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The protein therapeutics market was valued at US$ 318.4 billion in 2022. A CAGR of 6.3% is predicted from 2023 to 2031, reaching more than US$ 549.4 billion by 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.16757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.153274",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.153274",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.010908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.153274",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.106189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.075761",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.153274",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.153274",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Alzheimer's Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36655498/alzheimers-disease-diagnostics-treatment-market-revenues-to-reach-us-11-9-billion-by-2030-market-s",
    "time_published": "20240117T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate ( CAGR ) of 8.9%, reaching a value of US$11.9 billion by the end of 2030, up from US$6.5 billion ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.329342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.076513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.028056",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.01403",
        "ticker_sentiment_score": "0.16322",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.028056",
        "ticker_sentiment_score": "-0.053084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.042073",
        "ticker_sentiment_score": "0.148051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.111877",
        "ticker_sentiment_score": "0.14894",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors",
    "url": "https://www.zacks.com/stock/news/2211180/the-zacks-analyst-blog-highlights-apple-abbvie-toyota-motor-monster-beverage-and-general-motors",
    "time_published": "20240117T095900",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ee/885.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.173355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TM",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.048862",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.163397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.194204",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.037351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNST",
        "relevance_score": "0.138066",
        "ticker_sentiment_score": "0.037351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.069294",
        "ticker_sentiment_score": "0.143656",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' - Arch Capital Group  ( NASDAQ:ACGL ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673096/abbvie-arch-capital-gilead-sciences-and-a-telecom-giant-on-cnbcs-final-trades",
    "time_published": "20240118T143618",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD is an inexpensive way to give biotech exposure. Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/18/abbvie_shutterstock_2333939969.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.29847,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACGL",
        "relevance_score": "0.522333",
        "ticker_sentiment_score": "0.239132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HOOK",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.352976",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.522333",
        "ticker_sentiment_score": "0.571704",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.522333",
        "ticker_sentiment_score": "0.426395",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.522333",
        "ticker_sentiment_score": "0.496772",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Beaten-Down Stocks to Buy Hand Over Fist This Year",
    "url": "https://www.fool.com/investing/2024/01/18/2-beaten-down-stocks-to-buy-hand-over-fist-this/",
    "time_published": "20240118T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Don't give up on these stocks too soon.",
    "banner_image": "https://media.ycharts.com/charts/ca85a95a4349bc8333c49b9101ebccdc.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.219075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.115977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.226444",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.102156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ETSY",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.234769",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2024 Will Be a Good Year for the Pharma Industry: The Kiplinger Letter",
    "url": "https://www.kiplinger.com/business/a-good-year-for-the-pharma-industry-the-kiplinger-letter",
    "time_published": "20240118T133015",
    "authors": [
      "Matthew Housiaux"
    ],
    "summary": "2024: The Pharma Industry's Good Year Kiplinger's Personal Finance ...",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/UjiFXv5gKrsiSW4baf7dkN-415-80.jpg",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.237549,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.0803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "0.059379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.291182",
        "ticker_sentiment_score": "0.032821",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.066677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.19661",
        "ticker_sentiment_score": "-0.0803",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.099066",
        "ticker_sentiment_score": "0.066677",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/liquid-biopsy-in-cancer-diagnostics-global-market-is-likely-to-increase-at-a-massive-growth-rate-of-17-by-2028--delveinsight-302039144.html",
    "time_published": "20240119T220100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a Massive Growth Rate of ~17% by 2028 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.042033,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "A",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GH",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.188371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.132382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.188371",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "OCPNF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.132382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TECH",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIOCQ",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDSX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "-0.051475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTX",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEO",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.031816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.042271",
        "ticker_sentiment_score": "0.018936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.021143",
        "ticker_sentiment_score": "0.024956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hyaluronic Acid Serums Market Targets US$ 506.4 Million by 2033 at 5.9% CAGR, Persistence Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36697064/hyaluronic-acid-serums-market-targets-us-506-4-million-by-2033-at-5-9-cagr-persistence-market-rese",
    "time_published": "20240119T154500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Hyaluronic Acid Serums have witnessed significant growth in recent years, driven by increasing consumer awareness of skincare and anti-aging products.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.378706,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "0.296668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LFCR",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.022389",
        "ticker_sentiment_score": "-0.0018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades' - Autodesk  ( NASDAQ:ADSK ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36691104/pfizer-autodesk-abbvie-and-more-cnbcs-final-trades",
    "time_published": "20240119T135708",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund XLV as her final trade. Joshua Brown of Ritholtz Wealth Management picked Pfizer Inc. PFE, which bottomed in the middle of December.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/19/pfizer_shutterstock.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.193821,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.645516",
        "ticker_sentiment_score": "0.429571",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ADSK",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "-0.093655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.006477",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.541149",
        "ticker_sentiment_score": "0.104432",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Announces Dividend Increase",
    "url": "https://www.globenewswire.com/news-release/2024/01/19/2812286/0/en/Royalty-Pharma-Announces-Dividend-Increase.html",
    "time_published": "20240119T131500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167638,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.673107",
        "ticker_sentiment_score": "0.289522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.101048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Announces Dividend Increase - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36694014/royalty-pharma-announces-dividend-increase",
    "time_published": "20240119T131500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.156267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.648497",
        "ticker_sentiment_score": "0.281269",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.098011",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024",
    "url": "https://www.fool.com/investing/2024/01/21/my-5-top-dividend-stocks-to-buy-in-2024/",
    "time_published": "20240121T111700",
    "authors": [
      "Adria Cimino"
    ],
    "summary": "These stocks may help you win in 2024 -- no matter what the market does.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761894%2Fgettyimages-1172040755.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.344613,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.17327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.311035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.107532",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.226339",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.078099",
        "ticker_sentiment_score": "0.188048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Exceeds Market Returns: Some Facts to Consider",
    "url": "https://www.zacks.com/stock/news/2213772/abbvie-abbv-exceeds-market-returns-some-facts-to-consider",
    "time_published": "20240122T224517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default170.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.213799,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.613743",
        "ticker_sentiment_score": "0.261051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Gilead's stock tumbles toward biggest selloff in more than nine years as lung-cancer trial disappoints",
    "url": "https://www.marketwatch.com/story/gileads-stock-tumbles-toward-biggest-selloff-in-more-than-9-years-after-lung-cancer-treatment-trial-disappoints-785e6886",
    "time_published": "20240122T150400",
    "authors": [
      "",
      "Tomi Kilgore",
      "Eleanor Laise"
    ],
    "summary": "Shares of Gilead Sciences tumbled 9.7% early Monday after the company reported disappointing lung-cancer trial results.",
    "banner_image": "https://images.mktw.net/im-771567/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": -0.102145,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.122682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.182599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "-0.239508",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2213378/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240122T140010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.224012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.135263",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tissue Engineering Market is Expected to Reach $8.9 Billion | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36713761/tissue-engineering-market-is-expected-to-reach-8-9-billion-marketsandmarkets",
    "time_published": "20240122T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Chicago, Jan. 22, 2024 ( GLOBE NEWSWIRE ) -- Tissue Engineering market in terms of revenue was estimated to be worth $4.4 Billion in 2023 and is poised to reach $8.9 Billion by 2028, growing at a CAGR of 15.3% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.22176,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDXG",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TINLF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNN",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNPUF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAUHF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IART",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCEL",
        "relevance_score": "0.03792",
        "ticker_sentiment_score": "-0.040123",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html",
    "time_published": "20240122T043500",
    "authors": [],
    "summary": "USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.164961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLVSQ",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.083583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/implantable-drug-delivery-devices-global-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2028-assesses-delveinsight-302041477.html",
    "time_published": "20240123T223100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028 ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.262341,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTSUF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.028936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TFX",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.068904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARUXF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.074985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.079826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENDPQ",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCRPF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "-0.01558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRRMF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.068904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRUMF",
        "relevance_score": "0.081184",
        "ticker_sentiment_score": "0.063274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALC",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.088505",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LYPHF",
        "relevance_score": "0.054175",
        "ticker_sentiment_score": "0.074985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WST",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.025235",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PODD",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "-0.01558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.081184",
        "ticker_sentiment_score": "0.070488",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.027657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.027103",
        "ticker_sentiment_score": "0.176605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/01/36745167/1000-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today",
    "time_published": "20240123T193513",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 3.77% on an annualized basis producing an average annual return of 16.67%. Currently, AbbVie has a market capitalization of $290.47 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.983605",
        "ticker_sentiment_score": "0.387251",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Gilead  ( GILD )  Down as NSCLC Study Fails to Meet Primary Goal",
    "url": "https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal",
    "time_published": "20240123T163700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160144,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "-0.012369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "-0.012369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "-0.120509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.085866",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Passive Income Plays to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/01/23/2-passive-income-plays-to-buy-and-hold-forever/",
    "time_published": "20240123T145500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two income vehicles can safely supplement your retirement income.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F762064%2Fpassive-income-2.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999955"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.358112,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.147022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JPM",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.172611",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.147022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer",
    "url": "https://markets.businessinsider.com/news/stocks/alkeus-pharmaceuticals-appoints-seemi-khan-m-d-chief-medical-officer-1032987734",
    "time_published": "20240123T133000",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "CAMBRIDGE, Mass., Jan. 23, 2024 ( GLOBE NEWSWIRE ) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.",
    "banner_image": "https://ml.globenewswire.com/media/ZjIyMjQwNTUtOTM5My00OTNhLTk0MDMtOGExMDg1YmY4NGZmLTEyMTgyODE=/tiny/Alkeus-Pharmaceuticals.png",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.179659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSBHF",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.045765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.045765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.045765",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies",
    "url": "https://www.prnewswire.com/news-releases/accent-therapeutics-announces-75-million-series-c-financing-to-advance-small-molecule-precision-cancer-therapies-302041338.html",
    "time_published": "20240123T110000",
    "authors": [
      "Inc.",
      "Accent Therapeutics"
    ],
    "summary": "Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early clinical development, including Accent's first-in-class DHX9 inhibitor and newly unveiled, potentially best-in-class KIF18A ...",
    "banner_image": "https://mma.prnewswire.com/media/2048641/Accent_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.072022,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039418",
        "ticker_sentiment_score": "0.045323",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Genius Safe Stocks to Buy for 2024 and Beyond",
    "url": "https://www.fool.com/investing/2024/01/23/2-genius-safe-stocks-to-buy-for-2024-and-beyond/",
    "time_published": "20240123T101500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have considerable profits and tried-and-true dividends in common.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761857/businesswoman-working-finances-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.078877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.041354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.076708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234006",
        "ticker_sentiment_score": "0.072217",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "-0.030904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.002106",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead sinks after lung cancer drug fails to improve survival",
    "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/gilead-sinks-after-lung-cancer-drug-fails-to-improve-survival/3372692/",
    "time_published": "20240123T083127",
    "authors": [
      "Bloomberg"
    ],
    "summary": "Gilead Sciences Inc.'s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that's in one of the most promising classes in oncology.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/mitosis-g02ddf51c7_1920_20bede.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.034715,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "-0.098732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.072297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMGN",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.072297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "-0.044666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.072297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.004662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "-0.044666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36762162/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20240124T161601",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.148014,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.71032",
        "ticker_sentiment_score": "0.170348",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "-0.121364",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow",
    "url": "https://www.investors.com/news/stocks-with-rising-relative-strength-abbvie-3/",
    "time_published": "20240124T160100",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY",
      "GLENN LARKIN"
    ],
    "summary": "AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 68 to 71. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.332934,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZTS",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.391654",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WAVD, CERE, TGAN - Transphorm  ( NASDAQ:TGAN ) , Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36759460/shareholder-notice-halper-sadeh-llc-investigates-wavd-cere-tgan",
    "time_published": "20240124T144554",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: WaveDancer, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.052561,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WAVD",
        "relevance_score": "0.433523",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.099476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.099476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNECF",
        "relevance_score": "0.151539",
        "ticker_sentiment_score": "0.099476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TGAN",
        "relevance_score": "0.297661",
        "ticker_sentiment_score": "0.165362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Stocks With Rising Relative Strength: AbbVie",
    "url": "https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-abbvie-3/",
    "time_published": "20240124T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 68 to 71. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.329116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZTS",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.733479",
        "ticker_sentiment_score": "0.48203",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX",
    "url": "https://www.zacks.com/stock/news/2215726/pharma-stock-roundup-jnj-reports-q4-earnings-sny-inks-ma-deal-with-inbx",
    "time_published": "20240125T142600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.162707,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INBX",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.26579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMAM",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.067585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.119235",
        "ticker_sentiment_score": "-0.07664",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.400417",
        "ticker_sentiment_score": "0.232315",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2215498/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20240125T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.356438",
        "ticker_sentiment_score": "0.202905",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.122581",
        "ticker_sentiment_score": "0.068387",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 No-Brainer Dividend Stocks to Buy for the New Year",
    "url": "https://www.fool.com/investing/2024/01/25/no-brainer-dividend-stocks-to-buy-for-the-new-year/",
    "time_published": "20240125T102000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies have fantastic track records of maintaining and raising their payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/762006/getty-happy-couple-reassured-relief-relieved.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997902"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.232466,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DMPZF",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.079439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.170453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.076148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.071917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPZ",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.084436",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE",
    "url": "https://www.prnewswire.com/news-releases/cerevel-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-cerevel-therapeutics---cere-302045996.html",
    "time_published": "20240126T234100",
    "authors": [
      "Kahn Swick & Foti",
      "LLC"
    ],
    "summary": "CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1936950/THE_KSF_LOGO_1_v2.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.210541,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.455525",
        "ticker_sentiment_score": "0.197131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.455525",
        "ticker_sentiment_score": "0.197131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Apple, Boeing, Microsoft, Alphabet And A Fed Meeting, For Starters: Investing Action Plan",
    "url": "https://www.investors.com/research/investing-action-plan/apple-boeing-microsoft-alphabet-and-a-fed-meeting-for-starters-investing-action-plan/",
    "time_published": "20240126T223200",
    "authors": [
      "Investor's Business Daily",
      "ALAN R. ELLIOTT"
    ],
    "summary": "As the stock market pushes its rally toward the end of a third straight month, some of its biggest names line up for earnings releases in the coming week. Apple ( AAPL ) , Alphabet ( GOOGL ) , Microsoft ( MSFT ) and Meta Platforms ( META ) are part of the picture.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-FlagFlying-07-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141296,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.16668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.142777",
        "ticker_sentiment_score": "0.073727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.281018",
        "ticker_sentiment_score": "0.06179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.212736",
        "ticker_sentiment_score": "-0.037429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.050291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "0.012189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FLS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.053265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "-0.013276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.07479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANSS",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.075813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "0.086411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.107335",
        "ticker_sentiment_score": "-0.01194",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Preview: AbbVie  ( ABBV )  Q4 Earnings Expected to Decline",
    "url": "https://www.zacks.com/stock/news/2216550/earnings-preview-abbvie-abbv-q4-earnings-expected-to-decline",
    "time_published": "20240126T150015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.107599,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.262522",
        "ticker_sentiment_score": "-0.022119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site - PR Newswire",
    "url": "https://www.prnewswire.com/apac/news-releases/abbvie-expands-biologics-manufacturing-capacity-with-a-223-million-investment-in-singapore-manufacturing-site-302044676.html",
    "time_published": "20240126T010531",
    "authors": [],
    "summary": "AbbVie Expands Biologics Manufacturing Capacity with a $223 Million Investment in Singapore Manufacturing Site PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.358381,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.153152",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.153152",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.596978",
        "ticker_sentiment_score": "0.539691",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now",
    "url": "https://www.fool.com/investing/2024/01/28/2-high-yield-healthcare-stocks-to-buy-with-both-ha/",
    "time_published": "20240128T164200",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "All three of these stocks offer attractive dividend yields, but one looks risky.",
    "banner_image": "https://g.foolcdn.com/editorial/images/761876/dividend-investor-4-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.248016,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MPW",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.173239",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.102219",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs",
    "url": "https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html",
    "time_published": "20240128T130001",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/107343469-1701804491567-JJ-OB-Photo-ACJ-PRESS-1.jpg?v=1701804667&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999993"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.007249,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HESG",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.115639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.120651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.076984",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.049995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "0.054415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042838",
        "ticker_sentiment_score": "-0.019872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.021427",
        "ticker_sentiment_score": "-0.049995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.085553",
        "ticker_sentiment_score": "0.030376",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This week will make it clearer if the Fed will cut interest rates in March | Business",
    "url": "https://www.cnn.com/2024/01/28/business/stocks-week-ahead-economic-data-march-cut-fed/index.html",
    "time_published": "20240128T123000",
    "authors": [
      "Bryan Mena"
    ],
    "summary": "This week will make it clearer if the Fed will cut interest rates in March ...",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1845877607.jpg?c=16x9&q=w_800,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.999998"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.045759,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDLZ",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.021795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBLU",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.039643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.120569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.021795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NMR",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.021795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.039643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.045126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "X",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.021795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.046318",
        "ticker_sentiment_score": "-0.030626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLF",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "-0.035268",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.039643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.023169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks Enjoying Favorable Analyst Coverage",
    "url": "https://www.zacks.com/stock/news/2217509/3-stocks-enjoying-favorable-analyst-coverage",
    "time_published": "20240129T230800",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "All three of these stocks have seen upgrades from analysts in recent days. Is it time to buy?",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/2320.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      }
    ],
    "overall_sentiment_score": 0.424261,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DLTR",
        "relevance_score": "0.322233",
        "ticker_sentiment_score": "0.386603",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.493834",
        "ticker_sentiment_score": "0.587039",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.381949",
        "ticker_sentiment_score": "0.359706",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Sinks As Market Gains: Here's Why",
    "url": "https://www.zacks.com/stock/news/2217445/abbvie-abbv-stock-sinks-as-market-gains-heres-why",
    "time_published": "20240129T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default214.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.220471,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.661658",
        "ticker_sentiment_score": "0.353841",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36831249/abbvies-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-p",
    "time_published": "20240129T190456",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "William Blair has upgraded AbbVie Inc ABBV, noting confidence in the company's growth outlook over the near and long term as it heads into 2024.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/ABBV.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.366758,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.501836",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.501836",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.669433",
        "ticker_sentiment_score": "0.293503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? - SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/01/36820476/tech-titans-microsoft-apple-lead-magnificent-seven-earnings-wave-this-week-can-mega-caps-ignite-mar",
    "time_published": "20240129T105100",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "The past week's earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that would see the release of a slew of tech earnings reports. The Week That Was: Tesla, Inc. TSLA, Intel, Inc. INTC, and Texas Instruments, Inc.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Microsoft-and-Apple.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.116237,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AAPL",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.120513",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.129749",
        "ticker_sentiment_score": "-0.080978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "-0.071325",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLIC",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EA",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WHR",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SANM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SIRI",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROK",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EAT",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QRVO",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MET",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOLD",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.089914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FFIV",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.214557",
        "ticker_sentiment_score": "0.21009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUE",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NFLX",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.377798",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.144336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBLU",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWKS",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BZH",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.129749",
        "ticker_sentiment_score": "-0.103947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLF",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "-0.075054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dementia-and-movement-disorder-treatment-market-to-grow-by-usd-8-55-billion-market-share-trends-and-growth-analysis----technavio-302045378.html",
    "time_published": "20240129T101500",
    "authors": [],
    "summary": "Dementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.263428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUPN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACOR",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.125702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024",
    "url": "https://www.globenewswire.com/news-release/2024/01/30/2820516/0/en/Royalty-Pharma-To-Announce-Fourth-Quarter-And-Full-Year-2023-Financial-Results-On-February-15-2024.html",
    "time_published": "20240130T211500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.616842",
        "ticker_sentiment_score": "0.207962",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.094471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024",
    "url": "https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048384.html",
    "time_published": "20240130T190700",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. \u2022 Revenue from ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.283529,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.038592",
        "ticker_sentiment_score": "-0.016692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.017427",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024",
    "url": "https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-302048377.html",
    "time_published": "20240130T190200",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. \u2022 Revenue from ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.297336,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.041682",
        "ticker_sentiment_score": "-0.016812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "-0.017659",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024",
    "url": "https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024-865425678.html",
    "time_published": "20240130T190200",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited ( NSE: PPLPHARMA | BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023. \u2022 Revenue from ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.310316,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "-0.016764",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "-0.017553",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/n36852478/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024",
    "time_published": "20240130T190200",
    "authors": [
      "PRNewswire"
    ],
    "summary": "MUMBAI, India, Jan. 30, 2024 /PRNewswire/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.254223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.01547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "-0.016159",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024",
    "url": "https://www.benzinga.com/pressreleases/24/01/n36852483/piramal-pharma-limited-announces-consolidated-results-for-q3-and-9m-fy2024",
    "time_published": "20240130T190200",
    "authors": [
      "PRNewswire"
    ],
    "summary": "MUMBAI, India, Jan. 30, 2024 /CNW/ -- Piramal Pharma Limited PPLPHARMA, a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Third Quarter ( Q3 ) and Nine Months ( 9M ) ended 31st December 2023.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.254223,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.01547",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "-0.016159",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2218222/abbvie-abbv-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240130T185000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.197619,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.019975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.047278",
        "ticker_sentiment_score": "0.103777",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.40638",
        "ticker_sentiment_score": "0.269523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.233108",
        "ticker_sentiment_score": "0.137648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Earnings Expected to Grow: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2217983/eli-lilly-lly-earnings-expected-to-grow-should-you-buy",
    "time_published": "20240130T150056",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default302.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.149619,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.127026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.174903",
        "ticker_sentiment_score": "-0.001424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unveiling AbbVie  ( ABBV )  Q4 Outlook: Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2217823/unveiling-abbvie-abbv-q4-outlook-wall-street-estimates-for-key-metrics",
    "time_published": "20240130T141522",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.111104,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.344712",
        "ticker_sentiment_score": "0.077357",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Goldman Sachs, AbbVie And A Major Chipmaker: CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Goldman Sachs Gr  ( NYSE:GS ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/01/36838789/goldman-sachs-abbvie-and-a-major-chipmaker-cnbcs-final-trades",
    "time_published": "20240130T140014",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Steve Weiss of Short Hills Capital Partners said Taiwan Semiconductor Manufacturing Company Limited TSM goes higher. Taiwan Semiconductor Manufacturing is reportedly eyeing its second Japanese plant in the same town as its first in Kumamoto prefecture.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/30/analyst_trader_shutter.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.214773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "-0.051927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.595343",
        "ticker_sentiment_score": "0.409764",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.132368",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "0.590392",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSM",
        "relevance_score": "0.495015",
        "ticker_sentiment_score": "-0.179857",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU",
    "url": "https://www.benzinga.com/pressreleases/24/01/g36842900/jnana-therapeutics-announces-positive-clinical-proof-of-concept-achieved-with-jnt-517-a-potential-",
    "time_published": "20240130T131557",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Treatment with JNT-517 demonstrated a statistically significant mean blood phenylalanine reduction of 51% versus baseline Jnana has adapted the ongoing trial to accelerate the program and aims to advance JNT-517 directly into a pivotal study in early 2025",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.187465,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.035293",
        "ticker_sentiment_score": "0.149058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035293",
        "ticker_sentiment_score": "0.149058",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/01/36873044/this-is-what-whales-are-betting-on-abbvie",
    "time_published": "20240131T183103",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.140806,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.870696",
        "ticker_sentiment_score": "0.235456",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Two Titans Signal Strong End To Huge Week Of Earnings",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-meta-amazon-fuel-techs-china-woes-hit-apple-jobs-report-looms/",
    "time_published": "20240201T214400",
    "authors": [
      "Investor's Business Daily",
      "ED CARSON"
    ],
    "summary": "Dow Jones Futures: Meta, Amazon Fuel Techs Late, China Woes Hit Apple. Jobs Report Looms Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1MAIN_meta_012224_adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999819"
      }
    ],
    "overall_sentiment_score": 0.108941,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.030838",
        "ticker_sentiment_score": "0.021411",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.092331",
        "ticker_sentiment_score": "0.12622",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.036457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANET",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.164074",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DDOG",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "-0.121184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.022185",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.117868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.092331",
        "ticker_sentiment_score": "-0.201939",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.153275",
        "ticker_sentiment_score": "-0.132454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.18343",
        "ticker_sentiment_score": "0.193967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Beats Q4 Earnings Estimates",
    "url": "https://www.zacks.com/stock/news/2219249/merck-mrk-beats-q4-earnings-estimates",
    "time_published": "20240201T124502",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.144085,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/02/02/abbvie-abbv-q4-2023-earnings-call-transcript/",
    "time_published": "20240202T204515",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ABBV earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.279511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.162763",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.137931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.137931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.137931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.112055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.152907",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060583",
        "ticker_sentiment_score": "0.094248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.066542",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIGR",
        "relevance_score": "0.003369",
        "ticker_sentiment_score": "0.116318",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 Earnings Beat, Raises Sales View for Key Drugs",
    "url": "https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs",
    "time_published": "20240202T180400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998645"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.12283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHRS",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "-0.026577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.036926",
        "ticker_sentiment_score": "0.126273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.265849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.01294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.26213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.131161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",
    "url": "https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/",
    "time_published": "20240202T171500",
    "authors": [
      "IBD STAFF",
      "Investor's Business Daily"
    ],
    "summary": "Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/04/SSA-040816-shutterstock.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.029434,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MXL",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.026313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.145994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.045467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "-0.013684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYCB",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "-0.121209",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.136008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALGM",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.050168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHOP",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.154811",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.007675",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.113074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.016017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.109096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.005554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXT(EXP20091224)",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.155736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "-0.024213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.120391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.158384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.161989",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.036073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSTR",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.014716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.16469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.069943",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.136008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MANH",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.154811",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.133526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "POWL",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.053581",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.092797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.142727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOFI",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.010999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.059814",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WOLF",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "0.01579",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.033236",
        "ticker_sentiment_score": "-0.133526",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBNY",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "-0.102369",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.028998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.066414",
        "ticker_sentiment_score": "0.004048",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "-0.015004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NXT",
        "relevance_score": "0.016621",
        "ticker_sentiment_score": "0.155736",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/02/36912453/abbvie-lifts-long-term-outlook-for-new-immunology-drugs-even-as-q4-revenue-and-profit-fall",
    "time_published": "20240202T161237",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, AbbVie Inc ABBV reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/abbvie-shutter_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.179843,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.201177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.353898",
        "ticker_sentiment_score": "0.431451",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.779232",
        "ticker_sentiment_score": "0.419506",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nonfarm Payrolls Increased More Than Expected",
    "url": "https://www.zacks.com/stock/news/2220379/nonfarm-payrolls-increased-more-than-expected",
    "time_published": "20240202T154500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The big jobs numbers out this week came from this morning's U.S. Bureau of Labor Statistics' ( BLS ) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4e/1601.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.105021,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVX",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "-0.010201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "0.1648",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "-0.010201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BLS Jobs Up Big: 353K, 3.7% Unemployment",
    "url": "https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-37-unemployment",
    "time_published": "20240202T152200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "353K new jobs created for January are nearly double the 180K or so analysts were looking for.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/64/662.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.104976,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVX",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "-0.010144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.166188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "-0.010144",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "North America Cosmetic Surgery Market is Expected to Reach USD 29.2 billion, Advancing at a CAGR of 6.8% by 2031: Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36909586/north-america-cosmetic-surgery-market-is-expected-to-reach-usd-29-2-billion-advancing-at-a-cagr-of",
    "time_published": "20240202T140811",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The North America cosmetic surgery market is estimated to flourish at a CAGR of 6.8% from 2023 to 2031.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.430043,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.25434",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.05021",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.366855",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.253102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.106227",
        "ticker_sentiment_score": "0.079304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.162941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Expects Two Drugs To Top $27 Billion In Sales. And Neither Is Humira.",
    "url": "https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2023/",
    "time_published": "20240202T135600",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "AbbVie Stock Rises On Long-Term Guidance, Calling For $27 Billion From Two Key Drugs Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.23409,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.900719",
        "ticker_sentiment_score": "0.431729",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "4 Large Drug Stocks Trying to Survive the Industry Challenges",
    "url": "https://www.zacks.com/commentary/2220023/4-large-drug-stocks-trying-to-survive-the-industry-challenges",
    "time_published": "20240202T134700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.215569,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.15857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.065458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "0.236489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.118999",
        "ticker_sentiment_score": "0.140653",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.065458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.023885",
        "ticker_sentiment_score": "0.031019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q4 Earnings and Revenues Top Estimates",
    "url": "https://www.zacks.com/stock/news/2220125/abbvie-abbv-q4-earnings-and-revenues-top-estimates",
    "time_published": "20240202T134502",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default188.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.16185,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.139669",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.402403",
        "ticker_sentiment_score": "0.208814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's fourth-quarter sales top estimates despite plunging Humira revenues",
    "url": "https://www.marketwatch.com/story/abbvies-fourth-quarter-sales-top-estimates-despite-plunging-humira-revenues-f4fdf32b",
    "time_published": "20240202T124000",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "AbbVie on Friday reported fourth-quarter sales that topped analyst estimates, even as it faces low-cost competition for its top-seller Humira.",
    "banner_image": "https://images.mktw.net/im-28634865/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988787"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.170023,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IMGN",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.118113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.183895",
        "ticker_sentiment_score": "0.118113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.647749",
        "ticker_sentiment_score": "0.278672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36907360/nasdaq-futures-climb-as-meta-amazon-gains-offset-apple-slide-analyst-points-to-2-factors-reinforcin",
    "time_published": "20240202T122406",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. META, Amazon, Inc. AMZN, and Apple, Inc. AAPL. Earnings remain mixed, raising concerns about both the economy and corporate profit growth.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/nasdaq-shutter_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.986714"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.139355,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.020255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.016206",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.155001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BZH",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.020916",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fabulous Dividend Stocks to Buy in February",
    "url": "https://www.fool.com/investing/2024/02/04/3-fabulous-dividend-stocks-to-buy-in-february/",
    "time_published": "20240204T105000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks offer great dividends and more.",
    "banner_image": "https://g.foolcdn.com/editorial/images/763692/dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.311446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FCAP",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.085346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.344473",
        "ticker_sentiment_score": "0.205286",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.384233",
        "ticker_sentiment_score": "0.246892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AbbVie Stock Flew Higher on Monday",
    "url": "https://www.fool.com/investing/2024/02/05/why-abbvie-stock-flew-higher-on-monday/",
    "time_published": "20240205T235557",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "Investors and pundits alike continued to be impressed by the company's latest earnings report.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764108/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.074618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.512093",
        "ticker_sentiment_score": "0.307511",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vertex Scores Big With Its Next-Gen Cystic Fibrosis Drug",
    "url": "https://www.investors.com/news/technology/vrtx-stock-vertex-earnings-q4-2023/",
    "time_published": "20240205T212000",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "VRTX Stock Rises On Quarterly Beat As Next-Gen CF Drug Scores Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Vertex-04-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.26355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.6338",
        "ticker_sentiment_score": "0.274514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Amgen's Weight-Loss News Just Sent Lilly To A Record High",
    "url": "https://www.investors.com/news/technology/amgen-stock-slumps-as-it-looks-to-take-on-weight-loss-drugs-leaders-lilly-novo/",
    "time_published": "20240205T180800",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Amgen Stock Slumps As It Looks To Take On Weight-Loss Drugs Leaders Lilly, Novo Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-amgen-08-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.125806,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.459624",
        "ticker_sentiment_score": "0.267818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.07163",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.262422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.316846",
        "ticker_sentiment_score": "0.087971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This is Why AbbVie  ( ABBV )  is a Great Dividend Stock",
    "url": "https://www.zacks.com/stock/news/2221198/this-is-why-abbvie-abbv-is-a-great-dividend-stock",
    "time_published": "20240205T164504",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.378574,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.457977",
        "ticker_sentiment_score": "0.451413",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More",
    "url": "https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more",
    "time_published": "20240205T150900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090594,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.01809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXEL",
        "relevance_score": "0.270773",
        "ticker_sentiment_score": "-0.072387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.313674",
        "ticker_sentiment_score": "0.14336",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.046006",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2220890/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240205T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default182.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.171606,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.216376",
        "ticker_sentiment_score": "0.123181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054732",
        "ticker_sentiment_score": "-0.036005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDA",
        "relevance_score": "0.216376",
        "ticker_sentiment_score": "0.123181",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Better Dividend Stock: Pfizer vs. AbbVie",
    "url": "https://www.fool.com/investing/2024/02/05/better-dividend-stock-pfizer-vs-abbvie/",
    "time_published": "20240205T135400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Both offer above-average yields but which can deliver the most dividend income over the long run?",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F763718%2Fsmart-investor-looking-at-charts.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.177195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.554014",
        "ticker_sentiment_score": "0.09611",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.467081",
        "ticker_sentiment_score": "0.371785",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Analysts Boost Their Forecasts Following Strong Earnings - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/02/36932051/abbvie-analysts-boost-their-forecasts-following-strong-earnings",
    "time_published": "20240205T135026",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "AbbVie Inc ABBV reported better-than-expected fourth-quarter earnings on Friday. AbbVie reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion, ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/abbvie_-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "0.32152",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.930964",
        "ticker_sentiment_score": "0.437196",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.238133",
        "ticker_sentiment_score": "-0.215571",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday - Apellis Pharmaceuticals  ( NASDAQ:APLS ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/24/02/36931029/pinterest-to-rally-over-20-here-are-10-top-analyst-forecasts-for-monday",
    "time_published": "20240205T130926",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James cut the price target for Skechers U.S.A., Inc. SKX from $68 to $66.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/pinterest-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.257115,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKYW",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.402031",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MAT",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.111396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.169732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LYB",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.197246",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CI",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.151864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APLS",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.310742",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOV",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.227815",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.333159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PINS",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "-0.015201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MKL",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.115328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis",
    "url": "https://www.zacks.com/stock/news/2220698/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-abbvie-and-novartis",
    "time_published": "20240205T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.215514,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.011097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.152636",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.137409",
        "ticker_sentiment_score": "0.13715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DICE",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.030885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.24899",
        "ticker_sentiment_score": "0.156217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.20484",
        "ticker_sentiment_score": "0.234708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.023013",
        "ticker_sentiment_score": "0.062277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stocks To Watch: AbbVie Sees RS Rating Jump To 81",
    "url": "https://www.investors.com/ibd-data-stories/stocks-to-watch-abbvie-sees-rs-rating-jump-to-81/",
    "time_published": "20240205T080000",
    "authors": [
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "AbbVie ( ABBV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, with an increase from 78 to 81. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.389197,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZTS",
        "relevance_score": "0.338582",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.488777",
        "ticker_sentiment_score": "0.730533",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst - Axsome Therapeutics  ( NASDAQ:AXSM ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/02/36963990/ubs-bullish-on-this-depression-drug-maker-says-alzheimers-agitation-data-is-attract",
    "time_published": "20240206T191939",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "UBS initiated coverage on Axsome Therapeutics Inc AXSM, a biotech firm focused on developing and marketing therapies for central nervous disorders. UBS analyst is bullish on Axsom's depression drug Auvelity's launch and pipeline opportunities with upcoming late-stage clinical read-outs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/AXSM_0.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.181523,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRTX",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.324419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.440929",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.440929",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.26333",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.324419",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Novartis  ( NVS )  to Buy MorphoSys & Add Late-Stage Oncology Drug",
    "url": "https://www.zacks.com/stock/news/2221928/novartis-nvs-to-buy-morphosys-add-late-stage-oncology-drug",
    "time_published": "20240206T161600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2350.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.153888,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "INCY",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.120011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.195311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "-0.011244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "-0.014026",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/36959221/100-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today",
    "time_published": "20240206T160029",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.2%. Currently, AbbVie has a market capitalization of $303.65 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.983605",
        "ticker_sentiment_score": "0.387251",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2221648/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240206T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.240049,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.134944",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Magnificent Dividend Growth Stocks to Load Up On Right Now",
    "url": "https://www.fool.com/investing/2024/02/06/2-magnificent-dividend-growth-stocks-to-load-up-on/",
    "time_published": "20240206T140000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two dividend-growth stocks are fantastic buys.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F764055%2Fdividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.413788,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SPGI",
        "relevance_score": "0.23281",
        "ticker_sentiment_score": "0.443753",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.414044",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2221502/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20240206T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      }
    ],
    "overall_sentiment_score": 0.251851,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.05992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.05992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.335519",
        "ticker_sentiment_score": "0.293987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.05992",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Options Trading: A Deep Dive into Market Sentiment - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/02/36987440/abbvie-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240207T173050",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 12 unusual trades. Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.165263,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.77688",
        "ticker_sentiment_score": "0.079117",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis",
    "url": "https://www.benzinga.com/pressreleases/24/02/g36983512/anima-biotech-announces-preclinical-data-of-candidate-in-idiopathic-pulmonary-fibrosis",
    "time_published": "20240207T151700",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BERNARDSVILLE, N.J., Feb. 07, 2024 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.211481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.05729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stocks: 5 Biggest Companies in 2024",
    "url": "https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-10-pharmaceutical-companies/",
    "time_published": "20240208T211500",
    "authors": [
      "Meagen Seatter"
    ],
    "summary": "Companies in this sector are constantly researching and creating innovative treatments for various medical conditions, including immuno-oncology, neurology and rare diseases. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.",
    "banner_image": "https://investingnews.com/media-library/pills-spilling-out-of-a-pill-bottle-on-a-yellow-background.jpg?id=32933343&width=1200&height=800&quality=85&coordinates=65%2C0%2C66%2C0",
    "source": "Investing News Network",
    "category_within_source": "n/a",
    "source_domain": "investingnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.129917,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.038373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.045406",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.083975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.070123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042346",
        "ticker_sentiment_score": "0.089865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.02118",
        "ticker_sentiment_score": "0.111754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37017425/stakes-are-high-for-regenerons-eylea-hd-as-genentechs-vabysmo-continues-to-gain-momentum-prompting",
    "time_published": "20240208T201757",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Exton, Pennsylvania, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- As Age-Related Macular Degeneration ( AMD ) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.056976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.056976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.056976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCUL",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.056976",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's VYALEV\u2122  ( foslevodopa/foscarbidopa solution )  Available for the Treatment of Advanced Parkinson's Disease in Canada",
    "url": "https://www.newswire.ca/news-releases/abbvie-s-vyalev-tm-foslevodopa-foscarbidopa-solution-available-for-the-treatment-of-advanced-parkinson-s-disease-in-canada-839132860.html",
    "time_published": "20240208T130000",
    "authors": [
      "AbbVie Canada"
    ],
    "summary": "AbbVie's VYALEV\u2122 ( foslevodopa/foscarbidopa solution ) Available for the Treatment of Advanced Parkinson's Disease ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2336781/AbbVie_Canada_AbbVie_s_VYALEV___foslevodopa_foscarbidopa_solutio.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.228673,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.301778",
        "ticker_sentiment_score": "0.3086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Intrauterine Contraceptive Devices (IUD) Market to grow by USD 965.49 million at a CAGR of 3.98% from 2022 to 2027 ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/intrauterine-contraceptive-devices-iud-market-to-grow-by-usd-965-49-million-at-a-cagr-of-3-98-from-2022-to-2027--abbvie-inc-and-bayer-ag-are-among-the-key-companies---technavio-302056716.html",
    "time_published": "20240208T060000",
    "authors": [],
    "summary": "Intrauterine Contraceptive Devices ( IUD ) Market to grow by USD 965.49 million at a CAGR of 3.98% from 2022 to 2027 ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.204333,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COO",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.152018",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart' - Blackstone  ( NYSE:BX ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/02/37027275/jim-cramer-looks-at-blackstone-praises-mercadolibre-theyre-incredibly-smart",
    "time_published": "20240209T133343",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Freeport-McMoRan Inc. FCX could go higher by a \"couple of points, once the Chinese start manipulating their market higher, but that's all you're going to get from them. We have to go higher quality.\" Freeport-McMoRan confirmed that Kathleen L.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/09/jim_cramer_nyse_shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.297659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MELI",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "0.723451",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FCX",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "0.040864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "0.249713",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OXLC",
        "relevance_score": "0.543935",
        "ticker_sentiment_score": "0.550963",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.315242",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy",
    "url": "https://www.fool.com/investing/2024/02/11/these-17-words-from-abbvies-ceo-explain-why-the-st/",
    "time_published": "20240211T132500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drugmaker is handling its biggest obstacle yet relatively well.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764237/physician-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.264273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.624973",
        "ticker_sentiment_score": "0.346092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.183306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for AbbVie, Applied Materials & American Express",
    "url": "https://www.zacks.com/research-daily/2224591/top-stock-reports-for-abbvie-applied-materials-american-express",
    "time_published": "20240212T205300",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and American Express Company (AXP).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default183.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.180926,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMAT",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.323888",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.279732",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.289062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ABBV: Unleash Gain Potential With 3 Pharma Stocks to Consider",
    "url": "https://stocknews.com/news/abbv-gsk-amrx-unleash-gain-potential-with-3-pharma-stocks-to-consider/",
    "time_published": "20240212T180027",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "The rise in chronic diseases, advancements in technology, and a strong research and development pipeline have ignited a heightened demand for pharmaceutical products and services. Moreover, the pharmaceutical sector's resilience to economic fluctuations offers a stable environment for companies ...",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.244321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.024724",
        "ticker_sentiment_score": "0.158772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.194102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.1258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.186634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ZTS: Zoetis  ( ZTS ) : Analyzing Earnings for Potential Gains",
    "url": "https://stocknews.com/news/zts-gsk-abbv-nvo-zoetis-zts-analyzing-earnings-for-potential-gains/",
    "time_published": "20240212T174911",
    "authors": [
      "StockNews.com Staff"
    ],
    "summary": "Zoetis Inc. ( ZTS ) is a leading force in the realm of animal health, specializing in the discovery, development, manufacturing, and global distribution of vital medicines, vaccines, and diagnostic tools.",
    "banner_image": "https://stocknews.com/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "stocknews.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.306689,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZTS",
        "relevance_score": "0.738815",
        "ticker_sentiment_score": "0.45306",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.064079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.064079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.064079",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Three Stocks: AbbVie, Viking Therapeutics, and Cloudflare",
    "url": "https://moneymorning.com/2024/02/12/three-stocks-abbvie-viking-therapeutics-and-cloudflare/",
    "time_published": "20240212T150046",
    "authors": [],
    "summary": "Just like we spoke about in early December, AbbVie ( ABBV ) is starting to feel an acquisition spree it was on last year. And just as we said, long-dated put options back then would've yielded well now that the company lowered its guidance this morning due to the \"dilutive impact\" of its ...",
    "banner_image": null,
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.265342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NET",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.168033",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.350899",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.120585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY",
    "url": "https://www.zacks.com/stock/news/2224700/drug-biotech-stocks-q4-earnings-due-on-feb-13-biib-zts-incy",
    "time_published": "20240212T141600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.192214,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "-0.030905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.467081",
        "ticker_sentiment_score": "0.34523",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.372315",
        "ticker_sentiment_score": "0.051882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "-0.030905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.198927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "-0.030905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.322374",
        "ticker_sentiment_score": "0.264359",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "-0.030905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2224629/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240212T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default333.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.231001,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.119647",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.044007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBMT",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.118049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EGBN",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.079704",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen",
    "url": "https://www.marketwatch.com/story/abbvies-stock-dips-premarket-after-it-lowers-q1-guidance-to-reflect-dilutive-impact-of-immunogen-deal-close-5b6e9fea",
    "time_published": "20240212T125100",
    "authors": [
      "Ciara Linnane"
    ],
    "summary": "AbbVie Inc.'s stock fell 0.5% early Monday, after the biotech lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen.",
    "banner_image": "https://images.mktw.net/im-264386/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.048741,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.041183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.754476",
        "ticker_sentiment_score": "0.079838",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?",
    "url": "https://www.fool.com/investing/2024/02/12/is-it-too-late-to-buy-these-2-brilliant-passive-in/",
    "time_published": "20240212T123000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These incredible businesses have long histories of successes behind them, and more to come.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764307/getty-couple-happy-in-kitchen.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.210293,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GLDAF",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "-0.022456",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.072597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.04028",
        "ticker_sentiment_score": "0.041031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.276313",
        "ticker_sentiment_score": "0.123407",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.313817",
        "ticker_sentiment_score": "0.154311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Generic Drugs Market Size is Estimated to Reach USD 546.03 Billion by 2031, Growing at a CAGR of 4.1%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37064298/global-generic-drugs-market-size-is-estimated-to-reach-usd-546-03-billion-by-2031-growing-at-a-cag",
    "time_published": "20240212T114500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Generic medications are bioequivalent to name-brand medications, meaning they have the same active components and therapeutic results. Similarities exist in the dosages, risks, consequences, side effects, strengths, intended purposes, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.057295,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.059415",
        "ticker_sentiment_score": "-0.023004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "0.125607",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.045086",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Inhalation Anaesthesia Market Size is Projected to Reach USD 1.84 billion by 2031, Growing at a CAGR of 4.2%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37097748/global-inhalation-anaesthesia-market-size-is-projected-to-reach-usd-1-84-billion-by-2031-growing-a",
    "time_published": "20240213T155500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Inhalation Anaesthesia is a common method in medical procedures to achieve general anesthesia.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.277233,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035397",
        "ticker_sentiment_score": "0.122669",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights AbbVie, Applied Materials, American Express, Centene and Aspen",
    "url": "https://www.zacks.com/stock/news/2225190/the-zacks-analyst-blog-highlights-abbvie-applied-materials-american-express-centene-and-aspen",
    "time_published": "20240213T110000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "AbbVie, Applied Materials, American Express, Centene and Aspen are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8c/1247.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.101797,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMAT",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.235734",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.083643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.152445",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZPN",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNC",
        "relevance_score": "0.181819",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.129439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAM",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.083643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating",
    "url": "https://www.investors.com/news/abbvie-clears-key-benchmark-hitting-80-plus-rs-rating/",
    "time_published": "20240214T190200",
    "authors": [
      "GLENN LARKIN",
      "INVESTOR'S BUSINESS DAILY",
      "Investor's Business Daily"
    ],
    "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is AbbVie ( ABBV ) , which had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Wednesday.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.376675,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EOLS",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.357454",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Genmab Publishes 2023 Annual Report",
    "url": "https://www.globenewswire.com/news-release/2024/02/14/2829266/0/en/Genmab-Publishes-2023-Annual-Report.html",
    "time_published": "20240214T160200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.134216,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.417611",
        "ticker_sentiment_score": "0.145663",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZLAB",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.02372",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "0.077179",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.083727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.017036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.121404",
        "ticker_sentiment_score": "0.088215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.083727",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Clears Key Benchmark, Hitting 80-Plus RS Rating",
    "url": "https://www.investors.com/ibd-data-stories/abbvie-clears-key-benchmark-hitting-80-plus-rs-rating/",
    "time_published": "20240214T080000",
    "authors": [
      "Investor's Business Daily",
      "INVESTOR'S BUSINESS DAILY"
    ],
    "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is AbbVie ( ABBV ) , which had its Relative Strength ( RS ) Rating upgraded from 80 to 84 Wednesday.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.388742,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EOLS",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.785534",
        "ticker_sentiment_score": "0.552156",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Myelodysplastic Syndrome  ( MDS )  Drugs Global Market Report 2024: Strong Growth Projected with Increasing Incidences of Myeloid Leukemia As Per The Business Research Company's Myelodysplastic Syndrome  ( MDS )  Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37162474/myelodysplastic-syndrome-mds-drugs-global-market-report-2024-strong-growth-projected-with-increasi",
    "time_published": "20240215T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 15, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Myelodysplastic Syndrome ( MDS ) Drugs Global Market Report 2024, the myelodysplastic syndrome ( MDS ) drugs market size has exhibited robust growth in recent years, with the market poised to reach $3.47 billion ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.260752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.040004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.137016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.137016",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET\u00ae with Gilead's Trodelvy\u00ae in two Cancer Indications",
    "url": "https://www.prnewswire.com/news-releases/dragonfly-announces-clinical-collaboration-exploring-combinations-of-dragonflys-df1001-her-2-trinket-with-gileads-trodelvy-in-two-cancer-indications-302062613.html",
    "time_published": "20240215T140000",
    "authors": [
      "Inc.",
      "Dragonfly Therapeutics"
    ],
    "summary": "Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET\u00ae with ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232711,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.178281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.178281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET\u00ae with Gilead's Trodelvy\u00ae in two Cancer Indications",
    "url": "https://www.newswire.ca/news-releases/dragonfly-announces-clinical-collaboration-exploring-combinations-of-dragonfly-s-df1001-her-2-trinket-r-with-gilead-s-trodelvy-r-in-two-cancer-indications-802839382.html",
    "time_published": "20240215T140000",
    "authors": [
      "Dragonfly Therapeutics",
      "Inc."
    ],
    "summary": "Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET\u00ae with ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232711,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.178281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.068306",
        "ticker_sentiment_score": "0.178281",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CollPlant Issues Letter to Shareholders - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/collplant-issues-letter-to-shareholders-302063006.html",
    "time_published": "20240215T130000",
    "authors": [],
    "summary": "CollPlant Issues Letter to Shareholders PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.308497,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSYS",
        "relevance_score": "0.086996",
        "ticker_sentiment_score": "0.1522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.138763",
        "ticker_sentiment_score": "0.127752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Magnificent Growth Stocks to Buy With $500",
    "url": "https://www.fool.com/investing/2024/02/15/2-magnificent-growth-stocks-to-buy-with-500/",
    "time_published": "20240215T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "No need to break the bank to invest in promising stocks.",
    "banner_image": "https://media.ycharts.com/charts/9af8b50ffc1788153770b1ac93b6cb06.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248864,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VEEV",
        "relevance_score": "0.297301",
        "ticker_sentiment_score": "0.058483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.239895",
        "ticker_sentiment_score": "0.192579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056101",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What The Future Holds For Google's 'Other Bets'",
    "url": "https://www.investors.com/news/technology/other-bets-x-moonshots-future-google-stock/",
    "time_published": "20240216T154800",
    "authors": [
      "Investor's Business Daily",
      "REINHARDT KRAUSE"
    ],
    "summary": "Other Bets And X Moonshots Key Google Stock's Future Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/wGoog_2c201924.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.159278,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.647825",
        "ticker_sentiment_score": "0.257439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "-0.050985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "-0.035944",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.050832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVGI",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.147619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "-0.050985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.081926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VWAGY",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "-0.032837",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.045425",
        "ticker_sentiment_score": "0.116286",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.015149",
        "ticker_sentiment_score": "0.074076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.034053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.030292",
        "ticker_sentiment_score": "0.025574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ironwood  ( IRWD )  Q4 Earnings Miss, Revenues Beat Marginally",
    "url": "https://www.zacks.com/stock/news/2227354/ironwood-irwd-q4-earnings-miss-revenues-beat-marginally",
    "time_published": "20240216T143600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.099455,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.058615",
        "ticker_sentiment_score": "0.143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.249413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.17228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.111991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.286864",
        "ticker_sentiment_score": "0.114945",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months",
    "url": "https://www.fool.com/investing/2024/02/16/wall-street-thinks-these-3-stocks-are-hidden-gems/",
    "time_published": "20240216T105000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Analysts are quite bullish about these beaten-down stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765200/oil-rig-workers-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234969,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BABA",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "0.231642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SLB",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.140709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.366061",
        "ticker_sentiment_score": "0.015773",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.042253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Vanguard ETFs That Could Help You Retire a Millionaire",
    "url": "https://www.fool.com/investing/2024/02/17/5-vanguard-etfs-that-could-help-you-retire-a-milli/",
    "time_published": "20240217T095900",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Vanguard is one of the most trusted names on Wall Street.",
    "banner_image": "https://g.foolcdn.com/editorial/images/764751/exchange-traded-funds-graphic.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.202565,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.14679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.143983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.143983",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Growth Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/02/19/3-magnificent-growth-stocks-to-buy-right-now/",
    "time_published": "20240219T151500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/765520/happy-stock-investor-holding-smartphone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.264978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.27676",
        "ticker_sentiment_score": "0.342352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.160365",
        "ticker_sentiment_score": "0.311688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.040348",
        "ticker_sentiment_score": "0.044696",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.387075",
        "ticker_sentiment_score": "0.271117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2227821/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240219T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.154819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.208464",
        "ticker_sentiment_score": "0.119647",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2227796/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240219T140011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default244.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.228517,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.13848",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Oregon Rethinks Groundbreaking Drug Decriminalization Amid Escalating Opioid Crisis",
    "url": "https://www.benzinga.com/news/24/02/37197005/oregon-rethinks-groundbreaking-drug-decriminalization-amid-escalating-opioid-crisis",
    "time_published": "20240219T045232",
    "authors": [
      "Benzinga Neuro"
    ],
    "summary": "In the wake of the escalating opioid crisis, the state of Oregon is reconsidering its groundbreaking drug decriminalization legislation. This move comes as the state grapples with a surge in drug-related fatalities and a lack of effective implementation of the existing law.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/66th-SFS-carries-opioid-overdose-medicat_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.080168,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.108181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.108181",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Congenital Diaphragmatic Hernia Drugs Market Size is Expected to Reach $5.8 Billion By 2028 At A CAGR Of More Than 7% As Per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37216844/congenital-diaphragmatic-hernia-drugs-market-size-is-expected-to-reach-5-8-billion-by-2028-at-a-ca",
    "time_published": "20240220T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Congenital Diaphragmatic Hernia Drugs Global Market Report 2024, the global congenital diaphragmatic hernia ( CDH ) drugs market has experienced robust expansion in recent years, driven by various factors ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.35108,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.00901",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BeiGene  ( BGNE )  to Report Q4 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2228645/beigene-bgne-to-report-q4-earnings-whats-in-the-cards",
    "time_published": "20240220T154900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/60216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.252242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.045569",
        "ticker_sentiment_score": "0.061781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.639433",
        "ticker_sentiment_score": "0.343424",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.180798",
        "ticker_sentiment_score": "0.220865",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.136113",
        "ticker_sentiment_score": "0.111729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira",
    "url": "https://www.marketwatch.com/story/abbvie-taps-new-ceo-as-it-faces-fresh-competition-for-blockbuster-drug-humira-67b7bcbd",
    "time_published": "20240220T154600",
    "authors": [
      "Eleanor Laise"
    ],
    "summary": "AbbVie's founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday.",
    "banner_image": "https://images.mktw.net/im-822948/social",
    "source": "MarketWatch",
    "category_within_source": "Top Stories",
    "source_domain": "www.marketwatch.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.187585,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.200853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.783279",
        "ticker_sentiment_score": "0.330723",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez",
    "url": "https://www.cnbc.com/2024/02/20/abbvie-taps-robert-michael-as-ceo-succeeding-richard-gonzalez.html",
    "time_published": "20240220T150658",
    "authors": [
      "Annika Kim Constantino"
    ],
    "summary": "Michael, who is AbbVie's chief operating officer, will become the company's second-ever CEO since the company spun out from Abbott Laboratories in 2013.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106886633-16216093432021-05-21t145854z_868084266_rc29kn9d8g4p_rtrmadp_0_abbvie-usa.jpeg?v=1701366953&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.22236,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.288188",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "-0.072674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.116578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.054327",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease",
    "url": "https://www.globenewswire.com/news-release/2024/02/20/2831842/0/en/Disc-Medicine-Receives-FDA-Fast-Track-Designation-for-DISC-0974-for-the-Treatment-of-Anemia-in-Non-Dialysis-Dependent-Chronic-Kidney-Disease.html",
    "time_published": "20240220T133000",
    "authors": [
      "Disc Medicine Inc"
    ],
    "summary": "WATERTOWN, Mass., Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ca38ccab-c7d0-43bf-af35-e67b5bc64683",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.021804,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IRON",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.097813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.031992",
        "ticker_sentiment_score": "-0.114458",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2228267/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240220T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default91.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.267515,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.231884",
        "ticker_sentiment_score": "0.267105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.061498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SEC Crypto Unit Leader Resigns After Spearheading Coinbase Lawsuit",
    "url": "https://decrypt.co/218374/sec-crypto-lead-ladan-stewart-leaves-for-private-sector",
    "time_published": "20240221T182801",
    "authors": [
      "Andrew Throuvalas"
    ],
    "summary": "Ladan Stewart once led federal lawsuits against Ripple and Coinbase, but may now turn crypto advocate in the private sector.",
    "banner_image": "https://cdn.decrypt.co/resize/1024/height/512/wp-content/uploads/2024/02/Ladan-Stewart-White-and-Case-16x9-1-gID_7.jpg",
    "source": "Decrypt.co",
    "category_within_source": "n/a",
    "source_domain": "decrypt.co",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.007328,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.188143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "-0.047597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.188143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "0.012875",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  is a Top Dividend Stock Right Now: Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2229507/abbvie-abbv-is-a-top-dividend-stock-right-now-should-you-buy",
    "time_published": "20240221T164507",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default37.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.366143,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.453099",
        "ticker_sentiment_score": "0.439014",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Announces Appointment of New CEO Robert Michael",
    "url": "https://www.zacks.com/stock/news/2229455/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael",
    "time_published": "20240221T154300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3038.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACIU",
        "relevance_score": "0.343755",
        "ticker_sentiment_score": "0.168325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.210579",
        "ticker_sentiment_score": "0.172638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.714592",
        "ticker_sentiment_score": "0.343678",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.065297",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBYI",
        "relevance_score": "0.406745",
        "ticker_sentiment_score": "0.231943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "BOTOX\u00ae Cosmetic  ( onabotulinumtoxinA )  Announces Its 2024 Grant Program Supporting Women Entrepreneurs",
    "url": "https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-announces-its-2024-grant-program-supporting-women-entrepreneurs-302066719.html",
    "time_published": "20240221T130000",
    "authors": [
      "AbbVie"
    ],
    "summary": "FOR THE SECOND YEAR, BOTOX\u00ae COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY",
    "banner_image": "https://mma.prnewswire.com/media/2343804/AbbVie_US_FA_SM_00052___BTXC_x_IFW_Partnership_Announcement_60_16x9.mp4?p=medium",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.397104,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.499332",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology",
    "url": "https://www.prnewswire.com/news-releases/abbvie-and-tentarix-announce-collaboration-to-develop-conditionally-active-multi-specific-biologics-for-oncology-and-immunology-302068091.html",
    "time_published": "20240222T130500",
    "authors": [
      "AbbVie"
    ],
    "summary": "AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.157072,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.15402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.15402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.556122",
        "ticker_sentiment_score": "0.162593",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "5 Top No-Load Mutual Funds to Enhance Your Returns",
    "url": "https://www.zacks.com/stock/news/2229869/5-top-no-load-mutual-funds-to-enhance-your-returns",
    "time_published": "20240222T122100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in no-load mutual funds like FIKAX, FSPCX, VSMIX, STSEX and BMIIX to ensure high returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/20158.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.13505,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.065061",
        "ticker_sentiment_score": "0.165313",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.047642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRHI",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.046698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVE",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.046698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.047642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.046698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRV",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.041985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.044812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.081851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.044812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.032558",
        "ticker_sentiment_score": "0.047642",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/22/is-abbvie-stock-a-buy-now/",
    "time_published": "20240222T101500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F765217%2Frinvoq-and-skyrizi-sales-projections.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.284773,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.156807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.611103",
        "ticker_sentiment_score": "0.377153",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More",
    "url": "https://www.zacks.com/stock/news/2230738/pharma-stock-roundup-pfizers-velsipity-receives-eu-nod-abbv-gets-new-ceo-more",
    "time_published": "20240223T133700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.239347,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.121196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.426225",
        "ticker_sentiment_score": "0.156384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.061419",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.121196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.18671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.027784",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks That Are No-Brainer Buys Right Now",
    "url": "https://www.fool.com/investing/2024/02/24/3-dividend-stocks-that-are-no-brainer-buys-right-n/",
    "time_published": "20240224T120400",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks check off multiple boxes for investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/766429/man-with-arms-behind-head-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.279267,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CBAY",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.090452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.308614",
        "ticker_sentiment_score": "0.305134",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.153058",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.349945",
        "ticker_sentiment_score": "0.191869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.179454",
        "ticker_sentiment_score": "0.239576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. Approval of SIMLANDI\u00ae  ( adalimumab-ryvk )  injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/02/24/2834699/0/en/Alvotech-and-Teva-Announce-U-S-Approval-of-SIMLANDI-adalimumab-ryvk-injection-the-first-interchangeable-high-concentration-citrate-free-biosimilar-to-Humira.html",
    "time_published": "20240224T011500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": -0.014588,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.26804",
        "ticker_sentiment_score": "0.13876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018846",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.047092",
        "ticker_sentiment_score": "0.085055",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.009424",
        "ticker_sentiment_score": "0.052816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.009424",
        "ticker_sentiment_score": "0.052816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. Approval of SIMLANDI\u00ae  ( adalimumab-ryvk )  injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/02/24/2834698/0/en/Alvotech-and-Teva-Announce-U-S-Approval-of-SIMLANDI-adalimumab-ryvk-injection-the-first-interchangeable-high-concentration-citrate-free-biosimilar-to-Humira.html",
    "time_published": "20240224T011500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SIMLANDI ( adalimumab-ryvk ) injection, as an interchangeable biosimilar to Humira, ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": -0.014587,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.281814",
        "ticker_sentiment_score": "0.142281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018575",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.074201",
        "ticker_sentiment_score": "0.078817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.009288",
        "ticker_sentiment_score": "0.052754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.009288",
        "ticker_sentiment_score": "0.052754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Super Micro Computer Can Raise Money for Free. It's Bad News for Interest Rates.",
    "url": "https://www.barrons.com/amp/articles/super-micro-computer-can-raise-money-for-free-its-bad-news-for-interest-rates-689a2a05",
    "time_published": "20240224T002600",
    "authors": [
      "Randall W. Forsyth"
    ],
    "summary": "Why does the Federal Reserve need to lower interest rates when the capital markets are providing free money? That is, for tech winners such as Super Micro Computer , which was able to raise funds via a private convertible note deal this past week for $1.5 billion.",
    "banner_image": "https://images.barrons.com/im-92842922/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.243147,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.106015",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.029049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.029049",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.089461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.05749",
        "ticker_sentiment_score": "0.15999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global L-Carnitine Market Size is Estimated to Reach USD 267.60 million by 2030, Growing at a CAGR of 4.7%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37313090/global-l-carnitine-market-size-is-estimated-to-reach-usd-267-60-million-by-2030-growing-at-a-cagr-",
    "time_published": "20240226T150500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, Feb. 26, 2024 ( GLOBE NEWSWIRE ) -- L-carnitine is an amino acid that aids in fat metabolism and is used as a supplement in patients with low energy levels. Red meat, salmon, peanut butter, dairy, and dairy products naturally contain L-carnitine.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.266012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.036476",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CEVA",
        "relevance_score": "0.036476",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036476",
        "ticker_sentiment_score": "0.163449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2231539/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240226T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.210882,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BRX",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.183741",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.118854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EBMT",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "0.120441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EGBN",
        "relevance_score": "0.104228",
        "ticker_sentiment_score": "0.081647",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Teva Pharma Stock Trading Higher Today? - Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/02/37310868/why-is-generic-drugs-player-teva-pharma-stock-trading-higher-today",
    "time_published": "20240226T134824",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, Alvotech ALVO and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd TEVA, announced the FDA approved Simlandi ( adalimumab-ryvk ) injection, as an interchangeable biosimilar to AbbVie Inc's ABBV Humira.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Viersen--Germany---May-9--2020-Close-Up-_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.15171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.409503",
        "ticker_sentiment_score": "0.236081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.142298",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.409503",
        "ticker_sentiment_score": "0.186132",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cosmetic Surgery and Procedure Devices Market size is set to grow by USD 6.73 billion from 2022 to 2027, Rest of the ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/cosmetic-surgery-and-procedure-devices-market-size-is-set-to-grow-by-usd-6-73-billion-from-2022-to-2027--rest-of-the-world-to-occupy-26-market-share-technavio-302069774.html",
    "time_published": "20240226T082400",
    "authors": [],
    "summary": "Cosmetic Surgery and Procedure Devices Market size is set to grow by USD 6.73 billion from 2022 to 2027, Rest of the ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.280553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.046452",
        "ticker_sentiment_score": "0.213753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.046452",
        "ticker_sentiment_score": "0.213753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Vasomotor Menopausal Symptoms  ( VMS )  Treatment Market Analysis 2024-2028: Projected Market Size And Major Growth Factors As Per The Business Research Company's Vasomotor Menopausal Symptoms  ( VMS )  Treatment Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37340762/vasomotor-menopausal-symptoms-vms-treatment-market-analysis-2024-2028-projected-market-size-and-ma",
    "time_published": "20240227T163000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Vasomotor Menopausal Symptoms ( VMS ) Treatment Global Market Report 2024, the vasomotor menopausal symptoms ( VMS ) treatment market has witnessed substantial growth, driven by a myriad of factors including ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.183756,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.057545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRSQ",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.057545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2024 SaaS Management Index Reveals an Average of $18M in Annual License Waste, with Significant Security Risks ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/2024-saas-management-index-reveals-an-average-of-18m-in-annual-license-waste-with-significant-security-risks-from-employee-expensed-apps-302071679.html",
    "time_published": "20240227T130400",
    "authors": [],
    "summary": "2024 SaaS Management Index Reveals an Average of $18M in Annual License Waste, with Significant Security Risks ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.153434,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DASH",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.174003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEAM",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.174003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.174003",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/02/27/3-magnificent-dividend-growth-stocks-to-buy-now-ho/",
    "time_published": "20240227T104500",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These stocks don't offer the highest yields, but their payouts are growing fast.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F766804%2Fsmart-investor-looking-for-stocks-to-buy-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.360043,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.402348",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.222327",
        "ticker_sentiment_score": "0.237543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "-0.038443",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab  ( EPKINLY\u00ae )  for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/02/27/2835606/0/en/U-S-FDA-Accepts-for-Priority-Review-the-Supplemental-Biologics-License-Application-for-Epcoritamab-EPKINLY-for-Difficult-to-Treat-Relapsed-or-Refractory-Follicular-Lymphoma.html",
    "time_published": "20240227T004500",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media Release ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.062244,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.192864",
        "ticker_sentiment_score": "0.070774",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference",
    "url": "https://www.globenewswire.com/news-release/2024/02/28/2837454/0/en/Royalty-Pharma-to-Present-at-TD-Cowen-s-44th-Annual-Health-Care-Conference.html",
    "time_published": "20240228T211500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.287942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.102301",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/02/37368020/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
    "time_published": "20240228T160031",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.17%. Currently, AbbVie has a market capitalization of $313.90 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.160819,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.983605",
        "ticker_sentiment_score": "0.387251",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should First Trust Value Line Dividend ETF  ( FVD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2232902/should-first-trust-value-line-dividend-etf-fvd-be-on-your-investing-radar",
    "time_published": "20240228T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.247699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VALU",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.249245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ERIE",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.06173",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nearing Retirement? These Stocks Are as Cautious as They Come",
    "url": "https://www.fool.com/investing/2024/02/28/nearing-retirement-these-stocks-are-as-cautious-as/",
    "time_published": "20240228T104400",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.",
    "banner_image": "https://media.ycharts.com/charts/36fce26a2d1d75f1c1bc8adfac20211b.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.307533,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.038002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.159604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.361236",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.098111",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "C3.ai's  ( AI )  Stock Is Soaring After Earnings But is it Time to Buy?",
    "url": "https://www.zacks.com/stock/news/2234182/c3ais-ai-stock-is-soaring-after-earnings-but-is-it-time-to-buy",
    "time_published": "20240229T222200",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/53200.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.328,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BL",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.113563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.222232",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.222232",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Dividend Growth Stock: AbbVie or Amgen?",
    "url": "https://www.fool.com/investing/2024/02/29/better-dividend-growth-stock-abbvie-or-amgen/",
    "time_published": "20240229T144500",
    "authors": [
      "George Budwell"
    ],
    "summary": "A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F767246%2Fdividend-concept.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      }
    ],
    "overall_sentiment_score": 0.382731,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.457794",
        "ticker_sentiment_score": "0.560592",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.364529",
        "ticker_sentiment_score": "0.401299",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.167789",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK",
    "url": "https://www.zacks.com/stock/news/2233717/pharma-stock-roundup-fda-priority-tag-to-sny-abbv-filings-chmp-nod-for-azn-jnj-mrk",
    "time_published": "20240229T135000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.162872,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.188761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.062348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.166116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "-0.124137",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "-0.119146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.095068",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/02/29/is-abbvie-stock-a-buy-now/",
    "time_published": "20240229T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Some would say the growth story is over, but that view might be a bit myopic.",
    "banner_image": "https://media.ycharts.com/charts/c8545d39ac9bed18f1107ca089cc2cdd.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.241716,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.668128",
        "ticker_sentiment_score": "0.340936",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.155288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is iShares Core High Dividend ETF  ( HDV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2233587/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now",
    "time_published": "20240229T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default318.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999974"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.305184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.057628",
        "ticker_sentiment_score": "0.092963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.182014",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/02/29/2837584/0/en/argenx-Reports-Full-Year-2023-Financial-Results-and-Provides-Fourth-Quarter-Business-Update.html",
    "time_published": "20240229T060000",
    "authors": [
      "argenx SE"
    ],
    "summary": "$374 million in fourth quarter and $1.2 billion in full year global net product sales ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/be37b058-e737-46dc-b05a-c2240f4da489",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.202187,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZLAB",
        "relevance_score": "0.030311",
        "ticker_sentiment_score": "0.083086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060579",
        "ticker_sentiment_score": "0.12501",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.015158",
        "ticker_sentiment_score": "0.054592",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - argenx  ( NASDAQ:ARGX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/02/g37384243/argenx-reports-full-year-2023-financial-results-and-provides-fourth-quarter-business-update",
    "time_published": "20240229T060000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART\u00ae Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2024 On track to report data from six Phase 2 proof-of-concept trials by end of 2024",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.190732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZLAB",
        "relevance_score": "0.029673",
        "ticker_sentiment_score": "0.072516",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059304",
        "ticker_sentiment_score": "0.078995",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.014839",
        "ticker_sentiment_score": "0.054479",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "C3.ai  ( AI )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/02/29/c3ai-ai-q3-2024-earnings-call-transcript/",
    "time_published": "20240229T054519",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "AI earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.232074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.020274",
        "ticker_sentiment_score": "0.096661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.010138",
        "ticker_sentiment_score": "0.095006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BE",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.121241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.010138",
        "ticker_sentiment_score": "-0.011086",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRS",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.121241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.121241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.015207",
        "ticker_sentiment_score": "-0.001781",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.0758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FORR",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.049897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.121241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.101747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.010138",
        "ticker_sentiment_score": "0.048771",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTEFF",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.160116",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.010138",
        "ticker_sentiment_score": "-0.021753",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.010138",
        "ticker_sentiment_score": "0.0954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCMLF",
        "relevance_score": "0.020274",
        "ticker_sentiment_score": "0.134659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSL",
        "relevance_score": "0.005069",
        "ticker_sentiment_score": "0.121241",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats Stock Market Upswing: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2234900/abbvie-abbv-beats-stock-market-upswing-what-investors-need-to-know",
    "time_published": "20240301T224512",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $178.91, indicating a +1.62% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.179555,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.610329",
        "ticker_sentiment_score": "0.219822",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit",
    "url": "https://www.globenewswire.com/news-release/2024/03/01/2839059/0/en/NurExone-Presenting-Novel-Regulatory-Pathways-for-Exosomes-Therapies-at-Global-Summit.html",
    "time_published": "20240301T210400",
    "authors": [
      "NurExone Biologic Inc"
    ],
    "summary": "TORONTO and HAIFA, Israel, March 01, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc. ( TSXV: NRX ) ( Germany: J90 ) ( the \"Company\" or \"NurExone\" ) , a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina Sarel, the Head of CMC, Quality and Regulatory Affairs at NurExone, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/18124d4e-7adb-4ecf-906f-32ebd0f6f7f0",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.222805,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NRXBF",
        "relevance_score": "0.105372",
        "ticker_sentiment_score": "0.075124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.168956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37430770/nurexone-presenting-novel-regulatory-pathways-for-exosomes-therapies-at-global-summit",
    "time_published": "20240301T210400",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TORONTO and HAIFA, Israel, March 01, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.206386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.139999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRXBF",
        "relevance_score": "0.097655",
        "ticker_sentiment_score": "0.06889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.048919",
        "ticker_sentiment_score": "0.168604",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki\u2122, the first biosimilar of Stelara\u00ae  ( ustekinumab )  in Canada",
    "url": "https://www.newswire.ca/news-releases/jamp-pharma-group-announces-the-commercial-launch-and-product-availability-for-prjamteki-tm-the-first-biosimilar-of-stelara-r-ustekinumab-in-canada-892829386.html",
    "time_published": "20240301T192600",
    "authors": [
      "JAMP Pharma"
    ],
    "summary": "JAMP Pharma Group announces the commercial launch and product availability for PrJamteki\u2122, the first biosimilar of ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2352688/JAMP_Pharma_JAMP_Pharma_Group_announces_the_commercial_launch_an.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.322297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.06154",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Allergan Lawsuit  ( March Update ) ",
    "url": "https://www.forbes.com/advisor/legal/product-liability/allergan-lawsuit/",
    "time_published": "20240301T154803",
    "authors": [
      "Jessica Burgoyne"
    ],
    "summary": "Cosmetic surgery can help people feel more confident and comfortable with themselves. Unfortunately, some types of cosmetic surgery have historically increased the risk of life-threatening illnesses.",
    "banner_image": "https://www.forbes.com/advisor/wp-content/uploads/2024/02/image1-86.png",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.002416,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.046184",
        "ticker_sentiment_score": "0.102805",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2234476/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240301T140015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.239824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.122771",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List",
    "url": "https://www.forbes.com/sites/johndobosz/2024/03/02/berkshire-hathaway-has-168-billion-in-cash-these-stocks-should-be-on-buffetts-buy-list/",
    "time_published": "20240302T113000",
    "authors": [
      "John Dobosz"
    ],
    "summary": "Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65e22f56538bd9faeb687c8b/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.31919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AON",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.120496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CINF",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.209412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.175679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.095983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.087397",
        "ticker_sentiment_score": "0.078257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OXY",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.024634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.05833",
        "ticker_sentiment_score": "0.095983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.1708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SIGI",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.209412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WGO",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.117621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IAUGF",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.120496",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.044952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRSN",
        "relevance_score": "0.029184",
        "ticker_sentiment_score": "0.145623",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2235233/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240304T141003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default36.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.12016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRX",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.198287",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.125168",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE\u00ae TRIAL",
    "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html",
    "time_published": "20240305T120500",
    "authors": [
      "REGENXBIO Inc."
    ],
    "summary": "ROCKVILLE, Md., March 5, 2024 /PRNewswire/ -- REGENXBIO Inc. ( Nasdaq: RGNX ) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE\u00ae trial of RGX-202 in patients with Duchenne muscular dystrophy ( Duchenne ) ages 4 to11 years old, including RGX-202 ...",
    "banner_image": "https://mma.prnewswire.com/media/684531/RGNX_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.215955,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.389788",
        "ticker_sentiment_score": "0.227761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.040656",
        "ticker_sentiment_score": "0.059365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.020335",
        "ticker_sentiment_score": "0.122749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303",
    "url": "https://www.newswire.ca/news-releases/dragonfly-has-received-milestone-payment-following-dosing-of-first-patient-in-abbvie-phase-1-clinical-trial-evaluating-df4101-abbv-303-868856589.html",
    "time_published": "20240305T120000",
    "authors": [
      "Inc.",
      "Dragonfly Therapeutics"
    ],
    "summary": "Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281469,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.967875",
        "ticker_sentiment_score": "0.531833",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.212045",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2235767/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20240305T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.226809,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.208501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Slides as Market Rises: Facts to Know Before You Trade",
    "url": "https://www.zacks.com/stock/news/2237613/abbvie-abbv-stock-slides-as-market-rises-facts-to-know-before-you-trade",
    "time_published": "20240307T224520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed the most recent trading day at $180.57, moving -0.27% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default158.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.240895,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.323744",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Anima Biotech to Present at RNA Leaders Europe Congress",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37537122/anima-biotech-to-present-at-rna-leaders-europe-congress",
    "time_published": "20240307T151700",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BERNARDSVILLE, N.J., March 07, 2024 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, today announced their participation in the upcoming RNA Leaders Europe Congress taking place on March 13th - 14th, 2024 in Basel, Switzerland.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.081584,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.030303",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  is a Top Dividend Stock for Your Portfolio",
    "url": "https://www.zacks.com/stock/news/2238174/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio",
    "time_published": "20240308T164506",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.399064,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.45634",
        "ticker_sentiment_score": "0.492871",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This is Just the Beginning of Mind Medicine",
    "url": "https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/",
    "time_published": "20240308T155933",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, \"Why The Psychedelic Boom Is All but Inevitable\" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png",
    "source": "Money Morning",
    "category_within_source": "RSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.193082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.031875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.097077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.379691",
        "ticker_sentiment_score": "0.301289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer - BeiGene  ( NASDAQ:BGNE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37560438/fda-conditionally-approves-expanded-use-of-beigenes-combination-drug-for-certain-type-of-blood-ca",
    "time_published": "20240308T150238",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, the FDA granted accelerated approval to BeiGene Ltd's BGNE Brukinsa ( zanubrutinib ) for adult patients with relapsed or refractory ( R/R ) follicular lymphoma ( FL ) , in combination with Roche Holdings AG's RHHBY Gazyva ( obinutuzumab ) , after two or more lines of systemic therapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/BGNE.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.22397,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.317527",
        "ticker_sentiment_score": "0.237306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This is Just the Beginning of Mind Medicine",
    "url": "https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/",
    "time_published": "20240308T080000",
    "authors": [
      "Chris Johnson"
    ],
    "summary": "My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, \"Why The Psychedelic Boom Is All but Inevitable\" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.",
    "banner_image": "https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png",
    "source": "Money Morning",
    "category_within_source": "GoogleRSS",
    "source_domain": "moneymorning.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      }
    ],
    "overall_sentiment_score": 0.193082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.031875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.097077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.379691",
        "ticker_sentiment_score": "0.301289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.058676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MacroGenics  ( MGNX )  Q4 2023 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/03/08/macrogenics-mgnx-q4-2023-earnings-call-transcript/",
    "time_published": "20240308T053017",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "MGNX earnings call for the period ending December 31, 2023.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.15715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.006114",
        "ticker_sentiment_score": "0.08405",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HMELF",
        "relevance_score": "0.006114",
        "ticker_sentiment_score": "0.139243",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MGNX",
        "relevance_score": "0.048882",
        "ticker_sentiment_score": "0.062563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.012228",
        "ticker_sentiment_score": "0.065148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.024452",
        "ticker_sentiment_score": "0.082511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.006114",
        "ticker_sentiment_score": "0.092376",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.012228",
        "ticker_sentiment_score": "0.073709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.012228",
        "ticker_sentiment_score": "0.081069",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024",
    "url": "https://markets.businessinsider.com/news/stocks/3-unstoppable-mega-cap-stocks-that-every-investor-should-own-in-2024-1033148095",
    "time_published": "20240309T204911",
    "authors": [
      "Muslim Farooque"
    ],
    "summary": "Last year emerged as a time of unexpected resilience and expansion for the stock market driven by the strength of unstoppable mega-cap stocks. Notably, the S&P 500 wrapped up last year with a solid 24% gain, turning heads in the process.",
    "banner_image": "https://investorplace.com/wp-content/uploads/2022/04/nvda_nvidia1600-300x169.png",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.349018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PRFUF",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.223006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.172507",
        "ticker_sentiment_score": "0.323879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.106977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.172507",
        "ticker_sentiment_score": "0.232513",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology  ( AAD )  Annual Meeting",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37574324/samsung-bioepis-presents-two-abstracts-for-its-immunology-portfolio-at-the-2024-american-academy-o",
    "time_published": "20240309T150500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.064972,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.162802",
        "ticker_sentiment_score": "0.119639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OGN",
        "relevance_score": "0.023418",
        "ticker_sentiment_score": "0.066965",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Have $2,500? 2 Superior Growth Stocks to Buy in 2024",
    "url": "https://www.fool.com/investing/2024/03/09/have-2500-2-superior-growth-stocks-to-buy-in-2024/",
    "time_published": "20240309T075900",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses can pack a punch in your portfolio over the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/768357/cant-believe-it-shocked-looking-at-phone.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.12482,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RXDX",
        "relevance_score": "0.044718",
        "ticker_sentiment_score": "0.075287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.171946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Iron Deficiency Injectable Market Size Is Expected To Reach A Value Of $20.6 Billion By 2028 As Per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37591677/iron-deficiency-injectable-market-size-is-expected-to-reach-a-value-of-20-6-billion-by-2028-as-per",
    "time_published": "20240311T153000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "LONDON, March 11, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Iron Deficiency Injectable Global Market Report 2024, the iron deficiency injectable market is experiencing rapid growth, poised to expand from $12.75 billion in 2023 to $14.06 billion in 2024, representing a ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.194279,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101346",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.101346",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MoonLake Jumps As It Looks To Take On AbbVie Blockbuster, Humira",
    "url": "https://www.investors.com/news/technology/biotech-stock-moonlake-psoriatic-arthritis-treatment-abbvie-humira/",
    "time_published": "20240311T144110",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Biotech Stock MoonLake Rises After Arthritis Drug Tops AbbVie's Humira Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/Stock-DrugsResearch-09-shutter.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      }
    ],
    "overall_sentiment_score": 0.101441,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.055236",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.086457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MLTX",
        "relevance_score": "0.110209",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is MoonLake Immunotherapeutics Stock Trading Higher Today? - MoonLake  ( NASDAQ:MLTX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37587143/why-is-inflammatory-disease-focused-moonlake-immunotherapeutics-stock-trading-higher-today",
    "time_published": "20240311T135606",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Sunday, MoonLake Immunotherapeutics MLTX announced that continued treatment with Nanobody sonelokimab led to significant improvements across all key outcomes at 24-week data from the ARGO trial in psoriatic arthritis ( PsA ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/MLTX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172243,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.19257",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MLTX",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.348228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Pharmaceutical Stocks to Buy Hand Over Fist in March",
    "url": "https://www.fool.com/investing/2024/03/11/3-pharmaceutical-stocks-to-buy-hand-over-fist-in/",
    "time_published": "20240311T132800",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There are some great companies at attractive prices in the lucrative pharmaceutical space.",
    "banner_image": "https://g.foolcdn.com/editorial/images/767295/drug-development-pharmaceutical-pharma-research-researchers-doctors-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.234754,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.063941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.035129",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNA",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.151968",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.196",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2238528/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240311T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default132.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284931,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BRX",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.193868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.122324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.036003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2239120/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
    "time_published": "20240312T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default163.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.201828,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.120139",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J  ( JNJ )  Seeks Expanded Use of Tremfya for Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2239023/jj-jnj-seeks-expanded-use-of-tremfya-for-ulcerative-colitis",
    "time_published": "20240312T093900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.233709,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.140668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.013242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.080728",
        "ticker_sentiment_score": "0.140668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.12655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.142881",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  Dipped More Than Broader Market Today",
    "url": "https://www.zacks.com/stock/news/2240277/why-abbvie-abbv-dipped-more-than-broader-market-today",
    "time_published": "20240313T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.184433,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.549988",
        "ticker_sentiment_score": "0.196218",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hormonal Contraceptive Market is Set to Achieve Staggering USD 33.8 billion Valuation by 2031 with 5.0% CAGR | Analysis by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37649720/hormonal-contraceptive-market-is-set-to-achieve-staggering-usd-33-8-billion-valuation-by-2031-with",
    "time_published": "20240313T103400",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The forecasted market valuation of the global hormonal contraceptive market by 2031 is about US$ 33.8 billion. This market advancement is moderate at a CAGR of 5.0%.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.142798,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.054473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MITPF",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.074082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.084871",
        "ticker_sentiment_score": "0.015702",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.127007",
        "ticker_sentiment_score": "0.071114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "0.179055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MAYNF",
        "relevance_score": "0.042496",
        "ticker_sentiment_score": "-0.074082",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Top Fund Likes Microsoft, Visa, AT&T, and Other Dividend Growth Plays",
    "url": "https://www.barrons.com/amp/articles/top-fund-microsoft-visa-at-t-dividend-growth-61898126",
    "time_published": "20240313T053000",
    "authors": [
      "Lewis Braham"
    ],
    "summary": "Stocks that pay dividends can soften the impact when the market is falling. Yet they often prove a drag on the way up, compared with faster-growing companies. Achieving a balance between defense and offense can be tricky for investors.",
    "banner_image": "https://images.barrons.com/im-63489054/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.150346,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.163631",
        "ticker_sentiment_score": "0.083698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.082251",
        "ticker_sentiment_score": "-0.006277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "-0.050511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.041181",
        "ticker_sentiment_score": "0.154963",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "I-Mab Reports Full Year 2023 Financial Results and Business Update",
    "url": "https://www.prnewswire.com/news-releases/i-mab-reports-full-year-2023-financial-results-and-business-update-302089532.html",
    "time_published": "20240314T210000",
    "authors": [
      "I-Mab"
    ],
    "summary": "ROCKVILLE, Md., March 14, 2024 /PRNewswire/ -- I-Mab ( the \"Company\" ) ( NASDAQ: IMAB ) , a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial ...",
    "banner_image": "https://mma.prnewswire.com/media/821373/I_MAB_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.113554,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TCON",
        "relevance_score": "0.016107",
        "ticker_sentiment_score": "0.01434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.064362",
        "ticker_sentiment_score": "0.026045",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMAB",
        "relevance_score": "0.313617",
        "ticker_sentiment_score": "0.119041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.016107",
        "ticker_sentiment_score": "-0.012774",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/03/37711522/decoding-abbvies-options-activity-whats-the-big-picture",
    "time_published": "20240314T171608",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 69% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.199092,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.737923",
        "ticker_sentiment_score": "0.182849",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Monoclonal Antibody  ( mABs )  Therapeutics Market Worth $497.5 billion | MarketsandMarkets\u2122",
    "url": "https://www.prnewswire.com/news-releases/monoclonal-antibody-mabs-therapeutics-market-worth-497-5-billion--marketsandmarkets-302090362.html",
    "time_published": "20240315T143000",
    "authors": [
      "MarketsandMarkets"
    ],
    "summary": "CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...",
    "banner_image": "https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227469,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.073024",
        "ticker_sentiment_score": "0.08487",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.064394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024372",
        "ticker_sentiment_score": "0.081181",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.078722",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lutikizumab Clinical Trials Approved Bispecific Antibodies Market Insight",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37768775/lutikizumab-clinical-trials-approved-bispecific-antibodies-market-insight",
    "time_published": "20240317T170809",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.14381,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.120262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.185781",
        "ticker_sentiment_score": "0.043688",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "These 7 Index ETFs Are a Retiree's Best Friend",
    "url": "https://www.fool.com/investing/2024/03/17/these-7-index-etfs-are-a-retirees-best-friend/",
    "time_published": "20240317T140500",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "One of these ETFs has averaged annual gains of nearly 15% over the past decade.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768288%2Fgetty-looking-out-the-window-thinking-pondering-considering.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.211319,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.054454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "-0.021002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "-0.021002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.140993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMT",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.174211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.174211",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.140993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "-0.021002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks to Buy Hand Over Fist",
    "url": "https://www.fool.com/investing/2024/03/17/2-top-dividend-stocks-to-buy-hand-over-fist/",
    "time_published": "20240317T121500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Every company faces headwinds eventually. The top ones know how to bounce back.",
    "banner_image": "https://g.foolcdn.com/editorial/images/769084/physician-giving-medicine-to-elderly-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.241712,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.309539",
        "ticker_sentiment_score": "0.11082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.390931",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37789940/heres-how-much-100-invested-in-abbvie-10-years-ago-would-be-worth-today",
    "time_published": "20240318T153023",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 13.21%. Currently, AbbVie has a market capitalization of $316.78 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2242023/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240318T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default236.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.201121,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.122965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "-0.036005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.215894",
        "ticker_sentiment_score": "0.118044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.122328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Exceeds Market Returns: Some Facts to Consider",
    "url": "https://www.zacks.com/stock/news/2243069/abbvie-abbv-exceeds-market-returns-some-facts-to-consider",
    "time_published": "20240319T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $179.66, indicating a +0.66% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default219.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.207587,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.615462",
        "ticker_sentiment_score": "0.360315",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37829815/us-retinal-specialists-highlight-the-greatest-opportunity-for-gene-therapies",
    "time_published": "20240319T182000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, March 19, 2024 ( GLOBE NEWSWIRE ) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and safety.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.278804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADVM",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Analyst Reports for Mastercard, AbbVie & Salesforce",
    "url": "https://www.zacks.com/research-daily/2242883/top-analyst-reports-for-mastercard-abbvie-salesforce",
    "time_published": "20240319T164500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce, Inc. (CRM).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.295903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MA",
        "relevance_score": "0.223866",
        "ticker_sentiment_score": "0.612461",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.28364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.391872",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Autonomix Appoints Jennifer Cook as Chief Business Officer",
    "url": "https://www.globenewswire.com/news-release/2024/03/19/2848582/0/en/Autonomix-Appoints-Jennifer-Cook-as-Chief-Business-Officer.html",
    "time_published": "20240319T124500",
    "authors": [
      "Autonomix Medical",
      "Inc."
    ],
    "summary": "Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a130fc0d-2b10-4e88-960c-5dc427fd676e/image2.jpeg",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.29273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMIX",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.03538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.045931",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EQS-News: Newron presents 2023 financial results and provides 2024 outlook",
    "url": "https://markets.businessinsider.com/news/stocks/eqs-news-newron-presents-2023-financial-results-and-provides-2024-outlook-1033174657",
    "time_published": "20240319T060018",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "Newron presents 2023 financial results and provides 2024 outlook",
    "banner_image": "https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&amp;application_id=1861179&amp;application_name=news&amp;site_id=smarthouse",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.185013,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FCN",
        "relevance_score": "0.012193",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.012193",
        "ticker_sentiment_score": "0.038166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SVYSF",
        "relevance_score": "0.012193",
        "ticker_sentiment_score": "0.038166",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SUPN",
        "relevance_score": "0.012193",
        "ticker_sentiment_score": "0.037578",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849779/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.131766,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.085539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.166948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.053881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011791",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.166852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023579",
        "ticker_sentiment_score": "0.137997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035363",
        "ticker_sentiment_score": "0.215495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/20/2849778/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
    "time_published": "20240320T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.129421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.085519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.341699",
        "ticker_sentiment_score": "0.166635",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.053868",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.164818",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.023521",
        "ticker_sentiment_score": "0.135974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.035276",
        "ticker_sentiment_score": "0.214421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is First Trust Value Line Dividend ETF  ( FVD )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2243195/is-first-trust-value-line-dividend-etf-fvd-a-strong-etf-right-now",
    "time_published": "20240320T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.270418,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VALU",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "0.308775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ERIE",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.059703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.059703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez",
    "url": "https://www.zacks.com/stock/news/2243176/the-zacks-analyst-blog-highlights-mastercard-abbvie-salesforce-thermo-fisher-scientific-and-mondelez",
    "time_published": "20240320T094800",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/497.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.239803,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.257933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.041565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.447528",
        "ticker_sentiment_score": "0.29401",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.307924",
        "ticker_sentiment_score": "0.290302",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.15697",
        "ticker_sentiment_score": "0.041565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Recent Insider Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37873091/abbvie-recent-insider-activity",
    "time_published": "20240321T150155",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Making a noteworthy insider sell on March 20, Jeffrey R. Stewart, EVP at AbbVie ABBV, is reported in the latest SEC filing. What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Stewart executed a sale of 58,949 shares of AbbVie with a total ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.17337,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.308504",
        "ticker_sentiment_score": "0.175802",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's New 'Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval",
    "url": "https://www.forbes.com/sites/jamesfarrell/2024/03/22/abbvies-new-biological-missile-ovarian-cancer-treatment-gets-full-fda-approval/",
    "time_published": "20240322T211746",
    "authors": [
      "James Farrell"
    ],
    "summary": "The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered \"biological missiles\" because of their ability to precisely home in on cancer cells.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fdf51e23b387b61d5f3d14/0x0.jpg?format=jpg&crop=2742,1542,x0,y141,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.229492,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.356865",
        "ticker_sentiment_score": "-0.140201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
    "time_published": "20240322T161800",
    "authors": [],
    "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244345,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.020684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "0.099883",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "M&A is back. Expect losers to outnumber winners",
    "url": "https://www.moneycontrol.com/news/opinion/ma-is-back-expect-losers-to-outnumber-winners-12509121.html",
    "time_published": "20240322T093827",
    "authors": [],
    "summary": "Many publicly traded companies are now sitting on sizeable cash reserves and borrowing costs appear to be stable. Buyout funds, too, are awash with cash and itching to deploy it. The worry must be that financial firepower, frustration and a fear of missing out make for ill-disciplined ...",
    "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/08/Collage-Maker-07-Aug-2023-07-21-AM-1331.jpg?impolicy=website&width=168&height=118",
    "source": "Money Control",
    "category_within_source": "Business",
    "source_domain": "www.moneycontrol.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.110787,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MPC",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.118337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FI",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.02882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.02882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.043853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VOD",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.02882",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.028927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.198716",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.002958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LIN",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.026519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.028927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.198716",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.118337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "-0.002958",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Advances While Market Declines: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2245659/abbvie-abbv-advances-while-market-declines-some-information-for-investors",
    "time_published": "20240325T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default242.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.15886,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.5341",
        "ticker_sentiment_score": "0.217634",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nasdaq Turns Higher; Akanda Shares Plunge - Akanda  ( NASDAQ:AKAN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/03/37921085/nasdaq-turns-higher-akanda-shares-plunge",
    "time_published": "20240325T190039",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also fell, dropping, 0.12% to 5,227.95. In trading on Monday, industrials shares fell by 0.5%.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/25/image32.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.024025,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.381452",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FSR",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.058293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.30395",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AKAN",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.156484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SINT",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.13465",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.248682",
        "ticker_sentiment_score": "0.381452",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CYTO",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.26103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Crude Oil Moves Higher; US New Home Sales Fall In February - Akanda  ( NASDAQ:AKAN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/03/37917378/crude-oil-moves-higher-us-new-home-sales-fall-in-february",
    "time_published": "20240325T155441",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S&P 500 also fell, dropping, 0.16% to 5,226.01. In trading on Monday, communication services ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/25/crude_oil_4-_logo.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.004821,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.246167",
        "ticker_sentiment_score": "0.378661",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FSR",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "-0.057888",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NKTX",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.301981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AKAN",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.155413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SINT",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.133725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.246167",
        "ticker_sentiment_score": "0.378661",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CYTO",
        "relevance_score": "0.165598",
        "ticker_sentiment_score": "0.259304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  is a Great Dividend Stock Right Now",
    "url": "https://www.zacks.com/stock/news/2245594/why-abbvie-abbv-is-a-great-dividend-stock-right-now",
    "time_published": "20240325T154511",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.413133,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.489607",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? - Landos Biopharma  ( NASDAQ:LABP ) ",
    "url": "https://www.benzinga.com/general/biotech/24/03/37916785/why-is-ulcerative-colitis-focused-landos-biopharma-stock-trading-higher-on-monday",
    "time_published": "20240325T152758",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Monday, AbbVie Inc ABBV agreed to acquire Landos Biopharma Inc LABP for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/abbvie-shutter_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.30975,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.316168",
        "ticker_sentiment_score": "0.558933",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.213988",
        "ticker_sentiment_score": "0.349893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.502693",
        "ticker_sentiment_score": "0.494372",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc.  ( NYSE - AGTI ) , Landos Biopharma, Inc.  ( Nasdaq - LABP ) , Fusion Pharmaceuticals Inc.  ( Nasdaq - FUSN ) , Kinnate Biopharma Inc.  ( Nasdaq - KNTE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37916275/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-agiliti-inc-n",
    "time_published": "20240325T150959",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., March 25, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.256386,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.281993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AGTI",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.196355",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.174167",
        "ticker_sentiment_score": "0.210131",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.174167",
        "ticker_sentiment_score": "0.055047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNTE",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.230782",
        "ticker_sentiment_score": "0.299501",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Stocks Down; Chicago Fed National Activity Index Rises In February - Akanda  ( NASDAQ:AKAN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/03/37913994/us-stocks-down-chicago-fed-national-activity-index-rises-in-february",
    "time_published": "20240325T134215",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell 0.42% to 16,359.31. The S&P 500 also fell, dropping, 0.23% to 5,222.33.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/25/image48.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": -0.053352,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.401252",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AKAN",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.1644",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SINT",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.141497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.401252",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CYTO",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.27374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Professional Diversity Network  ( PDN )  Hosts Successful Virtual Career Fair for Women's History Month - Professional Diversity  ( NASDAQ:IPDN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37913201/professional-diversity-network-pdn-hosts-successful-virtual-career-fair-for-womens-history-month",
    "time_published": "20240325T131025",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.390048,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOLF",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IPDN",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.248139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YAMHF",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YAMCF",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.133657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2245413/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240325T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default237.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.197748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.122324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.036003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.214462",
        "ticker_sentiment_score": "0.117428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.108222",
        "ticker_sentiment_score": "0.122045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Professional Diversity Network  ( PDN )  Hosts Successful Virtual Career Fair for Women's History Month",
    "url": "https://www.globenewswire.com/news-release/2024/03/25/2851694/25762/en/Professional-Diversity-Network-PDN-Hosts-Successful-Virtual-Career-Fair-for-Women-s-History-Month.html",
    "time_published": "20240325T131000",
    "authors": [
      "Professional Diversity Network",
      "Inc."
    ],
    "summary": "CHICAGO, March 25, 2024 ( GLOBE NEWSWIRE ) -- Professional Diversity Network, Inc. ( NASDAQ: IPDN ) ( \"PDN\" or the \"Company\" ) , a developer and operator of online and in-person networks that provide access to networking, training, educational, and employment opportunities for diverse ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/59fb8289-a193-40b8-9bb7-3e1077fc84e4",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.225575,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOLF",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IPDN",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.147808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YAMHF",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YAMCF",
        "relevance_score": "0.043342",
        "ticker_sentiment_score": "0.098915",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2245364/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20240325T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default137.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.222393,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.096343",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases",
    "url": "https://www.prnewswire.com/news-releases/abbvie-to-acquire-landos-biopharma-further-strengthening-its-portfolio-in-inflammatory-and-autoimmune-diseases-302098124.html",
    "time_published": "20240325T123100",
    "authors": [
      "AbbVie"
    ],
    "summary": "NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. ( NYSE: ABBV ) ( \"AbbVie\" ) and Landos Biopharma, Inc. ( NASDAQ: LABP ) ( \"Landos\" ) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on ...",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.191421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.211938",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.024175",
        "ticker_sentiment_score": "0.138389",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.024175",
        "ticker_sentiment_score": "0.138389",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.306374",
        "ticker_sentiment_score": "0.161077",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases",
    "url": "https://www.globenewswire.com/news-release/2024/03/25/2851619/0/en/AbbVie-to-Acquire-Landos-Biopharma-Further-Strengthening-its-Portfolio-in-Inflammatory-and-Autoimmune-Diseases.html",
    "time_published": "20240325T123000",
    "authors": [
      "Landos Biopharma",
      "Inc."
    ],
    "summary": "- Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ) - Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis ( UC ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/72aed74a-99f6-43c2-b26f-52c13e27bd5d",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.18242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.074926",
        "ticker_sentiment_score": "0.223814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.146199",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Landos Biopharma  ( NASDAQ:LABP ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37911920/abbvie-to-acquire-landos-biopharma-further-strengthening-its-portfolio-in-inflammatory-and-autoimm",
    "time_published": "20240325T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 ( GLOBE NEWSWIRE ) -- AbbVie Inc. ABBV ( \"AbbVie\" ) and Landos Biopharma, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.184653,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.211094",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.024396",
        "ticker_sentiment_score": "0.13853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.024396",
        "ticker_sentiment_score": "0.13853",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.263424",
        "ticker_sentiment_score": "0.135299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Council Post: What's Driving Big Pharma's Recent Market Performance?",
    "url": "https://www.forbes.com/sites/forbesfinancecouncil/2024/03/25/whats-driving-big-pharmas-recent-market-performance/",
    "time_published": "20240325T110000",
    "authors": [
      "Dmitry Reykhart"
    ],
    "summary": "What's Driving Big Pharma's Recent Market Performance? Forbes ...",
    "banner_image": "https://blogs-images.forbes.com/assets/images/avatars/blog-4409_400_7bca6d487f6cc72cdf2f893001e4a3c2.jpg",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.105649,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.030387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.106227",
        "ticker_sentiment_score": "0.092964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KRTX",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.0289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.019247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "-0.124669",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.034965",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.106227",
        "ticker_sentiment_score": "0.026215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.0289",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - Mirum Pharmaceuticals  ( NASDAQ:MIRM ) , Century Therapeutics  ( NASDAQ:IPSC ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37910018/sagimet-biosciences-announces-appointment-of-tim-walbert-and-paul-hoelscher-to-its-board-of-direct",
    "time_published": "20240325T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN MATEO, Calif., March 25, 2024 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( ( Sagimet, NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase ( FASN ) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.164881,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "XCUR",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AUPH",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MIRM",
        "relevance_score": "0.049887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IPSC",
        "relevance_score": "0.049887",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPHM",
        "relevance_score": "0.049887",
        "ticker_sentiment_score": "0.019878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASRT",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "-0.021634",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGMT",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "0.019439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more",
    "url": "https://www.prnewswire.com/news-releases/global-urological-disorders-drugs-market-competitive-analysis-with-profiles-of-leading-companies-abbvie-astrazeneca-merck--co-novartis-pfizer-and-more-302098015.html",
    "time_published": "20240326T180000",
    "authors": [
      "Research and Markets"
    ],
    "summary": "Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.209074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.028151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.028151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.072655",
        "ticker_sentiment_score": "0.028151",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Assessing AbbVie's Performance Against Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37939828/assessing-abbvies-performance-against-competitors-in-biotechnology-industry",
    "time_published": "20240326T160033",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating AbbVie ABBV in relation to its major competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.199098,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.477986",
        "ticker_sentiment_score": "0.327914",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  to Buy Landos to Strengthen Autoimmune Portfolio",
    "url": "https://www.zacks.com/stock/news/2246081/abbvie-abbv-to-buy-landos-to-strengthen-autoimmune-portfolio",
    "time_published": "20240326T140300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.269273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.209463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.134214",
        "ticker_sentiment_score": "0.139734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.500995",
        "ticker_sentiment_score": "0.307657",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.023093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV",
    "url": "https://www.forbes.com/sites/katiejennings/2024/03/27/innovationrx-base-editing-pioneer-nicole-gaudelli-joins-gv/",
    "time_published": "20240327T215849",
    "authors": [
      "Katie Jennings"
    ],
    "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/660494100df8c256fcaaaf8d/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.166242,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BEAM",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.109945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LABP",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.103057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.063744",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRMNF",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.187223",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.103057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NMTC",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.071685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.103057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "-0.124735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERV",
        "relevance_score": "0.040553",
        "ticker_sentiment_score": "0.171285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/03/37966810/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
    "time_published": "20240327T180015",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.45% on an annualized basis producing an average annual return of 13.15%. Currently, AbbVie has a market capitalization of $317.49 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update",
    "url": "https://www.globenewswire.com/news-release/2024/03/27/2853469/0/en/OSE-Immunotherapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-Business-Strategy-Update.html",
    "time_published": "20240327T170000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "Financial highlights ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.165634,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.093289",
        "ticker_sentiment_score": "0.089618",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kuehn Law Encourages LABP, WRK, KAMN and TGAN Investors to Contact Law Firm - Landos Biopharma  ( NASDAQ:LABP ) , Kaman  ( NYSE:KAMN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37961607/kuehn-law-encourages-labp-wrk-kamn-and-tgan-investors-to-contact-law-firm",
    "time_published": "20240327T150756",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, March 27, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.351248,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WRK",
        "relevance_score": "0.398148",
        "ticker_sentiment_score": "0.539356",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.381152",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SMFTF",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.239833",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KAMN",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.180028",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RNECF",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.210458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TGAN",
        "relevance_score": "0.304428",
        "ticker_sentiment_score": "0.406368",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "C3.ai  ( AI ) , Paradyme Extend Partnership to Deliver AI Solutions",
    "url": "https://www.zacks.com/stock/news/2247476/c3ai-ai-paradyme-extend-partnership-to-deliver-ai-solutions",
    "time_published": "20240328T151700",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "C3.ai (AI) expands partnership agreement with Paradyme that aims at accelerating the delivery of AI solutions tailored for the U.S. Intelligence Community.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/21892.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.343955,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.13637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.268161",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.268161",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BE",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRS",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPS",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.268161",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCMLF",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSL",
        "relevance_score": "0.060085",
        "ticker_sentiment_score": "0.126004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs",
    "url": "https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvos-new-mas-fda-nod-to-jnj-mrk-pah-drugs",
    "time_published": "20240328T135000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.224037,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.093927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.238523",
        "ticker_sentiment_score": "0.213891",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.120632",
        "ticker_sentiment_score": "0.069053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.387075",
        "ticker_sentiment_score": "0.120962",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.080593",
        "ticker_sentiment_score": "-0.06506",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2247084/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20240328T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default132.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.203851,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.357293",
        "ticker_sentiment_score": "0.17435",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/03/28/2853788/0/en/Zymeworks-Announces-Appointment-of-Dr-Neil-Gallagher-to-its-Board-of-Directors.html",
    "time_published": "20240328T100000",
    "authors": [
      "Zymeworks Inc."
    ],
    "summary": "VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/de376a45-7a16-49db-8ad4-65ff45472c90",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.160217,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNDX",
        "relevance_score": "0.106227",
        "ticker_sentiment_score": "-0.033254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "-0.030396",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.070935",
        "ticker_sentiment_score": "0.102801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "-0.029149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.035502",
        "ticker_sentiment_score": "0.098234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors - Syndax Pharmaceuticals  ( NASDAQ:SNDX ) , Zymeworks  ( NASDAQ:ZYME ) ",
    "url": "https://www.benzinga.com/pressreleases/24/03/g37976956/zymeworks-announces-appointment-of-dr-neil-gallagher-to-its-board-of-directors",
    "time_published": "20240328T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "VANCOUVER, British Columbia, March 28, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.164791,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNDX",
        "relevance_score": "0.101012",
        "ticker_sentiment_score": "-0.032686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.067441",
        "ticker_sentiment_score": "-0.030256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.067441",
        "ticker_sentiment_score": "0.10043",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "-0.028974",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.033751",
        "ticker_sentiment_score": "0.095646",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "JEPI ETF: Turn Your Tax Return Into Monthly Dividends",
    "url": "https://markets.businessinsider.com/news/stocks/jepi-etf-turn-your-tax-return-into-monthly-dividends-1033209198",
    "time_published": "20240330T211523",
    "authors": [
      "Tipranks"
    ],
    "summary": "It's tax time again. If you are receiving a tax return, it's the perfect opportunity to consider buying a monthly dividend ETF to jumpstart your investment portfolio.",
    "banner_image": "https://lh7-us.googleusercontent.com/H1rJHSj0sOZ0PFZsgYzdo931fsHRfAdAoYT5SRAPRdxyaZjBrQCfTZlTg2CN26N1WNb-yW4MMrI_2HkneCScaicKdl-j15iKrLyR3tzJhYDSB1oCfC7vQkk4950grqYt4pBWwGjP41YvwJiMGVqRFRE?utm_source=markets.businessinsider.com&utm_medium=referral",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.338601,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.256263",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade",
    "url": "https://www.fool.com/investing/2024/03/30/3-reliable-dividend-growth-stocks-with-yields-abov/",
    "time_published": "20240330T091900",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These advantaged businesses have what it takes to keep raising their payouts.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770568%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      }
    ],
    "overall_sentiment_score": 0.238472,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.045412",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.049573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.133067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Little Biotech That Could Have Big Breakthroughs",
    "url": "https://www.barrons.com/amp/articles/voyager-therapeutics-stock-biotech-alzheimers-837ca163",
    "time_published": "20240330T070000",
    "authors": [
      "Bill Alpert"
    ],
    "summary": "Why Voyager Therapeutics Could Have Big Alzheimer's Breakthroughs ...",
    "banner_image": "https://images.barrons.com/im-56131088/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.052986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IONS",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.018683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.007188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.125554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "-0.017923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.247252",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Sees a More Significant Dip Than Broader Market: Some Facts to Know",
    "url": "https://www.zacks.com/stock/news/2248695/abbvie-abbv-sees-a-more-significant-dip-than-broader-market-some-facts-to-know",
    "time_published": "20240401T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $180.76, representing a -0.74% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.167137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.462395",
        "ticker_sentiment_score": "0.149403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ADTH, LABP, FUSN - AdTheorent Holding  ( NASDAQ:ADTH ) , Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38028852/shareholder-update-halper-sadeh-llc-investigates-adth-labp-fusn",
    "time_published": "20240401T171750",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 01, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AdTheorent Holding Company, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.235288,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.218879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADTH",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.120998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.307379",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.163545",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bristol Myers'  ( BMY )  Zeposia Fails Crohn's Disease Study",
    "url": "https://www.zacks.com/stock/news/2248660/bristol-myers-bmy-zeposia-fails-crohns-disease-study",
    "time_published": "20240401T164600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128352,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.331024",
        "ticker_sentiment_score": "0.215828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.288374",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.011148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.224383",
        "ticker_sentiment_score": "0.092719",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc.  ( Nasdaq - ADTH ) , Agiliti, Inc.  ( NYSE - AGTI ) , Landos Biopharma, Inc.  ( Nasdaq - LABP ) , Fusion Pharmaceuticals Inc.  ( Nasdaq - FUSN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38026483/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-adtheorent-ho",
    "time_published": "20240401T155119",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BALA CYNWYD, Pa., April 01, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.268309,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.249744",
        "ticker_sentiment_score": "0.299234",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AGTI",
        "relevance_score": "0.249744",
        "ticker_sentiment_score": "0.208844",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.188683",
        "ticker_sentiment_score": "0.22227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.188683",
        "ticker_sentiment_score": "0.058347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADTH",
        "relevance_score": "0.188683",
        "ticker_sentiment_score": "0.165264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.249744",
        "ticker_sentiment_score": "0.317624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2248260/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240401T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default309.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.226978,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.12824",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.207127",
        "ticker_sentiment_score": "0.114283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.207127",
        "ticker_sentiment_score": "0.119051",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year",
    "url": "https://www.globenewswire.com/news-release/2024/04/01/2855115/0/en/NEXGEL-Reports-Full-Year-2023-Revenue-of-4-1-Million-an-Increase-of-99-7-Year-Over-Year.html",
    "time_published": "20240401T115000",
    "authors": [
      "INC.",
      "NEXGEL"
    ],
    "summary": "LANGHORNE, Pa., April 01, 2024 ( GLOBE NEWSWIRE ) -- NEXGEL, Inc. ( \"NEXGEL\" or the \"Company\" ) ( NASDAQ: \"NXGL\" ) , a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0e76fff8-7aee-4b60-ba26-62dda9975939",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999696"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.199553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.128995",
        "ticker_sentiment_score": "0.143716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXGL",
        "relevance_score": "0.25464",
        "ticker_sentiment_score": "0.261774",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2248126/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240401T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default354.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193607,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.259727",
        "ticker_sentiment_score": "0.149109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.070705",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Meet The \"Magnificent Seven\" of Healthcare Stocks",
    "url": "https://www.fool.com/investing/2024/04/01/meet-the-magnificent-seven-of-healthcare-stocks/",
    "time_published": "20240401T083000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The tech sector doesn't have a monopoly on magnificent corporations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770839/person-sitting-and-working-at-a-desk.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.24052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.180009",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.125679",
        "ticker_sentiment_score": "0.255601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCA",
        "relevance_score": "0.248259",
        "ticker_sentiment_score": "0.115038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.28535",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.306284",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167032",
        "ticker_sentiment_score": "0.286408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.134207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.207928",
        "ticker_sentiment_score": "0.100054",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery  ( ASCRS )  Annual Meeting - Sight Sciences  ( NASDAQ:SGHT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38056873/sight-sciences-announces-the-results-of-the-three-year-prospective-gemini-trial-and-the-cross-over",
    "time_published": "20240402T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Clinical results demonstrate long-term efficacy of the OMNI\u00ae Surgical System for primary open-angle glaucoma and support use of TearCare\u00ae technology as a primary treatment for dry eye disease. MENLO PARK, Calif., April 02, 2024 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.185258,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SGHT",
        "relevance_score": "0.378572",
        "ticker_sentiment_score": "0.329351",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032825",
        "ticker_sentiment_score": "0.124366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38049628/cytokine-market-size-is-projected-to-reach-usd-148-56-billion-by-2031-growing-at-a-cagr-of-8-40-st",
    "time_published": "20240402T144000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.00724,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UCBJF",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035875",
        "ticker_sentiment_score": "-0.067573",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.071677",
        "ticker_sentiment_score": "-0.046635",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation",
    "url": "https://www.fool.com/investing/2024/04/02/got-3000-2-monster-growth-stocks-to-buy-right-now/",
    "time_published": "20240402T073600",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These stocks can deliver powerhouse portfolio growth in the years ahead.",
    "banner_image": "https://g.foolcdn.com/editorial/images/770995/getty-happy-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.350726,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.179734",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.049905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.343875",
        "ticker_sentiment_score": "0.214166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ULTA",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.206601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.044386",
        "ticker_sentiment_score": "0.206601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology",
    "url": "https://www.globenewswire.com/news-release/2024/04/02/2855627/0/en/OSE-Immunotherapeutics-Announces-Peer-Reviewed-Publication-on-Novel-Myeloid-Immune-Checkpoint-CLEC-1-in-Journal-of-Immunology.html",
    "time_published": "20240402T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.152368,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "0.075995",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape - FibroGen  ( NASDAQ:FGEN ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38070160/fibrogen-unveils-early-data-from-prostate-cancer-candidate-analyst-advocates-furthe",
    "time_published": "20240403T140227",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "FibroGen Inc FGEN announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 ( also known as FOR46 ) , a potential first-in-class anti-CD46 antibody drug conjugate ( ADC ) with an MMAE-containing payload.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/FGEN.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.098533,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "FTS",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.112694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.396574",
        "ticker_sentiment_score": "0.207835",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "-0.069518",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma\u2122 2024 - PR Newswire",
    "url": "https://www.prnewswire.com/apac/news-releases/great-place-to-work-unveils-top-10-best-workplaces-in-singapore-healthcare-and-biopharma-2024-302105205.html",
    "time_published": "20240403T040000",
    "authors": [],
    "summary": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma\u2122 2024 PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.585696,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.195043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.347092",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.200563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.108958",
        "ticker_sentiment_score": "0.152036",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In ABBV Options - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38094505/smart-money-is-betting-big-in-abbv-options",
    "time_published": "20240404T153120",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.108385,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.792512",
        "ticker_sentiment_score": "0.039895",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.100308",
        "ticker_sentiment_score": "-0.123502",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE",
    "url": "https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2023-full-year-financial-results-and-provides-corporate-update-302108303.html",
    "time_published": "20240404T111700",
    "authors": [
      "CollPlant"
    ],
    "summary": "COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/2378959/CollPlant.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.203402,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSYS",
        "relevance_score": "0.038843",
        "ticker_sentiment_score": "0.167986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.146309",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Unusual Options Activity For April 05 - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38117562/abbvie-unusual-options-activity-for-april-05",
    "time_published": "20240405T201559",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 25 trades. If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 68% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.129533,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.731515",
        "ticker_sentiment_score": "0.111144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.142904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2251047/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240405T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.224259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.119522",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III",
    "url": "https://www.zacks.com/stock/news/2251078/pharma-stock-roundup-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase-iii",
    "time_published": "20240405T120700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.016883,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.005005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "-0.046062",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.005005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "0.001436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.170878",
        "ticker_sentiment_score": "-0.103872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "-0.119965",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ocular Therapeutix\u2122 Announces Positive Phase 2 PAXTRAVA\u2122 Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting - Ocular Therapeutix  ( NASDAQ:OCUL ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38131154/ocular-therapeutix-announces-positive-phase-2-paxtrava-glaucoma-data-at-the-american-society-of-ca",
    "time_published": "20240406T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure ( IOP ) , statistically significant ( p<0.0001 ) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant Generally well tolerated with no impact on ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.143672,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.024102",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCUL",
        "relevance_score": "0.237435",
        "ticker_sentiment_score": "0.186103",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ocular Therapeutix\u2122 Announces Positive Phase 2 PAXTRAVA\u2122 Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/04/06/2858799/0/en/Ocular-Therapeutix-Announces-Positive-Phase-2-PAXTRAVA-Glaucoma-Data-at-the-American-Society-of-Cataract-and-Refractive-Surgery-2024-Annual-Meeting.html",
    "time_published": "20240406T140000",
    "authors": [
      "Ocular Therapeutix",
      "Inc."
    ],
    "summary": "Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure ( IOP ) , statistically significant ( p<0.0001 ) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/e2ff6070-e164-4804-b537-9e2f2e7a419c",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.146203,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.018118",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCUL",
        "relevance_score": "0.126308",
        "ticker_sentiment_score": "0.100366",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Dividend Stocks to Buy in April",
    "url": "https://www.fool.com/investing/2024/04/06/3-no-brainer-dividend-stocks-to-buy-in-april/",
    "time_published": "20240406T104900",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "Income investors will find a lot to like about these stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771862/hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.98396"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999993"
      }
    ],
    "overall_sentiment_score": 0.256746,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "0.211661",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.40711",
        "ticker_sentiment_score": "0.238109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.097263",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.40711",
        "ticker_sentiment_score": "0.084816",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aldeyra  ( ALDX )  Stock Rallies 43% in One Week: Here's Why",
    "url": "https://www.zacks.com/stock/news/2251543/aldeyra-aldx-stock-rallies-43-in-one-week-heres-why",
    "time_published": "20240406T103700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default102.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.08816,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.103005",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALDX",
        "relevance_score": "0.338004",
        "ticker_sentiment_score": "0.269235",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FGEN",
        "relevance_score": "0.215319",
        "ticker_sentiment_score": "-0.027616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.215319",
        "ticker_sentiment_score": "0.278932",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA",
    "url": "https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-fusn-labp-doma-302109626.html",
    "time_published": "20240406T014000",
    "authors": [
      "Halper Sadeh LLP"
    ],
    "summary": "NEW YORK, April 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to AstraZeneca.",
    "banner_image": "https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.262791,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.372322",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why AbbVie  ( ABBV )  Fell More Than Broader Market",
    "url": "https://www.zacks.com/stock/news/2252231/heres-why-abbvie-abbv-fell-more-than-broader-market",
    "time_published": "20240408T215019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default18.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.149562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.540358",
        "ticker_sentiment_score": "0.19035",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/giant-cell-arteritis-market-to-showcase-positive-growth-at-a-cagr-of-9-3-by-2034--delveinsight-302110122.html",
    "time_published": "20240408T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.163381,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.10608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.067284",
        "ticker_sentiment_score": "0.029061",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVBXF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MESO",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDHL",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNSA",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.069374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYNE",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LABP",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMAB",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYMD",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHJBF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.089629",
        "ticker_sentiment_score": "0.069374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGMF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAPAF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.026233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MOR",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.10608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAIPY",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABVX",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACRS",
        "relevance_score": "0.044885",
        "ticker_sentiment_score": "0.028414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLPG",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LBTSF",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SILO",
        "relevance_score": "0.022452",
        "ticker_sentiment_score": "0.024703",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2251803/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240408T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default152.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212542,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.101154",
        "ticker_sentiment_score": "0.127017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.111538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.200688",
        "ticker_sentiment_score": "0.116195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38141013/coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-annual-",
    "time_published": "20240408T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.086922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.052797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock A Better Pick Over AbbVie?",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/04/08/is-johnson--johnson-stock-a-better-pick-over-abbvie/",
    "time_published": "20240408T113050",
    "authors": [
      "Trefis Team"
    ],
    "summary": "We believe that the pharmaceuticals bellwether Johnson & Johnson ( NYSE: JNJ ) is currently a better pick over its peer AbbVie ( NYSE: ABBV ) .",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66138475c142148b65e3d00a/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.708596",
        "ticker_sentiment_score": "0.385571",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.479258",
        "ticker_sentiment_score": "0.317916",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DOMA, LABP, FUSN, CBNK",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38173230/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-doma-labp-fusn-cbnk",
    "time_published": "20240409T205802",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 09, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.284018,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.312761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.086245",
        "ticker_sentiment_score": "0.139476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBNK",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.373161",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.33514",
        "ticker_sentiment_score": "0.312761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - Enliven Therapeutics  ( NASDAQ:ELVN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38171595/enliven-therapeutics-appoints-dr-lori-kunkel-to-board-of-directors",
    "time_published": "20240409T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOULDER, Colo., April 09, 2024 ( GLOBE NEWSWIRE ) -- Enliven Therapeutics, Inc. ( Enliven or the Company ) ELVN, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.250521,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ORIC",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.061458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.061458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELVN",
        "relevance_score": "0.484408",
        "ticker_sentiment_score": "0.406538",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.074001",
        "ticker_sentiment_score": "0.061458",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for AbbVie, Salesforce & General Electric",
    "url": "https://www.zacks.com/research-daily/2252707/top-stock-reports-for-abbvie-salesforce-general-electric",
    "time_published": "20240409T184400",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General Electric Company (GE).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default72.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.338266,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.097062",
        "ticker_sentiment_score": "0.269672",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.399763",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.285526",
        "ticker_sentiment_score": "0.273592",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2252321/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20240409T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default200.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.248869,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.060031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.060031",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.337044",
        "ticker_sentiment_score": "0.236935",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.060031",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/09/3-dividend-growth-stocks-with-yields-above-3-that/",
    "time_published": "20240409T082100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Income-seeking investors can look forward to steady payout raises from these pharma stocks.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772112%2Finvestor-stock-charts-laptop-getty.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.207428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.057886",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.083778",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.058885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.027025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "0.217001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.06886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says - LENZ Therapeutics  ( NASDAQ:LENZ ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38190459/blindness-focused-lenz-therapeutics-investigational-eye-drop-ready-to-revolutionize",
    "time_published": "20240410T191901",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Last week, LENZ Therapeutics Inc LENZ released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Eyes_6.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.286499,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LENZ",
        "relevance_score": "0.664235",
        "ticker_sentiment_score": "0.37471",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.156781",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.25168",
        "ticker_sentiment_score": "0.227297",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Receives \u20ac8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi\u00ae in Lung Cancer",
    "url": "https://www.globenewswire.com/news-release/2024/04/10/2860967/0/en/OSE-Immunotherapeutics-Receives-8-4-M-in-Public-Funding-to-Support-the-Registration-Phase-3-Clinical-Trial-of-Cancer-Vaccine-Tedopi-in-Lung-Cancer.html",
    "time_published": "20240410T160000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Receives \u20ac8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi\u00ae in Lung Cancer Nantes, France - April 10, 2024 - 6:00 pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.150124,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.040212",
        "ticker_sentiment_score": "0.074249",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You Looking for a High-Growth Dividend Stock?",
    "url": "https://www.zacks.com/stock/news/2253493/are-you-looking-for-a-high-growth-dividend-stock",
    "time_published": "20240410T154507",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default225.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.380669,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.448316",
        "ticker_sentiment_score": "0.471952",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Nurix  ( NRIX )  Up on Upbeat Initial Data From Phase I Cancer Study",
    "url": "https://www.zacks.com/stock/news/2253429/nurix-nrix-up-on-upbeat-initial-data-from-phase-i-cancer-study",
    "time_published": "20240410T132900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121155,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.08309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.043186",
        "ticker_sentiment_score": "0.220289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.374",
        "ticker_sentiment_score": "0.034534",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.213423",
        "ticker_sentiment_score": "0.025152",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group",
    "url": "https://www.zacks.com/stock/news/2253407/the-zacks-analyst-blog-highlights-abbvie-salesforce-general-electric-the-tjx-companies-and-ubs-group",
    "time_published": "20240410T130300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie, Salesforce, General Electric, The TJX Companies and UBS Group are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/468.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.276453,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.254034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.400265",
        "ticker_sentiment_score": "0.20069",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.037466",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.338119",
        "ticker_sentiment_score": "0.336537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UBS",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "0.037466",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2254098/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20240411T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.129332,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.521961",
        "ticker_sentiment_score": "0.178019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alpine  ( ALPN )  Surges 37% on $4.9B Buyout Offer From Vertex",
    "url": "https://www.zacks.com/stock/news/2254800/alpine-alpn-surges-37-on-49b-buyout-offer-from-vertex",
    "time_published": "20240412T163600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.184498,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.231773",
        "ticker_sentiment_score": "0.044053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TVTX",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.034996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046999",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERA",
        "relevance_score": "0.093836",
        "ticker_sentiment_score": "0.187882",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.320081",
        "ticker_sentiment_score": "0.210238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In ABBV Options - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38221028/smart-money-is-betting-big-in-abbv-options",
    "time_published": "20240412T140403",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.20622,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.70655",
        "ticker_sentiment_score": "0.24703",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "-0.110654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "All International Medical Approval News and Press Releases from Cision Canada",
    "url": "https://www.newswire.ca/news-releases/health-latest-news/international-medical-approval-list/",
    "time_published": "20240413T050929",
    "authors": [],
    "summary": "VANCOUVER, BC, April 5, 2024 /CNW/ - Asep Medical Holdings Inc. ( \"Asep\" or the \"Company\" ) ( CSE: ASEP ) ( OTCQB: SEPSF ) ( FSE: JJ8 ) is very pleased to... MONTREAL, March 25, 2024 /CNW/ - Innodem Neurosciences, a leading digital health and AI company, announced today that its ...",
    "banner_image": "https://www.newswire.ca/content/dam/prnewswire/common/JournalistsBloggers.jpg",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.153564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DNPUF",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.079963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.079963",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.090738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENDPQ",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.185857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.093967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.079963",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Like This High-Yield Vanguard Fund, Then You'll Love These Two Dividend Stocks",
    "url": "https://www.fool.com/investing/2024/04/14/high-yield-vanguard-fund-etf-dividend-stocks-buy/",
    "time_published": "20240414T101500",
    "authors": [
      "and Lee Samaha",
      "Scott Levine",
      "Daniel Foelber"
    ],
    "summary": "Boost your passive income in a way that's right for you.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F772097%2Fgettyimages-1386479297-1200x800-5b2df79.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.250757,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PGPGF",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.038022",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.180019",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AEP",
        "relevance_score": "0.408446",
        "ticker_sentiment_score": "0.375101",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "-0.012684",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie a Millionaire Maker?",
    "url": "https://www.fool.com/investing/2024/04/14/is-abbvie-a-millionaire-maker/",
    "time_published": "20240414T052300",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Everything is going according to plan, and more growth is on the way.",
    "banner_image": "https://g.foolcdn.com/editorial/images/771959/two-investors-consider-a-stock-with-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.324719,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.38588",
        "ticker_sentiment_score": "0.414875",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.174265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38254668/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20240415T173121",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 61% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.176237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.757528",
        "ticker_sentiment_score": "0.167458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "-0.124574",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotech Stock Hits 2024 Low Side Effects In Rabbits Torpedo Schizophrenia Drug",
    "url": "https://www.investors.com/news/technology/biotech-stock-neumora-stock-rabbits-schizophrenia-drug/",
    "time_published": "20240415T140600",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "Neumora Therapeutics ( NMRA ) said Monday the Food and Drug Administration put its schizophrenia drug on hold after rabbits who received it experienced convulsions. In response, the biotech stock plunged.",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/Stock-BunniesCute-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.071999,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "-0.172745",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NMRA",
        "relevance_score": "0.532941",
        "ticker_sentiment_score": "0.118693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.085441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DXCM",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.24238",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.085441",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2255127/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240415T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default320.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.228365,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.137449",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.143913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study",
    "url": "https://www.globenewswire.com/news-release/2024/04/15/2862485/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-s-Columvi-meets-primary-endpoint-of-overall-survival-in-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-in-Phase-II.html",
    "time_published": "20240415T050000",
    "authors": [
      "F. Hoffmann-La Roche Ltd"
    ],
    "summary": "Basel, 15 April 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory ( R/R ) diffuse large B-cell lymphoma ( DLBCL ) , who have received at least one ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.202897,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.032251",
        "ticker_sentiment_score": "0.111503",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032251",
        "ticker_sentiment_score": "0.071787",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of SELARSDI\u2122  ( ustekinumab-aekn ) , biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2864156/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-SELARSDI-ustekinumab-aekn-biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240416T213000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., April 16, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.096029,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.325282",
        "ticker_sentiment_score": "0.186504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.069194",
        "ticker_sentiment_score": "0.089506",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.053772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011546",
        "ticker_sentiment_score": "0.053772",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03463",
        "ticker_sentiment_score": "0.108494",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of SELARSDI\u2122  ( ustekinumab-aekn ) , biosimilar to Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2864157/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-SELARSDI-ustekinumab-aekn-biosimilar-to-Stelara-ustekinumab.html",
    "time_published": "20240416T213000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, ICELAND & PARSIPPANY, NJ - Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) injection for ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.096007,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.323663",
        "ticker_sentiment_score": "0.185829",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.06883",
        "ticker_sentiment_score": "0.090486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.053745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011485",
        "ticker_sentiment_score": "0.053745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.045918",
        "ticker_sentiment_score": "0.105859",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Counterfeit Botox has been found in several states. Here's what consumers should know.",
    "url": "https://www.cnn.com/2024/04/16/health/counterfeit-botox-what-to-know/index.html",
    "time_published": "20240416T203300",
    "authors": [
      "Jacqueline Howard"
    ],
    "summary": "The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/20240416-fakebotoxsplit-super1x1.jpg?q=w_1110,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.057435,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.024273",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EOLS",
        "relevance_score": "0.024273",
        "ticker_sentiment_score": "0.134558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024273",
        "ticker_sentiment_score": "0.045453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVNC",
        "relevance_score": "0.024273",
        "ticker_sentiment_score": "0.134558",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA And CDC Launch Investigation Into Counterfeit Botox: What To Know",
    "url": "https://www.forbes.com/sites/ariannajohnson/2024/04/16/fda-and-cdc-launch-investigation-into-counterfeit-botox-what-to-know/",
    "time_published": "20240416T200950",
    "authors": [
      "Arianna Johnson"
    ],
    "summary": "What To Know About Counterfeit Botox Forbes ...",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661eda95f5f4c0c35485b8f5/0x0.jpg?format=jpg&crop=364,204,x1,y0,safe&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.122376,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades - Avalo Therapeutics  ( NASDAQ:AVTX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278240/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-",
    "time_published": "20240416T182500",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa ( HS ) and additional updates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/pharma-lab-worker-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.220261,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.231274",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.126301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVTX",
        "relevance_score": "0.729067",
        "ticker_sentiment_score": "0.434899",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective",
    "url": "https://www.globenewswire.com/news-release/2024/04/16/2863914/0/en/OSE-Immunotherapeutics-Global-License-to-Develop-a-Novel-Monoclonal-Antibody-for-the-Treatment-of-Chronic-Inflammation-Becomes-Effective.html",
    "time_published": "20240416T160000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 - OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121926,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.202705",
        "ticker_sentiment_score": "0.111783",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2255886/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240416T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default349.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.239793,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.107587",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Johnson & Johnson  ( JNJ )  Q1 Earnings Top Estimates",
    "url": "https://www.zacks.com/stock/news/2255793/johnson-johnson-jnj-q1-earnings-top-estimates",
    "time_published": "20240416T113002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default178.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.153019,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.137278",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.396052",
        "ticker_sentiment_score": "0.121187",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Increases Despite Market Slip: Here's What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2257220/abbvie-abbv-increases-despite-market-slip-heres-what-you-need-to-know",
    "time_published": "20240417T214517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.071065,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.527969",
        "ticker_sentiment_score": "0.162384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38300021/is-your-botox-real-or-fake-counterfeit-boxes-circulate-for-widely-used-antiwrinkle-treatment-cdc-",
    "time_published": "20240417T184223",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, the FDA issued a warning regarding the dangers associated with counterfeit versions of AbbVie Inc's ABBV Botox used for cosmetic purposes.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/Botox-Photo-by-anva-marketing-via-Pexels.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.100636,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.519739",
        "ticker_sentiment_score": "-0.10018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/04/38299327/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-100-today",
    "time_published": "20240417T180036",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $290.03 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Continuous Manufacturing Market Size is expected to reach USD 1,420.95 million by 2031, growing at a CAGR of 12.2%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38292943/continuous-manufacturing-market-size-is-expected-to-reach-usd-1-420-95-million-by-2031-growing-at-",
    "time_published": "20240417T135000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, April 17, 2024 ( GLOBE NEWSWIRE ) -- Continuous manufacturing is distinguished from batch manufacturing, which entails production execution in discrete steps separated by intervals by the uninterrupted feeding of raw materials into a manufacturing system and the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.263384,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.144008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.033277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.033277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.07079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.033277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03704",
        "ticker_sentiment_score": "0.033277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Declares Second Quarter 2024 Dividend",
    "url": "https://www.globenewswire.com/news-release/2024/04/17/2864512/0/en/Royalty-Pharma-Declares-Second-Quarter-2024-Dividend.html",
    "time_published": "20240417T121500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, April 17, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.709186",
        "ticker_sentiment_score": "0.320221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.107354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/global-radioimmunoassay-market-to-grow-at-a-minimal-cagr-of-3-by-2030--delveinsight-302119197.html",
    "time_published": "20240418T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.146788,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BMXMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "A",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTG",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EKTAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.173153",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DHR",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.060148",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TCRT",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLDX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSMXF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "0.02269",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOLX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARAY",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.082191",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.028388",
        "ticker_sentiment_score": "-0.0967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.056741",
        "ticker_sentiment_score": "-0.035994",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38321217/soon-to-be-acquired-cerevel-therapeutics-reveals-high-level-data-from-late-stage-parkinsons-disea",
    "time_published": "20240418T174409",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Cerevel Therapeutics Holdings Inc. CERE released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa ( LD ) in adults.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/18/Parkinsons-disease.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.28652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.443837",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "0.345848",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease",
    "url": "https://www.globenewswire.com/news-release/2024/04/18/2865216/0/en/Cerevel-Therapeutics-Announces-Positive-Topline-Results-for-Tavapadon-in-Phase-3-Adjunctive-Trial-for-People-Living-with-Parkinson-s-Disease.html",
    "time_published": "20240418T103000",
    "authors": [
      "Cerevel Therapeutics"
    ],
    "summary": "Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total \"on\" time without troublesome dyskinesia compared with placebo over 27 weeks ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/a08b2b75-1208-494e-96a4-a7f98dc0328a",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.116069,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.095289",
        "ticker_sentiment_score": "0.11709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.057261",
        "ticker_sentiment_score": "0.03402",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866360/0/en/NurExone-Presenting-on-Revolutionary-Spinal-Cord-Injury-Therapy-at-European-Conference-on-Exosomes-and-Regenerative-Medicine.html",
    "time_published": "20240419T200400",
    "authors": [
      "NurExone Biologic Inc"
    ],
    "summary": "NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/18124d4e-7adb-4ecf-906f-32ebd0f6f7f0",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.191538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NRXBF",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.078493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.044144",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAPR",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.044144",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38341957/nurexone-presenting-on-revolutionary-spinal-cord-injury-therapy-at-european-conference-on-exosomes",
    "time_published": "20240419T200400",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TORONTO and HAIFA, Israel, April 19, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.191182,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.140615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRXBF",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.072348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.044006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAPR",
        "relevance_score": "0.052685",
        "ticker_sentiment_score": "0.044006",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Bad News Heading Into AbbVie's First-Quarter Earnings Report",
    "url": "https://www.investors.com/news/technology/abbvie-stock-record-high-first-quarter-report-humira-biosimilars/",
    "time_published": "20240419T164300",
    "authors": [
      "ALLISON GATLIN",
      "Investor's Business Daily"
    ],
    "summary": "AbbVie Stock Is 10% Off Its Record High, And There's Bad News Heading Into Its First-Quarter Report Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/06/stock-AbbVie-04-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.016668,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.169343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.300394",
        "ticker_sentiment_score": "0.013134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.614697",
        "ticker_sentiment_score": "-0.263743",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Life Science Cares Launches in Switzerland",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866259/0/en/Life-Science-Cares-Launches-in-Switzerland.html",
    "time_published": "20240419T151200",
    "authors": [
      "Molecular Partners"
    ],
    "summary": "First international chapter of Life Science Cares established in Switzerland - bringing hearts and minds together by empowering the life sciences industry to support local communities First international chapter of Life Science Cares established in Switzerland - bringing hearts and minds ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d616da63-3d35-4029-ab81-0d347a78e4ba",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.084858,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "-0.015616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SWSDF",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.162766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Earnings Preview: AbbVie  ( ABBV )  Q1 Earnings Expected to Decline",
    "url": "https://www.zacks.com/stock/news/2258527/earnings-preview-abbvie-abbv-q1-earnings-expected-to-decline",
    "time_published": "20240419T140023",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.114412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.263467",
        "ticker_sentiment_score": "-0.006003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data",
    "url": "https://www.zacks.com/stock/news/2258354/pharma-stock-roundup-jnjs-q1-results-lly-abbv-rhhbys-successful-study-data",
    "time_published": "20240419T131500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.035644,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.054754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.155954",
        "ticker_sentiment_score": "0.042066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "-0.191191",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.039224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866132/0/en/Royalty-Pharma-to-Announce-First-Quarter-2024-Financial-Results-on-May-9-2024.html",
    "time_published": "20240419T121500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, April 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.213261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38332971/royalty-pharma-to-announce-first-quarter-2024-financial-results-on-may-9-2024",
    "time_published": "20240419T121500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.572601",
        "ticker_sentiment_score": "0.199984",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.090163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira\u00ae  ( adalimumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866057/0/en/Alvotech-signs-U-S-agreement-to-expand-access-for-newly-approved-high-concentration-interchangeable-biosimilar-to-Humira-adalimumab.html",
    "time_published": "20240419T101000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.315342,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.648497",
        "ticker_sentiment_score": "0.475653",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.065679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.065679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.065679",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira\u00ae  ( adalimumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/19/2866058/0/en/Alvotech-signs-U-S-agreement-to-expand-access-for-newly-approved-high-concentration-interchangeable-biosimilar-to-Humira-adalimumab.html",
    "time_published": "20240419T101000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, April 19, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.202323,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.096003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.096003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.060676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.590043",
        "ticker_sentiment_score": "0.293123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.060676",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.029876",
        "ticker_sentiment_score": "0.060676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why I Keep Buying This Ultra-High-Yielding ETF for Passive Income",
    "url": "https://www.fool.com/investing/2024/04/20/why-i-keep-buying-this-ultra-high-yielding-etf-for/",
    "time_published": "20240420T074400",
    "authors": [
      "Matt DiLallo"
    ],
    "summary": "The JPMorgan Equity Premium Income ETF produces a lucrative monthly passive income stream.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773398%2Fjepi-yield.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.358586,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TOP",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.286087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.175001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.058472",
        "ticker_sentiment_score": "0.175001",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38349204/can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsof",
    "time_published": "20240421T214515",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/21/The-Magnificent-Seven--7-Of-Largest-Us-T.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998917"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.145082,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MTH",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALV",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "-0.062571",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WDC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NSC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WHR",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HOG",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMB",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "-0.018992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QS",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMP",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BSX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKR",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMS",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZIONL",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PKG",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RCL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHTR",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNI",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STLD",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAT",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "B",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FI",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAP",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBLY",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYD",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.071787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HTZ",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.090201",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRCX",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COF",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GD",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WU",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.083782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NUE",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AON",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KLAC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "-0.028544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HUM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JBLU",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACI",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMUS",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEM",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAS",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLF",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ODFL",
        "relevance_score": "0.075161",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NEM",
        "relevance_score": "0.037622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38366584/take-action-the-m-a-class-action-firm-launches-legal-inquiry-for-the-merger-alpn-labp-swav-fusn",
    "time_published": "20240422T213316",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the \"M&A Class Action Firm\" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.270721,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.124976",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.085936",
        "ticker_sentiment_score": "0.139374",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUSN",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.312006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWAV",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.281733",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  to Report Q1 Earnings: What's in the Cards?",
    "url": "https://www.zacks.com/stock/news/2259539/abbvie-abbv-to-report-q1-earnings-whats-in-the-cards",
    "time_published": "20240422T165600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999965"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.203046,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.100099",
        "ticker_sentiment_score": "0.137083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.470606",
        "ticker_sentiment_score": "0.262532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.198628",
        "ticker_sentiment_score": "-0.003136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRPT",
        "relevance_score": "0.149656",
        "ticker_sentiment_score": "0.175155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Anthos Therapeutics Announces Appointment of Bill Meury as CEO",
    "url": "https://www.benzinga.com/pressreleases/24/04/g38359713/anthos-therapeutics-announces-appointment-of-bill-meury-as-ceo",
    "time_published": "20240422T150931",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CAMBRIDGE, Mass., April 22, 2024 ( GLOBE NEWSWIRE ) -- Anthos Therapeutics, Inc. ( Anthos ) , is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences ( BXLS ) , today announced the appointment of Bill Meury as CEO and member of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.054839,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BX",
        "relevance_score": "0.098497",
        "ticker_sentiment_score": "0.203007",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.019748",
        "ticker_sentiment_score": "0.124908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.019748",
        "ticker_sentiment_score": "0.093354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Buying the Dip in These 3 Undervalued Dividend Stocks",
    "url": "https://www.fool.com/investing/2024/04/22/buying-the-dip-in-these-3-undervalued-dividend-sto/",
    "time_published": "20240422T134700",
    "authors": [
      "Mark Roussin",
      "CPA"
    ],
    "summary": "All three of these stocks look intriguing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/773635/copy-of-dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.36848,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.724687",
        "ticker_sentiment_score": "0.686565",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2259047/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240422T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default55.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.096154,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.119729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.124719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "-0.036012",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Pacer US Cash Cows 100 ETF  ( COWZ )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2258916/is-pacer-us-cash-cows-100-etf-cowz-a-strong-etf-right-now",
    "time_published": "20240422T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default44.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999994"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.27334,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEN",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia, Tesla, Super Micro, Verizon, Informatica, Coinbase, Cardinal Health, and More Stock Market Movers",
    "url": "https://www.barrons.com/amp/articles/stock-market-movers-54b0c8a2",
    "time_published": "20240422T082900",
    "authors": [
      "Joe Woelfel"
    ],
    "summary": "Nvidia, Tesla, Super Micro, Salesforce, Verizon, and More Stock Market Movers ...",
    "banner_image": "https://images.barrons.com/im-807128/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.12376,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOLD",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.150676",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "-0.238833",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INFA",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.011716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.027539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.135815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.090736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEM",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.150676",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LI",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.042283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BA",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CDC issues health advisory about risks of counterfeit or mishandled Botox injections",
    "url": "https://www.cnn.com/2024/04/23/health/cdc-health-advisory-botox-injections/index.html",
    "time_published": "20240423T192400",
    "authors": [
      "Jacqueline Howard"
    ],
    "summary": "The US Centers for Disease Control and Prevention issued an advisory Tuesday about the risks of counterfeit or mishandled Botox injections after dangerous fake versions of the product have been found in several states.",
    "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/20240416-fakebotoxsplit-super1x1.jpg?q=w_1110,c_fill",
    "source": "CNN",
    "category_within_source": "Markets",
    "source_domain": "www.cnn.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.059773,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WBD",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.151946",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/04/38388038/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20240423T184550",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 46% ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.129632,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.769861",
        "ticker_sentiment_score": "0.063159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "-0.125596",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  Reports Next Week: Wall Street Expects Earnings Growth",
    "url": "https://www.zacks.com/stock/news/2260247/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth",
    "time_published": "20240423T140101",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default280.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.137784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.261117",
        "ticker_sentiment_score": "0.057509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "0.022696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gear Up for AbbVie  ( ABBV )  Q1 Earnings: Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2259945/gear-up-for-abbvie-abbv-q1-earnings-wall-street-estimates-for-key-metrics",
    "time_published": "20240423T131523",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default356.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.106617,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.351558",
        "ticker_sentiment_score": "0.081918",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer",
    "url": "https://www.prnewswire.com/news-releases/congruence-therapeutics-appoints-frank-taffy-as-chief-business-officer-302122964.html",
    "time_published": "20240423T120000",
    "authors": [
      "Congruence Therapeutics"
    ],
    "summary": "-Mr. Taffy joins from Schr\u00f6dinger, bringing a wealth of relevant expertise to Congruence-",
    "banner_image": "https://mma.prnewswire.com/media/1952949/Congruence_Therapeutics_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174218,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FBIO",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.213674",
        "ticker_sentiment_score": "0.148105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer",
    "url": "https://www.newswire.ca/news-releases/congruence-therapeutics-appoints-frank-taffy-as-chief-business-officer-865902512.html",
    "time_published": "20240423T120000",
    "authors": [
      "Congruence Therapeutics"
    ],
    "summary": "-Mr. Taffy joins from Schr\u00f6dinger, bringing a wealth of relevant expertise to Congruence-",
    "banner_image": "https://mma.prnewswire.com/media/1952949/Congruence_Therapeutics_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174218,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FBIO",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SDGR",
        "relevance_score": "0.213674",
        "ticker_sentiment_score": "0.148105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.027197",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Pacer US Cash Cows 100 ETF  ( COWZ )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2259747/should-pacer-us-cash-cows-100-etf-cowz-be-on-your-investing-radar",
    "time_published": "20240423T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default14.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.23939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEN",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.068464",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?",
    "url": "https://www.zacks.com/stock/news/2261491/will-healthcare-etfs-lose-momentum-as-q1-earnings-unfold",
    "time_published": "20240424T160500",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b3/30471.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.988915"
      }
    ],
    "overall_sentiment_score": 0.094139,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.030354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.176717",
        "ticker_sentiment_score": "-0.00714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.080874",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.234119",
        "ticker_sentiment_score": "0.078127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118354",
        "ticker_sentiment_score": "0.007886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Large Drug Stocks to Hold on to Amid Industry Challenges",
    "url": "https://www.zacks.com/commentary/2260758/4-large-drug-stocks-to-hold-on-to-amid-industry-challenges",
    "time_published": "20240424T140900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999491"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221236,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.11349",
        "ticker_sentiment_score": "0.144552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.022772",
        "ticker_sentiment_score": "0.06641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.135985",
        "ticker_sentiment_score": "0.157325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.022772",
        "ticker_sentiment_score": "0.06641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.135985",
        "ticker_sentiment_score": "0.157325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Coherus Announces Presentation at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/04/24/2868756/33333/en/Coherus-Announces-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html",
    "time_published": "20240424T140200",
    "authors": [
      "Inc.",
      "Coherus BioSciences"
    ],
    "summary": "REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/bacb58bf-ea23-4950-a845-933265930d07",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.02671,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.090304",
        "ticker_sentiment_score": "0.046557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045224",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?",
    "url": "https://www.zacks.com/stock/news/2261011/whats-in-store-for-these-5-pharma-bigwigs-in-q1-earnings",
    "time_published": "20240424T131900",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/58479.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.154863,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "-0.008857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "-0.080241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.342197",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.134722",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "-0.010985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118452",
        "ticker_sentiment_score": "0.061763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.04485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Op-ed: Here are 6 health-care stocks to watch now, amid a bumpy recovery",
    "url": "https://www.cnbc.com/2024/04/24/op-ed-here-are-health-care-stocks-to-watch-now-amid-a-bumpy-recovery.html",
    "time_published": "20240424T123001",
    "authors": [
      "Dave Sheaff Gilreath",
      "a certified financial planner and partner/founder and chief investment officer of Sheaff Brock Investment Advisors and Innovative Portfolio"
    ],
    "summary": "Health care, long an ailing stock market sector, has recovered over the past six months, with currently robust vital signs and strong growth projections.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/106408902-1582655595706gettyimages-936365986.jpg?v=1690462881&w=600&h=300&vtcrop=y",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MEDP",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.107262",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.072695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "-0.040715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "-0.024999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.092718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IQV",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.134491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2260775/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240424T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default254.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      }
    ],
    "overall_sentiment_score": 0.258582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.253605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.048656",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.048656",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mahesh Krishnan Elected to Halozyme's Board of Directors",
    "url": "https://www.prnewswire.com/news-releases/mahesh-krishnan-elected-to-halozymes-board-of-directors-302127757.html",
    "time_published": "20240425T204500",
    "authors": [
      "Inc.",
      "Halozyme Therapeutics"
    ],
    "summary": "SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( \"Halozyme\" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.230507,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "-0.000993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DVA",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "-0.001252",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.193344",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.047465",
        "ticker_sentiment_score": "0.083841",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study - AbbVie  ( NYSE:ABBV ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38440500/abbvies-dermatitis-drug-shown-superior-to-sanofiregenerons-dupixent-in-head-to-head-study",
    "time_published": "20240425T175829",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Thursday, AbbVie Inc ABBV released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib ( Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response ) versus dupilumab ( Dupixent, per its labeled dose ) for ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/25/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.004796,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.42503",
        "ticker_sentiment_score": "0.069659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.161819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie",
    "url": "https://www.zacks.com/stock/news/2262167/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-merck-and-abbvie",
    "time_published": "20240425T123300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998947"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.219201,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.128937",
        "ticker_sentiment_score": "0.112011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.010009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.171333",
        "ticker_sentiment_score": "0.209828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.061809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.150189",
        "ticker_sentiment_score": "0.150982",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALPN",
        "relevance_score": "0.021581",
        "ticker_sentiment_score": "0.061809",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why AbbVie Stock Stumbled Today Despite the Earnings Beat",
    "url": "https://www.fool.com/investing/2024/04/26/why-abbvie-stock-stumbled-today-despite-the-earnin/",
    "time_published": "20240426T200711",
    "authors": [
      "James Brumley"
    ],
    "summary": "Investors are struggling to see past the end of Humira's dominance.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774594/investor-reviewing-a-stock-portfolio.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.150623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.579393",
        "ticker_sentiment_score": "0.224549",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/04/26/abbvie-abbv-q1-2024-earnings-call-transcript/",
    "time_published": "20240426T191513",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ABBV earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.264409,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.107168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.058303",
        "ticker_sentiment_score": "0.043011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065576",
        "ticker_sentiment_score": "0.107762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.135624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.003647",
        "ticker_sentiment_score": "0.074008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost - Cigna Group  ( NYSE:CI ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost",
    "time_published": "20240426T184157",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Evernorth is a subsidiary of The Cigna Group CI.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/26/pharmaceutical.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.187732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.14149",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CI",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "0.104337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "0.230159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats on Q1 Earnings & Sales, Ups '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view",
    "time_published": "20240426T161000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.126215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.281693",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.299765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.074809",
        "ticker_sentiment_score": "0.063534",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PCE/Core PCE Numbers Came In Line With Expectations",
    "url": "https://www.zacks.com/stock/news/2263409/pcecore-pce-numbers-came-in-line-with-expectations",
    "time_published": "20240426T145300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pre-market futures are sunnier this morning. After seeing shadows in economic data related to the dreaded \"stagflation\" dynamic, Personal Income Expenditures ( PCE ) numbers for March look to have assuaged a bit of those fears this morning.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.102404,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.2653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.097765",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses",
    "url": "https://www.zacks.com/stock/news/2263401/pce-in-line-to-warmer-pre-market-calms-abbv-beats-xom-misses",
    "time_published": "20240426T143300",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3b/960.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.099873,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.170275",
        "ticker_sentiment_score": "0.23671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.088966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CPAP Stock Rockets As Quarterly Report Wipes Out Weight-Loss Woes",
    "url": "https://www.investors.com/news/technology/resmed-stock-resmed-earnings-q1-2024-cpaps-weight-loss-drugs/",
    "time_published": "20240426T140000",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "ResMed Stock Hits 8-Month High After Quarterly Beat Wipes Out Weight-Loss Drug Woes Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/04/Stock-Resmed-bldg-shutt.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      }
    ],
    "overall_sentiment_score": 0.234376,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.038661",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.729947",
        "ticker_sentiment_score": "0.392607",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook - Landos Biopharma  ( NASDAQ:LABP ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/04/38460664/ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-profit-outlook",
    "time_published": "20240426T135400",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Friday, AbbVie Inc ABBV reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23. Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92 billion. Sales were up 1.6% on an operational basis.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/26/AbbVie-Office.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.239075,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.542164",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.53784",
        "ticker_sentiment_score": "0.445661",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Beats Quarterly Views As Skyrizi Nearly Snags Humira's Title",
    "url": "https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q1-2024/",
    "time_published": "20240426T130300",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "AbbVie Stock: AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2018/11/Stock-abbvie-06-company.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.160859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.772973",
        "ticker_sentiment_score": "0.239306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats Q1 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2263059/abbvie-abbv-beats-q1-earnings-and-revenue-estimates",
    "time_published": "20240426T124502",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default224.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.161851,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.140485",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.20959",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Reports First-Quarter 2024 Financial Results",
    "url": "https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2024-financial-results-302128164.html",
    "time_published": "20240426T113500",
    "authors": [
      "AbbVie"
    ],
    "summary": "NORTH CHICAGO, Ill., April 26, 2024 /PRNewswire/ -- AbbVie ( NYSE:ABBV ) announced financial results for the first quarter ended March 31, 2024. \"We continue to demonstrate outstanding operational execution and delivered another quarter of strong results,\" said Richard A.",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.136111,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.129308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "0.129308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "-0.011861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.506284",
        "ticker_sentiment_score": "0.170816",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "MSFT, GOOGL Earnings Lift Nasdaq, S&P 500 Futures - But Can They Beat Inflation? - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/04/38455462/wall-street-futures-ride-high-on-microsoft-alphabet-cheer-but-will-inflation-data-burst-the-bubble-",
    "time_published": "20240426T104812",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Tech earnings could come to the market's rescue as traders remain jittery about the outcome of key inflation data due on Friday. AI giants Alphabet, Inc. GOOGL GOOG and Microsoft Corp. MSFT set a positive tone for tech companies with strong performances in the first quarter.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/26/Wall-Street--US-stocks.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": 0.130064,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AON",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.101145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "-0.292772",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ROKU",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "B",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NWL",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDOC",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RMD",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CL",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYD",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.109925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTC",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LPLA",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.151741",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CHTR",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "0.297034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.252042",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
    "url": "https://www.fool.com/investing/2024/04/27/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
    "time_published": "20240427T111500",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "You'll get dividends and more with these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774374/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.273184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.396888",
        "ticker_sentiment_score": "0.293766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.360171",
        "ticker_sentiment_score": "0.156442",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.176676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FCAP",
        "relevance_score": "0.041466",
        "ticker_sentiment_score": "0.086608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.284106",
        "ticker_sentiment_score": "0.173062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Better Dividend Stock: AbbVie or Johnson & Johnson?",
    "url": "https://www.fool.com/investing/2024/04/28/better-dividend-stock-abbvie-or-johnson-johnson/",
    "time_published": "20240428T082000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "One thing is for sure: Dividend seekers can't go wrong with either.",
    "banner_image": "https://media.ycharts.com/charts/606ca6d7bad2ded63e4e23f32d1c43b2.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.215112,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.596349",
        "ticker_sentiment_score": "0.286691",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "0.025897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.29997",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'",
    "url": "https://www.investors.com/news/technology/abbvie-stock-humira-biosimilars-first-quarter-2024/",
    "time_published": "20240429T162700",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "AbbVie Stock: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2022/04/Stock-abbvie-04-adobe.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.109504,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RMD",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "0.018363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.628843",
        "ticker_sentiment_score": "0.288988",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/global-medical-dynamometers-market-to-witness-upsurge-in-growth-at-a-cagr-of-6-by-2030--delveinsight-302131049.html",
    "time_published": "20240430T213100",
    "authors": [
      "DelveInsight Business Research",
      "LLP"
    ],
    "summary": "The medical dynamometers market is predicted to surge owing to the rise in bone-related conditions like osteoporosis and arthritis, along with an uptick in sports injuries and the expanding elderly demographic.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.359048,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AHKSF",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.049387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYYNF",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.049387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STMM",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.049387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.052484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.222563",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.012467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PBIGF",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.052484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIK",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.012467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DTST",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.314925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "EPRX",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.013843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.07295",
        "ticker_sentiment_score": "0.033218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.012467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.049387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.012467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.097161",
        "ticker_sentiment_score": "0.054812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLPG",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.052484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASBRF",
        "relevance_score": "0.048671",
        "ticker_sentiment_score": "0.049387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATBPF",
        "relevance_score": "0.024347",
        "ticker_sentiment_score": "0.012467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.07295",
        "ticker_sentiment_score": "0.033218",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition",
    "url": "https://apnews.com/article/ftc-drug-patents-prices-fda-6ee880c52028115a83b79553c486ec01",
    "time_published": "20240430T204900",
    "authors": [
      "MATTHEW PERRONE"
    ],
    "summary": "WASHINGTON ( AP ) - Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest effort by the Biden administration targeting pharmaceutical that drive up prices.",
    "banner_image": "https://dims.apnews.com/dims4/default/2272aed/2147483647/strip/true/crop/3866x2575+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F61%2Fd5%2F206499b334b8add0edf03fba72b8%2F3f0b7b7fc99a40abbed0e1c8498fb1b6",
    "source": "Associated Press",
    "category_within_source": "Markets",
    "source_domain": "apnews.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.101599,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "HHH",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.14945",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "-0.058857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.204936",
        "ticker_sentiment_score": "-0.212742",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "-0.182485",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Could Be a Great Choice",
    "url": "https://www.zacks.com/stock/news/2265269/abbvie-abbv-could-be-a-great-choice",
    "time_published": "20240430T154504",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default127.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.403058,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.451494",
        "ticker_sentiment_score": "0.492283",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?",
    "url": "https://www.zacks.com/stock/news/2265330/will-these-5-drugbiotech-stocks-beat-q1-earnings-forecast",
    "time_published": "20240430T152000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.158563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.043835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.253426",
        "ticker_sentiment_score": "0.062112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042953",
        "ticker_sentiment_score": "0.043835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.293841",
        "ticker_sentiment_score": "0.13754",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.129453",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.293841",
        "ticker_sentiment_score": "0.163676",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.333444",
        "ticker_sentiment_score": "0.138141",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks To Watch In May 2024",
    "url": "https://stockmarket.com/featured/2-dividend-stocks-to-watch-in-may-2024-2024-04-30",
    "time_published": "20240430T135920",
    "authors": [
      "Joe Samuel"
    ],
    "summary": "The stock market is where investors trade shares of publicly traded companies. Among various investment options, dividend stocks are popular for their potential to provide income through regular dividend payments.",
    "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2021/02/ABBV-stock.jpg",
    "source": "StockMarket.com",
    "category_within_source": "n/a",
    "source_domain": "stockmarket.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999987"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.274843,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PM",
        "relevance_score": "0.367141",
        "ticker_sentiment_score": "0.318463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.433523",
        "ticker_sentiment_score": "0.112737",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2264825/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240430T131002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.225217,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FHI",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.126078",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FNLC",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.081569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.126078",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genstar Names Keith Martino to Strategic Advisory Board",
    "url": "https://www.prnewswire.com/news-releases/genstar-names-keith-martino-to-strategic-advisory-board-302130928.html",
    "time_published": "20240430T120000",
    "authors": [
      "LLC",
      "Genstar Capital Management"
    ],
    "summary": "Experienced Pharma Executive to Advise on the Firm's Healthcare Investments",
    "banner_image": "https://mma.prnewswire.com/media/478462/Genstar_Capital_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      }
    ],
    "overall_sentiment_score": 0.270428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.025632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.025632",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira\u00ae  ( adalimumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/30/2871897/0/en/U-S-Commercialization-Agreement-with-Quallent-to-Drive-Patient-Savings-with-First-High-Concentration-Citrate-Free-Interchangeable-Biosimilar-to-Humira-adalimumab.html",
    "time_published": "20240430T080000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, ICELAND, PARSIPPANY, N.J., and TEL AVIV, ISRAEL ( April 30, 2024 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.199349,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.522506",
        "ticker_sentiment_score": "0.261934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018891",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.112974",
        "ticker_sentiment_score": "0.094511",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.018891",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.018891",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira\u00ae  ( adalimumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/04/30/2871900/0/en/U-S-Commercialization-Agreement-with-Quallent-to-Drive-Patient-Savings-with-First-High-Concentration-Citrate-Free-Interchangeable-Biosimilar-to-Humira-adalimumab.html",
    "time_published": "20240430T080000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AVIV, Israel, April 30, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.199344,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.521812",
        "ticker_sentiment_score": "0.261714",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018861",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.112797",
        "ticker_sentiment_score": "0.093334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.018861",
        "ticker_sentiment_score": "0.056844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.018861",
        "ticker_sentiment_score": "0.056844",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2265766/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
    "time_published": "20240501T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default288.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.228683,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.486627",
        "ticker_sentiment_score": "0.122419",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2265739/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings",
    "time_published": "20240501T125010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default214.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.365182,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANIP",
        "relevance_score": "0.387875",
        "ticker_sentiment_score": "0.374989",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.387875",
        "ticker_sentiment_score": "0.325613",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.067347",
        "ticker_sentiment_score": "0.143437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors",
    "url": "https://www.cnbc.com/2024/05/01/healthy-returns-humira-sales-are-falling-but-abbvie-has-successors.html",
    "time_published": "20240501T124027",
    "authors": [
      "Annika Kim Constantino",
      "Ashley Capoot"
    ],
    "summary": "AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.",
    "banner_image": "https://image.cnbcfm.com/api/v1/image/105457944-1537294775037gettyimages-94816661.jpeg?v=1714565982&w=1920&h=1080",
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.156364,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.037098",
        "ticker_sentiment_score": "0.063075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.037098",
        "ticker_sentiment_score": "0.039029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.037098",
        "ticker_sentiment_score": "0.093982",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.255259",
        "ticker_sentiment_score": "0.28018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.219809",
        "ticker_sentiment_score": "0.00707",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. Quality Dividend Growth ETF  ( DGRW )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2265601/is-wisdomtree-us-quality-dividend-growth-etf-dgrw-a-strong-etf-right-now",
    "time_published": "20240501T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999981"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.291298,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.186076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.280938",
        "ticker_sentiment_score": "0.348814",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38594664/1000-invested-in-this-stock-10-years-ago-would-be-worth-3-100-today",
    "time_published": "20240502T183017",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%. Currently, AbbVie has a market capitalization of $282.47 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Quarter of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/05/02/2874427/0/en/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2024.html",
    "time_published": "20240502T150100",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "May 2, 2024 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.156708,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15173",
        "ticker_sentiment_score": "0.110284",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.407844",
        "ticker_sentiment_score": "0.175143",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061003",
        "ticker_sentiment_score": "0.209114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030524",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ",
    "url": "https://www.globenewswire.com/news-release/2024/05/02/2874308/0/en/Aprea-Therapeutics-Announces-Appointment-of-Nadeem-Q-Mirza-M-D-M-P-H-as-Chief-Medical-Officer-and-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html",
    "time_published": "20240502T131500",
    "authors": [
      "Aprea Therapeutics"
    ],
    "summary": "New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c63a19fa-f624-43d3-852f-d5956983aef3",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.127871,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SLRX",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.005709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.005709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APRE",
        "relevance_score": "0.126617",
        "ticker_sentiment_score": "0.137677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.005709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "0.005709",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Aprea Therapeutics  ( NASDAQ:APRE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38583506/aprea-therapeutics-announces-appointment-of-nadeem-q-mirza-m-d-m-p-h-as-chief-medical-officer-and-",
    "time_published": "20240502T131500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "DOYLESTOWN, Pa., May 02, 2024 ( GLOBE NEWSWIRE ) -- Aprea Therapeutics, Inc. APRE ( \"Aprea\", or the \"Company\" ) , a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990893"
      }
    ],
    "overall_sentiment_score": 0.132511,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SLRX",
        "relevance_score": "0.030838",
        "ticker_sentiment_score": "0.005685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.030838",
        "ticker_sentiment_score": "0.005685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APRE",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.133322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VSTM",
        "relevance_score": "0.030838",
        "ticker_sentiment_score": "0.005685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.030838",
        "ticker_sentiment_score": "0.005685",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA  ( NYSE:FIX ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/earnings/24/05/38619689/pharma-stock-roundup-lly-nvo-pfe-q1-results-jnjs-new-plan-to-resolve-talc-claims",
    "time_published": "20240503T200026",
    "authors": [
      "Zacks"
    ],
    "summary": "The first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli Lilly LLY, Novo Nordisk NVO, Pfizer PFE and AbbVie ABBV announced their first-quarter results this week. J&J JNJ announced a new plan to completely resolve its talc-related lawsuits.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/03/christina-victoria-craft-zhys6xn7sue-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.127813,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.27317",
        "ticker_sentiment_score": "0.172176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.206685",
        "ticker_sentiment_score": "-0.02327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "0.211201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.172836",
        "ticker_sentiment_score": "-0.086207",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims",
    "url": "https://www.zacks.com/stock/news/2268082/pharma-stock-roundup-lly-nvo-pfe-q1-results-jnjs-new-plan-to-resolve-talc-claims",
    "time_published": "20240503T152900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999919"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.115606,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.267926",
        "ticker_sentiment_score": "0.164976",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.202648",
        "ticker_sentiment_score": "0.003265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.169437",
        "ticker_sentiment_score": "0.188599",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.169437",
        "ticker_sentiment_score": "-0.033654",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "url": "https://www.zacks.com/stock/news/2267923/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick",
    "time_published": "20240503T134011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default348.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.282726,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.252317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Reasons to Buy AbbVie Stock on the Dip",
    "url": "https://www.fool.com/investing/2024/05/05/3-reasons-to-buy-abbvie-stock-on-the-dip/",
    "time_published": "20240505T174400",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "A little patience with the drugmaker should pay off.",
    "banner_image": "https://g.foolcdn.com/editorial/images/774891/patient-taking-medicine.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.168056,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.542261",
        "ticker_sentiment_score": "0.293827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.143438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2268560/3-top-dividend-stocks-to-maximize-your-retirement-income",
    "time_published": "20240506T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.187297,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.216376",
        "ticker_sentiment_score": "0.123181",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc. - Pacific Software  ( OTC:PFSF ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38639089/pacific-software-inc-announces-a-landmark-asset-acquisition-from-dreamaderm-inc",
    "time_published": "20240506T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "DANA POINT, Calif., May 06, 2024 ( GLOBE NEWSWIRE ) -- Pacific Software Inc. ( \"PFSF\" ) acquired certain assets of Dreamaderm Inc. ( \"Dreamaderm\" ) through a Plan of Acquisition, dated January 24, 2024. PFSF will now be the exclusive holder of a patented, first-in-class cosmeceutical asset, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.245383,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFSF",
        "relevance_score": "0.423054",
        "ticker_sentiment_score": "0.265068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049424",
        "ticker_sentiment_score": "0.098186",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2268385/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20240506T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default82.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.271794,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.236396",
        "ticker_sentiment_score": "0.203485",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.119532",
        "ticker_sentiment_score": "0.067655",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva Stock Is Powering Ahead as Schizophrenia News Offsets Mixed Earnings",
    "url": "https://www.barrons.com/amp/articles/teva-pharmaceutical-earnings-stock-price-47c2f088",
    "time_published": "20240507T203000",
    "authors": [
      "Josh Nathan-Kazis"
    ],
    "summary": "Teva Earnings Are Wednesday. Here's What to Expect. ...",
    "banner_image": "https://images.barrons.com/im-47318648/social",
    "source": "Barrons",
    "category_within_source": "n/a",
    "source_domain": "www.barrons.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.066686,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.102747",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.070725",
        "ticker_sentiment_score": "0.22671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA\u00ae  ( pembrolizumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/05/07/2877258/37704/en/CytomX-Therapeutics-Announces-Clinical-Collaboration-with-Merck-to-Evaluate-CX-801-in-Combination-with-KEYTRUDA-pembrolizumab.html",
    "time_published": "20240507T201500",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "- CX-801 is a dually masked, conditionally activated IFN\u03b12b cytokine designed using the CytomX Probody\u00ae Therapeutic Platform ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.086459,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.046708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.049293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.046708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.046708",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS",
    "url": "https://www.prnewswire.com/news-releases/halozyme-reports-first-quarter-2024-financial-and-operating-results-302138771.html",
    "time_published": "20240507T200100",
    "authors": [
      "Inc.",
      "Halozyme Therapeutics"
    ],
    "summary": "Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.241464,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.077566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.077566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.077566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.213423",
        "ticker_sentiment_score": "0.053529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.179788",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.077566",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.021601",
        "ticker_sentiment_score": "0.077566",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioPorto A/S Appoints President and CEO of BioPorto Inc.",
    "url": "https://www.globenewswire.com/news-release/2024/05/07/2876582/0/en/BioPorto-A-S-Appoints-President-and-CEO-of-BioPorto-Inc.html",
    "time_published": "20240507T111000",
    "authors": [
      "BioPorto A/S"
    ],
    "summary": "May 7, 2024News release ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/b9686d8c-3706-4a6c-b22a-ae722c122c21",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.260449,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "0.079326",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.083897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38712713/cytomx-therapeutics-reports-first-quarter-2024-financial-results-and-provides-business-update",
    "time_published": "20240508T201000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 ( EGFRxCD3 T-cell engager ) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY\u00ae ADC, in solid tumors. Initial data anticipated in the first ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.12341,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.015392",
        "ticker_sentiment_score": "0.04007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.023608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061512",
        "ticker_sentiment_score": "0.078222",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.046154",
        "ticker_sentiment_score": "0.071763",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva Pharmaceutical Industries  ( TEVA )  Q1 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/05/08/teva-pharmaceutical-industries-teva-q1-2024-earnin/",
    "time_published": "20240508T180014",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "TEVA earnings call for the period ending March 31, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.299828,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "0.145476",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "0.019038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "0.099614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "0.099614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "0.099614",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APG",
        "relevance_score": "0.036552",
        "ticker_sentiment_score": "0.15312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.004571",
        "ticker_sentiment_score": "-0.014318",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Agilysys  ( NASDAQ:AGYS )  Upgraded at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/agilysys-nasdaqagys-upgraded-at-stocknews-com.html",
    "time_published": "20240508T174051",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Agilysys ( NASDAQ:AGYS - Free Report ) from a hold rating to a buy rating in a research note published on Tuesday. Separately, Needham & Company LLC boosted their price objective on shares of Agilysys from $92.00 to $100.00 and gave the stock a buy rating in a ...",
    "banner_image": "https://www.marketbeat.com/logos/agilysys-inc-logo.png?v=20221129104409",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.380824,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.105382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGYS",
        "relevance_score": "0.827318",
        "ticker_sentiment_score": "0.598455",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.105382",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bausch Health Companies  ( NYSE:BHC )  Downgraded to \"Hold\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/bausch-health-companies-nysebhc-downgraded-to-hold-at-stocknews-com.html",
    "time_published": "20240508T151328",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com cut shares of Bausch Health Companies ( NYSE:BHC - Free Report ) from a buy rating to a hold rating in a research note published on Tuesday morning. Other research analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/bausch-health-companies-inc-logo.jpg&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.206278,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AIH",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.124143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NMR",
        "relevance_score": "0.128478",
        "ticker_sentiment_score": "0.214469",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JEF",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.016006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.124143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.016006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.830764",
        "ticker_sentiment_score": "0.346066",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.064449",
        "ticker_sentiment_score": "0.124143",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Apple Hospitality REIT  ( NYSE:APLE )  Lifted to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/apple-hospitality-reit-nyseaple-lifted-to-hold-at-stocknews-com.html",
    "time_published": "20240508T135952",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Apple Hospitality REIT ( NYSE:APLE - Free Report ) from a sell rating to a hold rating in a research report released on Tuesday morning.",
    "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&Symbol=APLE",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.297928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.221547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "-0.029427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FTS",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.194421",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.080188",
        "ticker_sentiment_score": "0.221547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "APLE",
        "relevance_score": "0.841282",
        "ticker_sentiment_score": "0.530178",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Boise Cascade  ( NYSE:BCC )  Upgraded by StockNews.com to \"Buy\"",
    "url": "https://www.defenseworld.net/2024/05/08/boise-cascade-nysebcc-upgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240508T125840",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Boise Cascade ( NYSE:BCC - Free Report ) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. Other research analysts have also recently issued reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/boise-cascade-logo.jpg?v=20221122065123",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": 0.242657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.040806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.085858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCC",
        "relevance_score": "0.685927",
        "ticker_sentiment_score": "0.407207",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.040806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.085858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38697873/jnana-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference",
    "time_published": "20240508T120056",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, May 08, 2024 ( GLOBE NEWSWIRE ) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.284775,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.19144",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142565",
        "ticker_sentiment_score": "0.19144",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Assertio  ( NASDAQ:ASRT )  Rating Increased to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/assertio-nasdaqasrt-rating-increased-to-buy-at-stocknews-com.html",
    "time_published": "20240508T114016",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Assertio ( NASDAQ:ASRT - Free Report ) from a hold rating to a buy rating in a research report report published on Tuesday morning. Shares of ASRT stock opened at $1.11 on Tuesday. The company has a current ratio of 1.83, a quick ratio of 1.43 and a ...",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/assertio-holdings-inc-logo.jpg?v=20210413140648&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.288321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.090981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASRT",
        "relevance_score": "0.866386",
        "ticker_sentiment_score": "0.47576",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.090981",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades IES  ( NASDAQ:IESC )  to Buy",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-downgrades-ies-nasdaqiesc-to-buy.html",
    "time_published": "20240508T104042",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com lowered shares of IES ( NASDAQ:IESC - Free Report ) from a strong-buy rating to a buy rating in a research report released on Tuesday. Shares of NASDAQ:IESC opened at $170.96 on Tuesday. The business has a fifty day simple moving average of $121.55 and a 200 day simple moving ...",
    "banner_image": "https://www.marketbeat.com/logos/ies-holdings-inc-logo.jpg?v=20221208104507",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.331235,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.123209",
        "ticker_sentiment_score": "0.16694",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.152064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.152064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IESC",
        "relevance_score": "0.722198",
        "ticker_sentiment_score": "0.508265",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FOREX:EUR",
        "relevance_score": "0.06179",
        "ticker_sentiment_score": "0.152064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CASI Pharmaceuticals  ( NASDAQ:CASI )  Coverage Initiated by Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/casi-pharmaceuticals-nasdaqcasi-coverage-initiated-by-analysts-at-stocknews-com.html",
    "time_published": "20240508T093056",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com began coverage on shares of CASI Pharmaceuticals ( NASDAQ:CASI - Free Report ) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biotechnology company's stock. Shares of CASI opened at $2.66 on Tuesday.",
    "banner_image": "https://www.marketbeat.com/logos/casi-pharmaceuticals-inc-logo.png?v=20230112123042",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      }
    ],
    "overall_sentiment_score": 0.115268,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.134737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.134737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CASI",
        "relevance_score": "0.870696",
        "ticker_sentiment_score": "0.199995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alico  ( NASDAQ:ALCO )  Lifted to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/alico-nasdaqalco-lifted-to-hold-at-stocknews-com.html",
    "time_published": "20240508T093047",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Alico ( NASDAQ:ALCO - Free Report ) from a sell rating to a hold rating in a research report report published on Tuesday morning. Shares of NASDAQ ALCO opened at $26.02 on Tuesday. The stock has a fifty day moving average price of $28.10 and a 200 day moving ...",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/alico-inc-logo.jpg&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.277471,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALCO",
        "relevance_score": "0.903334",
        "ticker_sentiment_score": "0.466449",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.114572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.001016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.114572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Air Transport Services Group  ( NASDAQ:ATSG )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/air-transport-services-group-nasdaqatsg-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240508T093047",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com upgraded shares of Air Transport Services Group ( NASDAQ:ATSG - Free Report ) from a sell rating to a hold rating in a report issued on Tuesday morning. Other equities research analysts have also issued reports about the company.",
    "banner_image": "https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=ATSG",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.258118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATSG",
        "relevance_score": "0.725269",
        "ticker_sentiment_score": "0.407139",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCTR",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.186751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.058047",
        "ticker_sentiment_score": "0.097",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A-Mark Precious Metals  ( NASDAQ:AMRK )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/a-mark-precious-metals-nasdaqamrk-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T093046",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com downgraded shares of A-Mark Precious Metals ( NASDAQ:AMRK - Free Report ) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/a-mark-precious-metals-inc-logo.gif&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.319273,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BK",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "0.212081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.155859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMRK",
        "relevance_score": "0.724687",
        "ticker_sentiment_score": "0.49919",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "0.155859",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Werner Enterprises  ( NASDAQ:WERN )  Downgraded to Sell at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/werner-enterprises-nasdaqwern-downgraded-to-sell-at-stocknews-com.html",
    "time_published": "20240508T092643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com cut shares of Werner Enterprises ( NASDAQ:WERN - Free Report ) from a hold rating to a sell rating in a report issued on Tuesday. A number of other brokerages also recently weighed in on WERN. Robert W.",
    "banner_image": "https://www.marketbeat.com/logos/werner-enterprises-inc-logo.png?v=20221122111448",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.247947,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WERN",
        "relevance_score": "0.839418",
        "ticker_sentiment_score": "0.426309",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.14769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.04483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VCTR",
        "relevance_score": "0.106305",
        "ticker_sentiment_score": "0.196987",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.053271",
        "ticker_sentiment_score": "0.14769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Upgrades OneSpan  ( NASDAQ:OSPN )  to Buy",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-upgrades-onespan-nasdaqospn-to-buy.html",
    "time_published": "20240508T081351",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "OneSpan ( NASDAQ:OSPN - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/onespan-inc-logo-1200x675.jpg?v=20221209152122",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.290664,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.160073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059785",
        "ticker_sentiment_score": "0.160073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OSPN",
        "relevance_score": "0.884744",
        "ticker_sentiment_score": "0.470657",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Calithera Biosciences  ( NASDAQ:CALA )  Now Covered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/calithera-biosciences-nasdaqcala-now-covered-by-stocknews-com.html",
    "time_published": "20240508T075650",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com started coverage on shares of Calithera Biosciences ( NASDAQ:CALA - Get Free Report ) in a report issued on Wednesday. The firm set a \"hold\" rating on the biotechnology company's stock. Shares of NASDAQ CALA opened at $0.02 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/calithera-biosciences-inc-logo-1200x675.png?v=20230127064836",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.276274,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CALA",
        "relevance_score": "0.943189",
        "ticker_sentiment_score": "0.470769",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.140794",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.140794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CB Financial Services  ( NASDAQ:CBFV )  Earns Hold Rating from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/cb-financial-services-nasdaqcbfv-earns-hold-rating-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T075649",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com initiated coverage on shares of CB Financial Services ( NASDAQ:CBFV - Get Free Report ) in a report issued on Wednesday. The brokerage set a \"hold\" rating on the bank's stock. CBFV has been the topic of a number of other reports.",
    "banner_image": "https://www.marketbeat.com/logos/cb-financial-services-inc-logo-1200x675.PNG?v=20210308162205",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.272842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CBFV",
        "relevance_score": "0.893548",
        "ticker_sentiment_score": "0.458237",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.129002",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.107016",
        "ticker_sentiment_score": "0.129002",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Calumet Specialty Products Partners  ( NASDAQ:CLMT )  Earns Hold Rating from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/calumet-specialty-products-partners-nasdaqclmt-earns-hold-rating-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T075647",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com assumed coverage on shares of Calumet Specialty Products Partners ( NASDAQ:CLMT - Get Free Report ) in a research note issued on Wednesday. The brokerage set a \"hold\" rating on the oil and gas company's stock.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/calumet-specialty-products-partners-lp-logo-1200x675.gif&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.270806,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.149085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.214032",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.021192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.149085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLMT",
        "relevance_score": "0.824717",
        "ticker_sentiment_score": "0.444211",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Cinedigm  ( NASDAQ:CIDM )  Coverage Initiated at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/cinedigm-nasdaqcidm-coverage-initiated-at-stocknews-com.html",
    "time_published": "20240508T075647",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Equities researchers at StockNews.com began coverage on shares of Cinedigm ( NASDAQ:CIDM - Get Free Report ) in a research report issued on Wednesday. The brokerage set a \"hold\" rating on the stock. Shares of CIDM opened at $0.83 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/cinedigm-corp-logo-1200x675.png?v=20230911133935",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.2619,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.092538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.092538",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNVS",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.231184",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Consolidated Communications  ( NASDAQ:CNSL )  Now Covered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/consolidated-communications-nasdaqcnsl-now-covered-by-stocknews-com.html",
    "time_published": "20240508T075646",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Research analysts at StockNews.com began coverage on shares of Consolidated Communications ( NASDAQ:CNSL - Get Free Report ) in a report issued on Wednesday. The brokerage set a \"sell\" rating on the utilities provider's stock. Shares of Consolidated Communications stock opened at $4.27 on ...",
    "banner_image": "https://www.marketbeat.com/logos/consolidated-communications-holdings-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.205377,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.178049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.100531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNSL",
        "relevance_score": "0.84035",
        "ticker_sentiment_score": "0.345149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.100531",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSBC",
        "relevance_score": "0.074692",
        "ticker_sentiment_score": "0.140952",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades Flexsteel Industries  ( NASDAQ:FLXS )  to Hold",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-downgrades-flexsteel-industries-nasdaqflxs-to-hold.html",
    "time_published": "20240508T075645",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Flexsteel Industries ( NASDAQ:FLXS - Get Free Report ) was downgraded by analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Wednesday. Separately, TheStreet raised Flexsteel Industries from a \"c\" rating to a \"b-\" rating in a research ...",
    "banner_image": "https://www.marketbeat.com/logos/flexsteel-industries-inc-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.310305,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FLXS",
        "relevance_score": "0.900454",
        "ticker_sentiment_score": "0.515218",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.097193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.218446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VCTR",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.218446",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.097193",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "First Capital  ( NASDAQ:FCAP )  Receives New Coverage from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/first-capital-nasdaqfcap-receives-new-coverage-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T075645",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com began coverage on shares of First Capital ( NASDAQ:FCAP - Get Free Report ) in a report released on Wednesday. The firm set a \"hold\" rating on the savings and loans company's stock. FCAP opened at $28.03 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/first-capital-inc-logo-1200x675.png?v=20211203083401",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.224811,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FCAP",
        "relevance_score": "0.859898",
        "ticker_sentiment_score": "0.380401",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.136458",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.136458",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Initiates Coverage on SB Financial Group  ( NASDAQ:SBFG ) ",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-initiates-coverage-on-sb-financial-group-nasdaqsbfg.html",
    "time_published": "20240508T075643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com initiated coverage on shares of SB Financial Group ( NASDAQ:SBFG - Get Free Report ) in a research note issued to investors on Wednesday. The firm set a \"hold\" rating on the financial services provider's stock. NASDAQ:SBFG opened at $13.51 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/sb-financial-group-inc-logo-1200x675.png?v=20211213084842",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271742,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.11578",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBFG",
        "relevance_score": "0.764287",
        "ticker_sentiment_score": "0.433827",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.09439",
        "ticker_sentiment_score": "0.11578",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Conduent  ( NASDAQ:CNDT )  Upgraded by StockNews.com to \"Buy\"",
    "url": "https://www.defenseworld.net/2024/05/08/conduent-nasdaqcndt-upgraded-by-stocknews-com-to-buy.html",
    "time_published": "20240508T075643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Conduent ( NASDAQ:CNDT - Get Free Report ) was upgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Wednesday. Separately, Noble Financial began coverage on Conduent in a research report on Thursday, March 14th.",
    "banner_image": "https://www.marketbeat.com/logos/conduent-incorporated-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      }
    ],
    "overall_sentiment_score": 0.243003,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CNDT",
        "relevance_score": "0.862496",
        "ticker_sentiment_score": "0.407577",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.113728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.113728",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Paramount Global  ( NASDAQ:PARA )  Lifted to \"Hold\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/paramount-global-nasdaqpara-lifted-to-hold-at-stocknews-com.html",
    "time_published": "20240508T075643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Paramount Global ( NASDAQ:PARA - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a report released on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/paramount-global-logo-1200x675.png?v=20240426082816",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.252651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.198853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.133905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.198853",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.133905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PARA",
        "relevance_score": "0.817066",
        "ticker_sentiment_score": "0.416021",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "QUALCOMM  ( NASDAQ:QCOM )  Rating Lowered to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/qualcomm-nasdaqqcom-rating-lowered-to-buy-at-stocknews-com.html",
    "time_published": "20240508T075643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "QUALCOMM ( NASDAQ:QCOM - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research report issued on Wednesday. QCOM has been the subject of several other reports.",
    "banner_image": "https://www.marketbeat.com/logos/qualcomm-incorporated-logo-1200x675.png?v=20221020155845",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.305958,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.097632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.070674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.097632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.835692",
        "ticker_sentiment_score": "0.498287",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.070674",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Mesoblast  ( NASDAQ:MESO )  Downgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/mesoblast-nasdaqmeso-downgraded-by-stocknews-com.html",
    "time_published": "20240508T075643",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Mesoblast ( NASDAQ:MESO - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a research report issued to clients and investors on Wednesday. Separately, Cantor Fitzgerald reiterated an \"overweight\" rating on shares of Mesoblast in a ...",
    "banner_image": "https://www.marketbeat.com/logos/mesoblast-limited-logo-1200x675.jpg?v=20221212151556",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.173946,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MESO",
        "relevance_score": "0.844916",
        "ticker_sentiment_score": "0.294839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.006876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.006876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Initiates Coverage on SP Plus  ( NASDAQ:SP ) ",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-initiates-coverage-on-sp-plus-nasdaqsp-2.html",
    "time_published": "20240508T075642",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Research analysts at StockNews.com assumed coverage on shares of SP Plus ( NASDAQ:SP - Get Free Report ) in a research report issued on Wednesday. The firm set a \"hold\" rating on the business services provider's stock.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/sp-plus-corp-logo-1200x675.gif&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.266426,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TKOMF",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.195967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.104442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.135729",
        "ticker_sentiment_score": "0.195967",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.104442",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SP",
        "relevance_score": "0.76853",
        "ticker_sentiment_score": "0.427377",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NXP Semiconductors  ( NASDAQ:NXPI )  Upgraded at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/nxp-semiconductors-nasdaqnxpi-upgraded-at-stocknews-com.html",
    "time_published": "20240508T075642",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "NXP Semiconductors ( NASDAQ:NXPI - Get Free Report ) was upgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report issued on Wednesday. Other analysts have also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=NXPI",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.243882,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.047975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.047975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NXPI",
        "relevance_score": "0.828345",
        "ticker_sentiment_score": "0.404497",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Intuit  ( NASDAQ:INTU )  Downgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/intuit-nasdaqintu-downgraded-by-stocknews-com.html",
    "time_published": "20240508T075642",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Intuit ( NASDAQ:INTU - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research report issued on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/400px-Intuit_Logo.svg-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.247214,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.117848",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.063319",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INTU",
        "relevance_score": "0.770793",
        "ticker_sentiment_score": "0.400169",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.04794",
        "ticker_sentiment_score": "0.117848",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Begins Coverage on Jaguar Health  ( NASDAQ:JAGX ) ",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-begins-coverage-on-jaguar-health-nasdaqjagx.html",
    "time_published": "20240508T075642",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com assumed coverage on shares of Jaguar Health ( NASDAQ:JAGX - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a \"sell\" rating on the biotechnology company's stock. Shares of NASDAQ:JAGX opened at $0.30 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/jaguar-health-inc-logo-1200x675.png?v=20230118143843",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.111805,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.070365",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAGX",
        "relevance_score": "0.81111",
        "ticker_sentiment_score": "0.188567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.173333",
        "ticker_sentiment_score": "0.070365",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Trevena  ( NASDAQ:TRVN )  Research Coverage Started at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/trevena-nasdaqtrvn-research-coverage-started-at-stocknews-com.html",
    "time_published": "20240508T075641",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Stock analysts at StockNews.com initiated coverage on shares of Trevena ( NASDAQ:TRVN - Get Free Report ) in a research report issued to clients and investors on Wednesday. The firm set a \"sell\" rating on the biopharmaceutical company's stock.",
    "banner_image": "https://www.marketbeat.com/logos/trevena-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      }
    ],
    "overall_sentiment_score": 0.137943,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "-0.018469",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRVN",
        "relevance_score": "0.806129",
        "ticker_sentiment_score": "0.231012",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.09402",
        "ticker_sentiment_score": "-0.018469",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CapStar Financial  ( NASDAQ:CSTR )  Receives New Coverage from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/capstar-financial-nasdaqcstr-receives-new-coverage-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T075641",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com began coverage on shares of CapStar Financial ( NASDAQ:CSTR - Get Free Report ) in a report issued on Wednesday. The firm set a \"hold\" rating on the bank's stock. CapStar Financial stock opened at $20.10 on Wednesday. CapStar Financial has a 52 week low of $11.22 and a 52 week ...",
    "banner_image": "https://www.marketbeat.com/logos/capstar-financial-holdings-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.23712,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.126473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.126473",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Airgain  ( NASDAQ:AIRG )  Earns Hold Rating from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/airgain-nasdaqairg-earns-hold-rating-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T075641",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com initiated coverage on shares of Airgain ( NASDAQ:AIRG - Get Free Report ) in a report issued on Wednesday. The brokerage set a \"hold\" rating on the technology company's stock. NASDAQ:AIRG opened at $5.46 on Wednesday. Airgain has a 52 week low of $1.63 and a 52 week ...",
    "banner_image": "https://www.marketbeat.com/logos/airgain-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999956"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      }
    ],
    "overall_sentiment_score": 0.247155,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.216401",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.216401",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRG",
        "relevance_score": "0.70295",
        "ticker_sentiment_score": "0.295561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Rubicon Technology  ( NASDAQ:RBCN )  Coverage Initiated at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/rubicon-technology-nasdaqrbcn-coverage-initiated-at-stocknews-com.html",
    "time_published": "20240508T075641",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Stock analysts at StockNews.com started coverage on shares of Rubicon Technology ( NASDAQ:RBCN - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a \"sell\" rating on the semiconductor company's stock. Shares of NASDAQ:RBCN opened at $0.82 on Wednesday.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/RubiconLogo-1200x675.jpg&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.167102,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.060927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.060927",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ACNB  ( NASDAQ:ACNB )  Downgraded to \"Sell\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/acnb-nasdaqacnb-downgraded-to-sell-at-stocknews-com.html",
    "time_published": "20240508T073446",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "ACNB ( NASDAQ:ACNB - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Wednesday. Separately, Piper Sandler reduced their price objective on ACNB from $40.00 to $37.00 and set a \"neutral\" rating on the ...",
    "banner_image": "https://www.marketbeat.com/logos/acnb-co-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998962"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.27161,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.130809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.130809",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ambac Financial Group  ( NYSE:AMBC )  Upgraded at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/ambac-financial-group-nyseambc-upgraded-at-stocknews-com.html",
    "time_published": "20240508T073446",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Ambac Financial Group ( NYSE:AMBC - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a note issued to investors on Wednesday. AMBC stock opened at $18.04 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/ambac-financial-group-inc-logo-1200x675.jpg?v=20230815111537",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.2589,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "QUBHF",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.248868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.018275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMBC",
        "relevance_score": "0.798895",
        "ticker_sentiment_score": "0.421244",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.067919",
        "ticker_sentiment_score": "-0.018275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FHI",
        "relevance_score": "0.135347",
        "ticker_sentiment_score": "0.248868",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Aeterna Zentaris  ( NASDAQ:AEZS )  Coverage Initiated at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/aeterna-zentaris-nasdaqaezs-coverage-initiated-at-stocknews-com-2.html",
    "time_published": "20240508T073446",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com assumed coverage on shares of Aeterna Zentaris ( NASDAQ:AEZS - Get Free Report ) ( TSE:AEZ ) in a research note issued to investors on Wednesday. The firm set a \"sell\" rating on the biopharmaceutical company's stock. Aeterna Zentaris stock opened at $8.03 on ...",
    "banner_image": "https://www.marketbeat.com/logos/aeterna-zentaris-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      }
    ],
    "overall_sentiment_score": 0.16389,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.158776",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AEZS",
        "relevance_score": "0.87799",
        "ticker_sentiment_score": "0.281002",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "-0.042145",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.158776",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "TE Connectivity  ( NYSE:TEL )  Coverage Initiated at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/te-connectivity-nysetel-coverage-initiated-at-stocknews-com-2.html",
    "time_published": "20240508T073445",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com initiated coverage on shares of TE Connectivity ( NYSE:TEL - Get Free Report ) in a note issued to investors on Wednesday. The firm set a \"buy\" rating on the electronics maker's stock.",
    "banner_image": "https://www.marketbeat.com/logos/te-connectivity-ltd-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.325295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.072382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JEF",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.072382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEL",
        "relevance_score": "0.832645",
        "ticker_sentiment_score": "0.524909",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.108678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.072382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.050044",
        "ticker_sentiment_score": "0.108678",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Snowflake  ( NYSE:SNOW )  Downgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/snowflake-nysesnow-downgraded-by-stocknews-com.html",
    "time_published": "20240508T073444",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Snowflake ( NYSE:SNOW - Get Free Report ) was downgraded by analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a report released on Wednesday. Other analysts also recently issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/snowflake-inc-logo-1200x675.png?v=20200921121226",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.320653,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.24051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCORF",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.055428",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.048621",
        "ticker_sentiment_score": "0.24051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNOW",
        "relevance_score": "0.77735",
        "ticker_sentiment_score": "0.506556",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "StockNews.com Initiates Coverage on L.S. Starrett  ( NYSE:SCX ) ",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-initiates-coverage-on-l-s-starrett-nysescx.html",
    "time_published": "20240508T073444",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com began coverage on shares of L.S. Starrett ( NYSE:SCX - Get Free Report ) in a report issued on Wednesday. The firm set a \"buy\" rating on the stock. Shares of SCX stock opened at $16.08 on Wednesday. The company has a current ratio of 3.11, a quick ratio of 1.42 and a ...",
    "banner_image": "https://www.marketbeat.com/logos/the-ls-starrett-company-logo-1200x675.png?v=20230104144253",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.210198,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.12124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.12124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Enservco  ( NYSEAMERICAN:ENSV )  Now Covered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/enservco-nyseamericanensv-now-covered-by-stocknews-com.html",
    "time_published": "20240508T073443",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Research analysts at StockNews.com initiated coverage on shares of Enservco ( NYSEAMERICAN:ENSV - Get Free Report ) in a research report issued to clients and investors on Wednesday. The firm set a \"sell\" rating on the oil and gas producer's stock. ENSV stock opened at $0.21 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/enservco-corp-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.194499,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.233951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.233951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Birks Group  ( NYSEAMERICAN:BGI )  Earns Sell Rating from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/birks-group-nyseamericanbgi-earns-sell-rating-from-analysts-at-stocknews-com-2.html",
    "time_published": "20240508T073443",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com began coverage on shares of Birks Group ( NYSEAMERICAN:BGI - Get Free Report ) in a note issued to investors on Wednesday. The firm set a \"sell\" rating on the stock. BGI opened at $2.57 on Wednesday. Birks Group has a 12 month low of $2.25 and a 12 month ...",
    "banner_image": "https://www.marketbeat.com/logos/birks-group-inc-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.29451,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.246049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.246049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.140076",
        "ticker_sentiment_score": "0.246049",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Enerplus  ( NYSE:ERF )  Now Covered by Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/enerplus-nyseerf-now-covered-by-analysts-at-stocknews-com.html",
    "time_published": "20240508T073442",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com started coverage on shares of Enerplus ( NYSE:ERF - Get Free Report ) ( TSE:ERF ) in a research report issued on Wednesday. The brokerage set a \"hold\" rating on the oil and natural gas company's stock. ERF has been the subject of several other research ...",
    "banner_image": "https://www.marketbeat.com/logos/enerplus-co-logo-1200x675.jpg?v=20240426110522",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999976"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.322662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NKSH",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.090096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WHG",
        "relevance_score": "0.12645",
        "ticker_sentiment_score": "0.230136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ERF",
        "relevance_score": "0.847959",
        "ticker_sentiment_score": "0.523173",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.104363",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RBCPF",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.090096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.12645",
        "ticker_sentiment_score": "0.230136",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.063425",
        "ticker_sentiment_score": "0.104363",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lear  ( NYSE:LEA )  Downgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/lear-nyselea-downgraded-by-stocknews-com.html",
    "time_published": "20240508T073442",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Lear ( NYSE:LEA - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report released on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/lear-corporation-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.922939"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.292235,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCS",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "-0.009792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "-0.009792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "-0.009792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LEA",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.458633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BEN",
        "relevance_score": "0.085324",
        "ticker_sentiment_score": "0.25752",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.115889",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.115889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Avalon  ( NYSE:AWX )  Coverage Initiated by Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/avalon-nyseawx-coverage-initiated-by-analysts-at-stocknews-com.html",
    "time_published": "20240508T073442",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Research analysts at StockNews.com assumed coverage on shares of Avalon ( NYSE:AWX - Get Free Report ) in a note issued to investors on Wednesday. The firm set a \"hold\" rating on the stock. NYSE AWX opened at $2.13 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/avalon-holdings-co-logo-1200x675.png?v=20230619103845",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.094894,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.060403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WM",
        "relevance_score": "0.386875",
        "ticker_sentiment_score": "0.131626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "0.060403",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can-Fite BioPharma  ( NYSE:CANF )  Receives New Coverage from Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/can-fite-biopharma-nysecanf-receives-new-coverage-from-analysts-at-stocknews-com.html",
    "time_published": "20240508T073442",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma ( NYSE:CANF - Get Free Report ) in a report released on Wednesday. The brokerage set a \"hold\" rating on the stock. Shares of NYSE:CANF opened at $2.07 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/can-fite-biopharma-ltd-logo-1200x675.png?v=20230705115930",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      }
    ],
    "overall_sentiment_score": 0.095557,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.046035",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.046035",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Civeo  ( NYSE:CVEO )  Lifted to \"Strong-Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/civeo-nysecveo-lifted-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240508T073441",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Civeo ( NYSE:CVEO - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report released on Wednesday. Separately, Stifel Nicolaus upped their price target on Civeo from $30.00 to $31.00 and gave the company a \"buy\" rating in a ...",
    "banner_image": "https://www.marketbeat.com/logos/civeo-corp-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.274566,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NRHI",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.147736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVEO",
        "relevance_score": "0.912924",
        "ticker_sentiment_score": "0.463856",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.147736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.147736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "InnSuites Hospitality Trust  ( NYSE:IHT )  Research Coverage Started at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/innsuites-hospitality-trust-nyseiht-research-coverage-started-at-stocknews-com.html",
    "time_published": "20240508T073441",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com began coverage on shares of InnSuites Hospitality Trust ( NYSE:IHT - Get Free Report ) in a report released on Wednesday. The brokerage set a \"hold\" rating on the stock. IHT stock opened at $1.34 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/innsuites-hospitality-trust-logo-1200x675.jpg?v=20230515112809",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.356054,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.148056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.148056",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cummins  ( NYSE:CMI )  Raised to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/cummins-nysecmi-raised-to-buy-at-stocknews-com.html",
    "time_published": "20240508T073441",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Cummins ( NYSE:CMI - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Wednesday. CMI has been the subject of several other research reports.",
    "banner_image": "https://www.marketbeat.com/logos/cummins-inc-logo-1200x675.png?v=20231228134629",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.284527,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.011762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.011762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.011762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.093845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENV",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.217845",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.011762",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.093845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMI",
        "relevance_score": "0.767202",
        "ticker_sentiment_score": "0.393068",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Credit Suisse Group  ( NYSE:CS )  Now Covered by Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/credit-suisse-group-nysecs-now-covered-by-analysts-at-stocknews-com.html",
    "time_published": "20240508T073441",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investment analysts at StockNews.com started coverage on shares of Credit Suisse Group ( NYSE:CS - Get Free Report ) in a report issued on Wednesday. The brokerage set a \"hold\" rating on the financial services provider's stock. NYSE:CS opened at $0.89 on Wednesday.",
    "banner_image": "https://www.marketbeat.com/logos/credit-suisse-group-ag-logo-1200x675.png?v=20221109063955",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.33649,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.119109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.119109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comstock  ( NYSE:LODE )  Now Covered by Analysts at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/comstock-nyselode-now-covered-by-analysts-at-stocknews-com.html",
    "time_published": "20240508T073441",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "StockNews.com began coverage on shares of Comstock ( NYSE:LODE - Get Free Report ) in a report released on Wednesday. The firm set a \"sell\" rating on the stock. Shares of LODE stock opened at $0.25 on Wednesday. Comstock has a fifty-two week low of $0.24 and a fifty-two week high of $0.99.",
    "banner_image": "https://www.marketbeat.com/logos/comstock-inc-logo-1200x675.png?v=20230718054302",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      }
    ],
    "overall_sentiment_score": 0.175184,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.130817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.130817",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "El Pollo Loco  ( NASDAQ:LOCO )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/el-pollo-loco-nasdaqloco-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240508T073244",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "El Pollo Loco ( NASDAQ:LOCO - Get Free Report ) was upgraded by analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report issued on Monday. Separately, Truist Financial boosted their price objective on El Pollo Loco from $10.00 to $12.00 and gave the company a \"hold\" rating ...",
    "banner_image": "https://www.marketbeat.com/logos/el-pollo-loco-holdings-inc-logo-1200x675.png?v=20221213151001",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.288463,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.088362",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.116536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LOCO",
        "relevance_score": "0.864098",
        "ticker_sentiment_score": "0.477957",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.116536",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "British American Tobacco  ( NYSE:BTI )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/british-american-tobacco-nysebti-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T071641",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "British American Tobacco ( NYSE:BTI - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research report issued on Monday. Shares of BTI opened at $29.95 on Monday. British American Tobacco has a 1 year low of $28.25 and a 1 year ...",
    "banner_image": "https://www.marketbeat.com/logos/british-american-tobacco-plc-logo-1200x675.png?v=20221021075422",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.332052,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.05865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.002058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.05865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTI",
        "relevance_score": "0.795061",
        "ticker_sentiment_score": "0.524545",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BorgWarner  ( NYSE:BWA )  Lifted to \"Buy\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/borgwarner-nysebwa-lifted-to-buy-at-stocknews-com.html",
    "time_published": "20240508T063246",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "BorgWarner ( NYSE:BWA - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock.",
    "banner_image": "https://www.marketbeat.com/logos/Borg_Warner_logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.299547,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCS",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.052572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.052572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.052572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.215167",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.103099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BWA",
        "relevance_score": "0.692465",
        "ticker_sentiment_score": "0.458131",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.040691",
        "ticker_sentiment_score": "0.103099",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RJF",
        "relevance_score": "0.081276",
        "ticker_sentiment_score": "0.215167",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forum Energy Technologies  ( NYSE:FET )  Lowered to \"Hold\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/forum-energy-technologies-nysefet-lowered-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063245",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Forum Energy Technologies ( NYSE:FET - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued on Monday. Separately, TheStreet cut Forum Energy Technologies from a \"c\" rating to a \"d\" rating in a research note on ...",
    "banner_image": "https://www.marketbeat.com/logos/forum-energy-technologies-inc-logo-1200x675.png?v=20221220115327",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.298044,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.21214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.196764",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FET",
        "relevance_score": "0.781591",
        "ticker_sentiment_score": "0.475166",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.21214",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Hyatt Hotels  ( NYSE:H )  Upgraded by StockNews.com to \"Hold\"",
    "url": "https://www.defenseworld.net/2024/05/08/hyatt-hotels-nyseh-upgraded-by-stocknews-com-to-hold.html",
    "time_published": "20240508T063245",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Hyatt Hotels ( NYSE:H - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a report issued on Monday. H has been the subject of several other research reports.",
    "banner_image": "https://www.marketbeat.com/logos/hyatt-hotels-co-logo-1200x675.png?v=20221109133308",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.212599,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCS",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "-0.046059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "-0.046059",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "H",
        "relevance_score": "0.789566",
        "ticker_sentiment_score": "0.350057",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BK",
        "relevance_score": "0.090645",
        "ticker_sentiment_score": "0.196931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.040463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.045396",
        "ticker_sentiment_score": "0.040463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RJF",
        "relevance_score": "0.090645",
        "ticker_sentiment_score": "0.196931",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Welltower  ( NYSE:WELL )  Upgraded to \"Hold\" at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/welltower-nysewell-upgraded-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063244",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Welltower ( NYSE:WELL - Get Free Report ) was upgraded by StockNews.com from a \"sell\" rating to a \"hold\" rating in a research report issued to clients and investors on Monday. Other analysts have also recently issued reports about the company.",
    "banner_image": "https://www.marketbeat.com/logos/welltower-inc-logo-1200x675.jpg?v=20210524092835",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.803643"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.311032,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFG",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.176078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.264396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.176078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.264396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNS",
        "relevance_score": "0.062271",
        "ticker_sentiment_score": "0.040016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WELL",
        "relevance_score": "0.84035",
        "ticker_sentiment_score": "0.505925",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Manchester United  ( NYSE:MANU )  Upgraded at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/manchester-united-nysemanu-upgraded-at-stocknews-com.html",
    "time_published": "20240508T063242",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Manchester United ( NYSE:MANU - Get Free Report ) was upgraded by analysts at StockNews.com to a \"sell\" rating in a research report issued on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/manchester-united-plc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.267581,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MANU",
        "relevance_score": "0.88438",
        "ticker_sentiment_score": "0.448195",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.140345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.140345",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Lowers Kohl's  ( NYSE:KSS )  to Hold",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-lowers-kohls-nysekss-to-hold.html",
    "time_published": "20240508T063242",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Kohl's ( NYSE:KSS - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Monday. KSS has been the subject of a number of other research reports.",
    "banner_image": "https://www.marketbeat.com/logos/kohls-co-logo-1200x675.png?v=20221117151850",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.247199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KSS",
        "relevance_score": "0.883743",
        "ticker_sentiment_score": "0.418564",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.165126",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.067013",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.165126",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.067013",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AG Mortgage Investment Trust  ( NYSE:MITT )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/ag-mortgage-investment-trust-nysemitt-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240508T063242",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "AG Mortgage Investment Trust ( NYSE:MITT - Get Free Report ) was upgraded by investment analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research report issued on Monday. Other research analysts have also issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/ag-mortgage-investment-trust-inc-logo-1200x675.jpg?v=20221221142853",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.447245,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.239206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.22628",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.239206",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RJF",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.22628",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Phillips 66  ( NYSE:PSX )  Rating Lowered to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/phillips-66-nysepsx-rating-lowered-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063242",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Phillips 66 ( NYSE:PSX - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued on Monday. Other research analysts have also recently issued reports about the company.",
    "banner_image": "https://www.marketbeat.com/logos/phillips-66-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.752319"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.281919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "C",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.058721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.058721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSX",
        "relevance_score": "0.710619",
        "ticker_sentiment_score": "0.437092",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BNS",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.058721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.134247",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.058721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.044469",
        "ticker_sentiment_score": "0.134247",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ryman Hospitality Properties  ( NYSE:RHP )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/ryman-hospitality-properties-nyserhp-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T063102",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Ryman Hospitality Properties ( NYSE:RHP - Get Free Report ) was downgraded by StockNews.com from a \"hold\" rating to a \"sell\" rating in a research note issued to investors on Monday. RHP has been the topic of a number of other reports.",
    "banner_image": "https://www.marketbeat.com/logos/ryman-hospitality-properties-inc-logo-1200x675.png?v=20240426104912",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.332057,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFG",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.158757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.070533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.183195",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RHP",
        "relevance_score": "0.739411",
        "ticker_sentiment_score": "0.514206",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.183195",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.070533",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Banco Santander  ( NYSE:SAN )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/banco-santander-nysesan-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240508T063101",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Banco Santander ( NYSE:SAN - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a note issued to investors on Monday. Separately, Barclays raised shares of Banco Santander from an \"equal weight\" rating to an \"overweight\" rating ...",
    "banner_image": "https://www.marketbeat.com/logos/banco-santander-sa-logo-1200x675.jpg?v=20220526112848",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.33209,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SAN",
        "relevance_score": "0.882713",
        "ticker_sentiment_score": "0.541748",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.129947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.019368",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.129947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "U.S. Silica  ( NYSE:SLCA )  Now Covered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/u-s-silica-nyseslca-now-covered-by-stocknews-com.html",
    "time_published": "20240508T063059",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Analysts at StockNews.com assumed coverage on shares of U.S. Silica ( NYSE:SLCA - Get Free Report ) in a research note issued on Monday. The firm set a \"hold\" rating on the mining company's stock. Separately, Citigroup lifted their price target on U.S.",
    "banner_image": "https://www.marketbeat.com/logos/us-silica-holdings-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.267974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GRMN",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.151361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.151361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.050894",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Summit Midstream Partners  ( NYSE:SMLP )  Rating Increased to Strong-Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/summit-midstream-partners-nysesmlp-rating-increased-to-strong-buy-at-stocknews-com.html",
    "time_published": "20240508T063058",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Summit Midstream Partners ( NYSE:SMLP - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued on Monday. SMLP opened at $35.00 on Monday. Summit Midstream Partners has a twelve month low of $13.00 and a ...",
    "banner_image": "https://www.marketbeat.com/logos/summit-midstream-partners-lp-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.229584,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SMLP",
        "relevance_score": "0.855759",
        "ticker_sentiment_score": "0.385778",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.161199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "0.161199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Aldeyra Therapeutics  ( NASDAQ:ALDX )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/aldeyra-therapeutics-nasdaqaldx-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T063056",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Aldeyra Therapeutics ( NASDAQ:ALDX - Get Free Report ) was downgraded by analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a research report issued to clients and investors on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/aldeyra-therapeutics-inc-logo-1200x675.jpg?v=20200608155827",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.374171,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALDX",
        "relevance_score": "0.745773",
        "ticker_sentiment_score": "0.571139",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.137079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.259394",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.137079",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DB",
        "relevance_score": "0.113329",
        "ticker_sentiment_score": "0.259394",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AMERISAFE  ( NASDAQ:AMSF )  Rating Lowered to Sell at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/amerisafe-nasdaqamsf-rating-lowered-to-sell-at-stocknews-com.html",
    "time_published": "20240508T063055",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "AMERISAFE ( NASDAQ:AMSF - Get Free Report ) was downgraded by analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a report issued on Monday. Several other research analysts also recently commented on the company.",
    "banner_image": "https://www.marketbeat.com/logos/amerisafe-inc-logo-1200x675.jpg?v=20221202072144",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.295768,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMSF",
        "relevance_score": "0.861197",
        "ticker_sentiment_score": "0.485296",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.12729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.12729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AxoGen  ( NASDAQ:AXGN )  Rating Lowered to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/axogen-nasdaqaxgn-rating-lowered-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063054",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "AxoGen ( NASDAQ:AXGN - Get Free Report ) was downgraded by equities researchers at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research report issued to clients and investors on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/axogen-inc-logo-1200x675.jpg?v=20221212220715",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.235413,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXGN",
        "relevance_score": "0.704675",
        "ticker_sentiment_score": "0.297664",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.077112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055621",
        "ticker_sentiment_score": "0.077112",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "DMC Global  ( NASDAQ:BOOM )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/dmc-global-nasdaqboom-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T063053",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "DMC Global ( NASDAQ:BOOM - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a note issued to investors on Monday. Separately, Stifel Nicolaus cut their price objective on shares of DMC Global from $27.00 to $24.00 and set a \"buy\" ...",
    "banner_image": "https://www.marketbeat.com/logos/dmc-global-inc-logo-1200x675.jpg?v=20221214141707",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.230916,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.062125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BOOM",
        "relevance_score": "0.776097",
        "ticker_sentiment_score": "0.37574",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.178668",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.062125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AXT  ( NASDAQ:AXTI )  Rating Increased to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/axt-nasdaqaxti-rating-increased-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063053",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "AXT ( NASDAQ:AXTI - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a \"sell\" rating to a \"hold\" rating in a research note issued on Monday. Several other analysts have also recently weighed in on the stock.",
    "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/axt-inc-logo-1200x675.gif&w=240&h=240&zc=2",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.202694,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AXTI",
        "relevance_score": "0.868429",
        "ticker_sentiment_score": "0.344787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.071066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.192043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.071066",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Beacon Roofing Supply  ( NASDAQ:BECN )  Rating Lowered to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/beacon-roofing-supply-nasdaqbecn-rating-lowered-to-hold-at-stocknews-com.html",
    "time_published": "20240508T063053",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Beacon Roofing Supply ( NASDAQ:BECN - Get Free Report ) was downgraded by StockNews.com from a \"buy\" rating to a \"hold\" rating in a note issued to investors on Monday. Several other equities research analysts have also commented on BECN. Robert W.",
    "banner_image": "https://www.marketbeat.com/logos/beacon-roofing-supply-inc-logo-1200x675.png?v=20221117150154",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.287574,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BECN",
        "relevance_score": "0.729067",
        "ticker_sentiment_score": "0.411981",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.103437",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PNC",
        "relevance_score": "0.087663",
        "ticker_sentiment_score": "0.214663",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.043898",
        "ticker_sentiment_score": "0.103437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades Dorchester Minerals  ( NASDAQ:DMLP )  to Hold",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-downgrades-dorchester-minerals-nasdaqdmlp-to-hold.html",
    "time_published": "20240508T063052",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Dorchester Minerals ( NASDAQ:DMLP - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a research note issued to investors on Monday. DMLP opened at $31.94 on Monday. The stock has a fifty day moving average of $33.09 and a 200-day ...",
    "banner_image": "https://www.marketbeat.com/logos/dorchester-minerals-lp-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.392615,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DMLP",
        "relevance_score": "0.835692",
        "ticker_sentiment_score": "0.614317",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.267349",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.267349",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Columbia Banking System  ( NASDAQ:COLB )  Stock Rating Upgraded by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/columbia-banking-system-nasdaqcolb-stock-rating-upgraded-by-stocknews-com.html",
    "time_published": "20240508T063052",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Columbia Banking System ( NASDAQ:COLB - Get Free Report ) was upgraded by StockNews.com from a \"sell\" rating to a \"hold\" rating in a research report issued on Monday. COLB has been the subject of several other reports.",
    "banner_image": "https://www.marketbeat.com/logos/columbia-banking-system-inc-logo-1200x675.png?v=20240426131356",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999982"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.221564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FITB",
        "relevance_score": "0.1172",
        "ticker_sentiment_score": "0.231228",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "-0.023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FPAFF",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.204065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.112996",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COLB",
        "relevance_score": "0.859573",
        "ticker_sentiment_score": "0.374508",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.058759",
        "ticker_sentiment_score": "0.112996",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cimpress  ( NASDAQ:CMPR )  Rating Lowered to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/cimpress-nasdaqcmpr-rating-lowered-to-buy-at-stocknews-com.html",
    "time_published": "20240508T063052",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Cimpress ( NASDAQ:CMPR - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research report issued to clients and investors on Monday. CMPR has been the subject of a number of other reports.",
    "banner_image": "https://www.marketbeat.com/logos/cimpress-nv-logo-1200x675.png",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.288614,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFG",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.206841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.112484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.048657",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMPR",
        "relevance_score": "0.700132",
        "ticker_sentiment_score": "0.421922",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.051663",
        "ticker_sentiment_score": "0.048657",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades Identiv  ( NASDAQ:INVE )  to Sell",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-downgrades-identiv-nasdaqinve-to-sell.html",
    "time_published": "20240508T063051",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Identiv ( NASDAQ:INVE - Get Free Report ) was downgraded by research analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Monday. Separately, B.",
    "banner_image": "https://www.marketbeat.com/logos/identiv-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.284546,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.199903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.18518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.077593",
        "ticker_sentiment_score": "0.199903",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "INVE",
        "relevance_score": "0.855995",
        "ticker_sentiment_score": "0.468206",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Insmed  ( NASDAQ:INSM )  Rating Lowered to Sell at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/insmed-nasdaqinsm-rating-lowered-to-sell-at-stocknews-com.html",
    "time_published": "20240508T063051",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Insmed ( NASDAQ:INSM - Get Free Report ) was downgraded by StockNews.com from a \"hold\" rating to a \"sell\" rating in a research report issued to clients and investors on Monday. Other research analysts have also issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/insmed-incorporated-logo-1200x675.jpg?v=20221122124124",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.217487,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFG",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.200955",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TFC",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.05806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.05806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.05806",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.057296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "0.057296",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INSM",
        "relevance_score": "0.822729",
        "ticker_sentiment_score": "0.362572",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Investors Title  ( NASDAQ:ITIC )  Rating Increased to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/investors-title-nasdaqitic-rating-increased-to-buy-at-stocknews-com.html",
    "time_published": "20240508T063049",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Investors Title ( NASDAQ:ITIC - Get Free Report ) was upgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a research note issued to investors on Monday. Separately, TheStreet raised Investors Title from a \"c+\" rating to a \"b-\" rating in a report on Wednesday, ...",
    "banner_image": "https://www.marketbeat.com/logos/investors-title-logo-1200x675.png?v=20221215085244",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.325352,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.097245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.198922",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.094762",
        "ticker_sentiment_score": "0.097245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ITIC",
        "relevance_score": "0.878286",
        "ticker_sentiment_score": "0.532959",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Joint  ( NASDAQ:JYNT )  Rating Increased to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/joint-nasdaqjynt-rating-increased-to-buy-at-stocknews-com.html",
    "time_published": "20240508T063049",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Joint ( NASDAQ:JYNT - Get Free Report ) was upgraded by research analysts at StockNews.com from a \"hold\" rating to a \"buy\" rating in a report released on Monday. JYNT has been the subject of a number of other reports. B.",
    "banner_image": "https://www.marketbeat.com/logos/joint-corp-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.25758,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.164289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.164289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FFWM",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.156626",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JYNT",
        "relevance_score": "0.91494",
        "ticker_sentiment_score": "0.437911",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Lamar Advertising  ( NASDAQ:LAMR )  Stock Rating Lowered by StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/lamar-advertising-nasdaqlamr-stock-rating-lowered-by-stocknews-com.html",
    "time_published": "20240508T063049",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Lamar Advertising ( NASDAQ:LAMR - Get Free Report ) was downgraded by StockNews.com from a \"buy\" rating to a \"hold\" rating in a report released on Monday. Other equities analysts have also issued research reports about the stock.",
    "banner_image": "https://www.marketbeat.com/logos/lamar-advertising-company-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.278072,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LAMR",
        "relevance_score": "0.828538",
        "ticker_sentiment_score": "0.456435",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.143518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.143518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.061146",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "StockNews.com Downgrades Malibu Boats  ( NASDAQ:MBUU )  to Sell",
    "url": "https://www.defenseworld.net/2024/05/08/stocknews-com-downgrades-malibu-boats-nasdaqmbuu-to-sell.html",
    "time_published": "20240508T063048",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Malibu Boats ( NASDAQ:MBUU - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"hold\" rating to a \"sell\" rating in a note issued to investors on Monday. MBUU has been the subject of a number of other research reports.",
    "banner_image": "https://www.marketbeat.com/logos/malibu-boats-inc-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.322353,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TFC",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.038985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MBUU",
        "relevance_score": "0.777141",
        "ticker_sentiment_score": "0.509076",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.119748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.119748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KEY",
        "relevance_score": "0.053992",
        "ticker_sentiment_score": "0.038985",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alamo Group  ( NYSE:ALG )  Lowered to Hold at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/alamo-group-nysealg-lowered-to-hold-at-stocknews-com.html",
    "time_published": "20240508T061245",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Alamo Group ( NYSE:ALG - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report issued on Monday.",
    "banner_image": "https://www.marketbeat.com/logos/alamo-group-inc-logo-1200x675.png?v=20240424115941",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.244171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALG",
        "relevance_score": "0.783279",
        "ticker_sentiment_score": "0.396785",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.062359",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07031",
        "ticker_sentiment_score": "0.062359",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Adecoagro  ( NYSE:AGRO )  Rating Increased to Buy at StockNews.com",
    "url": "https://www.defenseworld.net/2024/05/08/adecoagro-nyseagro-rating-increased-to-buy-at-stocknews-com-2.html",
    "time_published": "20240508T061243",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "Adecoagro ( NYSE:AGRO - Get Free Report ) was upgraded by equities researchers at StockNews.com from a \"hold\" rating to a \"buy\" rating in a note issued to investors on Monday. Shares of AGRO stock opened at $11.28 on Monday. The stock has a fifty day moving average of $10.75 and a 200 day ...",
    "banner_image": "https://www.marketbeat.com/logos/adecoagro-sa-logo-1200x675.png?v=20221207110805",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999897"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.35465,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SEIC",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.321885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.149697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AGRO",
        "relevance_score": "0.885652",
        "ticker_sentiment_score": "0.574432",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.149697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ACCO Brands  ( NYSE:ACCO )  Downgraded by StockNews.com to Hold",
    "url": "https://www.defenseworld.net/2024/05/08/acco-brands-nyseacco-downgraded-by-stocknews-com-to-hold.html",
    "time_published": "20240508T061242",
    "authors": [
      "Defense World Staff"
    ],
    "summary": "ACCO Brands ( NYSE:ACCO - Get Free Report ) was downgraded by investment analysts at StockNews.com from a \"buy\" rating to a \"hold\" rating in a report released on Monday. Separately, Barrington Research reiterated an \"outperform\" rating and set a $7.50 price objective on shares of ACCO Brands in ...",
    "banner_image": "https://www.marketbeat.com/logos/acco-brands-corp-logo-1200x675.jpg",
    "source": "Stocknews.com",
    "category_within_source": "n/a",
    "source_domain": "www.defenseworld.net",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": 0.226638,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACCO",
        "relevance_score": "0.926237",
        "ticker_sentiment_score": "0.390728",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.062299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07913",
        "ticker_sentiment_score": "0.062299",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How This IBD 50 Stock Is Stacking Up Wins In 2024, And Outperforming Peers",
    "url": "https://www.investors.com/research/the-new-america/neurocrine-biosciences-ingrezza-pipeline-diversification-biotech-stock/",
    "time_published": "20240509T155100",
    "authors": [
      "Investor's Business Daily",
      "ALLISON GATLIN"
    ],
    "summary": "Neurocrine Biosciences Is Making Good On Its Ingrezza Diversification, And Its Biotech Stock Is Flying Investor's Business Daily ...",
    "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/wNAsales051324.jpg",
    "source": "Investors Business Daily",
    "category_within_source": "n/a",
    "source_domain": "www.investors.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.126494,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "OSCR",
        "relevance_score": "0.025514",
        "ticker_sentiment_score": "0.141152",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.042927",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.086446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.086446",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.025514",
        "ticker_sentiment_score": "0.313216",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.025514",
        "ticker_sentiment_score": "0.078936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38727487/coherus-announces-full-repayment-of-pharmakon-advisors-75-million-term-loan",
    "time_published": "20240509T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- New $38.7 million term loan with a May 2029 maturity - - $37.5 million royalty monetization financing based on future sales of LOQTORZI\u00ae and UDENYCA\u00ae -",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      }
    ],
    "overall_sentiment_score": 0.146385,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.012843",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0428",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Reports First Quarter 2024 Results - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38726290/royalty-pharma-reports-first-quarter-2024-results",
    "time_published": "20240509T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million Commitment to grow dividend by mid-single digit percentage annually",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.992549"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.188732,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.014885",
        "ticker_sentiment_score": "-0.102739",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.359084",
        "ticker_sentiment_score": "0.20783",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.014885",
        "ticker_sentiment_score": "0.068271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.014885",
        "ticker_sentiment_score": "0.062189",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab",
    "url": "https://www.globenewswire.com/news-release/2024/05/09/2878561/0/en/Royalty-Pharma-to-Acquire-Royalty-Interest-in-Sanofi-s-Frexalimab.html",
    "time_published": "20240509T104500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, May 09, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. ( ImmuNext ) for approximately $525 million in cash including estimated transaction costs.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.151701,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.314418",
        "ticker_sentiment_score": "0.196638",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.076026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.140867",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38725882/royalty-pharma-to-acquire-royalty-interest-in-sanofis-frexalimab",
    "time_published": "20240509T104500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma's development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.15868,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.306198",
        "ticker_sentiment_score": "0.192627",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.075707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.186738",
        "ticker_sentiment_score": "0.105675",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( ABBV )  - Analyzing AbbVie's Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/05/38769075/abbv-analyzing-abbvies-short-interest",
    "time_published": "20240510T191520",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has risen 4.05% since its last report. The company recently reported that it has 13.54 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.289997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.151778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Results for Q4 and FY2024",
    "url": "https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2024-302142540.html",
    "time_published": "20240510T175100",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, India, May 10, 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter ( Q4 ) and Full Year ( FY ) ended 31st March 2024. \u2022 Revenue from ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.351344,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.016782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.017591",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited Announces Results for Q4 and FY2024",
    "url": "https://www.newswire.ca/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2024-896348176.html",
    "time_published": "20240510T174500",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, India, May 10, 2024 /CNW/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter ( Q4 ) and Full Year ( FY ) ended 31st March 2024. \u2022 Revenue from Operations ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998682"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.351344,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CG",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.016782",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "-0.017591",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab",
    "url": "https://www.zacks.com/stock/news/2272311/pharma-stock-roundup-pfe-dmd-study-patient-death-fda-panel-meet-for-llys-donanemab",
    "time_published": "20240510T151800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": -0.090108,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "-0.010954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060541",
        "ticker_sentiment_score": "-0.125009",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.180236",
        "ticker_sentiment_score": "-0.070322",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.456544",
        "ticker_sentiment_score": "-0.119284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ironwood  ( IRWD )  Q1 Earnings & Revenues Fall Shy of Estimates",
    "url": "https://www.zacks.com/stock/news/2272308/ironwood-irwd-q1-earnings-revenues-fall-shy-of-estimates",
    "time_published": "20240510T151600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.090579,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.043108",
        "ticker_sentiment_score": "0.140459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.171181",
        "ticker_sentiment_score": "0.182113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.109253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.171181",
        "ticker_sentiment_score": "0.089219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENTX",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.081997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CollPlant Biotechnologies  ( CLGN )  Soars 8.2%: Is Further Upside Left in the Stock?",
    "url": "https://www.zacks.com/stock/news/2272226/collplant-biotechnologies-clgn-soars-82-is-further-upside-left-in-the-stock",
    "time_published": "20240510T135100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.234431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.524949",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.243933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Rock-Solid Dividend Stocks That Are Ideal for Retirees",
    "url": "https://www.fool.com/investing/2024/05/10/3-rock-solid-dividend-stocks-ideal-for-retirees/",
    "time_published": "20240510T133000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These are low-risk stocks with high yields.",
    "banner_image": "https://g.foolcdn.com/editorial/images/775891/couple-using-a-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.254137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "-0.03902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.329551",
        "ticker_sentiment_score": "0.133645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.124934",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.277118",
        "ticker_sentiment_score": "0.102301",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.16849",
        "ticker_sentiment_score": "0.05271",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC - First Ntl  ( NASDAQ:FXNC ) , Doma Holdings  ( NYSE:DOMA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38777028/shareholder-notice-halper-sadeh-llc-investigates-labp-doma-fxnc",
    "time_published": "20240511T200920",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 11, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Landos Biopharma, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.21031,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "0.22155",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSBA",
        "relevance_score": "0.100729",
        "ticker_sentiment_score": "0.103291",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.317105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FXNC",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.204108",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Earn $1000 Every Month From These 3 Stocks",
    "url": "https://www.fool.com/investing/2024/05/11/earn-1000-every-month-from-these-3-stocks/",
    "time_published": "20240511T123800",
    "authors": [
      "Mark Roussin",
      "CPA"
    ],
    "summary": "All 3 companies pay growing dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776930/copy-of-dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.379182,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.708902",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/05/11/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240511T075000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These pharmaceutical companies are top-notch dividend growth stocks for the future.",
    "banner_image": "https://media.ycharts.com/charts/de54d771ee8c900e644a4c59d571e905.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.967321"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.304021,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.163728",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.135875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.370831",
        "ticker_sentiment_score": "0.440998",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited annonce ses r\u00e9sultats pour le quatri\u00e8me trimestre et l'exercice 2024",
    "url": "https://www.prnewswire.com/news-releases/piramal-pharma-limited-annonce-ses-resultats-pour-le-quatrieme-trimestre-et-lexercice-2024-302143045.html",
    "time_published": "20240512T180700",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, Inde, 12 mai 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , une entreprise pharmaceutique de premier plan \u00e0 l'\u00e9chelle mondiale, a d\u00e9voil\u00e9 ses r\u00e9sultats autonomes et consolid\u00e9s pour le quatri\u00e8me trimestre ( T4 ) et l'exercice complet se terminant le 31 ...",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.006991,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.018568",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018568",
        "ticker_sentiment_score": "-0.034067",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Piramal Pharma Limited gibt Ergebnisse f\u00fcr das vierte Quartal und das Gesamtjahr 2024 bekannt",
    "url": "https://www.prnewswire.com/news-releases/piramal-pharma-limited-gibt-ergebnisse-fur-das-vierte-quartal-und-das-gesamtjahr-2024-bekannt-302143042.html",
    "time_published": "20240512T175700",
    "authors": [
      "Piramal Pharma Ltd"
    ],
    "summary": "MUMBAI, Indien, 12. Mai 2024 /PRNewswire/ -- Piramal Pharma Limited ( NSE: PPLPHARMA ) ( BSE: 543635 ) , ein weltweit f\u00fchrendes Pharmaunternehmen, gab heute seine Einzel- und Konzernergebnisse f\u00fcr das vierte Quartal ( Q4 ) und das Gesamtjahr ( GJ ) bis 31. M\u00e4rz 2024 bekannt.",
    "banner_image": "https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.154802,
    "overall_sentiment_label": "Somewhat-Bearish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.025985",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.180364",
        "ticker_sentiment_score": "-0.054907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.051943",
        "ticker_sentiment_score": "-0.019951",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38803951/in-ncla-amicus-win-and-ftc-amicus-loss-second-circuit-upholds-decision-dismissing-antitrust-suit",
    "time_published": "20240513T221400",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Washington, D.C., May 13, 2024 ( GLOBE NEWSWIRE ) -- Today the U.S. Court of Appeals for the Second Circuit unanimously upheld a district court decision dismissing the In re Bystolic antitrust lawsuit over reverse payments.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.063665,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "-0.108982",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Is the Dividend Payout for AbbVie Stock?",
    "url": "https://www.fool.com/investing/2024/05/13/what-is-the-dividend-payout-for-abbvie-stock/",
    "time_published": "20240513T150900",
    "authors": [
      "James Brumley"
    ],
    "summary": "The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776819/financial-analysis-company-filing-business-papers.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.080215,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.664604",
        "ticker_sentiment_score": "0.236555",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2272709/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks",
    "time_published": "20240513T131004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default208.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.279235,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.123615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CBAN",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "0.121966",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders",
    "url": "https://www.prnewswire.com/news-releases/abbvie-and-gilgamesh-pharmaceuticals-announce-collaboration-and-option-to-license-agreement-to-develop-next-generation-therapies-for-psychiatric-disorders-302143485.html",
    "time_published": "20240513T123900",
    "authors": [
      "AbbVie"
    ],
    "summary": "AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.287313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.153775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.049221",
        "ticker_sentiment_score": "0.153775",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.50287",
        "ticker_sentiment_score": "0.281875",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Upcoming Investor Conferences",
    "url": "https://www.globenewswire.com/news-release/2024/05/13/2880423/0/en/Royalty-Pharma-to-Present-at-Upcoming-Investor-Conferences.html",
    "time_published": "20240513T121500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, May 13, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the month of May: ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.158543,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.639616",
        "ticker_sentiment_score": "0.235688",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.145145",
        "ticker_sentiment_score": "0.096978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38787414/royalty-pharma-to-present-at-upcoming-investor-conferences",
    "time_published": "20240513T121500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 13, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.19103,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.224751",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.091067",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals  ( NASDAQ:CRBP ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data",
    "time_published": "20240514T173240",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/13/dalle_2024-05-13_18.59.57_-_.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.248127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CRBP",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "-0.01174",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRDL",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.287303",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "-0.089544",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRSQ",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.305104",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZYNE",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38824347/unpacking-the-latest-options-trading-trends-in-abbvie",
    "time_published": "20240514T173106",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.182852,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.845368",
        "ticker_sentiment_score": "0.315734",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.087185",
        "ticker_sentiment_score": "-0.023265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Boosts Neuropsychiatric Portfolio With New Deal",
    "url": "https://www.zacks.com/stock/news/2273681/abbvie-abbv-boosts-neuropsychiatric-portfolio-with-new-deal",
    "time_published": "20240514T161000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.303483,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "THRD",
        "relevance_score": "0.243701",
        "ticker_sentiment_score": "0.194991",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.163909",
        "ticker_sentiment_score": "0.158409",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.295076",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association  ( EHA )  Congress",
    "url": "https://www.globenewswire.com/news-release/2024/05/14/2881572/0/en/Genmab-to-Present-New-and-Updated-Results-From-Multiple-Clinical-Trials-Evaluating-Epcoritamab-Across-Various-B-Cell-Malignancies-at-the-2024-European-Hematology-Association-EHA-Co.html",
    "time_published": "20240514T140200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media ReleaseCOPENHAGEN, Denmark. May ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.100199,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.173832",
        "ticker_sentiment_score": "0.084482",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2273338/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20240514T130015",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      }
    ],
    "overall_sentiment_score": 0.230763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.484798",
        "ticker_sentiment_score": "0.149415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BioRestorative Therapies  ( NASDAQ: BRTX )  Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market - AbbVie  ( NYSE:ABBV ) , BioRestorative Therapies  ( NASDAQ:BRTX ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/05/38815704/biorestorative-therapies-nasdaq-brtx-announces-commercial-agreement-with-cartessa-further-expandi",
    "time_published": "20240514T130011",
    "authors": [
      "Faith Ashmore"
    ],
    "summary": "As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to reach a value of $232.49 billion by 2032, growing at a CAGR of 13.34% between 2024 and 2032.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/14/Screenshot-2024-05-14-at-6-27-53PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.421475,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.103778",
        "ticker_sentiment_score": "0.097719",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRTX",
        "relevance_score": "0.205807",
        "ticker_sentiment_score": "0.402324",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks That Are Passive Income Machines",
    "url": "https://www.fool.com/investing/2024/05/14/3-magnificent-stocks-that-are-passive-income-machi/",
    "time_published": "20240514T103000",
    "authors": [
      "and David Jagielski",
      "Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "These three companies have track records that should please investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/776733/physician-shaking-patients-hand.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.29313,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.342685",
        "ticker_sentiment_score": "0.330403",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.142799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.30211",
        "ticker_sentiment_score": "0.416428",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Announces New Employment Inducement Grants",
    "url": "https://www.globenewswire.com/news-release/2024/05/16/2883880/37704/en/CytomX-Therapeutics-Announces-New-Employment-Inducement-Grants.html",
    "time_published": "20240516T201500",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., May 16, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.17973,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.051259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.210473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.051259",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.051259",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,000 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/05/38878510/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-000-today",
    "time_published": "20240516T163024",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 1.96% on an annualized basis producing an average annual return of 15.08%. Currently, AbbVie has a market capitalization of $288.26 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Are You Looking for a High-Growth Dividend Stock?",
    "url": "https://www.zacks.com/stock/news/2274948/are-you-looking-for-a-high-growth-dividend-stock",
    "time_published": "20240516T154503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.403089,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.453099",
        "ticker_sentiment_score": "0.486382",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Kristin Chenoweth defends Ariana Grande over rumors that she was dating her 'Wicked' costar",
    "url": "https://www.businessinsider.com/kristin-chenoweth-defends-ariana-grande-over-wicked-costar-rumors-2024-5",
    "time_published": "20240516T132700",
    "authors": [
      "Mikhaila Friel"
    ],
    "summary": "Kristin Chenoweth defends Ariana Grande over 'Wicked' costar rumors - Business Insider ...",
    "banner_image": null,
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.092286,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.0852",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game - Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/markets/penny-stocks/24/05/38871754/pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game",
    "time_published": "20240516T125136",
    "authors": [
      "Upwallstreet"
    ],
    "summary": "On Sunday, Pfizer PFE and AstraZeneca Plc AZN were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year's \"Choose France\" business summit.",
    "banner_image": "https://cdn.benzinga.com/files/front-view-doctor-holding-tubes.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.082044,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.245408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.070186",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.238601",
        "ticker_sentiment_score": "0.063641",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.074679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.037248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.048425",
        "ticker_sentiment_score": "0.205291",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "-0.078925",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.074679",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.191929",
        "ticker_sentiment_score": "0.245408",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.329343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer - Ventyx Biosciences  ( NASDAQ:VTYX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38869730/ventyx-biosciences-announces-appointment-of-matthew-moore-as-chief-operating-officer",
    "time_published": "20240516T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN DIEGO, May 16, 2024 ( GLOBE NEWSWIRE ) -- Ventyx Biosciences, Inc. VTYX, ( \"Ventyx\" ) , a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.193977,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VTYX",
        "relevance_score": "0.088964",
        "ticker_sentiment_score": "0.07047",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.100847",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.044551",
        "ticker_sentiment_score": "0.100847",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst",
    "url": "https://markets.businessinsider.com/news/stocks/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst-1033400477",
    "time_published": "20240517T181254",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Cantor Fitzgerald has initiated coverage on AbbVie Inc ( NYSE:ABBV ) , a global pharma company. The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/17/AbbVie-Office.png",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.17885,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.096694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.120431",
        "ticker_sentiment_score": "0.094034",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst",
    "time_published": "20240517T174716",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Cantor Fitzgerald has initiated coverage on AbbVie Inc ABBV, a global pharma company. The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/AbbVie-Office.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.199592,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.414559",
        "ticker_sentiment_score": "0.106674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.214937",
        "ticker_sentiment_score": "0.130708",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Fight Against Cancer Enters a New Phase",
    "url": "https://www.kiplinger.com/business/fight-against-cancer-enters-new-phase",
    "time_published": "20240517T123017",
    "authors": [
      "Matthew Housiaux"
    ],
    "summary": "To help you understand what is going on in the health sector our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts ( Get a free issue of The Kiplinger Letter or subscribe ) .",
    "banner_image": "https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-320-80.png",
    "source": "Kiplinger",
    "category_within_source": "n/a",
    "source_domain": "www.kiplinger.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.010007,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.082808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "-0.049857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.082808",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "-0.049857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38891644/investigation-announcement-bfa-law-announces-an-ongoing-investigation-into-the-merger-between-cere",
    "time_published": "20240517T111200",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 17, 2024 ( GLOBE NEWSWIRE ) -- If you invested in Cerevel Therapeutics Holdings, Inc. CERE you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.21035,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.617765",
        "ticker_sentiment_score": "0.267612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "0.241257",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.178552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma major Glenmark gets USFDA nod for generic ophthalmic solution",
    "url": "https://www.business-standard.com/companies/news/pharma-major-glenmark-gets-usfda-nod-for-generic-ophthalmic-solution-124051700200_1.html",
    "time_published": "20240517T052442",
    "authors": [
      "Press Trust of India"
    ],
    "summary": "Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions.",
    "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-11/16/full/1700098009-925.jpg?im=FeatureCrop,size=(826,465)",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.328831,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.218817",
        "ticker_sentiment_score": "0.268488",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Glenmark Pharmaceuticals gets USFDA approval for its drug to treat glaucoma",
    "url": "https://www.financialexpress.com/business/healthcare-glenmark-pharmaceuticals-gets-usfda-approval-for-its-drug-to-treat-glaucoma-3491330/",
    "time_published": "20240517T051108",
    "authors": [
      "Health Desk"
    ],
    "summary": "Glenmark Pharmaceuticals Ltd. on Friday announced that it has received final approval from the United States Food & Drug Administration ( U.S. FDA ) for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%.",
    "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/02/Glenmark-Life-Sciences-Official.jpg",
    "source": "The Financial Express",
    "category_within_source": "n/a",
    "source_domain": "www.financialexpress.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.265652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.314226",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch",
    "url": "https://markets.businessinsider.com/news/stocks/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks-to-watch-1033400987",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol&#225;s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.341804,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.134749",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/05/38905472/cannabis-meets-prescription-drugs-steroids-and-ketamine-in-schedule-iii-what-it-means-key-stocks",
    "time_published": "20240518T141914",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act ( CSA ) . This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/17/dalle_2024-05-17_18.49.22_-_.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.327636,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.123682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.151999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175859",
        "ticker_sentiment_score": "-0.080549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.230325",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.067245",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117774",
        "ticker_sentiment_score": "0.19966",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What 9 Analyst Ratings Have To Say About Genmab",
    "url": "https://markets.businessinsider.com/news/stocks/what-9-analyst-ratings-have-to-say-about-genmab-1033404016",
    "time_published": "20240520T151722",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Genmab ( NASDAQ:GMAB ) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/analyst_ratings_image_2.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.174546,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.479385",
        "ticker_sentiment_score": "0.068535",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.051221",
        "ticker_sentiment_score": "-0.065991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.102231",
        "ticker_sentiment_score": "-0.072416",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?",
    "url": "https://www.fool.com/investing/2024/05/20/1-wall-street-analyst-thinks-abbvie-stock-is-going/",
    "time_published": "20240520T145801",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Revenue growth during what should be a disastrous patent cliff is encouraging.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777695/investor-sofa-laptop-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.293814,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.122894",
        "ticker_sentiment_score": "0.13515",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.357293",
        "ticker_sentiment_score": "0.465935",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn",
    "url": "https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-new-biomarker-data-suggesting-als-patients-may-benefit-from-longer-term-treatment-with-nurown-302149897.html",
    "time_published": "20240520T100000",
    "authors": [
      "BrainStorm Cell Therapeutics Inc."
    ],
    "summary": "BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.166032,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BCLI",
        "relevance_score": "0.077426",
        "ticker_sentiment_score": "0.118987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLNN",
        "relevance_score": "0.025845",
        "ticker_sentiment_score": "0.077426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025845",
        "ticker_sentiment_score": "0.077426",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886080/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, May 21, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.086813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.405299",
        "ticker_sentiment_score": "0.22023",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.054711",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.027382",
        "ticker_sentiment_score": "0.00379",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013693",
        "ticker_sentiment_score": "-0.038604",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2886079/0/en/Alvotech-Reports-Financial-Results-for-First-Quarter-of-2024-and-Provides-a-Business-Update.html",
    "time_published": "20240521T211400",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999822"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.111134,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.086839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.406356",
        "ticker_sentiment_score": "0.220633",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.054728",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.02746",
        "ticker_sentiment_score": "0.003792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.013732",
        "ticker_sentiment_score": "-0.038614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE  ( Nasdaq )  Share Offer by AbbVie, Contact the Firm for Details - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38935742/breaking-cerevel-investigation-bfa-law-is-investigating-the-45-per-cere-nasdaq-share-offer-by-abbv",
    "time_published": "20240521T103800",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 21, 2024 ( GLOBE NEWSWIRE ) -- Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.200875,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.255921",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.244013",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.175051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Teva and Alvotech Announce SIMLANDI\u00ae  ( adalimumab-ryvk )  Injection Now Available in the U.S.",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885215/0/en/Teva-and-Alvotech-Announce-SIMLANDI-adalimumab-ryvk-Injection-Now-Available-in-the-U-S.html",
    "time_published": "20240521T002500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, ICELAND & PARSIPPANY, NJ - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) and Alvotech ( NASDAQ: ALVO ) , today announced the availability of SIMLANDI ( adalimumab-ryvk ) injection in the U.S., as an interchangeable biosimilar to ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": -0.007299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.296131",
        "ticker_sentiment_score": "0.152357",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.056116",
        "ticker_sentiment_score": "0.079951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.053633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.053633",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011232",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Teva and Alvotech Announce SIMLANDI\u00ae  ( adalimumab-ryvk )  Injection Now Available in the U.S.",
    "url": "https://www.globenewswire.com/news-release/2024/05/21/2885214/0/en/Teva-and-Alvotech-Announce-SIMLANDI-adalimumab-ryvk-Injection-Now-Available-in-the-U-S.html",
    "time_published": "20240521T002500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 ( GLOBE NEWSWIRE ) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) and Alvotech ( NASDAQ: ALVO ) , today announced the availability of SIMLANDI ( adalimumab-ryvk ) injection in the ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": -0.007299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.295735",
        "ticker_sentiment_score": "0.15219",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.056038",
        "ticker_sentiment_score": "0.078947",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.053626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.053626",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011216",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline",
    "url": "https://www.globenewswire.com/news-release/2024/05/22/2886859/0/en/Royalty-Pharma-and-Cytokinetics-Announce-Expanded-Strategic-Funding-Collaboration-Totaling-Up-to-575-Million-to-Support-Commercial-Launch-of-Aficamten-and-to-Advance-R-D-Pipeline.html",
    "time_published": "20240522T201000",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      }
    ],
    "overall_sentiment_score": 0.138176,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CYTK",
        "relevance_score": "0.471559",
        "ticker_sentiment_score": "0.156602",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.076352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.012896",
        "ticker_sentiment_score": "0.067206",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/05/22/2886834/37704/en/CytomX-Therapeutics-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html",
    "time_published": "20240522T200500",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., May 22, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.114504,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.056493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.224903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.056493",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.056493",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline - Cytokinetics  ( NASDAQ:CYTK ) , Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38972645/cytokinetics-and-royalty-pharma-announce-expanded-strategic-funding-collaboration-totaling-up-to-5",
    "time_published": "20240522T200000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK and Royalty Pharma plc RPRX today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.131308,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.014648",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.014648",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTK",
        "relevance_score": "0.467527",
        "ticker_sentiment_score": "0.12276",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.145672",
        "ticker_sentiment_score": "0.052829",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.014648",
        "ticker_sentiment_score": "0.068146",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lilly  ( LLY )  Hits Record High on Crohn's Disease Study Data",
    "url": "https://www.zacks.com/stock/news/2277543/lilly-lly-hits-record-high-on-crohns-disease-study-data",
    "time_published": "20240522T171600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.278118,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.71235",
        "ticker_sentiment_score": "0.466357",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "0.220343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/05/38968961/this-is-what-whales-are-betting-on-abbvie",
    "time_published": "20240522T163113",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.740604",
        "ticker_sentiment_score": "0.346183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.023438",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Must-Own Stock for Any Portfolio",
    "url": "https://www.fool.com/investing/2024/05/22/a-must-own-stock-for-any-portfolio/",
    "time_published": "20240522T124200",
    "authors": [
      "CPA",
      "Mark Roussin"
    ],
    "summary": "This company offers growth, high yield, and dividend growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778200/gettyimages-1720247749.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.339253,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.70749",
        "ticker_sentiment_score": "0.664989",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Anavex Life Sciences Announces Expansion of Leadership Team",
    "url": "https://www.globenewswire.com/news-release/2024/05/22/2886374/29248/en/Anavex-Life-Sciences-Announces-Expansion-of-Leadership-Team.html",
    "time_published": "20240522T113000",
    "authors": [
      "Anavex Life Sciences Corp."
    ],
    "summary": "Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1b0f858f-4f7f-4f50-b691-a25307283fb5",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094946,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDGL",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.046615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.086479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GUTS",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.086479",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.173832",
        "ticker_sentiment_score": "0.024697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.086479",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Anavex Life Sciences Announces Expansion of Leadership Team - Anavex Life Sciences  ( NASDAQ:AVXL ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38960624/anavex-life-sciences-announces-expansion-of-leadership-team",
    "time_published": "20240522T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 22, 2024 ( GLOBE NEWSWIRE ) -- Anavex Life Sciences Corp. ( \"Anavex\" or the \"Company\" ) AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.104186,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MDGL",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.044348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.076096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GUTS",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.076096",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.031791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.033144",
        "ticker_sentiment_score": "0.076096",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Billion More Reasons to Buy AbbVie Stock",
    "url": "https://www.fool.com/investing/2024/05/22/2-billion-more-reasons-to-buy-abbvie-stock/",
    "time_published": "20240522T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This pharma giant just made a smart strategic acquisition.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777723/two-scientists-review-data-in-lab-bench.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.154261,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMPS",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.438836",
        "ticker_sentiment_score": "0.355285",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases",
    "url": "https://www.globenewswire.com/news-release/2024/05/22/2886169/0/en/OSE-Immunotherapeutics-and-Boehringer-Ingelheim-expand-collaboration-to-develop-first-in-class-treatments-for-cancer-and-cardio-renal-metabolic-diseases.html",
    "time_published": "20240522T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.207348,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.050786",
        "ticker_sentiment_score": "0.077998",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Strides Pharma Global receives USFDA approval for Sucralfate Oral Suspension",
    "url": "https://www.business-standard.com/markets/capital-market-news/strides-pharma-global-receives-usfda-approval-for-sucralfate-oral-suspension-124052200293_1.html",
    "time_published": "20240522T043700",
    "authors": [
      "Capital Market"
    ],
    "summary": "Strides Pharma Science announced that its stepdown wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration ( USFDA ) .",
    "banner_image": "https://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg",
    "source": "Business Standard",
    "category_within_source": "GoogleRSS",
    "source_domain": "www.business-standard.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.115165,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "-0.084518",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8  ( CCR8 )  Antibody, CHS-114, at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting - Coherus BioSciences  ( NASDAQ:CHRS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g38995719/coherus-presents-preliminary-results-from-phase-i-dose-escalation-study-of-its-anti-chemokine-rece",
    "time_published": "20240523T215106",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells ( Tregs ) was observed and depletion was maintained over the dosing interval, establishing ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.087031,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "-0.008327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023957",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8  ( CCR8 )  Antibody, CHS-114, at the 2024 American Society of Clinical Oncology  ( ASCO )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/05/23/2887728/33333/en/Coherus-Presents-Preliminary-Results-from-Phase-I-Dose-Escalation-Study-of-its-Anti-chemokine-receptor-8-CCR8-Antibody-CHS-114-at-the-2024-American-Society-of-Clinical-Oncology-ASC.html",
    "time_published": "20240523T215100",
    "authors": [
      "Inc.",
      "Coherus BioSciences"
    ],
    "summary": "CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/bacb58bf-ea23-4950-a845-933265930d07",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.084734,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.024724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHRS",
        "relevance_score": "0.049424",
        "ticker_sentiment_score": "-0.010994",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024724",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Completes Acquisition of Landos Biopharma",
    "url": "https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-landos-biopharma-302154650.html",
    "time_published": "20240523T200500",
    "authors": [
      "AbbVie"
    ],
    "summary": "- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis ( UC ) and Crohn's disease ( CD )",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.112695,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LABP",
        "relevance_score": "0.112269",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.154043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.056275",
        "ticker_sentiment_score": "0.154043",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.474763",
        "ticker_sentiment_score": "0.151725",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Approximately half of patients living with inflammatory bowel disease  ( IBD )  have suboptimally controlled disease, according to data from new Canadian study",
    "url": "https://www.newswire.ca/news-releases/approximately-half-of-patients-living-with-inflammatory-bowel-disease-ibd-have-suboptimally-controlled-disease-according-to-data-from-new-canadian-study-846163654.html",
    "time_published": "20240523T190600",
    "authors": [
      "AbbVie Canada"
    ],
    "summary": "Approximately half of patients living with inflammatory bowel disease ( IBD ) have suboptimally controlled disease ... Canada ...",
    "banner_image": "https://mma.prnewswire.com/media/2420961/AbbVie_Canada_Approximately_half_of_patients_living_with_inflamm.jpg?p=facebook",
    "source": "Canada Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.newswire.ca",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.143409,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.242078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  is a Top Value Stock for the Long-Term",
    "url": "https://www.zacks.com/stock/news/2277858/why-abbvie-abbv-is-a-top-value-stock-for-the-long-term",
    "time_published": "20240523T134011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default106.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.330638,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.551295",
        "ticker_sentiment_score": "0.269213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February - Cencora  ( NYSE:COR ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/05/39010333/after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stol",
    "time_published": "20240524T160024",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "U.S. drug wholesaler Cencora Inc COR, formerly AmerisourceBergen, is notifying affected individuals about their personal and highly sensitive medical information stolen during a cyberattack earlier this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/24/Crypto-hack-Photo-by-Bits-And-Splits-on-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.108839,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SSTK",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.798255",
        "ticker_sentiment_score": "0.148167",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "-0.036372",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More",
    "url": "https://www.zacks.com/stock/news/2278490/pharma-stock-roundup-azns-2030-sales-target-pfes-new-cost-cut-plan-more",
    "time_published": "20240524T131900",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.045562,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.449723",
        "ticker_sentiment_score": "0.024054",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.052918",
        "ticker_sentiment_score": "-0.124637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.057649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.449723",
        "ticker_sentiment_score": "0.07411",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 - AbbVie  ( NYSE:ABBV ) , Altamira Therapeutics  ( NASDAQ:CYTO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39006613/biotechs-zero-in-on-new-pancreatic-therapies-as-global-pancreatic-cancer-market-expected-reach-to-",
    "time_published": "20240524T124500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., May 24, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99737"
      }
    ],
    "overall_sentiment_score": 0.067719,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ONCY",
        "relevance_score": "0.092712",
        "ticker_sentiment_score": "-0.04397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.069028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CYTO",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.109192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.090241",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARVN",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "-0.038422",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/05/25/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240525T094600",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These dividend stocks are ideal for investors seeking long-term passive income.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778414/passive-income.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.362887,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCO",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.228123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.330876",
        "ticker_sentiment_score": "0.211311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PSA",
        "relevance_score": "0.267559",
        "ticker_sentiment_score": "0.371918",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Ishita Ghosh Wins A 2024 Global Recognition Award for Extraordinary Contributions in Technology, particularly in Data Science and Machine Learning",
    "url": "https://markets.businessinsider.com/news/stocks/ishita-ghosh-wins-a-2024-global-recognition-award-for-extraordinary-contributions-in-technology-particularly-in-data-science-and-machine-learning-1033420617",
    "time_published": "20240525T044315",
    "authors": [
      "Plentisoft"
    ],
    "summary": "Ishita Ghosh Wins A 2024 Global Recognition Award for Extraordinary Contributions in Technology, particularly in Data ... - Markets Insider ...",
    "banner_image": "https://storage.googleapis.com/mmstudio-images/gallery/AGUBlh69w0N2AXPYQJJy0zx0x363/1716534336860-0.png",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.493938,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.172864",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.098862",
        "ticker_sentiment_score": "0.2264",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FOREX:GBP",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.3185",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Forget Nvidia, Buy This Magnificent Healthcare Stock Instead",
    "url": "https://www.fool.com/investing/2024/05/26/forget-nvidia-buy-this-magnificent-healthcare-stoc/",
    "time_published": "20240526T121000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "AbbVie's returns haven't been great this year, but investors shouldn't overlook this promising growth stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/777844/a-couple-of-people-looking-at-charts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.287005,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.22861",
        "ticker_sentiment_score": "0.255539",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.057907",
        "ticker_sentiment_score": "0.13169",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.690822",
        "ticker_sentiment_score": "0.468434",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Neurocrine Biosciences Announces CEO Succession Plan",
    "url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-ceo-succession-plan-302157140.html",
    "time_published": "20240528T201400",
    "authors": [
      "Neurocrine Biosciences",
      "Inc."
    ],
    "summary": "Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors",
    "banner_image": "https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.083073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.049025",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOLTF",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VYGR",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.148182",
        "ticker_sentiment_score": "0.092192",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSBHF",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XENE",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.014904",
        "ticker_sentiment_score": "0.058902",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis - Sight Sciences  ( NASDAQ:SGHT ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39046503/sight-sciences-announces-the-publication-of-twelve-month-results-of-the-sahara-rct-demonstrating-i",
    "time_published": "20240528T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "MENLO PARK, Calif., May 28, 2024 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc. SGHT ( \"Sight Sciences,\" or the \"Company\" ) , an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.175611,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SGHT",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.220813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.028221",
        "ticker_sentiment_score": "0.12186",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL THERAPEUTICS ALERT: Cerevel's $45 Merger Offer From AbbVie is Under Investigation  ( Nasdaq: CERE )  - Contact BFA Law to Discuss How this Impacts You - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39035555/cerevel-therapeutics-alert-cerevels-45-merger-offer-from-abbvie-is-under-investigation-nasdaq-cere",
    "time_published": "20240528T112600",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, May 28, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between CERE Cerevel Therapeutics Holdings, Inc. and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.212455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.666827",
        "ticker_sentiment_score": "0.297576",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.280717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.175051",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million",
    "url": "https://www.globenewswire.com/news-release/2024/05/28/2888905/0/en/Royalty-Pharma-and-Agios-Pharmaceuticals-Enter-Into-Vorasidenib-Royalty-Agreement-for-905-Million.html",
    "time_published": "20240528T111000",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, May 28, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration ( FDA ) approval of ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.150022,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AGIO",
        "relevance_score": "0.032164",
        "ticker_sentiment_score": "0.127905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.454714",
        "ticker_sentiment_score": "0.274075",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032164",
        "ticker_sentiment_score": "0.075027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39035339/royalty-pharma-and-agios-pharmaceuticals-enter-into-vorasidenib-royalty-agreement-for-905-million",
    "time_published": "20240528T111000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.157017,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AGIO",
        "relevance_score": "0.031282",
        "ticker_sentiment_score": "0.116812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "0.269426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.031282",
        "ticker_sentiment_score": "0.074713",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Are Options Traders Betting on a Big Move in AbbVie  ( ABBV )  Stock?",
    "url": "https://www.zacks.com/stock/news/2280895/are-options-traders-betting-on-a-big-move-in-abbvie-abbv-stock",
    "time_published": "20240529T203200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default54.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.078456,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.567746",
        "ticker_sentiment_score": "0.119292",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach",
    "url": "https://www.benzinga.com/pressreleases/24/05/g39070557/lynch-carpenter-investigates-claims-in-cencora-inc-data-breach",
    "time_published": "20240529T174658",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PITTSBURGH, May 29, 2024 ( GLOBE NEWSWIRE ) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information of at least half a million individuals.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": -0.028843,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DNPUF",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.512093",
        "ticker_sentiment_score": "-0.254098",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACAD",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "-0.086454",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2280454/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240529T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default42.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.212984,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.488469",
        "ticker_sentiment_score": "0.123077",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Democratic Bill To Raise Drug Prices By Protecting Patent Trolls",
    "url": "https://www.forbes.com/sites/theapothecary/2024/05/29/the-democratic-bill-to-raise-drug-prices-by-protecting-patent-trolls/",
    "time_published": "20240529T123911",
    "authors": [
      "Avik Roy"
    ],
    "summary": "Reducing prescription drug prices has long been a goal of Democrats in Congress and the White House. But in a strange twist, a group of Senate Democrats-along with one Republican-has backed a bill that would increase drug prices by preventing people from challenging weak or invalid patents.",
    "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66571f15256b06a97d28af94/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
    "source": "Forbes",
    "category_within_source": "n/a",
    "source_domain": "www.forbes.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.073073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.024956",
        "ticker_sentiment_score": "0.106591",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07477",
        "ticker_sentiment_score": "0.034661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2280359/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20240529T102004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.227065,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.354741",
        "ticker_sentiment_score": "0.184139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Provides Business and Corporate Update",
    "url": "https://www.globenewswire.com/news-release/2024/05/30/2890988/0/en/OSE-Immunotherapeutics-Provides-Business-and-Corporate-Update.html",
    "time_published": "20240530T161500",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "\u2022 Three pharmaceutical agreements signed during the last three months: \u2022 New strategic partnership with AbbVie for OSE-230, a novel preclinical potential first-in-class program for the treatment of chronic inflammation. \u2022 Major partnership expansion with Boehringer Ingelheim: \u2022 Amendment of the ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.160417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.094538",
        "ticker_sentiment_score": "0.105039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SVYSF",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.061439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.057893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.01895",
        "ticker_sentiment_score": "0.012589",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks to Double Up on Right Now",
    "url": "https://www.fool.com/investing/2024/05/30/3-dividend-stocks-to-double-up-on-right-now/",
    "time_published": "20240530T094500",
    "authors": [
      "Keith Speights"
    ],
    "summary": "The stories for these great dividend stocks are better than many might think.",
    "banner_image": "https://g.foolcdn.com/editorial/images/778853/scientist-in-lab-young-african-american-female.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.149282,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "-0.067737",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.093913",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "0.188529",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.31282",
        "ticker_sentiment_score": "-0.028215",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gilead's  ( GILD )  Urothelial Cancer Study Did Not Meet Its Primary Goal",
    "url": "https://www.zacks.com/stock/news/2282325/gileads-gild-urothelial-cancer-study-did-not-meet-its-primary-goal",
    "time_published": "20240531T170100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.026955,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "0.097792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.015426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.189623",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "-0.012339",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2281786/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
    "time_published": "20240531T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.250748,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.059636",
        "ticker_sentiment_score": "0.117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.060738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.11894",
        "ticker_sentiment_score": "0.060738",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CERE  ( NASDAQ )  REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39124238/cere-nasdaq-reminder-bfa-law-reminds-cerevel-shareholders-to-inquire-about-ongoing-investigation-i",
    "time_published": "20240601T093600",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 01, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2211,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.326505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.267639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.171159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Preliminary Analysis of Data Evaluating Investigational Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/06/02/2891863/0/en/Preliminary-Analysis-of-Data-Evaluating-Investigational-Epcoritamab-DuoBody-CD3xCD20-Combination-Demonstrates-95-Overall-Response-Rate-in-Patients-with-Previously-Untreated-Follicu.html",
    "time_published": "20240602T213000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media Release ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.047681,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.076067",
        "ticker_sentiment_score": "0.074954",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 No-Brainer Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/02/3-no-brainer-stocks-to-buy-in-june/",
    "time_published": "20240602T100000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Now is the time to invest in these great stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779075/light-bulbs-with-dollar-sign-person-looking-up.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999612"
      }
    ],
    "overall_sentiment_score": 0.401751,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.408509",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.371254",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.369735",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Sinks As Market Gains: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2283000/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know",
    "time_published": "20240603T214520",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.166264,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.601928",
        "ticker_sentiment_score": "0.264995",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39148339/royalty-pharma-announces-pricing-of-1-5-billion-of-senior-unsecured-notes",
    "time_published": "20240603T211527",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 03, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following ( collectively, the \"Notes\" ) : $500 million of 5.150% Notes due 2029 ( the \"2029 Notes\" ) ;",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.96136"
      }
    ],
    "overall_sentiment_score": 0.101132,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BR",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.092136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCGLF",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.143105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.097394",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.07891",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.107554",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.084127",
        "ticker_sentiment_score": "0.107554",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes",
    "url": "https://www.globenewswire.com/news-release/2024/06/03/2892652/0/en/Royalty-Pharma-Announces-Pricing-of-1-5-Billion-of-Senior-Unsecured-Notes.html",
    "time_published": "20240603T211500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, June 03, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following ( collectively, the \"Notes\" ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.928139"
      }
    ],
    "overall_sentiment_score": 0.089466,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BR",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.097294",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SCGLF",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.143967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.305871",
        "ticker_sentiment_score": "0.094548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.044801",
        "ticker_sentiment_score": "0.079486",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.111854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.111854",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU - AbbVie  ( NYSE:ABBV ) , ALX Oncology Holdings  ( NASDAQ:ALXO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39140318/abbvie-skyrizi-gets-chmp-nod-for-ulcerative-colitis-in-eu",
    "time_published": "20240603T193211",
    "authors": [
      "Zacks"
    ],
    "summary": "AbbVie ABBV announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion, recommending approval of Skyrizi ( risankizumab ) in the EU to treat adults with moderately to severely active ulcerative colitis ( UC ) ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/national-cancer-institute-gcrsghdrniy-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.204399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.393855",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.061432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "-0.079258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENTX",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.031284",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39145122/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20240603T193044",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.178024,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.691734",
        "ticker_sentiment_score": "0.235387",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Could Be a Great Choice",
    "url": "https://www.zacks.com/stock/news/2282854/abbvie-abbv-could-be-a-great-choice",
    "time_published": "20240603T154508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default339.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.394959,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.453099",
        "ticker_sentiment_score": "0.467688",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU",
    "url": "https://www.zacks.com/stock/news/2282812/abbvie-abbv-skyrizi-gets-chmp-nod-for-ulcerative-colitis-in-eu",
    "time_published": "20240603T140500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.194847,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.47147",
        "ticker_sentiment_score": "0.387508",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.013008",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "-0.026036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ENTX",
        "relevance_score": "0.149966",
        "ticker_sentiment_score": "0.057129",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TJX, Sysco, Lululemon And A Healthcare Stock On CNBC's 'Final Trades' - Lululemon Athletica  ( NASDAQ:LULU ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/06/39135417/tjx-sysco-lululemon-and-a-healthcare-stock-on-cnbcs-final-trades",
    "time_published": "20240603T123034",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Brenda Vingiello of Sand Hill Global Advisors named The TJX Companies, Inc. TJX as her final trade. On May 22, TJX Companies reported better-than-expected first-quarter financial results.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/03/TJX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.209058,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LULU",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "-0.082908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SYY",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.23617",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.487842",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TJX",
        "relevance_score": "0.465901",
        "ticker_sentiment_score": "0.209171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2282432/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240603T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.193511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.124899",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.057385",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.057385",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Soars 3.2%: Is Further Upside Left in the Stock?",
    "url": "https://www.zacks.com/stock/news/2282406/abbvie-abbv-soars-32-is-further-upside-left-in-the-stock",
    "time_published": "20240603T063300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default323.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.206255,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.1352",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/06/04/2893448/0/en/Royalty-Pharma-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html",
    "time_published": "20240604T201500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, June 04, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.15171,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.041651",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.679474",
        "ticker_sentiment_score": "0.238975",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.157483",
        "ticker_sentiment_score": "0.101876",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39170730/royalty-pharma-to-present-at-the-goldman-sachs-45th-annual-global-healthcare-conference",
    "time_published": "20240604T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 04, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.186527,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.037408",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.616842",
        "ticker_sentiment_score": "0.224804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.094471",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stocks to Buy in June",
    "url": "https://www.fool.com/investing/2024/06/04/top-stocks-to-buy-in-june/",
    "time_published": "20240604T125200",
    "authors": [
      "CPA",
      "Mark Roussin"
    ],
    "summary": "Here are a few high-quality stocks trading at intriguing valuations.",
    "banner_image": "https://g.foolcdn.com/editorial/images/779492/gettyimages-1720247749.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.328676,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.615462",
        "ticker_sentiment_score": "0.460789",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/06/05/2-high-yield-dividend-stocks-to-buy-right-now/",
    "time_published": "20240605T133000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These two high-yield dividend stocks are top buys right now.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F779580%2Fdividends.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.1945,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.44059",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.319725",
        "ticker_sentiment_score": "0.15627",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant",
    "url": "https://www.globenewswire.com/news-release/2024/06/05/2893560/0/en/OSE-Immunotherapeutics-and-Nantes-University-Hospital-Present-Positive-Phase-1-2-Study-Evaluating-FR104-VEL-101-Immunotherapy-in-Renal-Transplant.html",
    "time_published": "20240605T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "Nantes, France - June 5, 2024, 7:30am CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173. Mnemo: OSE ) and Nantes University Hospital present positive Phase 1/2 analysis from first use of anti-CD28 FR104/VEL-101 in kidney transplantation in oral presentation at the Annual American Transplant ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.196076,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AHKSF",
        "relevance_score": "0.023304",
        "ticker_sentiment_score": "0.165473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASBRF",
        "relevance_score": "0.023304",
        "ticker_sentiment_score": "0.165473",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.046588",
        "ticker_sentiment_score": "0.078907",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39176527/ose-immunotherapeutics-and-nantes-university-hospital-present-positive-phase-12-study-evaluating-f",
    "time_published": "20240605T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Nantes, France - June 5, 2024, 7:30am CET - OSE Immunotherapeutics SA FR and Nantes University Hospital present positive Phase 1/2 analysis from first use of anti-CD28 FR104/VEL-101 in kidney transplantation in oral presentation at the Annual American Transplant Congress ( ATC ) held in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.195971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AHKSF",
        "relevance_score": "0.022536",
        "ticker_sentiment_score": "0.157062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ASBRF",
        "relevance_score": "0.022536",
        "ticker_sentiment_score": "0.157062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "-0.036917",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme's ENHANZE Product Gets New Patent Grant in EU - AbbVie  ( NYSE:ABBV ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",
    "url": "https://www.benzinga.com/news/24/06/39208619/halozymes-enhanze-product-gets-new-patent-grant-in-eu",
    "time_published": "20240606T193629",
    "authors": [
      "Zacks"
    ],
    "summary": "Halozyme Therapeutics HALO announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/joshua-mayo-objbg2lzjmg-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.177356,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANVS",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.090561",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHGCF",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.088707",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.083964",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.350833",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.093485",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39212271/abbvies-immunogen-acquired-elahere-meets-primary-goal-in-mid-stage-study-in-heavily-pretreated-ov",
    "time_published": "20240606T170245",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, AbbVie Inc ABBV released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine ( Elahere ) monotherapy in heavily pre-treated patients with folate receptor-alpha ( FR\u03b1 ) positive, platinum-sensitive ovarian cancer ( PSOC ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.075128,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.478939",
        "ticker_sentiment_score": "0.059073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Starts Late-Stage Study on Multiple Myeloma Drug",
    "url": "https://www.zacks.com/stock/news/2284943/abbvie-abbv-starts-late-stage-study-on-multiple-myeloma-drug",
    "time_published": "20240606T155300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.205173,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KPTI",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.017057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.241684",
        "ticker_sentiment_score": "0.109492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.18078",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.061315",
        "ticker_sentiment_score": "0.050214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.188978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.188978",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Halozyme's  ( HALO )  ENHANZE Product Gets New Patent Grant in EU",
    "url": "https://www.zacks.com/stock/news/2284729/halozymes-halo-enhanze-product-gets-new-patent-grant-in-eu",
    "time_published": "20240606T133100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/98/2216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.165463,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ANVS",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "-0.033429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CHGCF",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.234684",
        "ticker_sentiment_score": "-0.031557",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.348915",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.083997",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook",
    "url": "https://www.prnewswire.com/news-releases/halozyme-raises-full-year-2024-financial-guidance-and-updates-5-year-financial-outlook-302165654.html",
    "time_published": "20240606T123000",
    "authors": [
      "Halozyme Therapeutics",
      "Inc."
    ],
    "summary": "Company Granted New European Patent for ENHANZE\u00ae Drug Delivery Platform",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.166156,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.157827",
        "ticker_sentiment_score": "0.091508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.183651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.026474",
        "ticker_sentiment_score": "0.079426",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Professional Skincare Market size is set to grow by USD 4.22 billion from 2024-2028, Product innovation and product ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/professional-skincare-market-size-is-set-to-grow-by-usd-4-22-billion-from-2024-2028--product-innovation-and-product-line-extension-leading-to-product-premiumization-boost-the-market-technavio-302166014.html",
    "time_published": "20240607T233400",
    "authors": [],
    "summary": "Professional Skincare Market size is set to grow by USD 4.22 billion from 2024-2028, Product innovation and product ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.326497,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BDRFF",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSDOF",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REVRQ",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UL",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COTY",
        "relevance_score": "0.036983",
        "ticker_sentiment_score": "0.132755",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/antibiotics-market-size-is-set-to-grow-by-usd-16-63-billion-from-2024-2028--rising-prevalence-of-infectious-diseases-boost-the-market-technavio-302166383.html",
    "time_published": "20240607T211500",
    "authors": [],
    "summary": "Antibiotics Market size is set to grow by USD 16.63 billion from 2024-2028, Rising prevalence of infectious diseases ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.069745,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APNHF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MAYNF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.035086",
        "ticker_sentiment_score": "0.01328",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside",
    "url": "https://markets.businessinsider.com/news/stocks/goldman-sachs-optimistic-about-regenxbio-s-gene-therapy-pipeline-sees-over-160-upside-1033462338",
    "time_published": "20240607T194254",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Goldman Sachs has initiated coverage on Regenxbio Inc ( NASDAQ:RGNX ) , citing the potential for the company's gene therapy platform. The company's pipeline includes gene therapy candidates for ophthalmology ( wet AMD and diabetic retinopathy ) , Duchenne muscular dystrophy ( DMD ) , and Hunter ...",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/06/07/RGNX.png",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.191642,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.311079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "0.412701",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.233532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.155817",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside - Regenxbio  ( NASDAQ:RGNX ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39234044/goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upsid",
    "time_published": "20240607T183054",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Goldman Sachs has initiated coverage on Regenxbio Inc RGNX, citing the potential for the company's gene therapy platform. The company's pipeline includes gene therapy candidates for ophthalmology ( wet AMD and diabetic retinopathy ) , Duchenne muscular dystrophy ( DMD ) , and Hunter syndrome.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/RGNX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.203468,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.178943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.583619",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.359014",
        "ticker_sentiment_score": "0.222153",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "-0.230434",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability - Cigna Group  ( NYSE:CI ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-",
    "time_published": "20240607T143905",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "AbbVie Inc's ABBV top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year, Reuters reports. This raises concerns among drug pricing experts and analysts about the sustainability of the biosimilar ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/humira-complete-savings-card-r29-desktop.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.203195,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.28008",
        "ticker_sentiment_score": "0.18353",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.227848",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.367412",
        "ticker_sentiment_score": "0.149128",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval",
    "url": "https://www.zacks.com/stock/news/2285380/pharma-stock-roundup-llys-cfo-departs-abbv-azn-drugs-get-chmp-approval",
    "time_published": "20240607T142000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.106674,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.093901",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.133346",
        "ticker_sentiment_score": "0.097289",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.424317",
        "ticker_sentiment_score": "0.186385",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "0.001979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "0.008356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.044634",
        "ticker_sentiment_score": "-0.109142",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's  ( ABBV )  Ovarian Cancer Therapy Meets Study Goal",
    "url": "https://www.zacks.com/stock/news/2285430/abbvies-abbv-ovarian-cancer-therapy-meets-study-goal",
    "time_published": "20240607T141800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.09989,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.105372",
        "ticker_sentiment_score": "0.089136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.208914",
        "ticker_sentiment_score": "0.029403",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.105372",
        "ticker_sentiment_score": "0.089136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.357049",
        "ticker_sentiment_score": "0.108694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.259451",
        "ticker_sentiment_score": "0.143886",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Amazon.com  ( NASDAQ:AMZN ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/06/39226402/abbvie-amazon-goldman-sachs-and-2-major-health-care-stocks-on-cnbcs-final-trades",
    "time_published": "20240607T125956",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Jim Lebenthal of Cerity Partners said AbbVie Inc. ABBV is a very solid pharmaceutical company. The company has good dividend yield and attractive valuations, he added.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.221022,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.457566",
        "ticker_sentiment_score": "0.296475",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.639128",
        "ticker_sentiment_score": "-0.073233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.121037",
        "ticker_sentiment_score": "-0.120523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IQV",
        "relevance_score": "0.457566",
        "ticker_sentiment_score": "0.00892",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme  ( HALO )  Raises 2024 Financial Guidance, Stock Up 13%",
    "url": "https://www.zacks.com/stock/news/2285357/halozyme-halo-raises-2024-financial-guidance-stock-up-13",
    "time_published": "20240607T125900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/61649.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183598,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.114831",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "-0.029697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANVS",
        "relevance_score": "0.217346",
        "ticker_sentiment_score": "-0.031459",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.187804",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.054983",
        "ticker_sentiment_score": "0.114831",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel  ( Nasdaq: CERE )  Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your Rights - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39240144/cerevel-news-notification-bfa-law-alerts-cerevel-nasdaq-cere-shareholders-of-investigation-into-th",
    "time_published": "20240608T091200",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 08, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2211,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.326505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.267639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.171159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Laps the Stock Market: Here's Why",
    "url": "https://www.zacks.com/stock/news/2286284/abbvie-abbv-laps-the-stock-market-heres-why",
    "time_published": "20240610T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default316.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.220221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.600271",
        "ticker_sentiment_score": "0.310377",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39252267/if-you-invested-1000-in-this-stock-10-years-ago-you-would-have-3-100-today",
    "time_published": "20240610T143138",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.01%. Currently, AbbVie has a market capitalization of $297.95 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39273312/comparative-study-abbvie-and-industry-competitors-in-biotechnology-industry",
    "time_published": "20240611T150021",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating AbbVie ABBV in relation to its major competitors in the ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.323496,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.463192",
        "ticker_sentiment_score": "0.405983",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "BOTOX\u00ae Cosmetic  ( onabotulinumtoxinA )  Reveals 2024 Women Entrepreneur Grant Recipients",
    "url": "https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-reveals-2024-women-entrepreneur-grant-recipients-302169176.html",
    "time_published": "20240611T120000",
    "authors": [
      "AbbVie"
    ],
    "summary": "\u2022 For The Second Year, 20 Women Entrepreneurs Will Each Receive In Funding, Plus Access to Mentorship and Community-Helping to Close the Confidence Gap IRVINE, Calif., June 11, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company ( NYSE: ABBV ) revealed this year's 20 BOTOX\u00ae ...",
    "banner_image": "https://mma.prnewswire.com/media/2435237/Botox_Cosmetic_x_IFW_Announcement_Wave_1_Youtube.mp4?p=medium",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.094354,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.046139",
        "ticker_sentiment_score": "0.134057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.046139",
        "ticker_sentiment_score": "0.116124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.137803",
        "ticker_sentiment_score": "0.263821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2286400/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20240611T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default238.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      }
    ],
    "overall_sentiment_score": 0.286446,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.059546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.059546",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.381255",
        "ticker_sentiment_score": "0.189528",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.059546",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39295937/us-gastroenterologists-express-anticipation-for-approval-of-abbvies-skyrizi-in-ulcerative-colitis-",
    "time_published": "20240612T161832",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, June 12, 2024 ( GLOBE NEWSWIRE ) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie's Skyrizi ( risankizumab ) is expected to have a substantial impact on ulcerative colitis ( UC ) treatment.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.257903,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.171753",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.050254",
        "ticker_sentiment_score": "0.127259",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse",
    "url": "https://www.globenewswire.com/news-release/2024/06/12/2897762/0/en/OSE-Immunotherapeutics-KOL-Investor-Webinar-on-the-Therapeutic-Landscape-and-Unmet-Medical-Needs-in-Non-Small-Cell-Lung-Cancer-by-Dr-Stephen-Liu-and-Prof-Benjamin-Besse.html",
    "time_published": "20240612T160000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.09599,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.092213",
        "ticker_sentiment_score": "0.088843",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Enterprise SaaS Training Platform Learn to Win Closes $30 Million Series A Funding Round - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/enterprise-saas-training-platform-learn-to-win-closes-30-million-series-a-funding-round-302169853.html",
    "time_published": "20240612T132700",
    "authors": [],
    "summary": "Enterprise SaaS Training Platform Learn to Win Closes $30 Million Series A Funding Round PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.513861,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.061631",
        "ticker_sentiment_score": "0.266324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2287116/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240612T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default30.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.228111,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "0.158494",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/06/39312842/looking-into-abbvies-recent-short-interest",
    "time_published": "20240613T134515",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has risen 3.33% since its last report. The company recently reported that it has 16.49 million shares sold short, which is 0.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.9 days to cover their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.289997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.151778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease",
    "url": "https://www.prnewswire.com/news-releases/abbvie-and-futuregen-announce-license-agreement-to-develop-next-generation-therapy-for-inflammatory-bowel-disease-302171900.html",
    "time_published": "20240613T115900",
    "authors": [
      "AbbVie"
    ],
    "summary": "AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.183522,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.153765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.04912",
        "ticker_sentiment_score": "0.153765",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.501986",
        "ticker_sentiment_score": "0.134424",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel  ( Nasdaq: CERE ) ? BFA Law is Investigating and Encourages Investors to Contact the Firm - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39308959/cerevel-shareholder-reminder-is-45-per-share-enough-for-cerevel-nasdaq-cere-bfa-law-is-investigati",
    "time_published": "20240613T113500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 13, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.326996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.268476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.171426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",
    "url": "https://markets.businessinsider.com/news/stocks/pharma-stock-roundup-fda-panel-endorses-lly-s-donanemab-pfe-s-dmd-therapy-study-fails-1033480819",
    "time_published": "20240614T181101",
    "authors": [
      "Zacks"
    ],
    "summary": "This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's ( NYSE:LLY ) Alzheimer's disease drug, donanemab.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/06/14/national-cancer-institute-nfvdkihxylu-unsplash.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.119299,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.125025",
        "ticker_sentiment_score": "0.044093",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.200169",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "-0.102302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.30803",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39333999/pharma-stock-roundup-fda-panel-endorses-llys-donanemab-pfes-dmd-therapy-study-fails",
    "time_published": "20240614T173910",
    "authors": [
      "Zacks"
    ],
    "summary": "This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's LLY Alzheimer's disease drug, donanemab. Pfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for ambulatory boys with Duchenne muscular dystrophy failed to meet the primary ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/14/national-cancer-institute-nfvdkihxylu-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.123922,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.01642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.050948",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.120834",
        "ticker_sentiment_score": "0.155669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.120834",
        "ticker_sentiment_score": "0.017575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.307362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",
    "url": "https://www.zacks.com/stock/news/2288361/pharma-stock-roundup-fda-panel-endorses-llys-donanemab-pfes-dmd-therapy-study-fails",
    "time_published": "20240614T130500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.116569,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.03351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.056638",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.168232",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.118257",
        "ticker_sentiment_score": "0.032249",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039548",
        "ticker_sentiment_score": "0.306918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Buys Global Rights to Novel IBD Candidate",
    "url": "https://www.zacks.com/stock/news/2288305/abbvie-abbv-buys-global-rights-to-novel-ibd-candidate",
    "time_published": "20240614T125000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.18774,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RXDX",
        "relevance_score": "0.073321",
        "ticker_sentiment_score": "0.025275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.480536",
        "ticker_sentiment_score": "0.232952",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.217508",
        "ticker_sentiment_score": "0.10223",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "BFA Law Alert: Cerevel  ( CERE )  Shareholders are Encouraged to Contact the Firm about Investigation into Whether the $45 Per Share Offer is Enough",
    "url": "https://markets.businessinsider.com/news/stocks/bfa-law-alert-cerevel-cere-shareholders-are-encouraged-to-contact-the-firm-about-investigation-into-whether-the-45-per-share-offer-is-enough-1033479254",
    "time_published": "20240614T110600",
    "authors": [
      "NEWSFILE"
    ],
    "summary": "BFA Law Alert: Cerevel (CERE) Shareholders are Encouraged to Contact the Firm about Investigation into Whether the $45 Per Share Offer is Enough ...",
    "banner_image": "https://api.newsfilecorp.com/newsinfo/212896/208",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.225199,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.689652",
        "ticker_sentiment_score": "0.338702",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.290073",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.185105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/06/15/2899263/0/en/Roche-s-Phase-III-STARGLO-study-demonstrates-Columvi-significantly-extends-survival-in-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html",
    "time_published": "20240615T140000",
    "authors": [
      "F. Hoffmann-La Roche Ltd"
    ],
    "summary": "Basel, 15 June 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi\u00ae ( glofitamab ) in combination with gemcitabine and oxaliplatin ( GemOx ) versus MabThera\u00ae/Rituxan\u00ae ( rituximab ) in ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.117847,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.021218",
        "ticker_sentiment_score": "0.105295",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021218",
        "ticker_sentiment_score": "0.068014",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks That Could Pay You for Life",
    "url": "https://www.fool.com/investing/2024/06/16/2-dividend-stocks-that-could-pay-you-for-life/",
    "time_published": "20240616T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "There are other reasons to love these businesses, too.",
    "banner_image": "https://media.ycharts.com/charts/3bd652ae2c5fb62c2ed8b70314e36548.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.270085,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "V",
        "relevance_score": "0.411176",
        "ticker_sentiment_score": "0.365463",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.307669",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "0.135056",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer",
    "url": "https://www.globenewswire.com/news-release/2024/06/17/2900015/37704/en/CytomX-Therapeutics-Promotes-Chris-Ogden-to-Chief-Financial-Officer.html",
    "time_published": "20240617T201500",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., June 17, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.128854,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.046131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.143629",
        "ticker_sentiment_score": "0.076539",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.046131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.046131",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39366109/cytomx-therapeutics-promotes-chris-ogden-to-chief-financial-officer",
    "time_published": "20240617T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., June 17, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.133546,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.034087",
        "ticker_sentiment_score": "0.04386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.1692",
        "ticker_sentiment_score": "0.038735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034087",
        "ticker_sentiment_score": "0.04386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.034087",
        "ticker_sentiment_score": "0.04386",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer",
    "url": "https://www.globenewswire.com/news-release/2024/06/17/2899996/0/en/Autonomix-Enhances-Executive-Leadership-Team-with-Appointment-of-Proven-Medical-Technology-Leader-Brad-Hauser-as-President-and-Chief-Executive-Officer.html",
    "time_published": "20240617T200500",
    "authors": [
      "Inc.",
      "Autonomix Medical"
    ],
    "summary": "Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6e26d7e9-5acc-4d2a-80cc-fb5d10972f7d/image2.jpeg",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.214548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.064362",
        "ticker_sentiment_score": "-0.011042",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "-0.010483",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades' - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/news/24/06/39355721/nvidia-abbvie-vertex-pharmaceuticals-and-an-oil-giant-cnbcs-final-trades",
    "time_published": "20240617T124719",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Bryn Talkington of Requisite Capital Management named NVIDIA Corporation NVDA as her final trade. NVIDIA recently announced a 10-for-1 stock split. The semiconductor giant revealed this decision during its recent quarterly earnings report.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/17/trader-ai2.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.266102,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.357293",
        "ticker_sentiment_score": "0.22137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.137818",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.355944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MRO",
        "relevance_score": "0.24289",
        "ticker_sentiment_score": "0.25761",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.239412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "U.S. FDA Approves SKYRIZI\u00ae  ( risankizumab-rzaa )  for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease",
    "url": "https://www.prnewswire.com/news-releases/us-fda-approves-skyrizi-risankizumab-rzaa-for-ulcerative-colitis-expanding-abbvies-portfolio-across-inflammatory-bowel-disease-302176163.html",
    "time_published": "20240618T221800",
    "authors": [
      "AbbVie"
    ],
    "summary": "U.S. FDA Approves SKYRIZI\u00ae ( risankizumab-rzaa ) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": -0.068123,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.01435",
        "ticker_sentiment_score": "0.124053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.01435",
        "ticker_sentiment_score": "0.124053",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.240209",
        "ticker_sentiment_score": "0.062684",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Exceeds Market Returns: Some Facts to Consider",
    "url": "https://www.zacks.com/stock/news/2290081/abbvie-abbv-exceeds-market-returns-some-facts-to-consider",
    "time_published": "20240618T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $171.36, denoting a +0.99% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.237848,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.40231",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Mustang  ( MBIO )  Soars 477% on Data From Rare Blood Cancer Study",
    "url": "https://www.zacks.com/stock/news/2289934/mustang-mbio-soars-477-on-data-from-rare-blood-cancer-study",
    "time_published": "20240618T142200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.237839,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.402403",
        "ticker_sentiment_score": "0.446006",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.208166",
        "ticker_sentiment_score": "0.257682",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MBIO",
        "relevance_score": "0.275091",
        "ticker_sentiment_score": "0.014393",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday - NVIDIA  ( NASDAQ:NVDA ) ",
    "url": "https://www.benzinga.com/news/24/06/39380352/nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday",
    "time_published": "20240618T134427",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for The Kroger Co. KR from $58 to $60.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/18/California--United-States---March-02-202.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.284699,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AYI",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.014688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.061732",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MIRM",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.34567",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WING",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.297171",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KR",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.370555",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "-0.031161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MU",
        "relevance_score": "0.160633",
        "ticker_sentiment_score": "0.328876",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.196977",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "-0.136563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.238913",
        "ticker_sentiment_score": "0.221362",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference",
    "url": "https://www.globenewswire.com/news-release/2024/06/18/2900339/37704/en/CytomX-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Immune-Cell-Engager-Virtual-Conference.html",
    "time_published": "20240618T120000",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., June 18, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.140431,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.055734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.115574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.055734",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.055734",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel  ( Nasdaq:CERE ) ? Contact BFA Law about Ongoing Investigation into the Deal Price - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39373485/cerevel-stock-update-is-45-per-share-enough-for-cerevel-nasdaq-cere-contact-bfa-law-about-ongoing-",
    "time_published": "20240618T101300",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 18, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.326996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.268476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.171426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Reports on its 2024 General Shareholders' Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company's Growth",
    "url": "https://www.globenewswire.com/news-release/2024/06/19/2901234/0/en/OSE-Immunotherapeutics-Reports-on-its-2024-General-Shareholders-Meeting-and-the-Evolution-of-the-Board-of-Directors-Ready-to-Drive-the-Strategic-Company-s-Growth.html",
    "time_published": "20240619T161500",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "2024 General Shareholders' Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company's Growth Nantes, France - June 19, 2024, 6:15pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.192747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.093451",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MCLE",
        "relevance_score": "0.017496",
        "ticker_sentiment_score": "0.00846",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  is a Great Dividend Stock Right Now",
    "url": "https://www.zacks.com/stock/news/2290520/why-abbvie-abbv-is-a-great-dividend-stock-right-now",
    "time_published": "20240619T154508",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976671"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      }
    ],
    "overall_sentiment_score": 0.403089,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.453099",
        "ticker_sentiment_score": "0.486378",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why AbbVie  ( ABBV )  is a Strong Momentum Stock",
    "url": "https://www.zacks.com/stock/news/2290415/heres-why-abbvie-abbv-is-a-strong-momentum-stock",
    "time_published": "20240619T135004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.335858,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.207896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's  ( ABBV )  Skyrizi Gets FDA Nod for Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2290253/abbvies-abbv-skyrizi-gets-fda-nod-for-ulcerative-colitis",
    "time_published": "20240619T124500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.271502,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RXDX",
        "relevance_score": "0.054114",
        "ticker_sentiment_score": "0.024979",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.449184",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.161349",
        "ticker_sentiment_score": "0.082165",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors",
    "url": "https://www.globenewswire.com/news-release/2024/06/19/2901079/0/en/Jasper-Therapeutics-Announces-Appointment-of-Svetlana-Lucas-Ph-D-to-its-Board-of-Directors.html",
    "time_published": "20240619T120000",
    "authors": [
      "Jasper Therapeutics",
      "Inc."
    ],
    "summary": "REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc. ( Nasdaq: JSPR ) ( Jasper ) , a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ( CD117 ) to address mast cell driven diseases such as chronic ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ed6e5311-feff-4502-874f-39486c6ba17a",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.10061,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JSPR",
        "relevance_score": "0.063509",
        "ticker_sentiment_score": "0.098367",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATYR",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.063509",
        "ticker_sentiment_score": "-0.005012",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.03178",
        "ticker_sentiment_score": "-0.00473",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors - Jasper Therapeutics  ( NASDAQ:JSPR ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39397237/jasper-therapeutics-announces-appointment-of-svetlana-lucas-ph-d-to-its-board-of-directors",
    "time_published": "20240619T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "REDWOOD CITY, Calif., June 19, 2024 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.107548,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JSPR",
        "relevance_score": "0.090816",
        "ticker_sentiment_score": "0.082919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ATYR",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060617",
        "ticker_sentiment_score": "-0.005004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.030331",
        "ticker_sentiment_score": "-0.004693",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Super Smart Dividend Stocks to Buy With $10,000 Right Now",
    "url": "https://www.fool.com/investing/2024/06/19/the-smartest-dividend-stocks-to-buy-with-10000-rig/",
    "time_published": "20240619T081900",
    "authors": [
      "Bradley Guichard"
    ],
    "summary": "Don't sleep on the value of quality dividends.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F780762%2Fabbvie-guidance.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.29017,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.244897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.112532",
        "ticker_sentiment_score": "0.244897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.3796",
        "ticker_sentiment_score": "0.179106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.213591",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.191296",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.257142",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/06/39420779/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
    "time_published": "20240620T193032",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.28% on an annualized basis producing an average annual return of 12.11%. Currently, AbbVie has a market capitalization of $304.56 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here's Why Eli Lilly  ( LLY )  is Probably the Best Drug Stock Now",
    "url": "https://www.zacks.com/stock/news/2290782/heres-why-eli-lilly-lly-is-probably-the-best-drug-stock-now",
    "time_published": "20240620T130100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.233627,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166743",
        "ticker_sentiment_score": "0.240335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.153717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.273532",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.059562",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.12546",
        "ticker_sentiment_score": "0.068567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.041975",
        "ticker_sentiment_score": "-0.063648",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year",
    "url": "https://www.fool.com/investing/2024/06/20/10-stocks-to-build-a-dividend-portfolio-that-will/",
    "time_published": "20240620T124100",
    "authors": [
      "CPA",
      "Mark Roussin"
    ],
    "summary": "The power of compounding can build huge amounts of passive income.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781113/gettyimages-1720247749.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.345564,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.659096",
        "ticker_sentiment_score": "0.508083",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel  ( Nasdaq:CERE ) ? Contact BFA Law about Continuing Investigation into the Offer - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39407836/cerevel-investor-reminder-think-45-per-share-is-too-low-for-cerevel-nasdaq-cere-contact-bfa-law-ab",
    "time_published": "20240620T110700",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 20, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.221109,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.636698",
        "ticker_sentiment_score": "0.326996",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.303175",
        "ticker_sentiment_score": "0.268476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.103331",
        "ticker_sentiment_score": "0.171426",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco  ( June 18 - 21 ) ",
    "url": "https://www.globenewswire.com/news-release/2024/06/20/2901374/0/en/OSE-Immunotherapeutics-Presents-Preclinical-Data-on-mRNA-Therapeutic-Platform-for-the-Treatment-of-Inflammatory-and-Autoimmune-Disorders-at-the-FOCIS-Annual-Meeting-San-Francisco-J.html",
    "time_published": "20240620T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disordersat the FOCIS Annual Meeting, San Francisco ( June ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.017029,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.104911",
        "ticker_sentiment_score": "0.089527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco  ( June 18 - 21 ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39404696/ose-immunotherapeutics-presents-preclinical-data-on-mrna-therapeutic-platform-for-the-treatment-of",
    "time_published": "20240620T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco ( June 18 - 21 )",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": -0.0073,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.104002",
        "ticker_sentiment_score": "-0.041232",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dry-eye-syndrome-drugs-market-size-is-set-to-grow-by-usd-2-13-billion-from-2024-2028--growing-geriatric-population-boost-the-market-technavio-302178705.html",
    "time_published": "20240621T215500",
    "authors": [],
    "summary": "Dry Eye Syndrome Drugs Market size is set to grow by USD 2.13 billion from 2024-2028, Growing geriatric population ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.145318,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.03458",
        "ticker_sentiment_score": "0.021037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Halozyme Announces argenx Receives FDA Approval for VYVGART\u00ae Hytrulo Co-Formulated with ENHANZE\u00ae for Chronic Inflammatory Demyelinating Polyneuropathy",
    "url": "https://www.prnewswire.com/news-releases/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-co-formulated-with-enhanze-for-chronic-inflammatory-demyelinating-polyneuropathy-302179423.html",
    "time_published": "20240621T211500",
    "authors": [
      "Halozyme Therapeutics",
      "Inc."
    ],
    "summary": "Halozyme Announces argenx Receives FDA Approval for VYVGART\u00ae Hytrulo Co-Formulated with ENHANZE\u00ae for ... PR ...",
    "banner_image": "https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.179962,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.083481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.083481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABOS",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.083481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.100038",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HALO",
        "relevance_score": "0.087027",
        "ticker_sentiment_score": "-0.072203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.192425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.083481",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "0.083481",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/hospital-infection-therapeutics-market-size-is-set-to-grow-by-usd-3-46-billion-from-2024-2028--increase-in-incidence-and-prevalence-of-respiratory-disorders-boost-the-market-technavio-302177964.html",
    "time_published": "20240621T210500",
    "authors": [],
    "summary": "Hospital Infection Therapeutics Market size is set to grow by USD 3.46 billion from 2024-2028, Increase in incidence ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.097863,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAYZF",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACHL",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.032207",
        "ticker_sentiment_score": "0.010439",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",
    "url": "https://markets.businessinsider.com/news/stocks/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly-1033497156",
    "time_published": "20240621T194801",
    "authors": [],
    "summary": "Chicago, IL - June 21, 2024 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/06/21/jason-briscoe-amlfrl8lgls-unsplash.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238116,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.209402",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.121918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.081552",
        "ticker_sentiment_score": "0.069954",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.06016",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040829",
        "ticker_sentiment_score": "-0.06354",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly - Johnson & Johnson  ( NYSE:JNJ ) , Eli Lilly and Co  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39432381/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T193114",
    "authors": [
      "Zacks"
    ],
    "summary": "Chicago, IL - June 21, 2024 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/21/jason-briscoe-amlfrl8lgls-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.23596,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.208813",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.133763",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.486415",
        "ticker_sentiment_score": "0.240245",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.080055",
        "ticker_sentiment_score": "0.069699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.159305",
        "ticker_sentiment_score": "0.067239",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "-0.063462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39439586/check-out-what-whales-are-doing-with-abbv",
    "time_published": "20240621T191755",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.150363,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.653175",
        "ticker_sentiment_score": "0.221819",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs",
    "url": "https://www.zacks.com/stock/news/2291505/pharma-stock-roundup-fda-nod-to-mrks-new-jab-expanded-use-of-abbv-azn-drugs",
    "time_published": "20240621T134500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.183887,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "0.009107",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.11166",
        "ticker_sentiment_score": "0.108087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",
    "url": "https://www.zacks.com/stock/news/2291339/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly",
    "time_published": "20240621T115900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.235581,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.208275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.120071",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.478768",
        "ticker_sentiment_score": "0.243569",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "0.069463",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.156461",
        "ticker_sentiment_score": "0.062196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "-0.06338",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top 10 Companies Dominating the Global Drug Delivery Systems Market",
    "url": "https://www.prnewswire.com/news-releases/top-10-companies-dominating-the-global-drug-delivery-systems-market-302178938.html",
    "time_published": "20240621T085300",
    "authors": [
      "BCC Research LLC"
    ],
    "summary": "\"Revolutionizing Healthcare Horizons: Delving Deep into Advanced Drug Delivery Systems ( ADDS ) and Forecasting an Explosive $359.1 Billion Market Growth by 2028, BCC Research Study\" BOSTON, June 21, 2024 /PRNewswire/ -- Demand for effective solutions has never been so urgent to prevent global ...",
    "banner_image": "https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.368737,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BSX",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.139046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.139046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.139046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.157812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.139046",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDT",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.157812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.157812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.157812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "CEREVEL  ( NASDAQ:CERE )  INVESTOR ALERT: Cerevel's $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the Firm - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39444517/cerevel-nasdaq-cere-investor-alert-cerevels-45-per-share-offer-is-being-investigated-by-bfa-law-sh",
    "time_published": "20240622T100400",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 22, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2211,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.326505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.267639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.171159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income",
    "url": "https://www.zacks.com/stock/news/2292086/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income",
    "time_published": "20240624T131003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default129.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.215485,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FITB",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.106255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.155451",
        "ticker_sentiment_score": "0.106255",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now",
    "url": "https://www.zacks.com/stock/news/2291993/if-you-invested-1000-in-abbvie-a-decade-ago-this-is-how-much-itd-be-worth-now",
    "time_published": "20240624T123002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default164.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.180042,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.720339",
        "ticker_sentiment_score": "0.308289",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "-0.025004",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies",
    "url": "https://www.globenewswire.com/news-release/2024/06/24/2902731/0/en/OSE-Immunotherapeutics-Announces-Commercial-and-Revenue-Sharing-Agreement-in-the-Field-of-CAR-T-cell-Therapies.html",
    "time_published": "20240624T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 - 7:30am CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.122307,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.135538",
        "ticker_sentiment_score": "0.082036",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39449502/ose-immunotherapeutics-announces-commercial-and-revenue-sharing-agreement-in-the-field-of-car-t-ce",
    "time_published": "20240624T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NANTES, France, June 24, 2024 - 7:30am CET - OSE Immunotherapeutics SA FR, today announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.117465,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.133841",
        "ticker_sentiment_score": "-0.046268",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2293176/abbvie-abbv-stock-dips-while-market-gains-key-facts",
    "time_published": "20240625T214517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.20541,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.541943",
        "ticker_sentiment_score": "0.217601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39480818/abbvies-parkinsons-disease-therapy-hits-fda-roadblock",
    "time_published": "20240625T135823",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Tuesday, AbbVie Inc ABBV announced it received an FDA Complete Response Letter ( CRL ) for the New Drug Application ( NDA ) for ABBV-951 ( foscarbidopa/foslevodopa ) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/25/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.25257,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.855019",
        "ticker_sentiment_score": "0.443555",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie: FDA Issues CRL For ABBV-951",
    "url": "https://markets.businessinsider.com/news/stocks/abbvie-fda-issues-crl-for-abbv-951-1033503482",
    "time_published": "20240625T122800",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "AbbVie: FDA Issues CRL For ...",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.108227,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.999424",
        "ticker_sentiment_score": "0.21409",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Pacer US Cash Cows 100 ETF  ( COWZ )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2292633/is-pacer-us-cash-cows-100-etf-cowz-a-strong-etf-right-now",
    "time_published": "20240625T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default255.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.282108,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEN",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.060813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.060813",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.060813",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CEREVEL  ( NASDAQ:CERE )  STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm - Cerevel Therapeutics Hldg  ( NASDAQ:CERE ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39472411/cerevel-nasdaq-cere-stock-alert-cerevels-45-per-share-deal-is-being-investigated-by-bfa-law-shareh",
    "time_published": "20240625T090600",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, June 25, 2024 ( GLOBE NEWSWIRE ) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. CERE and AbbVie, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2211,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.634626",
        "ticker_sentiment_score": "0.326505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.301933",
        "ticker_sentiment_score": "0.267639",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.171159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
    "url": "https://www.fool.com/investing/2024/06/25/3-high-yield-dividend-stocks-to-buy-now-for-a-life/",
    "time_published": "20240625T083100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781428/investment-advisor-with-client-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.337507,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DG",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.198961",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DLTR",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.198961",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MCO",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.187039",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.234484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMBK",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.085883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARCC",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.20159",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "O",
        "relevance_score": "0.274012",
        "ticker_sentiment_score": "0.318176",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone",
    "url": "https://www.globenewswire.com/news-release/2024/06/26/2904866/0/en/Nxera-Pharma-Receives-US-10-Million-from-AbbVie-as-Collaboration-Targeting-Neurological-Diseases-Achieves-First-R-D-Milestone.html",
    "time_published": "20240626T230500",
    "authors": [
      "Nxera Pharma"
    ],
    "summary": "Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd ( \"Nxera\". TSE 4565 ) , announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5cc74d52-c86f-4e21-8684-3496281fee15",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.207566,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SOLTF",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.091574",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.214304",
        "ticker_sentiment_score": "0.21956",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "EPKINLY\u00ae  ( epcoritamab-bysp )  Approved by U.S. FDA for Patients with Relapsed or Refractory  ( R/R )  Follicular Lymphoma  ( FL ) ",
    "url": "https://www.globenewswire.com/news-release/2024/06/26/2904865/0/en/EPKINLY-epcoritamab-bysp-Approved-by-U-S-FDA-for-Patients-with-Relapsed-or-Refractory-R-R-Follicular-Lymphoma-FL.html",
    "time_published": "20240626T230300",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.046246,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.18343",
        "ticker_sentiment_score": "0.127441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.045785",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors",
    "url": "https://www.benzinga.com/pressreleases/24/06/g39503803/cour-pharmaceuticals-appoints-tim-walbert-to-its-board-of-directors",
    "time_published": "20240626T141500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHICAGO, June 26, 2024 ( GLOBE NEWSWIRE ) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of \ufb01rst-in-class, disease-modifying therapies designed to induce antigen-speci\ufb01c tolerance for immune-mediated diseases, today announced the appointment of Tim ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.283658,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "-0.077173",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MIRM",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.084073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IPSC",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.084073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SGMT",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.084073",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Parkinson's Candidate Faces 2nd FDA Rejection",
    "url": "https://www.zacks.com/stock/news/2293526/abbvie-abbv-parkinsons-candidate-faces-2nd-fda-rejection",
    "time_published": "20240626T130500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party manufacturing facilities.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135521,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALGS",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.034894",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.755649",
        "ticker_sentiment_score": "0.427668",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ALXO",
        "relevance_score": "0.279813",
        "ticker_sentiment_score": "0.029689",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RAPT",
        "relevance_score": "0.279813",
        "ticker_sentiment_score": "0.029689",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Healthcare Mutual Funds Thriving Amid Economic Shifts",
    "url": "https://www.zacks.com/stock/news/2293547/3-healthcare-mutual-funds-thriving-amid-economic-shifts",
    "time_published": "20240626T122200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Healthcare mutual funds such as FPHAX, VGHCX and PHSTX are increasingly favored as solid investments amid economic volatility and change in consumer sentiment.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.200567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.048706",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.050435",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.034051",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.05234",
        "ticker_sentiment_score": "0.043727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.104455",
        "ticker_sentiment_score": "0.052588",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck's Lung Cancer Candidate Faces FDA Rejection - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/06/39529859/mercks-lung-cancer-candidate-faces-fda-rejection",
    "time_published": "20240627T183920",
    "authors": [
      "Zacks"
    ],
    "summary": "Merck MRK and its partner Daiichi Sankyo announced that the FDA has issued a complete response letter ( \"CRL\" ) to the biologics license application ( BLA ) seeking accelerated approval for patritumab deruxtecan for previously-treated EGFR-mutated non-small cell lung cancer ( NSCLC ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/louis-reed-pwckf7l4-no-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.097665,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.396052",
        "ticker_sentiment_score": "-0.148776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.270523",
        "ticker_sentiment_score": "0.178522",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.396052",
        "ticker_sentiment_score": "-0.148776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.204647",
        "ticker_sentiment_score": "-0.08602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.068896",
        "ticker_sentiment_score": "0.085279",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway - Genmab  ( NASDAQ:GMAB ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39532534/abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expan",
    "time_published": "20240627T172209",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, the FDA approved Epkinly ( epcoritamab-bysp ) as the first and only T-cell-engaging bispecific antibody administered subcutaneously for adults with relapsed or refractory follicular lymphoma ( r/r F ) after two or more lines of prior therapy.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/27/AbbVie-Office.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.244706,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.258351",
        "ticker_sentiment_score": "0.264722",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.339745",
        "ticker_sentiment_score": "0.325199",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.173958",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking At AbbVie's Recent Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/06/39530338/looking-at-abbvies-recent-unusual-options-activity",
    "time_published": "20240627T160325",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "High-rolling investors have positioned themselves bearish on AbbVie ABBV, and it's important for retail traders to take note. \\This activity came to our attention today through Benzinga's tracking of publicly available options data.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.130235,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.661658",
        "ticker_sentiment_score": "0.178828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Expands AbbVie's  ( ABBV )  Epkinly Label in Follicular Lymphoma",
    "url": "https://www.zacks.com/stock/news/2294519/fda-expands-abbvies-abbv-epkinly-label-in-follicular-lymphoma",
    "time_published": "20240627T150300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.211535,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARQT",
        "relevance_score": "0.170576",
        "ticker_sentiment_score": "0.048214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.516185",
        "ticker_sentiment_score": "0.318272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.253426",
        "ticker_sentiment_score": "0.180514",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.212301",
        "ticker_sentiment_score": "0.100135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Merck's  ( MRK )  Lung Cancer Candidate Faces FDA Rejection",
    "url": "https://www.zacks.com/stock/news/2294389/mercks-mrk-lung-cancer-candidate-faces-fda-rejection",
    "time_published": "20240627T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.080875,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "-0.144615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.164786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "-0.144615",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "-0.083564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.085346",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Acquires Celsius Therapeutics",
    "url": "https://www.prnewswire.com/news-releases/abbvie-acquires-celsius-therapeutics-302184570.html",
    "time_published": "20240627T132600",
    "authors": [
      "AbbVie"
    ],
    "summary": "\u2022 Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 ( TREM1 ) antibody for the treatment of inflammatory bowel disease ( IBD )",
    "banner_image": "https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.07273,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.153999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.053509",
        "ticker_sentiment_score": "0.153999",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.454174",
        "ticker_sentiment_score": "0.147977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Trending Stock AbbVie Inc.  ( ABBV )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2294161/is-trending-stock-abbvie-inc-abbv-a-buy-now",
    "time_published": "20240627T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.219078,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.483888",
        "ticker_sentiment_score": "0.154748",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Introducing All\u0113 Payment Plans, Powered by Cherry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/06/n39523245/introducing-all-payment-plans-powered-by-cherry",
    "time_published": "20240627T123000",
    "authors": [
      "PRNewswire"
    ],
    "summary": "All\u0113 Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.02439,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.015091",
        "ticker_sentiment_score": "0.129914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015091",
        "ticker_sentiment_score": "0.129914",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07535",
        "ticker_sentiment_score": "0.159478",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Pacer US Cash Cows 100 ETF  ( COWZ )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2294064/should-pacer-us-cash-cows-100-etf-cowz-be-on-your-investing-radar",
    "time_published": "20240627T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.217286,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LEN",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.068857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.068857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.124486",
        "ticker_sentiment_score": "0.068857",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Can AbbVie Stock Keep Outpacing the S&P 500?",
    "url": "https://www.fool.com/investing/2024/06/27/is-abbvie-stock-a-buy/",
    "time_published": "20240627T093000",
    "authors": [
      "George Budwell"
    ],
    "summary": "AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?",
    "banner_image": "https://media.ycharts.com/charts/327e7a2db356c67887f93cfa1cfa3c2c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.237457,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.712905",
        "ticker_sentiment_score": "0.475643",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "-0.010209",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders",
    "url": "https://www.globenewswire.com/news-release/2024/06/28/2906175/0/en/LSL-Pharma-Group-Announces-Voting-Results-of-Its-Annual-and-Special-Meeting-of-Shareholders.html",
    "time_published": "20240628T213700",
    "authors": [
      "LSL Pharma Group Inc."
    ],
    "summary": "BOUCHERVILLE, Qu\u00e9bec, June 28, 2024 ( GLOBE NEWSWIRE ) -- LSL PHARMA GROUP INC. ( TSXV: LSL, LSL.DB ) ( \"the Company\" or \"LSL Pharma\" ) , a Canadian integrated pharmaceutical company, is pleased to announce the results of its annual and special meeting of shareholders held today in Montr\u00e9al, ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/42cd8aa0-727c-4122-a278-a2ea11633331",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.260968,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALC",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HESG",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VLEEF",
        "relevance_score": "0.060848",
        "ticker_sentiment_score": "0.056",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone's ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market",
    "url": "https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html",
    "time_published": "20240628T200400",
    "authors": [
      "NurExone Biologic Inc"
    ],
    "summary": "Prestigious Eye Institute Exploring New Indication for ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8d4b0f07-b60a-4068-a562-18f53cef6575/210524-optic-nerve-regeneration-photo-2.jpg",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.101534,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.024446",
        "ticker_sentiment_score": "0.083585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024446",
        "ticker_sentiment_score": "0.083585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.024446",
        "ticker_sentiment_score": "0.083585",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.024446",
        "ticker_sentiment_score": "0.083585",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN",
    "url": "https://www.zacks.com/stock/news/2294903/pharma-stock-roundup-fdas-crl-to-mrk-abbv-phase-iii-study-failures-for-nvo-azn",
    "time_published": "20240628T131300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.026565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.054721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.439786",
        "ticker_sentiment_score": "0.035409",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.03319",
        "ticker_sentiment_score": "0.054721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.164806",
        "ticker_sentiment_score": "0.010094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.229149",
        "ticker_sentiment_score": "-0.079077",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's  ( ABBV )  Celsius Therapeutics Deal to Boost IBD Presence",
    "url": "https://www.zacks.com/stock/news/2294838/abbvies-abbv-celsius-therapeutics-deal-to-boost-ibd-presence",
    "time_published": "20240628T125100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.19152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.679765",
        "ticker_sentiment_score": "0.4445",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ROIV",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.053281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.025233",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.072",
        "ticker_sentiment_score": "0.053281",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.213674",
        "ticker_sentiment_score": "0.100806",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2294734/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240628T102004",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.269207,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IVZ",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.240627",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.048612",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.048612",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Epcoritamab  ( TEPKINLY\u00ae )  Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/06/28/2905653/0/en/Epcoritamab-TEPKINLY-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Adults-with-Relapsed-Refractory-Follicular-Lymphoma.html",
    "time_published": "20240628T060000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.040731,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.266585",
        "ticker_sentiment_score": "0.086387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.090389",
        "ticker_sentiment_score": "0.067325",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone's ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market",
    "url": "https://markets.businessinsider.com/news/stocks/nurexone-s-exopten-being-studied-as-glaucoma-treatment-for-us-3-4-billion-market-1033516512",
    "time_published": "20240629T010123",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "TORONTO and HAIFA, Israel, June 28, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc. ( TSXV: NRX ) , ( OTCQB: NRXBF ) , ( Germany: J90 ) ( the \"Company\" or \"NurExone\" ) , a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore the potential of NurExone's ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/8d4b0f07-b60a-4068-a562-18f53cef6575/210524-optic-nerve-regeneration-photo-2.jpg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.115698,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.128115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.083044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.083044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.083044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.023191",
        "ticker_sentiment_score": "0.083044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yielding Healthcare Stocks to Buy With $1,000 in July",
    "url": "https://www.fool.com/investing/2024/07/01/3-high-yielding-healthcare-stocks-to-buy-with-1000/",
    "time_published": "20240701T144800",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "These reliable dividend payers are no-brainer buys right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782176/individual-investors-at-home-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225924,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.388018",
        "ticker_sentiment_score": "0.244885",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "0.399523",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.10097",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Gets CHMP Nod for Lymphoma Drug's Expanded Use",
    "url": "https://www.zacks.com/stock/news/2295441/abbvie-abbv-gets-chmp-nod-for-lymphoma-drugs-expanded-use",
    "time_published": "20240701T123700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.219259,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.145717",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.504646",
        "ticker_sentiment_score": "0.263857",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Robert Michael Assumes Role Of CEO",
    "url": "https://markets.businessinsider.com/news/stocks/abbvie-s-robert-michael-assumes-role-of-ceo-1033519348",
    "time_published": "20240701T121718",
    "authors": [
      "markets.businessinsider.com"
    ],
    "summary": "( RTTNews ) - AbbVie ( ABBV ) , a pharmaceutical company, announced on Monday that Robert Michael has assumed the role of Chief Executive Officer and has joined the Board with effect from July 1. As announced earlier, Michael succeeds Richard Gonzalez, who has been appointed as the Executive ...",
    "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg",
    "source": "Business Insider",
    "category_within_source": "RSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.105931,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.971845",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Magnificent Stocks Retirees Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/01/3-magnificent-stocks-retirees-can-buy-and-hold-for/",
    "time_published": "20240701T105000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks could be ideal for investors in their golden years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/781952/hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.277972,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.295358",
        "ticker_sentiment_score": "0.16518",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.171485",
        "ticker_sentiment_score": "0.202911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.254751",
        "ticker_sentiment_score": "0.177268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck  ( MRK )  Gets CHMP Nod for PAH Drug Winrevair in Europe",
    "url": "https://www.zacks.com/stock/news/2295379/merck-mrk-gets-chmp-nod-for-pah-drug-winrevair-in-europe",
    "time_published": "20240701T093000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.247262,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.150305",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.063933",
        "ticker_sentiment_score": "0.129126",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UTHR",
        "relevance_score": "0.190167",
        "ticker_sentiment_score": "0.26268",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.127456",
        "ticker_sentiment_score": "0.206629",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'",
    "url": "https://www.globenewswire.com/news-release/2024/07/01/2906374/0/en/OSE-Immunotherapeutics-Announces-Publication-of-Preclinical-Efficacy-Results-with-Lusvertikimab-in-Acute-Lymphoblastic-Leukemia-in-the-Journal-Blood.html",
    "time_published": "20240701T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood' Nantes, France - July 1st, 2024 - 7:30 am CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.052698,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.095612",
        "ticker_sentiment_score": "0.070572",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39567534/ose-immunotherapeutics-announces-publication-of-preclinical-efficacy-results-with-lusvertikimab-in",
    "time_published": "20240701T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.054974,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.039786",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bankers wary despite jump in US corporate fundraising",
    "url": "https://www.ft.com/content/5678e73f-840a-4210-afa6-2059c95a6d81",
    "time_published": "20240702T040014",
    "authors": [
      "Nicholas Megaw",
      "Harriet Clarfelt"
    ],
    "summary": "First-half activity boosted by companies bringing forward deals to avoid pre-election market volatility ...",
    "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd6c748xw2pzm8.cloudfront.net%2Fprod%2F6d2c1c60-34bf-11ef-8887-f72e8593880a-standard.png?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
    "source": "Financial Times",
    "category_within_source": "Markets",
    "source_domain": "www.ft.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.071946,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AS",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.135617",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.113575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.113575",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULS",
        "relevance_score": "0.042723",
        "ticker_sentiment_score": "0.135617",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "A Closer Look at AbbVie's Options Market Dynamics - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39621483/a-closer-look-at-abbvies-options-market-dynamics",
    "time_published": "20240703T164642",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.094908,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.702434",
        "ticker_sentiment_score": "0.125178",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Jul 3, 2024",
    "url": "https://www.zacks.com/stock/news/2296547/company-news-for-jul-3-2024",
    "time_published": "20240703T132400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies in The News Are: TSLA, AAPL, IQ, ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a4/1056.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.192859,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "IQ",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "0.77524",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "0.746231",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "-0.526922",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.7887",
        "ticker_sentiment_score": "0.016233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dermatology Devices Market size is set to grow by USD 154.23 billion from 2024-2028, Increasing prevalence of skin ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/dermatology-devices-market-size-is-set-to-grow-by-usd-154-23-billion-from-2024-2028--increasing-prevalence-of-skin-disorders-to-boost-the-market-growth-technavio-302188850.html",
    "time_published": "20240704T213000",
    "authors": [],
    "summary": "Dermatology Devices Market size is set to grow by USD 154.23 billion from 2024-2028, Increasing prevalence of skin ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.130844,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRKR",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SHPHF",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02029",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.024053",
        "ticker_sentiment_score": "0.02504",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "HDV vs. SCHD: Which Is the Better Dividend ETF?",
    "url": "https://markets.businessinsider.com/news/stocks/hdv-vs-schd-which-is-the-better-dividend-etf-%C2%A0-1033527764",
    "time_published": "20240704T015532",
    "authors": [
      "Tipranks"
    ],
    "summary": "The iShares Core High Dividend ETF ( NYSEARCA:HDV ) and the Schwab U.S. Dividend Equity ETF ( NYSEARCA:SCHD ) are two popular dividend ETFs from blue-chip sponsors. Both are cost-effective options with low expense ratios, feature portfolios of well-known dividend stocks, and have dividend yields ...",
    "banner_image": "https://blog.tipranks.com/wp-content/uploads/2024/07/image-62-1024x555.png?utm_source=markets.businessinsider.com&utm_medium=referral",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.305428,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.221681",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.067089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.067089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.075279",
        "ticker_sentiment_score": "0.216793",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.289786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.037681",
        "ticker_sentiment_score": "0.289786",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Aesthetic Devices Market Size in France is set to grow by USD 279 million from 2024-2028, Rise in awareness ... - PR Newswire",
    "url": "https://www.prnewswire.com/news-releases/aesthetic-devices-market-size-in-france-is-set-to-grow-by-usd-279-million-from-2024-2028-rise-in-awareness-regarding-aesthetic-surgeries-to-boost-the-market-growth-technavio-302189592.html",
    "time_published": "20240705T213500",
    "authors": [],
    "summary": "Aesthetic Devices Market Size in France is set to grow by USD 279 million from 2024-2028, Rise in awareness ... PR ...",
    "banner_image": null,
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.22431,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.02372",
        "ticker_sentiment_score": "0.066915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.02372",
        "ticker_sentiment_score": "-0.021746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERO",
        "relevance_score": "0.02372",
        "ticker_sentiment_score": "-0.021746",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.02372",
        "ticker_sentiment_score": "-0.021746",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD",
    "url": "https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-llys-kisunla-snys-dupixent-gets-eu-nod-for-copd",
    "time_published": "20240705T141600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.167399,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.036637",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.173582",
        "ticker_sentiment_score": "0.085146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.120564",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORINY",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.06065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "-0.105939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.028349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.188766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Boston Partners Mutual Funds for Maximum Returns",
    "url": "https://www.zacks.com/stock/news/2297115/2-boston-partners-mutual-funds-for-maximum-returns",
    "time_published": "20240705T110900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Boston Partners mutual funds like BPRRX and BPAVX for a diversified portfolio approach.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.277178,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.057967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.222892",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",
    "url": "https://markets.businessinsider.com/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664",
    "time_published": "20240707T141621",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.",
    "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/07/Valparaiso-In-Usa---March-21--2024-Wegov.jpeg",
    "source": "Business Insider",
    "category_within_source": "GoogleRSS",
    "source_domain": "markets.businessinsider.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.038569,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.007019",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "-0.076293",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.166551",
        "ticker_sentiment_score": "0.054044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.007019",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "url": "https://www.zacks.com/stock/news/2297911/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks",
    "time_published": "20240708T163831",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default174.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.234715,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ARE",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.137698",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.112686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "-0.036028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/07/39667656/1000-invested-in-abbvie-10-years-ago-would-be-worth-this-much-today",
    "time_published": "20240708T140028",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.09% on an annualized basis producing an average annual return of 12.01%. Currently, AbbVie has a market capitalization of $293.54 billion.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $250 Right Now",
    "url": "https://www.fool.com/investing/2024/07/08/the-smartest-dividend-stocks-to-buy-with-250-right/",
    "time_published": "20240708T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "$250 will go a long way with these great dividend stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/782548/scientists-in-a-lab.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.341741,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.43494",
        "ticker_sentiment_score": "0.34451",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARCC",
        "relevance_score": "0.318897",
        "ticker_sentiment_score": "0.44459",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche",
    "url": "https://www.zacks.com/stock/news/2297514/the-zacks-analyst-blog-highlights-eli-lilly-sanofi-merck-astrazenecas-and-roche",
    "time_published": "20240708T092900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.171743,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.195814",
        "ticker_sentiment_score": "0.075088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "-0.120218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORINY",
        "relevance_score": "0.065866",
        "ticker_sentiment_score": "0.065434",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "-0.105074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.032961",
        "ticker_sentiment_score": "0.028172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.163687",
        "ticker_sentiment_score": "0.161687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthcare Staffing Shortages, Mental Health Awareness and Other Recent Health News Trends",
    "url": "https://www.prnewswire.com/resources/news-trends/health-news-trends-may-june-2024/",
    "time_published": "20240709T183234",
    "authors": [],
    "summary": "A look at health news from PR Newswire in May and June that you might have missed. The past two months have been busy ones in the healthcare space. During May and June, PR Newswire distributed more than 5,700 health-related press releases.",
    "banner_image": "https://www.prnewswire.com/content/dam/prnewswire/miscellaneous/Health-Trends-MayJune-2024.png",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.13924,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.021917",
        "ticker_sentiment_score": "0.011299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043818",
        "ticker_sentiment_score": "0.133981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DGX",
        "relevance_score": "0.021917",
        "ticker_sentiment_score": "0.063971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ULS",
        "relevance_score": "0.021917",
        "ticker_sentiment_score": "0.011299",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.021917",
        "ticker_sentiment_score": "-0.077741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.021917",
        "ticker_sentiment_score": "-0.077741",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Eli Lilly  ( LLY )  to Buy Morphic for $3.2B, Boost IBD Presence",
    "url": "https://www.zacks.com/stock/news/2298543/eli-lilly-lly-to-buy-morphic-for-32b-boost-ibd-presence",
    "time_published": "20240709T141700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.193747,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.36255",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MORF",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.068382",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.165658",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ROIV",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.05304",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.025065",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.05304",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now",
    "url": "https://www.zacks.com/stock/news/2299043/if-you-invested-1000-in-halozyme-therapeutics-a-decade-ago-this-is-how-much-itd-be-worth-now",
    "time_published": "20240710T123003",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default358.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.199984,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HALO",
        "relevance_score": "0.439243",
        "ticker_sentiment_score": "0.335871",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.06623",
        "ticker_sentiment_score": "0.028029",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2298984/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20240710T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.269282,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.246582",
        "ticker_sentiment_score": "0.23018",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.068938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.068938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.068938",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2300329/abbvie-abbv-gains-as-market-dips-what-you-should-know",
    "time_published": "20240711T214517",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $169.91, representing a +1.05% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default128.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.168156,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.546745",
        "ticker_sentiment_score": "0.213712",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight",
    "url": "https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html",
    "time_published": "20240711T213100",
    "authors": [
      "LLP",
      "DelveInsight Business Research"
    ],
    "summary": "The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.",
    "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.097856,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "-0.052735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ARQT",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "-0.052735",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.027682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CARA",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APGE",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CGEM",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLUE",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.104751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRTHF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NRIX",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "0.106642",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AKESF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCCC",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALDX",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.031644",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRDF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.102283",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.099373",
        "ticker_sentiment_score": "-0.001064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACLX",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYMR",
        "relevance_score": "0.049784",
        "ticker_sentiment_score": "0.110774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYSI",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRVS",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IOVA",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALLK",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "-0.053652",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TIL",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "-0.019809",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RNAC",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.028471",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "-0.001011",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVMD",
        "relevance_score": "0.074615",
        "ticker_sentiment_score": "0.082227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYKOF",
        "relevance_score": "0.024904",
        "ticker_sentiment_score": "0.02309",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia Research and Treatment",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39738154/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-research-and-trea",
    "time_published": "20240711T194137",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON, July 11, 2024 ( GLOBE NEWSWIRE ) -- Novotech, the global full-service clinical Contract Research Organization ( CRO ) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has today released a significant research report ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.265367,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.148208",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.040416",
        "ticker_sentiment_score": "0.148208",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US - Cigna Group  ( NYSE:CI ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/07/39720968/is-big-pharma-poised-to-take-over-cannabis-3-companies-already-manage-8-in-10-drug-prescriptions",
    "time_published": "20240711T190101",
    "authors": [
      "Nicol\u00e1s Jose Rodriguez"
    ],
    "summary": "The U.S. Federal Trade Commission ( FTC ) recently highlighted the significant influence of pharmacy benefit managers ( PBMs ) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/10/dalle_2024-07-10_21.07.18_-_a_giant_prescription_pill_container_made_of_yellow_plastic_with_a_white_cap_positioned_prominently_as_if_taking_over_expansive_cannabis_fields_in_the.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.149085,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.088577",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.064323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.124809",
        "ticker_sentiment_score": "0.064323",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.062597",
        "ticker_sentiment_score": "0.077018",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39737253/abbvie-unusual-options-activity",
    "time_published": "20240711T184730",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.078576,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.084423",
        "ticker_sentiment_score": "-0.138518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.756417",
        "ticker_sentiment_score": "0.105646",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Up 24% in a Year: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2300044/abbvie-abbv-up-24-in-a-year-buy-sell-or-hold-the-stock",
    "time_published": "20240711T141400",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.229682,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.135983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "-0.084159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.692985",
        "ticker_sentiment_score": "0.339667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2299799/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
    "time_published": "20240711T130016",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.250523,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.159247",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath - Eli Lilly and Co  ( NYSE:LLY ) , Axsome Therapeutics  ( NASDAQ:AXSM ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/07/39726993/a-redux-of-the-lyrica-cymbalta-fibromyalgia-war-of-the-2010s-may-look-more-like-david-vs-goliath",
    "time_published": "20240711T120018",
    "authors": [
      "James Blacker"
    ],
    "summary": "The following post was written and/or published as a collaboration between Benzinga's in-house sponsored content team and Tonix Pharmaceuticals Holding Corp. The sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/Screenshot-2024-07-10-at-9-08-28PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.079298,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.008517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032871",
        "ticker_sentiment_score": "0.102629",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.163243",
        "ticker_sentiment_score": "0.104851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.130926",
        "ticker_sentiment_score": "-0.008517",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.065685",
        "ticker_sentiment_score": "0.103349",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian",
    "url": "https://www.zacks.com/stock/news/2299655/the-zacks-analyst-blog-highlights-novo-nordisk-abbvie-astrazeneca-air-t-and-united-guardian",
    "time_published": "20240711T083100",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.137072,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "UG",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.064731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.064731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AIRT",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.064731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.007342",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.241085",
        "ticker_sentiment_score": "0.153896",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "HR Asia Best Companies to Work for in Asia Taiwan 2024 Honors 92 Champions Ushering in a New Generation Workforce",
    "url": "https://www.prnewswire.com/apac/news-releases/hr-asia-best-companies-to-work-for-in-asia-taiwan-2024-honors-92-champions-ushering-in-a-new-generation-workforce-302194603.html",
    "time_published": "20240711T082400",
    "authors": [
      "Business Media International"
    ],
    "summary": "TAIPEI, July 11, 2024 /PRNewswire/ -- HR Asia, the leading publication in the human resources industry, announces the winners of its prestigious HR Asia Best Companies to Work for in Asia 2024 - Taiwan awards.",
    "banner_image": "https://mma.prnewswire.com/media/2459072/Congratulations_to_the_Winners_of_2024_Taiwan_HR_Asia_Best_Companies_to_Work_in_Asia.jpg?p=facebook",
    "source": "PR Newswire",
    "category_within_source": "n/a",
    "source_domain": "www.prnewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.581041,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.267119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.267119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALIZF",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.267119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DRVN",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.256873",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVT",
        "relevance_score": "0.043499",
        "ticker_sentiment_score": "0.267119",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case - Cencora  ( NYSE:COR ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39754495/abbvie-appeals-to-supreme-court-over-attorney-client-privilege-in-long-standing-androgel-case",
    "time_published": "20240712T173905",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "AbbVie Inc ABBV has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.093565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.713878",
        "ticker_sentiment_score": "-0.324822",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "MCK",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "-0.097938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COR",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "-0.097938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.310843",
        "ticker_sentiment_score": "-0.334379",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AbbVie Gains As Market Dips: What You Should Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39741337/abbvie-gains-as-market-dips-what-you-should-know",
    "time_published": "20240712T152820",
    "authors": [
      "Zacks"
    ],
    "summary": "The most recent trading session ended with AbbVie ABBV standing at $169.91, reflecting a +1.05% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily loss of 0.88%. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/national-cancer-institute-uxnbyoejxce-unsplash.jpg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.186835,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.526455",
        "ticker_sentiment_score": "0.209246",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks to Buy and Hold",
    "url": "https://www.fool.com/investing/2024/07/14/3-dividend-growth-stocks-to-buy-and-hold/",
    "time_published": "20240714T103000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "What's better than a dividend? A dividend that's growing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783166/dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.369079,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.351184",
        "ticker_sentiment_score": "0.45701",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.351184",
        "ticker_sentiment_score": "0.184731",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.224072",
        "ticker_sentiment_score": "0.12827",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Stocks That Still Look Like Bargains",
    "url": "https://www.fool.com/investing/2024/07/14/3-high-yield-dividend-stocks-that-still-look-like/",
    "time_published": "20240714T082700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The prices of these reliable dividend payers haven't kept pace with the frothy stock market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783254/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.208126,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADC",
        "relevance_score": "0.27838",
        "ticker_sentiment_score": "0.266088",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CURN",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "-0.012004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.3892",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056808",
        "ticker_sentiment_score": "0.098933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.298133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Files for Rinvoq in Giant Cell Arteritis in US & EU",
    "url": "https://www.zacks.com/stock/news/2301793/abbvie-abbv-files-for-rinvoq-in-giant-cell-arteritis-in-us-eu",
    "time_published": "20240715T151300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.081697,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ACRV",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.069783",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADPT",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.027508",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.38716",
        "ticker_sentiment_score": "0.129898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RAPT",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.027523",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/15/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240715T103800",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These companies stand out for their pedigrees, robust financials, and future growth prospects.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783101/healthcare-chemist.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.917436"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.316063,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.411549",
        "ticker_sentiment_score": "0.239918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.369456",
        "ticker_sentiment_score": "0.364863",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.143131",
        "ticker_sentiment_score": "0.090953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Declares Third Quarter 2024 Dividend",
    "url": "https://www.globenewswire.com/news-release/2024/07/17/2914905/0/en/Royalty-Pharma-Declares-Third-Quarter-2024-Dividend.html",
    "time_published": "20240717T201500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, July 17, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.709186",
        "ticker_sentiment_score": "0.320221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.10599",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Declares Third Quarter 2024 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39825470/royalty-pharma-declares-third-quarter-2024-dividend",
    "time_published": "20240717T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, July 17, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the close of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.213652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.642555",
        "ticker_sentiment_score": "0.303227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.146025",
        "ticker_sentiment_score": "0.097316",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/39821610/abbvie-unusual-options-activity",
    "time_published": "20240717T170110",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.095141,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.022769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.76367",
        "ticker_sentiment_score": "0.209641",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Absurdly Cheap Stocks to Buy and Hold for Years",
    "url": "https://www.fool.com/investing/2024/07/17/3-absurdly-cheap-stocks-to-buy-and-hold-for-years/",
    "time_published": "20240717T122500",
    "authors": [
      "David Jagielski"
    ],
    "summary": "You can buy these solid stocks at some attractive discounts right now.",
    "banner_image": "https://g.foolcdn.com/editorial/images/783387/people-discussing-a-sales-report.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990786"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.397238,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PYPL",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.396996",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.247838",
        "ticker_sentiment_score": "0.25182",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.306963",
        "ticker_sentiment_score": "0.340346",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Teva's Migraine Treatment Found Effective For Children As Young As 6 - Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6",
    "time_published": "20240718T160636",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Teva Pharmaceutical Industries Ltd TEVA announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy ( fremanezumab ) for the prevention of episodic migraine in children and adolescent patients aged 6-17.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/18/Child-headache-migraine.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.215142,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.138785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.194242",
        "ticker_sentiment_score": "0.031183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.377142",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tissue Engineering Market Size is Expected to Reach USD 12.43 Billion by 2032, Growing at a CAGR of 14.40%: Straits Research",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39840284/tissue-engineering-market-size-is-expected-to-reach-usd-12-43-billion-by-2032-growing-at-a-cagr-of",
    "time_published": "20240718T142000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "New York, United States, July 18, 2024 ( GLOBE NEWSWIRE ) -- As per the Latest Report by Straits Research, the global tissue engineering market size was valued at USD 4,333.61 million in 2023. It is projected to reach USD 12,425.62 million by 2032, growing at a CAGR of 14.40% during the forecast ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.139932,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ZBH",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.06908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "-0.007971",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DAR",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.049815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BDX",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.06908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.06908",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORGO",
        "relevance_score": "0.042048",
        "ticker_sentiment_score": "0.06908",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Preview: AbbVie  ( ABBV )  Q2 Earnings Expected to Decline",
    "url": "https://www.zacks.com/stock/news/2304507/earnings-preview-abbvie-abbv-q2-earnings-expected-to-decline",
    "time_published": "20240718T140123",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default327.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.145585,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.301315",
        "ticker_sentiment_score": "0.008969",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Rises As Market Takes a Dip: Key Facts",
    "url": "https://www.zacks.com/stock/news/2305599/abbvie-abbv-rises-as-market-takes-a-dip-key-facts",
    "time_published": "20240719T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default282.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.112265,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.463792",
        "ticker_sentiment_score": "0.078265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Gastroparesis Treatment Market Size Estimated to Rise at a CAGR of 4.6%, Projected to Reach US$ 10.3 Billion by 2034: Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39862578/gastroparesis-treatment-market-size-estimated-to-rise-at-a-cagr-of-4-6-projected-to-reach-us-10-3-",
    "time_published": "20240719T153426",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , July 19, 2024 ( GLOBE NEWSWIRE ) -- The global gastroparesis treatment market ( \uc704\ub9c8\ube44 \uce58\ub8cc \uc2dc\uc7a5 ) stood at US$ 6.3 billion in 2023, and the global market is projected to reach US$ 10.3 billion in 2034.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.165074,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.051084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.139175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.083455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "-0.234127",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ETER",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "0.139175",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.035138",
        "ticker_sentiment_score": "-0.234127",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data",
    "url": "https://www.zacks.com/stock/news/2305154/pharma-stock-roundup-jnj-nvs-q2-earnings-rhhbys-positive-obesity-pill-data",
    "time_published": "20240719T132600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.143768,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "-0.110727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.349153",
        "ticker_sentiment_score": "0.06668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024",
    "url": "https://www.globenewswire.com/news-release/2024/07/19/2915853/0/en/Royalty-Pharma-to-Announce-Second-Quarter-2024-Financial-Results-on-August-8-2024.html",
    "time_published": "20240719T121500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, July 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.213261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39857926/royalty-pharma-to-announce-second-quarter-2024-financial-results-on-august-8-2024",
    "time_published": "20240719T121500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, July 19, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.172807,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.572601",
        "ticker_sentiment_score": "0.199984",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "0.090163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "10 Best Dividend Growth Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/07/21/10-best-dividend-growth-stocks-to-buy-and-hold-for/",
    "time_published": "20240721T143000",
    "authors": [
      "George Budwell"
    ],
    "summary": "Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784033%2Fdividend-bank-roll.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.803643"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.414524,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.313895",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.088064",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NDSN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.248651",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.31512",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.288706",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NKE",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.264207",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.095517",
        "ticker_sentiment_score": "0.175948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.103087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142847",
        "ticker_sentiment_score": "0.189064",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Q2 Earnings in Full Swing This week",
    "url": "https://www.zacks.com/stock/news/2306183/q2-earnings-in-full-swing-this-week",
    "time_published": "20240722T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "It's a new trading week that's starting slowly, but don't be fooled. This is our first full week of Q2 earnings season, with no fewer than 845 companies scheduled to report results by the end of Friday.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/2662.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.03315,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.049817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.235062",
        "ticker_sentiment_score": "0.124134",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.158",
        "ticker_sentiment_score": "0.028668",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?",
    "url": "https://www.fool.com/investing/2024/07/22/abbvie-could-soar-24-according-to-a-wall-street-an/",
    "time_published": "20240722T144100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The big pharma company's top drug is losing ground, but its dividend keeps rising.",
    "banner_image": "https://media.ycharts.com/charts/3dfbc2d588b6bc329a81fadb412211f4.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.103354,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.063998",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.048034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.048034",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.357049",
        "ticker_sentiment_score": "0.193114",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "0.003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RVNC",
        "relevance_score": "0.052801",
        "ticker_sentiment_score": "-0.058001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "First Full Week of Q2 Earnings, PCE Out Friday",
    "url": "https://www.zacks.com/stock/news/2306101/first-full-week-of-q2-earnings-pce-out-friday",
    "time_published": "20240722T141200",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "No fewer than 845 companies are scheduled to report this week, including Alphabet (GOOGL) and Tesla (TSLA) Tuesday.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2f/61766.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.033117,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.048798",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.227716",
        "ticker_sentiment_score": "0.104422",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GM",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.028094",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Before Q2 Earnings: To Buy or Not to Buy?",
    "url": "https://www.zacks.com/stock/news/2306144/abbvie-abbv-stock-before-q2-earnings-to-buy-or-not-to-buy",
    "time_published": "20240722T134900",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.211511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.609347",
        "ticker_sentiment_score": "0.29209",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2307083/will-these-5-medical-stocks-surpass-q2-earnings-forecasts",
    "time_published": "20240723T151300",
    "authors": [
      "Ahan Chakraborty"
    ],
    "summary": "Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "-0.00153",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.345139",
        "ticker_sentiment_score": "0.007258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.00992",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.039614",
        "ticker_sentiment_score": "0.362362",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.234307",
        "ticker_sentiment_score": "0.082219",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.118452",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.196132",
        "ticker_sentiment_score": "0.035205",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Earnings Preview: Pfizer  ( PFE )  Q2 Earnings Expected to Decline",
    "url": "https://www.zacks.com/stock/news/2306951/earnings-preview-pfizer-pfe-q2-earnings-expected-to-decline",
    "time_published": "20240723T140101",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.123818,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.261584",
        "ticker_sentiment_score": "-0.004004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.17618",
        "ticker_sentiment_score": "0.021295",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference\u00ae  ( AAIC\u00ae )  2024",
    "url": "https://www.globenewswire.com/news-release/2024/07/23/2917072/0/en/Alector-to-Present-Data-on-Pipeline-Focus-Areas-at-the-Alzheimer-s-Association-International-Conference-AAIC-2024.html",
    "time_published": "20240723T110000",
    "authors": [
      "Alector LLC"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., July 23, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/cc1d53f9-03a6-42d4-aba2-ab4ce7b73508",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.121256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.088799",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.565003",
        "ticker_sentiment_score": "0.26062",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is First Trust Value Line Dividend ETF  ( FVD )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2306543/is-first-trust-value-line-dividend-etf-fvd-a-strong-etf-right-now",
    "time_published": "20240723T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default92.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.265734,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.051985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.051985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VALU",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.294579",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "0.051985",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q2 Earnings?",
    "url": "https://www.zacks.com/stock/news/2308035/what-lies-in-store-for-healthcare-etfs-in-q2-earnings",
    "time_published": "20240724T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/2961.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980716"
      }
    ],
    "overall_sentiment_score": 0.169447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.052088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.016864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.082674",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "0.142692",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.007802",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39933878/abbvie-earnings-preview-will-humiras-expiry-new-ceo-fuel-a-bullish-surge",
    "time_published": "20240724T141604",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "AbbVie Inc ABBV will report second-quarter earnings on Thursday and Wall Street expects $2.96 in earnings per share and $14 billion in revenues as the company reports before market hours.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/24091240/Screenshot-2024-07-24-at-6.42.16-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.270841,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "-0.054931",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.795061",
        "ticker_sentiment_score": "0.040274",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39933250/emerging-gene-therapies-signal-transformative-shift-in-retinal-disorder-treatment-according-to-sph",
    "time_published": "20240724T135616",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA., June 20, 2024, July 24, 2024 ( GLOBE NEWSWIRE ) -- The American Society of Retinal Specialists ( ASRS ) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.253994,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RGNX",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "-0.026649",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.097854",
        "ticker_sentiment_score": "-0.008639",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADVM",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.144817",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDMT",
        "relevance_score": "0.049019",
        "ticker_sentiment_score": "0.144817",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences",
    "url": "https://www.zacks.com/stock/news/2307978/the-zacks-analyst-blog-highlights-boston-scientific-thermo-fisher-scientific-align-technology-and-edwards-lifesciences",
    "time_published": "20240724T131900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1d/1298.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.158332,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VKTX",
        "relevance_score": "0.151778",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.361582",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.189076",
        "ticker_sentiment_score": "0.05321",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.298113",
        "ticker_sentiment_score": "0.00645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038162",
        "ticker_sentiment_score": "0.009893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.03072",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis",
    "url": "https://www.globenewswire.com/news-release/2024/07/24/2917736/0/en/OSE-Immunotherapeutics-Announces-Positive-Efficacy-Results-for-Lusvertikimab-in-the-Phase-2-trial-for-the-treatment-of-Ulcerative-Colitis.html",
    "time_published": "20240724T065500",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis \u2022 Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study \u2022 ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.169647,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.097457",
        "ticker_sentiment_score": "0.078696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39924109/ose-immunotherapeutics-announces-positive-efficacy-results-for-lusvertikimab-in-the-phase-2-trial-",
    "time_published": "20240724T065500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study Favorable safety and tolerability profile in the whole patient population across the two doses tested and during the open label phase of treatment",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.167054,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "-0.040308",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why AbbVie Stock Was Cruising Higher on Thursday",
    "url": "https://www.fool.com/investing/2024/07/25/why-abbvie-stock-was-cruising-higher-on-thursday/",
    "time_published": "20240725T202502",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "The market was impressed with a notable increase in full-year guidance.",
    "banner_image": "https://g.foolcdn.com/editorial/images/784666/patient-and-physician-smiling-during-a-visit.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.270272,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.745397",
        "ticker_sentiment_score": "0.336592",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q2 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/07/25/abbvie-abbv-q2-2024-earnings-call-transcript/",
    "time_published": "20240725T193015",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ABBV earnings call for the period ending June 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.297172,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.028783",
        "ticker_sentiment_score": "0.030114",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032893",
        "ticker_sentiment_score": "0.024226",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004113",
        "ticker_sentiment_score": "0.119645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004113",
        "ticker_sentiment_score": "0.119645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.004113",
        "ticker_sentiment_score": "0.119645",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.004113",
        "ticker_sentiment_score": "0.111928",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "[Latest] US Biotechnology Market Size/Share Worth USD 1797.8 Billion by 2033 at a 12.3% CAGR: Custom Market Insights  ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39966281/latest-us-biotechnology-market-sizeshare-worth-usd-1797-8-billion-by-2033-at-a-12-3-cagr-custom-ma",
    "time_published": "20240725T173000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Austin, TX, USA, July 25, 2024 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled \"US Biotechnology Market Size, Trends and Insights By Technology ( Nanobiotechnology, Tissue Engineering and Regeneration, DNA Sequencing, Cell-based Assays, Fermentation, PCR ...",
    "banner_image": "https://ml.globenewswire.com/media/74609d89-5437-4826-b7b8-31238ea2e65c/small/cmi-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.276326,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SFSVF",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.06074",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRSN",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.087091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.070334",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.063349",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.162841",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.030958",
        "ticker_sentiment_score": "0.01749",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.114919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.015482",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Beats on Q2 Earnings & Sales, Ups '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2309203/abbvie-abbv-beats-on-q2-earnings-sales-ups-24-eps-view",
    "time_published": "20240725T142100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.137565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.113062",
        "ticker_sentiment_score": "0.28265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.330286",
        "ticker_sentiment_score": "0.219964",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.075516",
        "ticker_sentiment_score": "0.063588",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and",
    "time_published": "20240725T141807",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/25/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.12256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.767202",
        "ticker_sentiment_score": "0.138429",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Analysts See AbbVie  ( ABBV )  as a Buy: Should You Invest?",
    "url": "https://www.zacks.com/stock/news/2308830/wall-street-analysts-see-abbvie-abbv-as-a-buy-should-you-invest",
    "time_published": "20240725T133010",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_07252024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.274337,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.359262",
        "ticker_sentiment_score": "0.177123",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Tops Q2 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2308650/abbvie-abbv-tops-q2-earnings-and-revenue-estimates",
    "time_published": "20240725T124503",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default47.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999997"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.1393,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.141551",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected - AbbVie  ( NYSE:ABBV ) , Axsome Therapeutics  ( NASDAQ:AXSM ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g39956575/global-fibromyalgia-treatment-market-projected-to-reach-3-86-billion-by-2031-as-positive-growth-tr",
    "time_published": "20240725T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., July 25, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this ...",
    "banner_image": "https://ml.globenewswire.com/media/f326183f-8829-42af-8851-525b1d7503ed/small/finacialnews-logo-final-01-2-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.993856"
      }
    ],
    "overall_sentiment_score": 0.103598,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "-0.016712",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.030218",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.157227",
        "ticker_sentiment_score": "0.071552",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AXSM",
        "relevance_score": "0.079",
        "ticker_sentiment_score": "0.077694",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie the Best Dividend Stock for You?",
    "url": "https://www.fool.com/investing/2024/07/25/is-abbvie-the-best-dividend-stock-for-you/",
    "time_published": "20240725T114500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The drug company has a famously strong dividend record -- and that looks set to continue.",
    "banner_image": "https://media.ycharts.com/charts/fbebcded5b4c405d0aec6046ac35dfea.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.299449,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.054607",
        "ticker_sentiment_score": "0.150827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.662393",
        "ticker_sentiment_score": "0.441617",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Staring At Another Down Session: What's Driving Futures Lower - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",
    "url": "https://www.benzinga.com/news/earnings/24/07/39954566/nasdaq-s-p-futures-slide-on-more-negative-tech-tidings-as-focus-shifts-to-q2-gdp-data-strategist-sa",
    "time_published": "20240725T112310",
    "authors": [
      "Shanthi Rexaline"
    ],
    "summary": "Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/25/Stocks-Photo-by-Jirapong-Manustrong-on-S.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999767"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.142857"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.142857"
      }
    ],
    "overall_sentiment_score": -0.012126,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TER",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "-0.049745",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "F",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LVS",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BYD",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.060306",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "STM",
        "relevance_score": "0.160419",
        "ticker_sentiment_score": "-0.049282",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKYW",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ORLY",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNP",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XRX",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNPR",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HON",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.174415",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAL",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EW",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DECK",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NOW",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HAS",
        "relevance_score": "0.032294",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRSN",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.064536",
        "ticker_sentiment_score": "-0.265976",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992204/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growt",
    "time_published": "20240726T185410",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, AbbVie Inc. ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/26/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.294166,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GS",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "0.184311",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CVS",
        "relevance_score": "0.095138",
        "ticker_sentiment_score": "0.158671",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.597213",
        "ticker_sentiment_score": "0.240492",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday - Lockheed Martin  ( NYSE:LMT ) ",
    "url": "https://www.benzinga.com/news/24/07/39985890/lockheed-martin-to-rally-over-14-here-are-10-top-analyst-forecasts-for-friday",
    "time_published": "20240726T142718",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. RBC Capital increased RTX Corporation RTX price target from $102 to $115.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/26/xrdDAFpAYVS7ks2-j5355176885743217828-t23.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.250165,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MCQEF",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.258086",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TYL",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.209271",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RMBS",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.27659",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.104473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.090736",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSCO",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.274654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DOW",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "-0.166426",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.303762",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.077601",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.16171",
        "ticker_sentiment_score": "0.156375",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COUR",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.122092",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IMAX",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.340863",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TREE",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "-0.038967",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News",
    "url": "https://www.zacks.com/stock/news/2310103/pharma-stock-roundup-azn-sny-abbv-q2-earnings-pfe-mrks-positive-pipeline-news",
    "time_published": "20240726T142600",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.081675,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.215255",
        "ticker_sentiment_score": "0.07536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.180056",
        "ticker_sentiment_score": "0.005985",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.03631",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.10863",
        "ticker_sentiment_score": "0.006618",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.144491",
        "ticker_sentiment_score": "0.001293",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Jul 26, 2024",
    "url": "https://www.zacks.com/stock/news/2309611/company-news-for-jul-26-2024",
    "time_published": "20240726T075000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: ABBV, VLO, NOC, LUV.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6c/1976.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.332673,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VLO",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.437657",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.555839",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NOC",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.659814",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.144761",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference\u00ae 2024  ( AAIC\u00ae )  - Alector  ( NASDAQ:ALEC ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/07/g40000681/alector-presents-baseline-characteristics-for-invoke-2-phase-2-clinical-trial-of-al002-at-the-alzh",
    "time_published": "20240728T120500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease ( AD ) --",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.185725,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.215757",
        "ticker_sentiment_score": "0.223926",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.361188",
        "ticker_sentiment_score": "0.283163",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference\u00ae 2024  ( AAIC\u00ae ) ",
    "url": "https://www.globenewswire.com/news-release/2024/07/28/2919971/0/en/Alector-Presents-Baseline-Characteristics-for-INVOKE-2-Phase-2-Clinical-Trial-of-AL002-at-the-Alzheimer-s-Association-International-Conference-2024-AAIC.html",
    "time_published": "20240728T120500",
    "authors": [
      "Alector LLC"
    ],
    "summary": "--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease ( AD ) -- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/cc1d53f9-03a6-42d4-aba2-ab4ce7b73508",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.181509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.169279",
        "ticker_sentiment_score": "0.196146",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.382088",
        "ticker_sentiment_score": "0.248458",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to to Begin Clinical Testing",
    "url": "https://www.benzinga.com/pressreleases/24/07/r40020556/parvus-therapeutics-has-received-orphan-drug-designation-for-primary-biliary-cholangitis-and-human",
    "time_published": "20240729T190008",
    "authors": [
      "PR.com"
    ],
    "summary": "South San Francisco, CA July 29, 2024 -- ( PR.com ) -- Parvus Therapeutics announced today that the U.S.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.215704,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.105604",
        "ticker_sentiment_score": "-0.007851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/07/40047654/bristol-myers-johnson-johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-pri",
    "time_published": "20240730T181215",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Four major pharmaceutical companies involved in the first U.S. negotiations over Medicare drug prices expect limited business impact despite anticipated price cuts.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/30/BristolMeyersSquibb-Courtesyof-02-LVL-Ex.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.047931,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.346884",
        "ticker_sentiment_score": "0.130231",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.307811",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.177802",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2311694/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20240730T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.208321,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.49219",
        "ticker_sentiment_score": "0.120229",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "url": "https://www.zacks.com/stock/news/2311659/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
    "time_published": "20240730T125012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default13.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999682"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.411353,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UTHR",
        "relevance_score": "0.383905",
        "ticker_sentiment_score": "0.428578",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.383905",
        "ticker_sentiment_score": "0.356274",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AWON",
        "relevance_score": "0.066598",
        "ticker_sentiment_score": "0.190611",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "A Closer Look at AbbVie's Options Market Dynamics - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/07/40072788/a-closer-look-at-abbvies-options-market-dynamics",
    "time_published": "20240731T151603",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 16 unusual trades. Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722438960_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.128293,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "-0.110654",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.70655",
        "ticker_sentiment_score": "0.133277",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies",
    "url": "https://www.benzinga.com/pressreleases/24/07/g40063506/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv111-a-cd19-directed-in-situ-ca",
    "time_published": "20240731T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor ( CAR ) -T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by end of 2024 -",
    "banner_image": "https://ml.globenewswire.com/media/7d7a1216-4d9a-4a9d-9f9d-696a5a85a1ef/small/umoja-biopharma-logo-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.141467,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.092927",
        "ticker_sentiment_score": "0.134807",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRGNF",
        "relevance_score": "0.046543",
        "ticker_sentiment_score": "0.032663",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy AbbVie  ( ABBV )  After Q2 Beat, Guidance Raise?",
    "url": "https://www.zacks.com/stock/news/2314470/should-you-buy-abbvie-abbv-after-q2-beat-guidance-raise",
    "time_published": "20240801T154100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.980509"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.259898,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CERE",
        "relevance_score": "0.067252",
        "ticker_sentiment_score": "-0.086189",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.745397",
        "ticker_sentiment_score": "0.380934",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer - Aptose Biosciences  ( NASDAQ:APTO ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40094946/nodthera-announces-appointment-of-greg-chow-as-chief-financial-and-business-officer",
    "time_published": "20240801T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Greg brings over 25 years of public and private company leadership experience",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.248122,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.132857",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APTO",
        "relevance_score": "0.099476",
        "ticker_sentiment_score": "0.143884",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.028828",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OBDC",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.04",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.04",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40088983/otsuka-pharmaceutical-to-acquire-jnana-therapeutics-inc",
    "time_published": "20240801T040125",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "- Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria ( PKU ) -",
    "banner_image": "https://ml.globenewswire.com/media/d4d2626e-3fcc-40c0-9829-45785fc9a4ef/small/jnanatherapeutics-logo-fullcolor-rgb-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285424,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.151551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03443",
        "ticker_sentiment_score": "0.151551",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/08/40142784/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
    "time_published": "20240802T210019",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.89% on an annualized basis producing an average annual return of 13.7%. Currently, AbbVie has a market capitalization of $334.03 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1722632415_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat",
    "url": "https://www.zacks.com/stock/news/2314997/buy-2-biotech-bigwigs-set-to-gain-on-possible-earnings-beat",
    "time_published": "20240802T111900",
    "authors": [
      "Nalak Das"
    ],
    "summary": "Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/94/73176.jpg?v=1582705986",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      }
    ],
    "overall_sentiment_score": 0.210736,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.19696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARGX",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.19696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.183948",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.19696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "0.19696",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2316241/will-these-5-medical-stocks-surpass-q2-earnings-forecasts",
    "time_published": "20240805T153600",
    "authors": [
      "Kanishka Das"
    ],
    "summary": "Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e6/2070.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.203258,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.038677",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.278618",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.210884",
        "ticker_sentiment_score": "0.050423",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "-0.009196",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.244987",
        "ticker_sentiment_score": "0.126514",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035555",
        "ticker_sentiment_score": "0.023124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2315688/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20240805T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196134,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.193723",
        "ticker_sentiment_score": "0.118569",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.129866",
        "ticker_sentiment_score": "0.070234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.",
    "url": "https://www.fool.com/investing/2024/08/05/worried-about-a-market-correction-2-high-yield-div/",
    "time_published": "20240805T095600",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.",
    "banner_image": "https://g.foolcdn.com/editorial/images/785854/smart-investor-looking-at-stock-charts-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.918141"
      }
    ],
    "overall_sentiment_score": 0.050877,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.068603",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054359",
        "ticker_sentiment_score": "0.054981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.266828",
        "ticker_sentiment_score": "0.237324",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare",
    "url": "https://www.cnbc.com/2024/08/06/healthy-returns-drugmakers-on-new-negotiated-prices-with-medicare.html",
    "time_published": "20240806T183827",
    "authors": [],
    "summary": "Drugmakers appear to be less concerned about the impact of negotiated prices on their businesses in the short term. Meanwhile, health care heads to Hollywood.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.13248,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NFLX",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.129101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "-0.108452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "-0.108452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WBD",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.129101",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.039033",
        "ticker_sentiment_score": "0.144887",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.116725",
        "ticker_sentiment_score": "-0.007979",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie, Leidos, KKR And More On CNBC's 'Final Trades' - iShares U.S. Healthcare ETF  ( ARCA:IYH ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/news/24/08/40188325/abbvie-leidos-kkr-and-more-on-cnbcs-final-trades",
    "time_published": "20240806T124342",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Jim Lebenthal of Cerity Partners said AbbVie Inc. ABBV is a very strong health care provider. On July 25, AbbVie reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/06/trader-ai3.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.167539,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.483434",
        "ticker_sentiment_score": "0.06387",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.060596",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LDOS",
        "relevance_score": "0.483434",
        "ticker_sentiment_score": "0.302679",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2316605/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
    "time_published": "20240806T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default63.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      }
    ],
    "overall_sentiment_score": 0.319842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.172507",
        "ticker_sentiment_score": "0.277231",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.115509",
        "ticker_sentiment_score": "0.066729",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Warren Buffett's Approach To Investing In Election Years - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/education/24/08/40225783/warren-buffetts-approach-to-investing-in-election-years",
    "time_published": "20240807T153349",
    "authors": [
      "Aaron Bry"
    ],
    "summary": "Warren Buffett, known as the \"Oracle of Omaha,\" is regarded as one of the best American investors of all time. Still running the Berkshire Hathaway BRK BRK at 93 years old, Buffett has navigated his portfolio through various bull markets, downturns and election cycles.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/07/warren-buffett-ai3.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.226374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DE",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.077779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.077779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.202139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.202139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.080458",
        "ticker_sentiment_score": "0.025774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.202139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LUV",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.077779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.202139",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.160099",
        "ticker_sentiment_score": "0.077779",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Half of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2927105/0/en/Genmab-Announces-Financial-Results-for-the-First-Half-of-2024.html",
    "time_published": "20240808T150300",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "August 8, 2024 Copenhagen, Denmark. Interim Report for the First Six Months Ended June ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.159131,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.094514",
        "ticker_sentiment_score": "0.083836",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.420483",
        "ticker_sentiment_score": "0.18174",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.125789",
        "ticker_sentiment_score": "0.110067",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.03157",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Updates 2024 Financial Guidance",
    "url": "https://www.globenewswire.com/news-release/2024/08/08/2927103/0/en/Genmab-Updates-2024-Financial-Guidance.html",
    "time_published": "20240808T150000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.09079,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.544495",
        "ticker_sentiment_score": "0.120768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.079261",
        "ticker_sentiment_score": "0.016397",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039679",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2318763/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20240808T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default224.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.217222,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.354741",
        "ticker_sentiment_score": "0.183029",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.121959",
        "ticker_sentiment_score": "0.068236",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ironwood Q2 Earnings & Revenues Fall Shy of Estimates - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40290046/ironwood-q2-earnings-revenues-fall-shy-of-estimates",
    "time_published": "20240809T200356",
    "authors": [
      "Zacks"
    ],
    "summary": "Ironwood Pharmaceuticals, Inc. IRWD reported break-even earnings for the second quarter of 2024 compared with the Zacks Consensus Estimate of earnings of 17 cents per share. The company had recorded adjusted earnings of 31 cents per share in the year-ago quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/df/73846.jpg?v=724416703",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.031257,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.049835",
        "ticker_sentiment_score": "0.16918",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.110315",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.043125",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.197413",
        "ticker_sentiment_score": "0.107347",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.245339",
        "ticker_sentiment_score": "0.140679",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ironwood  ( IRWD )  Q2 Earnings & Revenues Fall Shy of Estimates",
    "url": "https://www.zacks.com/stock/news/2320139/ironwood-irwd-q2-earnings-revenues-fall-shy-of-estimates",
    "time_published": "20240809T145600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.983783"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.009603,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.050465",
        "ticker_sentiment_score": "0.142287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.150592",
        "ticker_sentiment_score": "0.101358",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.295867",
        "ticker_sentiment_score": "0.041311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.199859",
        "ticker_sentiment_score": "0.099933",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.118752",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/09/2927551/0/en/Nxera-Pharma-Operational-Highlights-and-Consolidated-Results-for-the-Second-Quarter-and-First-Half-2024.html",
    "time_published": "20240809T063000",
    "authors": [
      "Nxera Pharma"
    ],
    "summary": "Tokyo, Japan and Cambridge, UK, 9 August 2024 - Nxera Pharma ( \"the Company\" or \"Nxera\". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2024. The full report can be found here.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5cc74d52-c86f-4e21-8684-3496281fee15",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.203146,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.024521",
        "ticker_sentiment_score": "0.101765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOLTF",
        "relevance_score": "0.073471",
        "ticker_sentiment_score": "0.11441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IDRSF",
        "relevance_score": "0.024521",
        "ticker_sentiment_score": "0.031288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CNTA",
        "relevance_score": "0.024521",
        "ticker_sentiment_score": "0.101765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.024521",
        "ticker_sentiment_score": "0.101765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:JPY",
        "relevance_score": "0.520413",
        "ticker_sentiment_score": "0.116671",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks Retirees Should Absolutely Love",
    "url": "https://www.fool.com/investing/2024/08/10/3-stocks-retirees-should-absolutely-love/",
    "time_published": "20240810T105000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "All of these stocks can provide steady income to retired investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786551/getty-couple-high-five-happy.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      }
    ],
    "overall_sentiment_score": 0.357659,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.350564",
        "ticker_sentiment_score": "0.47517",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.179788",
        "ticker_sentiment_score": "0.13077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.223659",
        "ticker_sentiment_score": "0.234937",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Pfizer Stock a Buy Now After Earnings?",
    "url": "https://www.fool.com/investing/2024/08/11/is-pfizer-stock-a-buy-now-after-earnings/",
    "time_published": "20240811T141500",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This pharmaceutical blue chip could be ready to rally higher.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F786395%2Fpfizer-bullish-stock-outlook-2024.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999162"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.329972,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.74586",
        "ticker_sentiment_score": "0.573978",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.17096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "0.17096",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should Investors Buy Eli Lilly's  ( LLY )  Stock After Strong Q2 Results?",
    "url": "https://www.zacks.com/commentary/2320976/should-investors-buy-eli-lillys-lly-stock-after-strong-q2-results",
    "time_published": "20240812T220200",
    "authors": [
      "Shaun Pruitt"
    ],
    "summary": "As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.995015"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.229144,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.602879",
        "ticker_sentiment_score": "0.41072",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.088057",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.088057",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Revance Therapeutics Stock Trading Higher? - Revance Therapeutics  ( NASDAQ:RVNC ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40318072/botox-innovator-revance-therapeutics-goes-private-in-over-900m-deal",
    "time_published": "20240812T155055",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. RVNC. Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.313041,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.220192",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RVNC",
        "relevance_score": "0.499789",
        "ticker_sentiment_score": "0.263505",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2320403/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20240812T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default335.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.249439,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.337811",
        "ticker_sentiment_score": "0.239601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Microdermabrasion Devices Market is Projected to Achieve US$ 549.0 Mn Milestone by 2031 with a CAGR of 7.5%, Investment Opportunities | Report by Transparency Market Research, Inc",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40354229/microdermabrasion-devices-market-is-projected-to-achieve-us-549-0-mn-milestone-by-2031-with-a-cagr",
    "time_published": "20240813T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global microdermabrasion devices market ( \u30de\u30a4\u30af\u30ed\u30c0\u30fc\u30de\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u30c7\u30d0\u30a4\u30b9\u5e02\u5834 ) was worth US$ 290.3 Mn in 2022 and is expected to reach ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/0ad08915-27bd-4305-a12c-ed05c1ce895e/microdermabrasion-devices-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.350003,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.048973",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.116348",
        "ticker_sentiment_score": "0.06846",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHG",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.038906",
        "ticker_sentiment_score": "0.059627",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View - AbbVie  ( NYSE:ABBV ) , Biogen  ( NASDAQ:BIIB ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40344193/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view",
    "time_published": "20240813T172417",
    "authors": [
      "Zacks"
    ],
    "summary": "The second-quarter earnings season has come to an end for large drug and biotech companies, with Eli Lilly LLY reporting its results last week. Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/cf/74103.jpg?v=720680589",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.257179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.422599",
        "ticker_sentiment_score": "0.362428",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.296969",
        "ticker_sentiment_score": "0.213455",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.185484",
        "ticker_sentiment_score": "0.134731",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.04677",
        "ticker_sentiment_score": "0.216503",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Research Reports for Alphabet, AbbVie & QUALCOMM",
    "url": "https://www.zacks.com/research-daily/2321068/top-research-reports-for-alphabet-abbvie-qualcomm",
    "time_published": "20240813T164800",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), AbbVie Inc. (ABBV) and QUALCOMM Incorporated (QCOM), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default96.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.252633,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.062429",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.061473",
        "ticker_sentiment_score": "0.277345",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.182967",
        "ticker_sentiment_score": "0.360231",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View",
    "url": "https://www.zacks.com/stock/news/2321388/3-big-drug-stocks-to-watch-on-raised-2024-earnings-sales-view",
    "time_published": "20240813T142700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.252511,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.423718",
        "ticker_sentiment_score": "0.357685",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.2978",
        "ticker_sentiment_score": "0.213738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.131924",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.046907",
        "ticker_sentiment_score": "0.20352",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is Syros Pharmaceuticals Stock Trading Lower On Tuesday? - Syros Pharmaceuticals  ( NASDAQ:SYRS ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40339304/cancer-focused-syros-pharmaceuticals-stops-mid-stage-leukemia-combo-therapy-study-cites-disappoin",
    "time_published": "20240813T134117",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Syros Pharmaceuticals Inc. SYRS stock is trading lower on Tuesday after the company issued an update on the SELECT-AML-1 Phase 2 trial.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/13/SYRS.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.021561,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SYRS",
        "relevance_score": "0.277958",
        "ticker_sentiment_score": "-0.124604",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.187463",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40373981/decoding-abbvies-options-activity-whats-the-big-picture",
    "time_published": "20240814T170038",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1723654835_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.160137,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "WFC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.022558",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.106941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.736438",
        "ticker_sentiment_score": "0.281965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Syros  ( SYRS )  Falls 62% on Phase II Leukemia Study Termination",
    "url": "https://www.zacks.com/stock/news/2322133/syros-syrs-falls-62-on-phase-ii-leukemia-study-termination",
    "time_published": "20240814T141900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.134003,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SYRS",
        "relevance_score": "0.282234",
        "ticker_sentiment_score": "-0.088436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TRDA",
        "relevance_score": "0.335519",
        "ticker_sentiment_score": "0.129695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.188128",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Alphabet, AbbVie, Qualcomm and Flanigan's",
    "url": "https://www.zacks.com/stock/news/2322064/the-zacks-analyst-blog-highlights-alphabet-abbvie-qualcomm-and-flanigans",
    "time_published": "20240814T130100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Alphabet, AbbVie, Qualcomm and Flanigan's are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/701.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.249683,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.111488",
        "ticker_sentiment_score": "0.046039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.193328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.325924",
        "ticker_sentiment_score": "0.293544",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen",
    "url": "https://www.zacks.com/stock/news/2322034/the-zacks-analyst-blog-highlights-eli-lilly-pfizer-abbvie-and-biogen",
    "time_published": "20240814T124900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999365"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.252246,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.426105",
        "ticker_sentiment_score": "0.33308",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.306144",
        "ticker_sentiment_score": "0.197729",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.199767",
        "ticker_sentiment_score": "0.11812",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.067221",
        "ticker_sentiment_score": "0.10124",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Federated Hermes Mutual Funds for Strong Returns",
    "url": "https://www.zacks.com/stock/news/2321738/3-federated-hermes-mutual-funds-for-strong-returns",
    "time_published": "20240814T104900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Invest in Federated Hermes funds like FGSKX, QAMNX and QKACX for diverse and reliable returns.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/344.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.239374,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.13115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.13115",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRWD",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.051026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMP",
        "relevance_score": "0.064276",
        "ticker_sentiment_score": "0.051026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPOT",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.029416",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FHI",
        "relevance_score": "0.624973",
        "ticker_sentiment_score": "0.314992",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128135",
        "ticker_sentiment_score": "0.079045",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931252/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141571,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.461321",
        "ticker_sentiment_score": "0.217177",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.055246",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011148",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.078729",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022295",
        "ticker_sentiment_score": "0.114565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/08/15/2931251/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html",
    "time_published": "20240815T201500",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Aug. 15, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999941"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.451494"
      }
    ],
    "overall_sentiment_score": 0.141566,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.085082",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.460377",
        "ticker_sentiment_score": "0.21687",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.055234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.011123",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:ISK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:SEK",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.078708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.022243",
        "ticker_sentiment_score": "0.114538",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2322450/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20240815T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.22421,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.125582",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biden administration to release prices for first 10 drugs subject to landmark Medicare negotiations",
    "url": "https://www.cnbc.com/2024/08/15/medicare-releases-prices-for-first-10-drugs-subject-to-negotiations.html",
    "time_published": "20240815T090001",
    "authors": [],
    "summary": "It is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but is strongly opposed by drugmakers.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Business",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.061655,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.02686",
        "ticker_sentiment_score": "0.150738",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.025037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.067751",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.053689",
        "ticker_sentiment_score": "-0.072897",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.02686",
        "ticker_sentiment_score": "-0.054794",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income",
    "url": "https://www.fool.com/investing/2024/08/17/3-high-yielding-dividend-growth-stocks-that-retire/",
    "time_published": "20240817T140000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786770/a-person-counting-money-in-their-living-room.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999967"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.356372,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PLD",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "0.520726",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CERE",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.119432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.417995",
        "ticker_sentiment_score": "0.444782",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054857",
        "ticker_sentiment_score": "0.033885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.369946",
        "ticker_sentiment_score": "0.222933",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More",
    "url": "https://www.fool.com/investing/2024/08/18/3-high-yield-stocks-to-buy-now-that-have-increased/",
    "time_published": "20240818T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "These stocks dividends continue to flow and grow.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787338/pipeline-welder.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.320799,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ENB",
        "relevance_score": "0.431765",
        "ticker_sentiment_score": "0.308717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.019215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.316439",
        "ticker_sentiment_score": "0.415507",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "These 3 Healthcare Companies Had the Top-Selling Drugs Last Year",
    "url": "https://www.fool.com/investing/2024/08/18/these-3-healthcare-companies-had-top-selling-drugs/",
    "time_published": "20240818T071900",
    "authors": [
      "David Jagielski"
    ],
    "summary": "This list of top-selling drugs could look drastically different in a few years.",
    "banner_image": "https://g.foolcdn.com/editorial/images/786783/doctor-giving-a-patient-medication.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.980716"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      }
    ],
    "overall_sentiment_score": 0.15999,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.313254",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.164282",
        "ticker_sentiment_score": "0.224065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "TEPKINLY\u00ae  ( epcoritamab )  Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/08/19/2932382/0/en/TEPKINLY-epcoritamab-Receives-Second-European-Commission-Approval-for-the-Treatment-of-Adults-with-Relapsed-Refractory-Follicular-Lymphoma.html",
    "time_published": "20240819T180000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Company Announcement ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.043423,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GMAB",
        "relevance_score": "0.162255",
        "ticker_sentiment_score": "0.086457",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.067996",
        "ticker_sentiment_score": "0.100287",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40473859/unpacking-the-latest-options-trading-trends-in-abbvie",
    "time_published": "20240820T204637",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724186794_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.097874,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.722311",
        "ticker_sentiment_score": "0.057659",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.137127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.137127",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.022769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Physician Dispensed Cosmeceuticals Market to Reach USD 19 Billion by 2031, Driven by Rising Social Media Influence and Post-Pandemic Focus on Physical Appearance, Reports Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40469477/physician-dispensed-cosmeceuticals-market-to-reach-usd-19-billion-by-2031-driven-by-rising-social-",
    "time_published": "20240820T173000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- The global physician dispensed cosmeceuticals market ( Markt f\u00fcr von \u00c4rzten abgegebene Cosmeceuticals ) was worth US$ 8.5 Billion in 2020 and is expected to reach US$ 19.0 Billion by 2031 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/98dafa7b-023a-4ac6-be46-5f44ae9e225c/physician-dispensed-cosmeceuticals-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.181007,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAWW",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.045122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.04797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRBZF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "-0.032819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.045122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ELAB",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.11716",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.045122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNOA",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.045122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRLCF",
        "relevance_score": "0.03399",
        "ticker_sentiment_score": "0.045122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.101725",
        "ticker_sentiment_score": "0.075001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Gets Nod in EU for Lymphoma Drug's Expanded Use",
    "url": "https://www.zacks.com/stock/news/2324436/abbvie-abbv-gets-nod-in-eu-for-lymphoma-drugs-expanded-use",
    "time_published": "20240820T134400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.217551,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.582526",
        "ticker_sentiment_score": "0.216827",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ARCT",
        "relevance_score": "0.287537",
        "ticker_sentiment_score": "0.161566",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.231884",
        "ticker_sentiment_score": "0.124796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ILMN",
        "relevance_score": "0.175009",
        "ticker_sentiment_score": "0.154006",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should iShares Core High Dividend ETF  ( HDV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2324124/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar",
    "time_published": "20240820T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.244841,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.059488",
        "ticker_sentiment_score": "0.117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.192288",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.118647",
        "ticker_sentiment_score": "0.067448",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Strategic Opportunities in Thin Film Drug Manufacturing Market to Expand to USD 16.5 Billion by 2034, Driving Industry Growth | Transparency Market Research Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40496737/strategic-opportunities-in-thin-film-drug-manufacturing-market-to-expand-to-usd-16-5-billion-by-20",
    "time_published": "20240821T223000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global thin film drug manufacturing market ( \ubc15\ub9c9 \uc758\uc57d\ud488 \uc81c\uc870 \uc2dc\uc7a5 ) was worth US$ 6.4 Billion in 2023 and is expected to reach ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/5e02ab07-d708-45c6-b7ca-2da7cde3a76e/thin-film-drug-manufacturing-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.307216,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.051439",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RSCI",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.238122",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SVYSF",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DNPUF",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INDV",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSUMF",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.064796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.036756",
        "ticker_sentiment_score": "0.088445",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40503390/solid-organ-transplant-market-is-projected-to-grow-at-a-4-9-cagr-reaching-7-88-billion-by-2034-fac",
    "time_published": "20240822T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- Fact.MR, a leading market research company, in its newly published industry report, reveals that the solid organ transplant market is estimated to reach a valuation of US$ 4.9 billion in 2024 and further advance at a CAGR of 4.9% between 2024 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6be56177-9068-4549-b1c0-056a89323da6/solid-organ-transplant-sot-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.34484,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AHKSF",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMDX",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.116875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMRX",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASBRF",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.031405",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences",
    "url": "https://www.globenewswire.com/news-release/2024/08/23/2935072/0/en/NurExone-Biologic-Invited-to-Present-Groundbreaking-ExoPTEN-Therapy-at-Prestigious-September-Conferences.html",
    "time_published": "20240823T200300",
    "authors": [
      "NurExone Biologic Inc"
    ],
    "summary": "NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1514c671-cc84-4bcb-82d7-b834fce40882",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.129812,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.027319",
        "ticker_sentiment_score": "0.13088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.027319",
        "ticker_sentiment_score": "0.134643",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences - NurExone Biologic  ( OTC:NRXBF ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40535947/nurexone-biologic-invited-to-present-groundbreaking-exopten-therapy-at-prestigious-september-confe",
    "time_published": "20240823T200300",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "TORONTO and HAIFA, Israel, Aug. 23, 2024 ( GLOBE NEWSWIRE ) -- NurExone Biologic Inc.",
    "banner_image": "https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.131972,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.025761",
        "ticker_sentiment_score": "0.129872",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025761",
        "ticker_sentiment_score": "0.133815",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets - Novo Nordisk  ( NYSE:NVO ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets",
    "time_published": "20240823T182118",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/23/10-Celebrities-Open-Up-About-Their-Ozemp.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Economy - Fiscal",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.129693,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.327317",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.327317",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "0.299961",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "-0.327317",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More",
    "url": "https://www.zacks.com/stock/news/2326355/pharma-stock-roundup-fda-nod-to-pfe-mrna-new-covid-jabs-more",
    "time_published": "20240823T141500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.102717,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.0699",
        "ticker_sentiment_score": "-0.071271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.16463",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "-0.105939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "-0.004386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.096589",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.104683",
        "ticker_sentiment_score": "0.085203",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.031017",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.034984",
        "ticker_sentiment_score": "0.147163",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? Buy This ETF and Hold It Forever",
    "url": "https://www.fool.com/investing/2024/08/23/want-decades-of-passive-income-buy-this-etf-and-ho/",
    "time_published": "20240823T114200",
    "authors": [
      "Justin Pope"
    ],
    "summary": "This do-it-all fund is an excellent option for any dividend investor.",
    "banner_image": "https://media.ycharts.com/charts/c06fdfa8725771456142413714f62d3c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.348125,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TXN",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.043769",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Friday's big stock stories: What's likely to move the market in the next trading session",
    "url": "https://www.cnbc.com/2024/08/22/fridays-big-stock-stories-whats-likely-to-move-the-market-in-the-next-trading-session.html",
    "time_published": "20240823T000408",
    "authors": [],
    "summary": "A surge in Treasury yields on Thursday pressured stocks ahead of the Federal Reserve chairman's speech on Friday. Here's what CNBC TV will be watching.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Top News",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.09926,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "UHS",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AFL",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACGL",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPG",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ISRG",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRO",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXR",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSA",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.185316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.090474",
        "ticker_sentiment_score": "0.273568",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "1 Dividend Growth ETF That Can Turbocharge Your Portfolio",
    "url": "https://www.fool.com/investing/2024/08/24/1-dividend-growth-etf-that-can-turbocharge-your-po/",
    "time_published": "20240824T114500",
    "authors": [
      "George Budwell"
    ],
    "summary": "The iShares Core Dividend Growth ETF offers investors exposure to high-quality companies with a history of consistent dividend growth.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788308%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.519426,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.232262",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.281063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Unstoppable Dividend Stocks to Buy Right Now",
    "url": "https://www.fool.com/investing/2024/08/25/3-unstoppable-dividend-stocks-to-buy-right-now/",
    "time_published": "20240825T223000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "These stocks are the A-team for income investors.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788183/two-people-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.382955,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.365654",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.282777",
        "ticker_sentiment_score": "0.335334",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.237204",
        "ticker_sentiment_score": "0.186795",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Johnson & Johnson Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/08/25/is-johnson-johnson-stock-a-buy/",
    "time_published": "20240825T101700",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company hasn't performed well in recent years, ...",
    "banner_image": "https://media.ycharts.com/charts/71fe3f647f1b2fe425706bcc6788928c.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.028838,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.051886",
        "ticker_sentiment_score": "-0.079975",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.637738",
        "ticker_sentiment_score": "0.055075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Unusual Options Activity For August 26 - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40560312/abbvie-unusual-options-activity-for-august-26",
    "time_published": "20240826T181537",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 33% ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724696134_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.144114,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "-0.143215",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.827318",
        "ticker_sentiment_score": "0.250754",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Donald Trump Owns These 21 Dividend Kings. Should You?",
    "url": "https://www.fool.com/investing/2024/08/26/donald-trump-owns-these-21-dividend-kings-should-y/",
    "time_published": "20240826T094600",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Some of Trump's Dividend Kings deserve a crown more than others.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F788310%2Ftrump-at-podium-image-source-official-white-house-photo-by-shealah-craighead.webp&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.996023"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.295291,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PH",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.11256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FRT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.336597",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.109253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.249154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Biologics Market Size to Surge to USD 855.8 Billion by 2031 with a 6.9% CAGR, Fueled by Advanced Targeting of Biological Pathways - Report by Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40589602/biologics-market-size-to-surge-to-usd-855-8-billion-by-2031-with-a-6-9-cagr-fueled-by-advanced-tar",
    "time_published": "20240827T213000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 27, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global biologics market ( \uc0dd\ubb3c\ud559 \uc2dc\uc7a5 ) was worth US$ 515.6 Billion in 2022 and is expected to reach US$ 855.8 Billion by the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/160ec401-8f80-4a37-bcad-8a849aaefcd1/biologics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.151777,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.057473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.091509",
        "ticker_sentiment_score": "0.066724",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.061081",
        "ticker_sentiment_score": "0.111073",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.052779",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.030563",
        "ticker_sentiment_score": "0.121768",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/m-a/24/08/40586451/regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna",
    "time_published": "20240827T192226",
    "authors": [
      "Anthony Noto"
    ],
    "summary": "Some 3 million Americans, and approximately 24 million people worldwide, are likely looking forward to a pivotal date next month in which U.S. regulators are expected to decide on whether to approve a new - more innovative - schizophrenia drug. What Happened: The U.S.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/27/Medication.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Mergers",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.151577,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.212701",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "-0.030727",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.244109",
        "ticker_sentiment_score": "0.239266",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented",
    "url": "https://www.fool.com/investing/2024/08/27/3-ways-the-democratic-partys-platform-could-impact/",
    "time_published": "20240827T134500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "There's no reason to succumb to gloom and doom here.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788172/three-investors-meet-with-paperwork.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.11129,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "-0.021991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "0.144686",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.023858",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.048036",
        "ticker_sentiment_score": "-0.021991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "-0.023858",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2327391/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
    "time_published": "20240827T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.270237,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.184363",
        "ticker_sentiment_score": "0.196439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.123526",
        "ticker_sentiment_score": "0.068619",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/08/28/2937375/0/en/Royalty-Pharma-to-Present-at-Morgan-Stanley-s-22nd-Annual-Global-Healthcare-Conference.html",
    "time_published": "20240828T201500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.287942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.102301",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/08/g40611990/royalty-pharma-to-present-at-morgan-stanleys-22nd-annual-global-healthcare-conference",
    "time_published": "20240828T201500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.213648,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.619618",
        "ticker_sentiment_score": "0.271889",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.094766",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors - Neurocrine Biosciences  ( NASDAQ:NBIX ) ",
    "url": "https://www.benzinga.com/general/biotech/24/08/40604853/as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-d",
    "time_published": "20240828T151626",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 ( NBI-'568 ) in adults with schizophrenia. NBI-'568 is the first investigational, oral, muscarinic M4 selective agonist.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/28/NBIX.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.153327,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.041182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "-0.111364",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock",
    "url": "https://www.fool.com/investing/2024/08/28/prediction-eli-lillys-latest-move-will-threaten-ab/",
    "time_published": "20240828T103200",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "It'll be a while before there's any impact, but it could be a big deal.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788184/3-investors-gather-around-a-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.222917,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.248343",
        "ticker_sentiment_score": "0.081925",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Options Trading: A Deep Dive into Market Sentiment - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/08/40636705/abbvie-options-trading-a-deep-dive-into-market-sentiment",
    "time_published": "20240829T193156",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bearish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1724959913_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.184093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.078611",
        "ticker_sentiment_score": "-0.022769",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.722311",
        "ticker_sentiment_score": "0.20909",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results",
    "url": "https://www.zacks.com/stock/news/2329161/neurocrine-stock-down-19-on-mixed-schizophrenia-study-results",
    "time_published": "20240829T153200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.047273,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "-0.039621",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOLTF",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.041426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.370418",
        "ticker_sentiment_score": "0.2782",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.300394",
        "ticker_sentiment_score": "0.081352",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Pfizer  ( PFE )  Down 5.9% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2329064/why-is-pfizer-pfe-down-59-since-last-earnings-report",
    "time_published": "20240829T153108",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default29.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999858"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.076349,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.344302",
        "ticker_sentiment_score": "0.16878",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.101367",
        "ticker_sentiment_score": "0.020312",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.025406",
        "ticker_sentiment_score": "-0.012854",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2328775/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20240829T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.208403,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.125582",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2328667/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20240829T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default80.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.260316,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.171282",
        "ticker_sentiment_score": "0.218383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bull Market Buys: 3 Dividend Stocks to Own for the Long Run",
    "url": "https://www.fool.com/investing/2024/08/29/bull-market-buys-3-dividend-stocks-to-own-for-the/",
    "time_published": "20240829T095000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "There are three operative words with these dividend stocks: buy and hold.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788680/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.220152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HD",
        "relevance_score": "0.064623",
        "ticker_sentiment_score": "0.10427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UPS",
        "relevance_score": "0.429671",
        "ticker_sentiment_score": "0.174449",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.534445",
        "ticker_sentiment_score": "0.323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher",
    "url": "https://www.fool.com/investing/2024/08/30/2-monster-stocks-you-can-buy-right-now-before-they/",
    "time_published": "20240830T134500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These businesses can stand the test of time in a diversified portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788639/getty-happy-victory-profits-winning-success-gains-pleased.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.244036,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAVA",
        "relevance_score": "0.142005",
        "ticker_sentiment_score": "0.135819",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.366736",
        "ticker_sentiment_score": "0.145436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.047559",
        "ticker_sentiment_score": "0.073038",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/08/30/3-rock-solid-pharma-stocks-to-buy-now-and-hold-for/",
    "time_published": "20240830T104500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "These three have secure core businesses, plus multiple paths to grow.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788607/doctor-and-nurse-talk-with-investor.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.238076,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.003168",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.134339",
        "ticker_sentiment_score": "0.043756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "-0.004225",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Incredibly Cheap Healthcare Stocks to Buy Now",
    "url": "https://www.fool.com/investing/2024/08/30/2-incredibly-cheap-healthcare-stocks-to-buy-now/",
    "time_published": "20240830T082000",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "Top healthcare stocks are a great addition to any portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788637/businesswoman-remote-work-from-cafe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.159101,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.046724",
        "ticker_sentiment_score": "0.063473",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.274834",
        "ticker_sentiment_score": "0.183876",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.152439",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/09/01/2-high-yield-dividend-stocks-to-buy-in-september-a/",
    "time_published": "20240901T095300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "A drugmaker and a telecom business have what it takes to safely boost your passive income stream.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789010/investors-evaluating-a-stock-purchase-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206401,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "T",
        "relevance_score": "0.222838",
        "ticker_sentiment_score": "0.160048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.328819",
        "ticker_sentiment_score": "0.231537",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.056407",
        "ticker_sentiment_score": "0.058914",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Best Dividend Growth ETF to Invest $1,000 in Right Now",
    "url": "https://www.fool.com/investing/2024/09/01/the-best-dividend-growth-etf-to-invest-1000-in-rig/",
    "time_published": "20240901T090800",
    "authors": [
      "James Brumley"
    ],
    "summary": "Little things can turn into big things given enough time.",
    "banner_image": "https://media.ycharts.com/charts/c3d84a32487890a9195ce82005fb9612.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.353125,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.235561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.235561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SWK",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.068502",
        "ticker_sentiment_score": "0.137524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KVUE",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.102595",
        "ticker_sentiment_score": "0.205493",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.295624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CLX",
        "relevance_score": "0.034282",
        "ticker_sentiment_score": "0.039491",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks You Can Safely Hold Through a Recession",
    "url": "https://www.fool.com/investing/2024/09/02/2-dividend-stocks-you-can-safely-hold-through-a/",
    "time_published": "20240902T124500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These stocks can help you sleep peacefully at night, even in bad times.",
    "banner_image": "https://g.foolcdn.com/editorial/images/788898/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      }
    ],
    "overall_sentiment_score": 0.210419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.264515",
        "ticker_sentiment_score": "0.155202",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05387",
        "ticker_sentiment_score": "0.072757",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High",
    "url": "https://www.fool.com/investing/2024/09/02/2-reasons-bristol-myers-squibb-could-be-bargain-/",
    "time_published": "20240902T114500",
    "authors": [
      "Dan Victor"
    ],
    "summary": "Rebounding growth could make shares of this leading drugmaker a big winner.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F789033%2Fscreenshot-2024-08-29-110730.png&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.998311"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.32985,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.103999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.103999",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.344872",
        "ticker_sentiment_score": "0.05258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.059341",
        "ticker_sentiment_score": "0.103999",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Capital Strength ETF  ( FTCS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2330056/should-first-trust-capital-strength-etf-ftcs-be-on-your-investing-radar",
    "time_published": "20240902T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default120.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.279928,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.125134",
        "ticker_sentiment_score": "0.063244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.125134",
        "ticker_sentiment_score": "0.063244",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2331022/abbvie-abbv-gains-as-market-dips-what-you-should-know",
    "time_published": "20240903T214522",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) concluded the recent trading session at $197.69, signifying a +0.7% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default360.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928769"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.151741,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.615462",
        "ticker_sentiment_score": "0.127527",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement - Royalty Pharma  ( NASDAQ:RPRX ) , Ascendis Pharma  ( NASDAQ:ASND ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40697339/royalty-pharma-and-ascendis-pharma-enter-into-150-million-royalty-funding-agreement",
    "time_published": "20240903T211432",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX and Ascendis Pharma A/S ASND today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.187468,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASND",
        "relevance_score": "0.099787",
        "ticker_sentiment_score": "0.042345",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.262413",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025008",
        "ticker_sentiment_score": "0.073155",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement",
    "url": "https://www.globenewswire.com/news-release/2024/09/03/2940138/0/en/Royalty-Pharma-and-Ascendis-Pharma-Enter-Into-150-Million-Royalty-Funding-Agreement.html",
    "time_published": "20240903T211400",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.187567,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASND",
        "relevance_score": "0.10322",
        "ticker_sentiment_score": "0.043823",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.278726",
        "ticker_sentiment_score": "0.26911",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025873",
        "ticker_sentiment_score": "0.073526",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - Royalty Pharma  ( NASDAQ:RPRX ) , Ascendis Pharma  ( NASDAQ:ASND ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40697118/ascendis-pharma-and-royalty-pharma-enter-into-150-million-royalty-funding-agreement",
    "time_published": "20240903T210629",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Ascendis Pharma A/S ASND and Royalty Pharma plc RPRX today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding ...",
    "banner_image": "https://ml.globenewswire.com/media/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8/small/ascendis-final-logo-7-23-15-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      }
    ],
    "overall_sentiment_score": 0.182934,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASND",
        "relevance_score": "0.124421",
        "ticker_sentiment_score": "0.196244",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.316064",
        "ticker_sentiment_score": "0.277603",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.024982",
        "ticker_sentiment_score": "0.07222",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement",
    "url": "https://www.globenewswire.com/news-release/2024/09/03/2940137/0/en/Ascendis-Pharma-and-Royalty-Pharma-Enter-into-150-Million-Royalty-Funding-Agreement.html",
    "time_published": "20240903T210600",
    "authors": [
      "Ascendis Pharma"
    ],
    "summary": "Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH\u00ae U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      }
    ],
    "overall_sentiment_score": 0.180635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASND",
        "relevance_score": "0.102778",
        "ticker_sentiment_score": "0.043768",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.301624",
        "ticker_sentiment_score": "0.285821",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025761",
        "ticker_sentiment_score": "0.073478",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. Quality Dividend Growth ETF  ( DGRW )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2330649/is-wisdomtree-us-quality-dividend-growth-etf-dgrw-a-strong-etf-right-now",
    "time_published": "20240903T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default327.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999816"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.308411,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.057767",
        "ticker_sentiment_score": "0.186098",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.282886",
        "ticker_sentiment_score": "0.419989",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?",
    "url": "https://www.zacks.com/stock/news/2331470/abbvie-stock-up-almost-20-in-3-months-buy-sell-or-hold",
    "time_published": "20240904T143500",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.302096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.083802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.078354",
        "ticker_sentiment_score": "0.083802",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.720733",
        "ticker_sentiment_score": "0.462319",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth - AbbVie  ( NYSE:ABBV ) , BioNTech  ( NASDAQ:BNTX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40708048/new-research-reveals-emergence-of-new-variants-of-coronavirus-to-boost-covid-19-therapeutics-marke",
    "time_published": "20240904T131500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for therapies and treatments.",
    "banner_image": "https://ml.globenewswire.com/media/f326183f-8829-42af-8851-525b1d7503ed/small/finacialnews-logo-final-01-2-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999819"
      }
    ],
    "overall_sentiment_score": 0.100019,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SBFM",
        "relevance_score": "0.150278",
        "ticker_sentiment_score": "0.048598",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.040854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.074845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVAX",
        "relevance_score": "0.117159",
        "ticker_sentiment_score": "0.050685",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.016796",
        "ticker_sentiment_score": "0.092151",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.083833",
        "ticker_sentiment_score": "0.065437",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Hepatitis Therapeutics Market Size worth USD 21.9 Billion by 2031, with a CAGR of 3.6% - Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40702929/hepatitis-therapeutics-market-size-worth-usd-21-9-billion-by-2031-with-a-cagr-of-3-6-transparency-",
    "time_published": "20240904T102900",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- As per the report published by Transparency Market Research, the global hepatitis therapeutics market ( \uac04\uc5fc \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was worth US$ 16.0 Bn in 2022 and is expected to reach US$ 21.9 Bn by ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/13b06318-4fed-44fc-a8c7-ead09c4757a0/hepatitis-therapeutics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.234976,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "0.059668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "-0.047083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "-0.047083",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.116914",
        "ticker_sentiment_score": "0.070861",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "-0.098845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039096",
        "ticker_sentiment_score": "-0.047083",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration - ATAI Life Sciences  ( NASDAQ:ATAI ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cannabis/24/09/40736485/psychedelic-drugs-market-set-to-grow-by-1-37b-by-2028-driven-by-mental-health-disorders-and-ai-i",
    "time_published": "20240905T165346",
    "authors": [
      "Juan Sp\u00ednelli"
    ],
    "summary": "The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/05/3.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.176509,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CMPS",
        "relevance_score": "0.077094",
        "ticker_sentiment_score": "0.137835",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MNMD",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.15347",
        "ticker_sentiment_score": "0.175227",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40733456/heres-how-much-100-invested-in-abbvie-10-years-ago-would-be-worth-today",
    "time_published": "20240905T150022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.33% on an annualized basis producing an average annual return of 13.01%. Currently, AbbVie has a market capitalization of $343.21 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725548419_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40725227/pseudarthrosis-treatment-market-is-projected-to-reach-1-37-billion-at-a-cagr-4-6-by-2034-fact-mr-r",
    "time_published": "20240905T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- According to a new industry report released by Fact.MR, revenue from the global pseudarthrosis treatment market is estimated to reach US$ 879.4 million in 2024 and thereafter increase at a CAGR of 4.6% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/f8090b1b-bbdf-4755-97c9-4726ee946522/pseudarthrosis-treatment-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.302869,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ZBH",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OFIX",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.068418",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALPMF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Opthea Announces Executive Leadership Changes and Senior Hires",
    "url": "https://www.globenewswire.com/news-release/2024/09/05/2941142/0/en/Opthea-Announces-Executive-Leadership-Changes-and-Senior-Hires.html",
    "time_published": "20240905T100000",
    "authors": [
      "Opthea Limited"
    ],
    "summary": "Daniel Geffken appointed Chief Financial Officer ad interim ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6b4960e3-b3f5-41cb-8993-66ea0b111361",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.185047,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPT",
        "relevance_score": "0.289805",
        "ticker_sentiment_score": "0.146881",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.057119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRES",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.072386",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.057119",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.089",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.019764",
        "ticker_sentiment_score": "0.057119",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Opthea Announces Executive Leadership Changes and Senior Hires",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40725232/opthea-announces-executive-leadership-changes-and-senior-hires",
    "time_published": "20240905T100000",
    "authors": [],
    "summary": "Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access",
    "banner_image": null,
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.18494,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OPT",
        "relevance_score": "0.277328",
        "ticker_sentiment_score": "0.137725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PTAIF",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.054932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRES",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.087583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.071958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GLP",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.054932",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.087583",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNS",
        "relevance_score": "0.018876",
        "ticker_sentiment_score": "0.054932",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/05/got-1000-healthcare-stocks-buy-and-hold-forever/",
    "time_published": "20240905T085000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "There is something for everybody in America's $4.5 trillion healthcare market.",
    "banner_image": "https://g.foolcdn.com/editorial/images/787539/healthcare-nurse.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "IPO",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.379156,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.374821",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "0.214468",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.152178",
        "ticker_sentiment_score": "0.199721",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.345674",
        "ticker_sentiment_score": "0.381327",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Peering Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/40755858/peering-into-abbvies-recent-short-interest",
    "time_published": "20240906T193022",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has risen 15.15% since its last report. The company recently reported that it has 20.19 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725651019_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.289997,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.151778",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 No-Brainer Dividend Stocks to Buy in September",
    "url": "https://www.fool.com/investing/2024/09/08/3-no-brainer-dividend-stocks-to-buy-in-september/",
    "time_published": "20240908T113000",
    "authors": [
      "and Prosper Junior Bakiny",
      "Keith Speights",
      "David Jagielski"
    ],
    "summary": "These stocks pay great dividends and could be long-term winners.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789832/couple-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.988915"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      }
    ],
    "overall_sentiment_score": 0.279552,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.334573",
        "ticker_sentiment_score": "0.115261",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.29485",
        "ticker_sentiment_score": "0.302575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AbbVie  ( ABBV )  Outpaced the Stock Market Today",
    "url": "https://www.zacks.com/stock/news/2333666/why-abbvie-abbv-outpaced-the-stock-market-today",
    "time_published": "20240909T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default206.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.231392,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.468029",
        "ticker_sentiment_score": "0.289771",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Spotlight on AbbVie: Analyzing the Surge in Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40781676/spotlight-on-abbvie-analyzing-the-surge-in-options-activity",
    "time_published": "20240909T201552",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1725912949_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.206152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.084722",
        "ticker_sentiment_score": "-0.023111",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.758085",
        "ticker_sentiment_score": "0.235125",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Things You Need to Know if You Buy AbbVie Stock Today",
    "url": "https://www.fool.com/investing/2024/09/09/3-things-you-need-to-know-if-you-buy-abbvie-stock/",
    "time_published": "20240909T160500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "This dynamic big pharma is undergoing a few key changes.",
    "banner_image": "https://g.foolcdn.com/editorial/images/789927/doctor-and-businessman-working-on-digital-tablet-in-the-office.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.246889,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.193207",
        "ticker_sentiment_score": "0.149755",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.042028",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.064973",
        "ticker_sentiment_score": "0.059427",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY\u00ae, in a Phase 1 Study in Patients with Solid Tumors",
    "url": "https://www.globenewswire.com/news-release/2024/09/09/2942754/37704/en/CytomX-Therapeutics-Announces-First-Patient-Dosed-with-CX-801-a-Dually-Masked-Interferon-Alpha-2b-PROBODY-in-a-Phase-1-Study-in-Patients-with-Solid-Tumors.html",
    "time_published": "20240909T120000",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study ( ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.076989,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.047495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.195498",
        "ticker_sentiment_score": "0.045242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.047495",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.047495",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is iShares Core High Dividend ETF  ( HDV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2333155/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now",
    "time_published": "20240909T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default123.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.222797,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLK",
        "relevance_score": "0.057352",
        "ticker_sentiment_score": "0.08195",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.169336",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.060923",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Visa, AbbVie & Anheuser-Busch",
    "url": "https://www.zacks.com/research-daily/2334072/top-stock-reports-for-visa-abbvie-anheuser-busch",
    "time_published": "20240910T205300",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.400296,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UG",
        "relevance_score": "0.098659",
        "ticker_sentiment_score": "0.229969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.147516",
        "ticker_sentiment_score": "0.433074",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.147516",
        "ticker_sentiment_score": "0.259405",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies - Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40801368/teva-announces-80m-settlement-to-baltimore-city-continues-opioid-litigation-against-other-compani",
    "time_published": "20240910T180913",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd TEVA to resolve claims against the company for its role in the city's opioid epidemic.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/10/Viersen--Germany---May-9--2020-Close-Up-.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.118906,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.22595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2333740/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20240910T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default13.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.235886,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.239895",
        "ticker_sentiment_score": "0.223559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.121343",
        "ticker_sentiment_score": "0.068087",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Summit Therapeutics a Buy Now?",
    "url": "https://www.fool.com/investing/2024/09/10/is-summit-therapeutics-a-buy-now/",
    "time_published": "20240910T082700",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790126/scientist-checking-samples-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      }
    ],
    "overall_sentiment_score": 0.073412,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AKESF",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "0.065938",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.017444",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.04823",
        "ticker_sentiment_score": "-0.112923",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.283323",
        "ticker_sentiment_score": "-0.011028",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi\u00ae in Second-Line Non-Small Cell Lung Cancer",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40785595/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study-for-cancer-va",
    "time_published": "20240910T053000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi\u00ae in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada, Europe and United Kingdom after successful regulatory authorizations in 14 countries.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.103986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.053449",
        "ticker_sentiment_score": "0.053001",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi\u00ae in Second-Line Non-Small Cell Lung Cancer",
    "url": "https://www.globenewswire.com/news-release/2024/09/10/2943357/0/en/OSE-Immunotherapeutics-Announces-Global-Launch-of-Artemia-Phase-3-Registration-Study-for-Cancer-Vaccine-Tedopi-in-Second-Line-Non-Small-Cell-Lung-Cancer.html",
    "time_published": "20240910T053000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi\u00ae in",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.094393,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.100835",
        "ticker_sentiment_score": "0.074022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars - UnitedHealth Group  ( NYSE:UNH ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars",
    "time_published": "20240911T185913",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "UnitedHealth Group Inc. UNH reportedly announced on Tuesday that it will remove AbbVie Inc.'s ABBV blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/11/Konskie--Poland---January-05--2019-Unite.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.216359,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.342093",
        "ticker_sentiment_score": "0.261477",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.1277",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.123593",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.342093",
        "ticker_sentiment_score": "0.320237",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40819497/what-the-options-market-tells-us-about-abbvie",
    "time_published": "20240911T173135",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726075892_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.19219,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.647749",
        "ticker_sentiment_score": "0.274151",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian",
    "url": "https://www.zacks.com/stock/news/2334349/the-zacks-analyst-blog-highlights-visa-abbvie-anheuser-busch-servotronics-and-united-guardian",
    "time_published": "20240911T094700",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/119.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.5"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.891286"
      }
    ],
    "overall_sentiment_score": 0.357025,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BUD",
        "relevance_score": "0.122062",
        "ticker_sentiment_score": "0.047718",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UG",
        "relevance_score": "0.202028",
        "ticker_sentiment_score": "0.192711",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.146862",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.241284",
        "ticker_sentiment_score": "0.297689",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis",
    "url": "https://www.zacks.com/stock/news/2335423/fda-grants-label-expansion-to-jjs-tremfya-in-ulcerative-colitis",
    "time_published": "20240912T153900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.280659,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.277154",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.191675",
        "ticker_sentiment_score": "0.31084",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.253646",
        "ticker_sentiment_score": "0.384992",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2335095/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
    "time_published": "20240912T130019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.250962,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.126498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Is Considered a Good Investment by Brokers: Is That True?",
    "url": "https://www.zacks.com/stock/news/2335790/abbvie-abbv-is-considered-a-good-investment-by-brokers-is-that-true",
    "time_published": "20240913T133033",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_09132024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.268701,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.358521",
        "ticker_sentiment_score": "0.166109",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?",
    "url": "https://www.fool.com/investing/2024/09/13/is-abbvie-still-a-strong-buy-after-tripling-sp-500/",
    "time_published": "20240913T091500",
    "authors": [
      "Bradley Guichard"
    ],
    "summary": "The stock has been a winner, but there may be better times ahead for buying.",
    "banner_image": "https://media.ycharts.com/charts/de7e51430c0480223d1586554f8aa336.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.332763,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.858272",
        "ticker_sentiment_score": "0.482098",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More",
    "url": "https://www.fool.com/investing/2024/09/14/investing-in-biotech-pharma-stocks-pay-attention/",
    "time_published": "20240914T131500",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Financial factors aren't the only things that are worth paying attention to.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790452/investor-holds-glasses-while-considering-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.185104,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.092569",
        "ticker_sentiment_score": "0.118947",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/14/3-stocks-to-buy-and-hold-forever/",
    "time_published": "20240914T113000",
    "authors": [
      "Keith Speights",
      "David Jagielski",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These stocks are built for the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790595/hands-behind-head-young-man.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.977154"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.302576,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.420783",
        "ticker_sentiment_score": "0.432652",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.218423",
        "ticker_sentiment_score": "0.259411",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.074855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.044222",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/14/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20240914T095100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "Their dividends are solid. And their businesses are built for the long run.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790433/young-woman-smiling-hands-behind-head.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.298876,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VZ",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "0.322912",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.27065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.316439",
        "ticker_sentiment_score": "0.220745",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Can AbbVie Regain Its Status As a Top Dividend Growth Stock?",
    "url": "https://www.fool.com/investing/2024/09/16/can-abbvie-regain-its-status-as-a-top-dividend-gro/",
    "time_published": "20240916T110000",
    "authors": [
      "George Budwell"
    ],
    "summary": "The dividend growth powerhouse is turning the corner.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F790803%2Fu-turn.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.312508,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.409171",
        "ticker_sentiment_score": "0.390142",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.085629",
        "ticker_sentiment_score": "0.129735",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Dips While Market Gains: Key Facts",
    "url": "https://www.zacks.com/stock/news/2337464/abbvie-abbv-stock-dips-while-market-gains-key-facts",
    "time_published": "20240917T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default316.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.200813,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.596978",
        "ticker_sentiment_score": "0.309647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer",
    "url": "https://www.globenewswire.com/news-release/2024/09/17/2947831/0/en/Structure-Therapeutics-Strengthens-Executive-Team-with-Promotion-of-Blai-Coll-M-D-Ph-D-to-Chief-Medical-Officer-and-Appointment-of-Ashley-Hall-J-D-as-Chief-Development-Officer.html",
    "time_published": "20240917T200500",
    "authors": [
      "Structure Therapeutics Inc."
    ],
    "summary": "SAN FRANCISCO, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- Structure Therapeutics Inc. ( NASDAQ: GPCR ) , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6c9a8c36-cd22-4d2c-8d95-9a940b2e0c1f",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.169629,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ESPR",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.029967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.245693",
        "ticker_sentiment_score": "0.159578",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.014432",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPHM",
        "relevance_score": "0.035661",
        "ticker_sentiment_score": "0.029967",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer - Structure Therapeutics  ( NASDAQ:GPCR ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40908571/structure-therapeutics-strengthens-executive-team-with-promotion-of-blai-coll-m-d-ph-d-to-chief-me",
    "time_published": "20240917T200500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SAN FRANCISCO, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- Structure Therapeutics Inc. GPCR, a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.174192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ESPR",
        "relevance_score": "0.033703",
        "ticker_sentiment_score": "0.027795",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GPCR",
        "relevance_score": "0.296264",
        "ticker_sentiment_score": "0.178543",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.033703",
        "ticker_sentiment_score": "0.013348",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPHM",
        "relevance_score": "0.033703",
        "ticker_sentiment_score": "0.027795",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RHHBY or ABBV: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2337293/rhhby-or-abbv-which-is-the-better-value-stock-right-now",
    "time_published": "20240917T154009",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY vs. ABBV: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default158.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.464854,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.664882",
        "ticker_sentiment_score": "0.538031",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Shiba Inu Burn Rate Jumps 14,500%, Marketing Lead Warns of 'Heavy Market Manipulation, Not Even Elon Can Boost Doge'; Trump vs. Harris: Vice President Leads in Key Swing State and 2 Critical Counties - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/news/24/09/40901825/shiba-inu-burn-rate-jumps-14-500-marketing-lead-warns-of-heavy-market-manipulation-not-even-elon-can",
    "time_published": "20240917T144747",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "Goya Foods CEO Claims Biden-Harris Policies Are Deepening Poverty Crisis: 'We've Just Gone From Bad To Worse' Trump Vs. Harris: Vice President Leads In This 'Must-Win' Swing State And 2 'Bellwether' Counties, But 25% Say They Are Still Ignorant Of Her Policies",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/17/Dogecoin-Doge--Ethereum-Eth--Bitcoin-Btc.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Blockchain",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.014893,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.350461",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.251105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.097259",
        "ticker_sentiment_score": "-0.040791",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LRHC",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.36652",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SBUX",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESLOF",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.251105",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DPRO",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.33942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.071146",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRVL",
        "relevance_score": "0.04872",
        "ticker_sentiment_score": "-0.198978",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Mental Health Market to Surpass Market Valuation of USD 544.63 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40897547/mental-health-market-to-surpass-market-valuation-of-usd-544-63-billion-by-2031-skyquest-technology",
    "time_published": "20240917T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Mental Health Market will reach a value of USD 544.63 Billion by 2031, with a CAGR of 3.5% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.102378,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "JNJ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "0.153396",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ALKS",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JAZZ",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HKMPF",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.036091",
        "ticker_sentiment_score": "-0.017939",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' - TransDigm Gr  ( NYSE:TDG ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/09/40896322/transdigm-bjs-wholesale-abbvie-and-more-on-cnbcs-final-trades",
    "time_published": "20240917T115533",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group Incorporated TDG. On Aug. 6, TransDigm Group reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/17/trader-chart-ai.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.328419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BJ",
        "relevance_score": "0.217834",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.321673",
        "ticker_sentiment_score": "0.420216",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.109956",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.419733",
        "ticker_sentiment_score": "0.689663",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40893311/chemotherapy-induced-nausea-and-vomiting-treatment-market-is-set-to-reach-us-12-688-0-million-by-2",
    "time_published": "20240917T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy induced nausea and vomiting treatment market is estimated to reach a valuation of US$ 6,823.0 million in 2024 and is expected to grow at a ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/3fed7b97-2ab9-4c49-8ce9-a90c9311fbef/chemotherapy-induced-nausea-and-vomiting-treatment.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.152391,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KNBWF",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KYKOF",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.098524",
        "ticker_sentiment_score": "-0.06907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OPHLF",
        "relevance_score": "0.065775",
        "ticker_sentiment_score": "0.024109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Stock Market ETFs to Buy With $1,000 and Hold Forever",
    "url": "https://www.fool.com/investing/2024/09/17/stock-market-etf-buy-1000-hold-forever-schd/",
    "time_published": "20240917T085000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These three winning funds can build wealth no matter your investing style.",
    "banner_image": "https://g.foolcdn.com/editorial/images/790575/compounding-investment-returns.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.421144,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LMT",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.144001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.144001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.144001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.144001",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.059194",
        "ticker_sentiment_score": "0.20343",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Octane Medical Innovation Forum to be held on Oct 8-9 in Irvine, California",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40919837/octane-medical-innovation-forum-to-be-held-on-oct-8-9-in-irvine-california",
    "time_published": "20240918T133500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "IRVINE, Calif., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- via InvestorWire - Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources and capital to fuel technology growth in Southern California, is pleased to announce that the Octane Medical Innovation Forum ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.434322,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CAUD",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.259217",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.054007",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.025487",
        "ticker_sentiment_score": "0.054007",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Progress Brings Industry Leaders Together to Share Insights on AI and Data at MarkLogic World Tour US 2024 - Progress Software  ( NASDAQ:PRGS ) ",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40917762/progress-brings-industry-leaders-together-to-share-insights-on-ai-and-data-at-marklogic-world-tour",
    "time_published": "20240918T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Innovators from Dupont, Salesforce, Yale and more to explore the future of data, generative AI, knowledge management and data visualization",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.345712,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "DSSMY",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.058903",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PRGS",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "0.261394",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/40941673/competitor-analysis-evaluating-abbvie-and-competitors-in-biotechnology-industry",
    "time_published": "20240919T150055",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie ABBV against its key competitors in the Biotechnology ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726758052_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.326071,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.470482",
        "ticker_sentiment_score": "0.404573",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again",
    "url": "https://www.fool.com/investing/2024/09/19/2-unstoppable-sp-500-stocks-that-keep-beating-the/",
    "time_published": "20240919T082100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.",
    "banner_image": "https://media.ycharts.com/charts/7ef36588d43167e8f5cf0bba57887894.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.233824,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.446546",
        "ticker_sentiment_score": "0.215965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.343279",
        "ticker_sentiment_score": "0.286432",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/40964682/bristol-myers-acquired-drug-karxt-poised-for-fda-approval-as-first-new-type-of-schizophrenia-trea",
    "time_published": "20240920T191255",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The experimental drug KarXT, developed by Karuna Therapeutics, is expected to receive FDA approval later this month ( Sept. 26 ) , marking a significant breakthrough in schizophrenia treatment.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/20/pharmaceutical.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.227579,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NHPEF",
        "relevance_score": "0.102013",
        "ticker_sentiment_score": "0.218034",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.300403",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.224147",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Spotlight on AbbVie: Analyzing the Surge in Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/40964648/spotlight-on-abbvie-analyzing-the-surge-in-options-activity",
    "time_published": "20240920T190922",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 12% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1726859359_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.249702,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.714116",
        "ticker_sentiment_score": "0.276655",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Ocular Drug Delivery Technology Market Size to Reach a Valuation of USD 30.2 billion by 2034, advancing at an 5.7% CAGR | Exclusive Report by Transparency Market Research",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40983689/ocular-drug-delivery-technology-market-size-to-reach-a-valuation-of-usd-30-2-billion-by-2034-advan",
    "time_published": "20240923T150159",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 23, 2024 ( GLOBE NEWSWIRE ) -- The ocular drug delivery technology industry ( Industrie f\u00fcr Augenarzneimittelverabreichungstechnologie ) globally generated US$ 16.3 billion in revenue by 2023.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/1582f930-5297-45c8-b704-82c9e34843ea/ocular-drug-delivery-technology-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.269681,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALIM",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.050075",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.052232",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLSD",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EYPT",
        "relevance_score": "0.064018",
        "ticker_sentiment_score": "0.077207",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.134512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.095899",
        "ticker_sentiment_score": "0.048452",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "OCUL",
        "relevance_score": "0.032035",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer",
    "url": "https://www.zacks.com/stock/news/2339997/ema-committee-endorses-abbvies-elahere-in-ovarian-cancer",
    "time_published": "20240923T140000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.090565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.061212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.236281",
        "ticker_sentiment_score": "0.072917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.095707",
        "ticker_sentiment_score": "0.061212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.326129",
        "ticker_sentiment_score": "0.099094",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.236281",
        "ticker_sentiment_score": "0.133504",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Behind the Scenes of AbbVie's Latest Options Trends - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/09/41012628/behind-the-scenes-of-abbvies-latest-options-trends",
    "time_published": "20240924T183048",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 40% ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727202645_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.219501,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.774013",
        "ticker_sentiment_score": "0.292422",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR",
    "url": "https://www.benzinga.com/pressreleases/24/09/g40997521/cancer-supportive-care-product-market-is-set-to-surge-at-6-9-cagr-to-reach-us-68-93-billion-by-203",
    "time_published": "20240924T100000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Sept. 24, 2024 ( GLOBE NEWSWIRE ) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024 and thereafter advance at a CAGR of 6.9% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/4051ce21-f8ad-45c0-a815-b601fdab078e/cancer-supportive-care-product-market.jpg",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.279437,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WLDS",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "0.551007",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HRTX",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.029618",
        "ticker_sentiment_score": "-0.013415",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Suffers a Larger Drop Than the General Market: Key Insights",
    "url": "https://www.zacks.com/stock/news/2341577/abbvie-abbv-suffers-a-larger-drop-than-the-general-market-key-insights",
    "time_published": "20240925T214521",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The latest trading day saw AbbVie (ABBV) settling at $191.26, representing a -1.16% change from its previous close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.142841,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.617188",
        "ticker_sentiment_score": "0.210515",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/09/25/2952754/0/en/Alvotech-Initiates-Confirmatory-Patient-Study-for-AVT16-a-Proposed-Biosimilar-to-Entyvio.html",
    "time_published": "20240925T090100",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar candidate to Entyvio\u00ae ( vedolizumab ) .",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.130113,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALVO",
        "relevance_score": "0.460754",
        "ticker_sentiment_score": "0.214547",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.064492",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.022264",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio\u00ae",
    "url": "https://www.globenewswire.com/news-release/2024/09/25/2952753/0/en/Alvotech-Initiates-Confirmatory-Patient-Study-for-AVT16-a-Proposed-Biosimilar-to-Entyvio.html",
    "time_published": "20240925T090000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland, Sept. 25, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for AVT16, a biosimilar ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.127743,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.091919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.091919",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.455525",
        "ticker_sentiment_score": "0.210099",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.021978",
        "ticker_sentiment_score": "0.063462",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/09/41057551/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
    "time_published": "20240926T213025",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 12.86%. Currently, AbbVie has a market capitalization of $338.87 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727386222_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update",
    "url": "https://www.globenewswire.com/news-release/2024/09/26/2954035/0/en/OSE-Immunotherapeutics-Announces-Historic-H1-2024-Results-and-Provides-Corporate-Update.html",
    "time_published": "20240926T160000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "\u2022 Total H1 2024 incomes of \u20ac82.5 million thanks to Company's new partnerships. \u2022 New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature. \u2022 Major partnership expansion with Boehringer Ingelheim: \u2022 Amendment of the collaboration and licensing ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.207651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.167411",
        "ticker_sentiment_score": "0.11659",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/09/41050209/abbvie-says-pivotal-trial-for-parkinsons-candidate-meets-its-primary-goal-in-patients-with-early-",
    "time_published": "20240926T151433",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, AbbVie Inc ABBV released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/26/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.154571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.453501",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead",
    "url": "https://www.fool.com/investing/2024/09/26/forget-novo-nordisk-buy-this-magnificent-dividend/",
    "time_published": "20240926T123000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Even the mighty Novo Nordisk can't hold a candle to its peer in this area.",
    "banner_image": "https://media.ycharts.com/charts/274fc80dee3744f630d06f23387c1cae.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.318167,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.550151",
        "ticker_sentiment_score": "0.412957",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.159675",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MPW",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.014039",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.294446",
        "ticker_sentiment_score": "0.406178",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "WBA",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "-0.014039",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2341689/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20240926T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default18.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      }
    ],
    "overall_sentiment_score": 0.250919,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.066784",
        "ticker_sentiment_score": "0.125682",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.1331",
        "ticker_sentiment_score": "0.063957",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": " ( ABBV )  - Analyzing AbbVie's Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/09/41075801/abbv-analyzing-abbvies-short-interest",
    "time_published": "20240927T204525",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has fallen 8.18% since its last report. The company recently reported that it has 17.79 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727469922_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc",
    "time_published": "20240927T190608",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy ( xanomeline and trospium chloride, KarXT ) , an oral medication for schizophrenia in adults. BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/27/xrdDAFyeYvElyk2-j4009736908334739714-t23.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.223701,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.201523",
        "ticker_sentiment_score": "0.16941",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.298264",
        "ticker_sentiment_score": "0.14243",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal",
    "url": "https://www.zacks.com/stock/news/2342912/abbvs-newly-added-parkinsons-disease-drug-meets-second-study-goal",
    "time_published": "20240927T174000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174812,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ADMA",
        "relevance_score": "0.320974",
        "ticker_sentiment_score": "0.162079",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.061738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.269776",
        "ticker_sentiment_score": "0.127832",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BVS",
        "relevance_score": "0.370733",
        "ticker_sentiment_score": "0.167278",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment",
    "url": "https://www.zacks.com/stock/news/2342752/bristol-myers-stock-up-on-fda-nod-for-schizophrenia-treatment",
    "time_published": "20240927T140300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fb/27696.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.255092,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KRYS",
        "relevance_score": "0.254307",
        "ticker_sentiment_score": "0.212823",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128822",
        "ticker_sentiment_score": "0.295926",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.192183",
        "ticker_sentiment_score": "0.092915",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.192183",
        "ticker_sentiment_score": "0.044855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2342457/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20240927T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.22455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.086676",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Anima Biotech to Present at 3\u02b3\u1d48 Annual AI/ML Enabled Drug Discovery during Discovery on Target",
    "url": "https://www.benzinga.com/pressreleases/24/09/g41103897/anima-biotech-to-present-at-3-annual-aiml-enabled-drug-discovery-during-discovery-on-target",
    "time_published": "20240930T202036",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BERNARDSVILLE, N.J., Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- Anima Biotech, the Tech.Bio leader in Visual Biology for drug discovery, will showcase its Lightning AI platform at the 3rd annual AI/ML-Enabled Drug Discovery Session, \"Leveraging GenAI to Improve Speed, Efficiency and Effectiveness,\" as ...",
    "banner_image": "https://ml.globenewswire.com/media/a1b72e90-ebca-405d-8165-fb75d362211f/small/anima-biotech-logo-new-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.20025,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.111967",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V",
    "url": "https://www.zacks.com/stock/news/2343487/abbvie-seeks-approval-for-lung-cancer-candidate-teliso-v",
    "time_published": "20240930T151400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990678"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.139338,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ANIP",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.296295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KRYS",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.241241",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.421485",
        "ticker_sentiment_score": "-0.022834",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FULC",
        "relevance_score": "0.288893",
        "ticker_sentiment_score": "0.032659",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Analysts Think AbbVie  ( ABBV )  Is a Good Investment: Is It?",
    "url": "https://www.zacks.com/stock/news/2343294/wall-street-analysts-think-abbvie-abbv-is-a-good-investment-is-it",
    "time_published": "20240930T133012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_09302024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.890401"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.292851,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.360005",
        "ticker_sentiment_score": "0.166612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades' - Meta Platforms  ( NASDAQ:META ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/09/41092098/meta-accenture-disney-and-a-major-health-care-stock-on-cnbcs-final-trades",
    "time_published": "20240930T124356",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. META is hitting on all cylinders. On Sept. 26, Rosenblatt analyst Barton Crockett maintained Meta Platforms with a Buy and raised the price target from $643 to $811.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/30/Meta-Platforms_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.251415,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.333257",
        "ticker_sentiment_score": "0.171436",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.434142",
        "ticker_sentiment_score": "0.447971",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "VRTS",
        "relevance_score": "0.114137",
        "ticker_sentiment_score": "-0.067966",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ACN",
        "relevance_score": "0.434142",
        "ticker_sentiment_score": "-0.025788",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "15 Best Dividend Stocks for Lifelong Passive Income",
    "url": "https://www.fool.com/investing/2024/09/30/15-best-dividend-stocks-for-lifelong-passive-incom/",
    "time_published": "20240930T101500",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 15 dividend stocks can deliver stable passive income for life.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792319%2Fgrowth.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.865346"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.472024,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "TGT",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.218295",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MO",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.247106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.221423",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.253685",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.331384",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.274812",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "O",
        "relevance_score": "0.082963",
        "ticker_sentiment_score": "0.225766",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.090333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.218615",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.207667",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.205458",
        "ticker_sentiment_score": "0.302178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "-0.049878",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PM",
        "relevance_score": "0.124164",
        "ticker_sentiment_score": "0.312981",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should You Buy AbbVie Stock After Recent Parkinson's Study Success?",
    "url": "https://www.zacks.com/stock/news/2344351/should-you-buy-abbvie-stock-after-recent-parkinsons-study-success",
    "time_published": "20241001T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.538269"
      }
    ],
    "overall_sentiment_score": 0.298836,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.082318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.064885",
        "ticker_sentiment_score": "0.082318",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.671398",
        "ticker_sentiment_score": "0.432166",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41120929/exciting-advances-in-ulcerative-colitis-treatments-skyrizi-gains-early-momentum-following-fda-appr",
    "time_published": "20241001T145133",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, Oct. 01, 2024 ( GLOBE NEWSWIRE ) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis ( UC ) market, with a surge in advanced therapies receiving FDA approval.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.29391,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.048523",
        "ticker_sentiment_score": "0.135498",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2343786/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
    "time_published": "20241001T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default69.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.23368,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SCHW",
        "relevance_score": "0.058188",
        "ticker_sentiment_score": "0.12399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LMT",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.066855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.066855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.116067",
        "ticker_sentiment_score": "0.066855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Best Dividend Growth Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/02/5-best-dividend-growth-stocks-to-buy-in-october/",
    "time_published": "20241002T113000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These five stocks are known for their generous dividend programs and robust business models.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792592%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.42385,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.096412",
        "ticker_sentiment_score": "0.273852",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AXP",
        "relevance_score": "0.128306",
        "ticker_sentiment_score": "0.207605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.064362",
        "ticker_sentiment_score": "0.214791",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.128306",
        "ticker_sentiment_score": "0.138586",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.096412",
        "ticker_sentiment_score": "0.191718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Suffers a Larger Drop Than the General Market: Key Insights",
    "url": "https://www.zacks.com/stock/news/2345671/abbvie-abbv-suffers-a-larger-drop-than-the-general-market-key-insights",
    "time_published": "20241003T214522",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972476"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.145276,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.52949",
        "ticker_sentiment_score": "0.159945",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal - AbbVie  ( NYSE:ABBV ) , UnitedHealth Group  ( NYSE:UNH ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41169892/blue-shield-of-california-slashes-humira-biosimilar-prices-in-landmark-deal",
    "time_published": "20241003T163655",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.'s ABBV Humira, one of the world's most expensive and widely used drugs.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/humira-complete-savings-card-r29-desktop.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.168572,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "UNH",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.24258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.320279",
        "ticker_sentiment_score": "-0.259475",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "FSNUF",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "0.113442",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Comparing AbbVie With Industry Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41166974/comparing-abbvie-with-industry-competitors-in-biotechnology-industry",
    "time_published": "20241003T150054",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AbbVie ABBV and its primary competitors in the Biotechnology ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727967651_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.276156,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.534294",
        "ticker_sentiment_score": "0.356734",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Behind the Scenes of AbbVie's Latest Options Trends - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41166377/behind-the-scenes-of-abbvies-latest-options-trends",
    "time_published": "20241003T143610",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 15 unusual trades. Delving into the details, we found 33% of traders were bullish, while 46% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1727966166_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.212046,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.622414",
        "ticker_sentiment_score": "0.118565",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected - AbbVie  ( NYSE:ABBV ) , GSK  ( NYSE:GSK ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte",
    "time_published": "20241003T142218",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, the U.S. Department of Health and Human Services ( HHS ) , working via the Centers for Medicare & Medicaid Services ( CMS ) , released final guidance for the second cycle of the Medicare Drug Price Negotiation Program. This initiative aims to provide lower drug prices ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/03/Prescription-Drugs.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.190221,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "-0.567923",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "-0.654431",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.202366",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Healthcare Mutual Funds to Grab on the Sector's 2024 Revival",
    "url": "https://www.zacks.com/stock/news/2345148/3-healthcare-mutual-funds-to-grab-on-the-sectors-2024-revival",
    "time_published": "20241003T094700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "JNGLX, PHSTX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/2257.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.220792,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JHG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.188222",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.064413",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.060436",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.049939",
        "ticker_sentiment_score": "0.043936",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.099683",
        "ticker_sentiment_score": "0.066765",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.099683",
        "ticker_sentiment_score": "0.069956",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More",
    "url": "https://www.zacks.com/stock/news/2346320/pharma-stock-roundup-fda-approves-snys-dupixent-for-copd-more",
    "time_published": "20241004T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.955357"
      }
    ],
    "overall_sentiment_score": 0.091334,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.182684",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.235366",
        "ticker_sentiment_score": "0.031172",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.095327",
        "ticker_sentiment_score": "0.071683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.047749",
        "ticker_sentiment_score": "-0.123788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.189298",
        "ticker_sentiment_score": "0.099977",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs",
    "url": "https://www.zacks.com/stock/news/2345929/abbvie-cuts-2024-earnings-guidance-to-include-acquisition-costs",
    "time_published": "20241004T131100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999326"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.229059,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.13576",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.31583",
        "ticker_sentiment_score": "0.072391",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.584103",
        "ticker_sentiment_score": "0.385825",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now",
    "url": "https://www.fool.com/investing/2024/10/05/2-top-dividend-stocks-yielding-3-or-more-to-buy/",
    "time_published": "20241005T101500",
    "authors": [
      "Rachel Warren"
    ],
    "summary": "These companies can lend growth and dividend returns to a long-term investor's portfolio.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792527/investing-woman-wall-street-suit-stocks-finance-1.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.94762"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.181548,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.143415",
        "ticker_sentiment_score": "0.089662",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.030721",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ICNB",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "-0.024285",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.036037",
        "ticker_sentiment_score": "0.084206",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KHC",
        "relevance_score": "0.380802",
        "ticker_sentiment_score": "0.195899",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades",
    "url": "https://www.fool.com/investing/2024/10/05/want-1-million-in-retirement-3-stocks-to-buy-now-a/",
    "time_published": "20241005T084500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Investors can find market-trouncing blue chip stocks in the healthcare industry.",
    "banner_image": "https://media.ycharts.com/charts/101205710d2eec3e01faedec405c08eb.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.35083,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.19113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.275246",
        "ticker_sentiment_score": "0.267149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.164612",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Magnificent Dividend Stocks to Buy in October",
    "url": "https://www.fool.com/investing/2024/10/06/3-magnificent-dividend-stocks-to-buy-in-october/",
    "time_published": "20241006T095000",
    "authors": [
      "David Jagielski",
      "Keith Speights",
      "and Prosper Junior Bakiny"
    ],
    "summary": "These dividend stocks are great picks as the fall season gets underway.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792876/retired-woman-investing-laptop-401k-ira.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      }
    ],
    "overall_sentiment_score": 0.334621,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.389014",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.067748",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LDNXF",
        "relevance_score": "0.047185",
        "ticker_sentiment_score": "0.147599",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.277433",
        "ticker_sentiment_score": "0.354037",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.213443",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?",
    "url": "https://www.fool.com/investing/2024/10/06/billionaires-are-loading-up-on-this-high-yield-div/",
    "time_published": "20241006T083100",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Declining earnings haven't scared billionaire investors away from this stock.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792959/investor-looks-worried-at-computer-in-a-living-room-setting-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.247688,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.585687",
        "ticker_sentiment_score": "0.37233",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.200856",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BGNE",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "-0.055095",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) ",
    "url": "https://www.benzinga.com/news/24/10/41203961/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yield",
    "time_published": "20241007T111929",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071249/image-31.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.147671,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.100972",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "0.137668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WFC",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "-0.088797",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "-0.081375",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.093653",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.18602",
        "ticker_sentiment_score": "-0.101754",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Bio-Path Holdings Stock Soaring On Tuesday? - Cassava Sciences  ( NASDAQ:SAVA ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41228945/nano-cap-bio-path-takes-plunge-in-weight-loss-race-initiates-obesity-program-with-drug-candidate-",
    "time_published": "20241008T132713",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Bio-Path Holdings, Inc., BPTH stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/08/BPTH.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.178856,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BPTH",
        "relevance_score": "0.555911",
        "ticker_sentiment_score": "0.24186",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.240489",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Will AbbVie  ( ABBV )  Beat Estimates Again in Its Next Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2348483/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report",
    "time_published": "20241009T161014",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default164.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.322719,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.428632",
        "ticker_sentiment_score": "0.44693",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "AbbVie's Options: A Look at What the Big Money is Thinking - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41254224/abbvies-options-a-look-at-what-the-big-money-is-thinking",
    "time_published": "20241009T154551",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728488748_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189464,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.660632",
        "ticker_sentiment_score": "0.288698",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.076115",
        "ticker_sentiment_score": "0.054851",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2348085/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241009T130017",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default360.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.202093,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.485711",
        "ticker_sentiment_score": "0.089242",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings",
    "url": "https://www.zacks.com/stock/news/2348049/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings",
    "time_published": "20241009T125012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default290.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999973"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.395939,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SOLV",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.319683",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.392948",
        "ticker_sentiment_score": "0.385146",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend ETFs to Buy to Generate Passive Income",
    "url": "https://www.fool.com/investing/2024/10/09/3-high-yield-dividend-etfs-to-buy-to-generate-pass/",
    "time_published": "20241009T121500",
    "authors": [
      "Lawrence Rothman",
      "CFA"
    ],
    "summary": "These ETFs pay handsome dividend yields.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792958%2Fgettyimages-1413845348-1200x800-5b2df791.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": -0.043106,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "TTE",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTI",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MORN",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "-0.010113",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VOD",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.069697",
        "ticker_sentiment_score": "0.067485",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.138863",
        "ticker_sentiment_score": "-0.188017",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson's and Related Disorders",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41247181/vanqua-bio-announces-positive-interim-results-from-phase-1-clinical-trial-of-vq-101-an-orally-admi",
    "time_published": "20241009T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase ( GCase ) in humans In healthy volunteers, VQ-101 was well tolerated and achieved peripheral and cerebrospinal fluid ( CSF ) exposures supporting once daily dosing",
    "banner_image": "https://ml.globenewswire.com/media/c1551e7d-0244-4a1f-a88f-207d4ad12830/small/vanqua-logo-vertical-stack-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.225485,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.04531",
        "ticker_sentiment_score": "0.075631",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2347940/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
    "time_published": "20241009T102008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default1.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999996"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.31989,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.171688",
        "ticker_sentiment_score": "0.292708",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.114956",
        "ticker_sentiment_score": "0.066606",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Moves -0.21%: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2349032/abbvie-abbv-stock-moves--021-what-you-should-know",
    "time_published": "20241010T214518",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) reachead $194.35 at the closing of the latest trading day, reflecting a -0.21% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default342.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.197295,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.541943",
        "ticker_sentiment_score": "0.258925",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41280182/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-400-today",
    "time_published": "20241010T193113",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.55% on an annualized basis producing an average annual return of 13.48%. Currently, AbbVie has a market capitalization of $341.52 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728588670_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceutical Excipient for Taste Masking Market to Surpass US$ 1.58 Billion, Forecasted Growth at a 5% CAGR by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41268882/pharmaceutical-excipient-for-taste-masking-market-to-surpass-us-1-58-billion-forecasted-growth-at-",
    "time_published": "20241010T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- As per Fact.MR, a market research and intelligence provider, the global pharmaceutical excipients for taste masking market is estimated to attain a valuation of US$ 972.9 million in 2024 and further advance at a CAGR of 5% from 2024 to 2034.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/130b08b4-5e41-47ef-b4e6-2cab786a2d98/pharmaceutical-excipient-for-taste-masking-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.301961,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AHKSF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASBRF",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTLT",
        "relevance_score": "0.037155",
        "ticker_sentiment_score": "0.056337",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2348655/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20241010T102002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.182104,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.256989",
        "ticker_sentiment_score": "0.117587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.063265",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Declares Fourth Quarter 2024 Dividend",
    "url": "https://www.globenewswire.com/news-release/2024/10/11/2961990/0/en/Royalty-Pharma-Declares-Fourth-Quarter-2024-Dividend.html",
    "time_published": "20241011T121500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.183506,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.709186",
        "ticker_sentiment_score": "0.320221",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.10599",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma Declares Fourth Quarter 2024 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41289797/royalty-pharma-declares-fourth-quarter-2024-dividend",
    "time_published": "20241011T121500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.23156,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.614086",
        "ticker_sentiment_score": "0.296695",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.094182",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2349124/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20241011T102005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default62.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.201287,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.353898",
        "ticker_sentiment_score": "0.182705",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.",
    "url": "https://www.fool.com/investing/2024/10/12/sp-500-warren-buffett-income-investors/",
    "time_published": "20241012T094000",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors.",
    "banner_image": "https://media.ycharts.com/charts/5729640a46f26b5fb18c6b12011941a8.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.30179,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.426824",
        "ticker_sentiment_score": "0.364633",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.056143",
        "ticker_sentiment_score": "0.143928",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PG",
        "relevance_score": "0.112008",
        "ticker_sentiment_score": "0.241559",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "0.255637",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/10/41317696/looking-into-abbvies-recent-short-interest",
    "time_published": "20241014T164527",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has fallen 16.83% since its last report. The company recently reported that it has 14.86 million shares sold short, which is 0.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.01 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1728924324_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why Is Bausch + Lomb Stock Trading Higher On Monday? - Bausch & Lomb  ( NYSE:BLCO ) , Bausch Health Companies  ( NYSE:BHC ) ",
    "url": "https://www.benzinga.com/news/large-cap/24/10/41313679/bausch-lomb-sale-process-gains-momentum-as-tpg-and-blackstone-join-forces",
    "time_published": "20241014T140438",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported. Last month, Bausch + Lomb said it was considering a sale.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Bridgewater--Nj--Usa---August-23--2022-B.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.184926,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BLCO",
        "relevance_score": "0.699089",
        "ticker_sentiment_score": "0.026462",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "-0.135597",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "-0.144271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.024904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "APOS",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "-0.093076",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.342487",
        "ticker_sentiment_score": "0.147188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Magnificent Dividend Stocks to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/14/2-magnificent-dividend-stocks-buy-and-hold-forever/",
    "time_published": "20241014T134500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies have compelling track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/792621/patient-and-doctor-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.261025,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.382925",
        "ticker_sentiment_score": "0.403956",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade",
    "url": "https://www.fool.com/investing/2024/10/14/prediction-these-2-high-yield-dividend-stocks-will/",
    "time_published": "20241014T093400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Buying these stocks gives you a great chance to beat the benchmark.",
    "banner_image": "https://media.ycharts.com/charts/b70093536649e985b7237ba42d183bd4.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99977"
      }
    ],
    "overall_sentiment_score": 0.124552,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.41608",
        "ticker_sentiment_score": "0.170316",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.373611",
        "ticker_sentiment_score": "0.155744",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "13 Years of Empowering Patients: Annual Breast Reconstruction Awareness Day Planned for Oct. 16",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41331234/13-years-of-empowering-patients-annual-breast-reconstruction-awareness-day-planned-for-oct-16",
    "time_published": "20241015T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Arlington Heights, Ill, Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- The American Society of Plastic Surgeons ( ASPS ) in partnership with The Plastic Surgery Foundation ( PSF ) proudly announces the 13th annual Breast Reconstruction Awareness Day USA ( BRA Day ) on Wednesday, Oct. 16.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.29698,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.0362",
        "ticker_sentiment_score": "0.347282",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2350364/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20241015T102006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999953"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.28508,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.066484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.066484",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.385455",
        "ticker_sentiment_score": "0.226327",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114409",
        "ticker_sentiment_score": "0.066484",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024",
    "url": "https://www.globenewswire.com/news-release/2024/10/16/2964479/0/en/Royalty-Pharma-to-Announce-Third-Quarter-2024-Financial-Results-on-November-6-2024.html",
    "time_published": "20241016T201500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.135727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.628066",
        "ticker_sentiment_score": "0.213261",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.141726",
        "ticker_sentiment_score": "0.095681",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Falls More Steeply Than Broader Market: What Investors Need to Know",
    "url": "https://www.zacks.com/stock/news/2352701/abbvie-abbv-falls-more-steeply-than-broader-market-what-investors-need-to-know",
    "time_published": "20241017T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default355.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.147422,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.469457",
        "ticker_sentiment_score": "0.243178",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Top Stock Reports for AbbVie, ADP & Analog Devices",
    "url": "https://www.zacks.com/research-daily/2352151/top-stock-reports-for-abbvie-adp-analog-devices",
    "time_published": "20241017T210000",
    "authors": [
      "Mark Vickery"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data Processing, Inc. (ADP) and Analog Devices, Inc. (ADI), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Village Super Market, Inc. (VLGEA).",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.23521,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VLGEA",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "-0.15298",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158173",
        "ticker_sentiment_score": "0.270226",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.105836",
        "ticker_sentiment_score": "-0.029683",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRHGF",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.201735",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TAYD",
        "relevance_score": "0.053035",
        "ticker_sentiment_score": "0.158986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Presents New \"Cis-Demasking\" Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index",
    "url": "https://www.globenewswire.com/news-release/2024/10/17/2965108/0/en/OSE-Immunotherapeutics-Presents-New-Cis-Demasking-Bispecific-Technology-for-the-Design-of-Cytokine-Drugs-with-Improved-Therapeutic-Index.html",
    "time_published": "20241017T160000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173. Mnemo: OSE ) , today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences: ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.198355,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.10389",
        "ticker_sentiment_score": "0.090373",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41384990/fda-approves-abbvies-parkinsons-treatment-medicare-coverage-expected-next-year",
    "time_published": "20241017T153142",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Thursday, the FDA approved AbbVie Inc's ABBV Vyalev ( foscarbidopa and foslevodopa ) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations in adults with advanced Parkinson's disease ( PD ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/abbvie-shutter_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      }
    ],
    "overall_sentiment_score": 0.222623,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.409171",
        "ticker_sentiment_score": "0.284837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Analysis: AbbVie And Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41383808/market-analysis-abbvie-and-competitors-in-biotechnology-industry",
    "time_published": "20241017T150048",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing AbbVie ABBV alongside its primary competitors in ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729177245_0_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.231672,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.571516",
        "ticker_sentiment_score": "0.342304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Analyst Predicts Bitcoin High In Weeks, $90K By Year-End; TSMC Nears $1 Trillion Valuation After 8% Premarket Surge - Top Headlines Today While US Slept",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41382444/analyst-predicts-bitcoin-high-in-weeks-90k-by-year-end-tsmc-nears-1-trillion-valuation-aft",
    "time_published": "20241017T140916",
    "authors": [
      "Akanksha Bakshi"
    ],
    "summary": "ESMA Pushes For Stronger Crypto Regulations Under MiCA Framework Crypto Advocate Reacts To Elizabeth Warren's 'Return On Investment' Allegations Against John Deaton, Outlines ROI He Expects From GOP Candidate Bitcoin Defies Election Jitters, Analyst Sees King Crypto Scaling $70K Milestone Again ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/Soccer--Bitcoin.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.95493"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.124857,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "WIT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.029991",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXPE",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.215881",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OPTGF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.17618",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TCTZF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.232828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.236822",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.130509",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.439347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.136545",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BX",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.320095",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TDG",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ADIL",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.22969",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "WKSP",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.01087",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SAVE",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.496092",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "UBER",
        "relevance_score": "0.072435",
        "ticker_sentiment_score": "0.049572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BABA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.249701",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DEA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GOOG",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.187983",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.099709",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAH",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.168272",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.439347",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "NOK",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "-0.365491",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "TME",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.232828",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PSX",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.286902",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.108466",
        "ticker_sentiment_score": "0.11775",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:ETH",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.146588",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.187071",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:SHIB",
        "relevance_score": "0.036255",
        "ticker_sentiment_score": "0.113275",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:DOGE",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.171497",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell  ( Treg )  Inducing pMHC Nanomedicine Therapy",
    "url": "https://www.benzinga.com/pressreleases/24/10/r41382005/parvus-announces-first-human-subject-dosed-in-a-clinical-trial-with-pvt201-a-first-in-class-off-th",
    "time_published": "20241017T135500",
    "authors": [
      "PR.com"
    ],
    "summary": "South San Francisco, CA October 17, 2024 -- ( PR.com ) -- Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.105151,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.057079",
        "ticker_sentiment_score": "0.007008",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Does 'Very Well,' Cramer's Favorite? Abbott Laboratories - Abbott Laboratories  ( NYSE:ABT ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories",
    "time_published": "20241017T124934",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said AbbVie Inc. ABBV is doing \"very, very well.\" However, he added that Abbott Laboratories ABT remains his favorite in the group right now. AbbVie was founded in 2013 when it became a separate company from Abbott.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/17/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.262289,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABT",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.086907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SG",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.141787",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CORZQ",
        "relevance_score": "0.309539",
        "ticker_sentiment_score": "0.340065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ORCL",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.534909",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.493128",
        "ticker_sentiment_score": "0.041475",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CLOV",
        "relevance_score": "0.209365",
        "ticker_sentiment_score": "0.155277",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GXO",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.345606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs",
    "url": "https://www.zacks.com/stock/news/2353423/pharma-stock-roundup-jnjs-q3-earnings-fda-nod-to-some-new-drugs",
    "time_published": "20241018T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.96136"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.139439,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.1871",
        "ticker_sentiment_score": "0.065313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.140896",
        "ticker_sentiment_score": "0.01117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.232661",
        "ticker_sentiment_score": "0.026981",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.364053",
        "ticker_sentiment_score": "0.037861",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market",
    "url": "https://www.zacks.com/stock/news/2353214/the-zacks-analyst-blog-highlights-abbvie-automatic-data-processing-analog-devices-taylor-devices-and-village-super-market",
    "time_published": "20241018T133800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market are part of the Zacks top Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/78/424.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.210657,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VLGEA",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "-0.011117",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.148844",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.143796",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADI",
        "relevance_score": "0.208644",
        "ticker_sentiment_score": "0.016678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SRHGF",
        "relevance_score": "0.042196",
        "ticker_sentiment_score": "0.198893",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TAYD",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.118052",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev",
    "url": "https://www.zacks.com/stock/news/2353175/abbvie-secures-fda-approval-for-parkinsons-disease-drug-vyalev",
    "time_published": "20241018T130400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.216696,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ALNY",
        "relevance_score": "0.177475",
        "ticker_sentiment_score": "0.065424",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.193328",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.386211",
        "ticker_sentiment_score": "0.074678",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.220809",
        "ticker_sentiment_score": "0.118346",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Amgen Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/10/18/is-amgen-stock-a-buy/",
    "time_published": "20241018T113200",
    "authors": [
      "Dan Victor"
    ],
    "summary": "This biotech leader could be poised to rally higher.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F794114%2Famgen-stock-bullish-outlook-2025.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.986564"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.306775,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.190047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.674081",
        "ticker_sentiment_score": "0.464583",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.060236",
        "ticker_sentiment_score": "0.190047",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.12013",
        "ticker_sentiment_score": "0.095937",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Growth Stocks That Could Be Bargain Buys Right Now",
    "url": "https://www.fool.com/investing/2024/10/18/3-growth-stocks-that-could-be-bargain-buys-right-n/",
    "time_published": "20241018T092000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks trade at less than 20 times their estimated future profits.",
    "banner_image": "https://g.foolcdn.com/editorial/images/793887/a-person-looking-at-a-chart-on-their-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.243481,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SMCI",
        "relevance_score": "0.169676",
        "ticker_sentiment_score": "0.240371",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.3397",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is Pfizer's Attractive Valuation Enough to Invest in the Stock?",
    "url": "https://www.zacks.com/stock/news/2355264/is-pfizers-attractive-valuation-enough-to-invest-in-the-stock",
    "time_published": "20241022T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.140727,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.105141",
        "ticker_sentiment_score": "0.06673",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.645091",
        "ticker_sentiment_score": "0.172398",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966767/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Alvotech"
    ],
    "summary": "Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) in a new presentation, 130 mg/26 mL ( 5 mg/mL ) ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.072236,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.083327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.083327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.05602",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.29234",
        "ticker_sentiment_score": "0.167389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.093918",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011081",
        "ticker_sentiment_score": "0.05602",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966769/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Alvotech"
    ],
    "summary": "REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.07223,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.291438",
        "ticker_sentiment_score": "0.166953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055186",
        "ticker_sentiment_score": "0.091906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab ) ",
    "url": "https://www.globenewswire.com/news-release/2024/10/22/2966770/0/en/Alvotech-and-Teva-Announce-U-S-FDA-Approval-of-Additional-Presentation-of-SELARSDI-ustekinumab-aekn-Expanding-its-Label-to-Include-Further-Indications-Approved-for-Reference-Produc.html",
    "time_published": "20241022T110000",
    "authors": [
      "Teva Pharmaceutical Industries Ltd"
    ],
    "summary": "REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.07223,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.083302",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.291438",
        "ticker_sentiment_score": "0.166953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.055186",
        "ticker_sentiment_score": "0.091906",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.011046",
        "ticker_sentiment_score": "0.056003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI\u2122  ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara\u00ae  ( ustekinumab )  - Alvotech  ( NASDAQ:ALVO ) , Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41447702/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aek",
    "time_published": "20241022T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn's disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.069704,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.083187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.083187",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LTUS",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.047381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALVO",
        "relevance_score": "0.317391",
        "ticker_sentiment_score": "0.164642",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.054334",
        "ticker_sentiment_score": "0.080851",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KMDA",
        "relevance_score": "0.010875",
        "ticker_sentiment_score": "0.047381",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Analysts Estimate AbbVie  ( ABBV )  to Report a Decline in Earnings: What to Look Out for",
    "url": "https://www.zacks.com/stock/news/2355947/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings-what-to-look-out-for",
    "time_published": "20241023T140142",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default360.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.137846,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.047917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.262994",
        "ticker_sentiment_score": "-0.004022",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2355778/should-you-buy-sell-or-hold-pfizer-stock-before-q3-earnings",
    "time_published": "20241023T134600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/1434.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.99489"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.153848,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.055855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.083541",
        "ticker_sentiment_score": "0.058608",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.436009",
        "ticker_sentiment_score": "0.245807",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.041828",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
    "url": "https://www.zacks.com/stock/news/2355592/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
    "time_published": "20241023T130018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default268.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.219419,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.484798",
        "ticker_sentiment_score": "0.122129",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Beat the Nasdaq With This Cash-Gushing Dividend Stock",
    "url": "https://www.fool.com/investing/2024/10/23/beat-the-nasdaq-with-this-cash-gushing-dividend-st/",
    "time_published": "20241023T105000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "The company is performing well despite recently losing its biggest growth driver.",
    "banner_image": "https://media.ycharts.com/charts/1e4214ac7ed64e44b91332f6a4fbd401.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.858979"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.209965,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.091987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AAPL",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.091987",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.558244",
        "ticker_sentiment_score": "0.251438",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.116997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.064919",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Outperforms Broader Market: What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2357268/abbvie-abbv-outperforms-broader-market-what-you-need-to-know",
    "time_published": "20241024T214519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.99246"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.115433,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.606946",
        "ticker_sentiment_score": "0.168048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "FeganScott Launches Investigation into Abbott Laboratories Employees Credit Union Data Breach",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41530304/feganscott-launches-investigation-into-abbott-laboratories-employees-credit-union-data-breach",
    "time_published": "20241024T201542",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CHICAGO, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- Attorneys at the law firm FeganScott have launched an investigation into the Abbott Laboratories Employees Credit Union ( ALEC ) data breach, which, according to company reports, occurred during an August cyberattack against the Illinois-based credit ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.130969,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.128512",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.109455",
        "ticker_sentiment_score": "0.082027",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41526721/check-out-what-whales-are-doing-with-abbv",
    "time_published": "20241024T180040",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1729792837_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.21082,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.740328",
        "ticker_sentiment_score": "0.247056",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.007075",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News",
    "url": "https://www.zacks.com/stock/news/2358087/pharma-stock-roundup-rhhby-earnings-drug-pipeline-regulatory-news",
    "time_published": "20241025T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Economy - Macro",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.149324,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.040145",
        "ticker_sentiment_score": "-0.121631",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.12003",
        "ticker_sentiment_score": "0.087885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.237358",
        "ticker_sentiment_score": "0.085841",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.159569",
        "ticker_sentiment_score": "0.124271",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.275423",
        "ticker_sentiment_score": "0.164258",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?",
    "url": "https://www.zacks.com/stock/news/2358024/merck-to-report-q3-earnings-to-buy-or-not-to-buy-mrk-stock",
    "time_published": "20241025T164200",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.990999"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.9973"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.199513,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.090565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.076847",
        "ticker_sentiment_score": "0.090565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.152983",
        "ticker_sentiment_score": "0.145759",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.038468",
        "ticker_sentiment_score": "0.086736",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What Lies in Store for Healthcare ETFs in Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2357907/what-lies-in-store-for-healthcare-etfs-in-q3-earnings",
    "time_published": "20241025T150000",
    "authors": [
      "Sweta Killa"
    ],
    "summary": "Big stocks are likely to dominate the returns of the healthcare ETF going into Q3 earnings announcements.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/2723.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.995015"
      }
    ],
    "overall_sentiment_score": 0.15352,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.108324",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175433",
        "ticker_sentiment_score": "-0.008537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.02845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.232439",
        "ticker_sentiment_score": "0.160577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.117486",
        "ticker_sentiment_score": "0.010135",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2357873/should-abbvie-stock-be-in-your-portfolio-pre-q3-earnings",
    "time_published": "20241025T131600",
    "authors": [
      "Sundeep Ganoria"
    ],
    "summary": "Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.9545"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.273432,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.12123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.09495",
        "ticker_sentiment_score": "0.12123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.449106",
        "ticker_sentiment_score": "0.348312",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Curious about AbbVie  ( ABBV )  Q3 Performance? Explore Wall Street Estimates for Key Metrics",
    "url": "https://www.zacks.com/stock/news/2357641/curious-about-abbvie-abbv-q3-performance-explore-wall-street-estimates-for-key-metrics",
    "time_published": "20241025T131524",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default189.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.129256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.346642",
        "ticker_sentiment_score": "0.147661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees",
    "url": "https://www.fool.com/investing/2024/10/25/3-high-yielding-dividend-stocks-that-can-be-ideal/",
    "time_published": "20241025T123000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "These stocks yield between 2.8% and 3.3% in dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/794671/a-person-working-on-their-computer.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.723405"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.335958,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KO",
        "relevance_score": "0.349857",
        "ticker_sentiment_score": "0.321005",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.204503",
        "ticker_sentiment_score": "0.219647",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.302553",
        "ticker_sentiment_score": "0.295383",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks You Can Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/",
    "time_published": "20241026T113000",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "These healthcare stocks have fantastic dividend track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/795225/couple-looking-at-laptop.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.320127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.328455",
        "ticker_sentiment_score": "0.280552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.167904",
        "ticker_sentiment_score": "0.151135",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.289381",
        "ticker_sentiment_score": "0.406408",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?",
    "url": "https://www.zacks.com/stock/news/2358849/will-these-5-big-drug-stocks-surpass-q3-earnings-forecasts",
    "time_published": "20241028T160600",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.196752,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.036211",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.035956",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.185306",
        "ticker_sentiment_score": "0.034366",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.117668",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.037387",
        "ticker_sentiment_score": "-0.009697",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41605057/abbvie-chart-reflects-bearish-signals-ahead-of-q3-earnings",
    "time_published": "20241029T161517",
    "authors": [
      "Surbhi Jain"
    ],
    "summary": "AbbVie Inc ABBV will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29101832/Screenshot-2024-10-29-at-7.47.56-PM.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.980922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.078986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.818461",
        "ticker_sentiment_score": "0.060713",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.096671",
        "ticker_sentiment_score": "0.05253",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer  ( PFE )  Surpasses Q3 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2359235/pfizer-pfe-surpasses-q3-earnings-and-revenue-estimates",
    "time_published": "20241029T115504",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Pfizer (PFE) delivered earnings and revenue surprises of 65.62% and 16.53%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.148423,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.404563",
        "ticker_sentiment_score": "0.146695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.140485",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Passive Income ETFs for Your Retirement Strategy",
    "url": "https://www.fool.com/investing/2024/10/29/3-passive-income-etfs-for-your-retirement-strategy/",
    "time_published": "20241029T083000",
    "authors": [
      "George Budwell"
    ],
    "summary": "With Social Security's uncertain future, these three ETFs offer compelling income opportunities for retirement planning.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795539%2Fretirement.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999939"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.47552,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.191912",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TT",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.24897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.24897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "QCOM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.191912",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HPQ",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.24897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABNB",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HPE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SO",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.24897",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NUE",
        "relevance_score": "0.055109",
        "ticker_sentiment_score": "0.056855",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Novartis  ( NYSE:NVS ) ",
    "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni",
    "time_published": "20241030T191203",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% ( +10% on constant currency ) , beating the consensus of $12.76 billion. Guidance: Novartis also raised its 2024 full-year guidance again this year.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Stein--Switzerland---February-18--2020-N.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.222077,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KYMR",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INCY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.21686",
        "ticker_sentiment_score": "-0.123398",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.313386",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.073098",
        "ticker_sentiment_score": "-0.114885",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "YMAB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.050921",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.152993",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.145583",
        "ticker_sentiment_score": "0.117188",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Biogen  ( BIIB )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/30/biogen-biib-q3-2024-earnings-call-transcript/",
    "time_published": "20241030T174512",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "BIIB earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.249582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.004812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.004812",
        "ticker_sentiment_score": "-0.019182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.033676",
        "ticker_sentiment_score": "0.090799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.004812",
        "ticker_sentiment_score": "0.005549",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004812",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ESALF",
        "relevance_score": "0.028868",
        "ticker_sentiment_score": "0.090056",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.091235",
        "ticker_sentiment_score": "0.118426",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.004812",
        "ticker_sentiment_score": "0.153768",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday? - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/markets/cryptocurrency/24/10/41632224/wall-street-mixed-semiconductors-tumble-as-amd-disappoints-alphabet-rallies-smci-plummets-",
    "time_published": "20241030T173506",
    "authors": [
      "Piero Cingari"
    ],
    "summary": "Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. The U.S. economy grew at an annualized rate of 2.8% in the third quarter, according to advance estimates.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/semiconductor.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.838487"
      }
    ],
    "overall_sentiment_score": 0.193292,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.29601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MDLZ",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "META",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDDT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SMCI",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "-0.327517",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.071784",
        "ticker_sentiment_score": "0.383541",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SNAP",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ADP",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.13792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GRMN",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MSFT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "V",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAT",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMD",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.083351",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CMG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BKNG",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CB",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.142989",
        "ticker_sentiment_score": "0.222777",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Q3 2024 Earnings Call Transcript",
    "url": "https://www.fool.com/earnings/call-transcripts/2024/10/30/abbvie-abbv-q3-2024-earnings-call-transcript/",
    "time_published": "20241030T173019",
    "authors": [
      "Motley Fool Transcribing"
    ],
    "summary": "ABBV earnings call for the period ending September 30, 2024.",
    "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.304269,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.072052",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.047888",
        "ticker_sentiment_score": "0.089859",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCS",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.113875",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.008712",
        "ticker_sentiment_score": "-0.00529",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.004356",
        "ticker_sentiment_score": "0.079427",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.008712",
        "ticker_sentiment_score": "0.091949",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View",
    "url": "https://www.zacks.com/stock/news/2360933/abbvie-trumps-q3-earnings-sales-estimates-raises-24-eps-view",
    "time_published": "20241030T160500",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.947132"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.083128,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.445959",
        "ticker_sentiment_score": "0.292145",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.094204",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/10/41629098/abbvies-options-frenzy-what-you-need-to-know",
    "time_published": "20241030T153036",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730302233_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.211398,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.805127",
        "ticker_sentiment_score": "0.365507",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.073773",
        "ticker_sentiment_score": "0.082637",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/general/biotech/24/10/41626490/abbvie-tops-q3-expectations-as-skyrizi-rinvoq-drive-growth",
    "time_published": "20241030T141740",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Wednesday, AbbVie Inc. ABBV reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92. Net revenues reached $14.46 billion, up 3.8%, beating the consensus of $14.28 billion. Sales were up 4.9% on an operational basis.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/30/Galicia--Spain-June-8--2020--Smart-Phone.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.189127,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.645091",
        "ticker_sentiment_score": "0.243674",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Surpasses Q3 Earnings and Revenue Estimates",
    "url": "https://www.zacks.com/stock/news/2360394/abbvie-abbv-surpasses-q3-earnings-and-revenue-estimates",
    "time_published": "20241030T125002",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.74% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default7.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999992"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.159575,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SNDL",
        "relevance_score": "0.207571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.401331",
        "ticker_sentiment_score": "0.174265",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Growth Stocks to Buy and Never Sell",
    "url": "https://www.fool.com/investing/2024/10/30/3-dividend-growth-stocks-to-buy-and-never-sell/",
    "time_published": "20241030T110000",
    "authors": [
      "George Budwell"
    ],
    "summary": "These 3 dividend growth stocks have crushed the market and show no signs of slowing down.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795643%2Fdividends-alternative.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.998356"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      }
    ],
    "overall_sentiment_score": 0.5035,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "COST",
        "relevance_score": "0.272788",
        "ticker_sentiment_score": "0.301464",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.274489",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.165788",
        "ticker_sentiment_score": "0.325336",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Wednesday's big stock stories: What's likely to move the market in the next trading session",
    "url": "https://www.cnbc.com/2024/10/29/wednesdays-big-stock-stories-whats-likely-to-move-the-market.html",
    "time_published": "20241030T003015",
    "authors": [],
    "summary": "The Nasdaq Composite notched a fresh record on Tuesday ahead of earnings from tech's heavy hitters. Here's what CNBC is watching going into Wednesday.",
    "banner_image": null,
    "source": "CNBC",
    "category_within_source": "Investing",
    "source_domain": "www.cnbc.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.360215"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.067986,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TOL",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "-0.250824",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "META",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.024253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PHM",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NYT",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.101143",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DJT",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.153021",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.065506",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Market Analysis: AbbVie And Competitors In Biotechnology Industry - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/10/41656590/market-analysis-abbvie-and-competitors-in-biotechnology-industry",
    "time_published": "20241031T150054",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie ABBV against its key competitors in the ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730386850_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.875462"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.304228,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.471718",
        "ticker_sentiment_score": "0.413007",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41650384/cytomx-therapeutics-to-report-third-quarter-2024-financial-results-on-november-7-2024",
    "time_published": "20241031T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.109476,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.048799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.263942",
        "ticker_sentiment_score": "0.074256",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.048799",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.089462",
        "ticker_sentiment_score": "0.048799",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Body Contouring Devices Market to Hit USD 3.00 Billion by 2029 with 11.4% CAGR | MarketsandMarkets\u2122",
    "url": "https://www.benzinga.com/pressreleases/24/10/g41650447/body-contouring-devices-market-to-hit-usd-3-00-billion-by-2029-with-11-4-cagr-marketsandmarkets",
    "time_published": "20241031T120000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Delray Beach, FL, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- The global body contouring devices market is expected to grow from USD 1.74 billion in 2024 to USD 3.00 billion by 2029, at a CAGR of 11.4%.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.18632,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.109622",
        "ticker_sentiment_score": "0.102776",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BHC",
        "relevance_score": "0.073209",
        "ticker_sentiment_score": "0.100756",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VERO",
        "relevance_score": "0.036643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "INMD",
        "relevance_score": "0.109622",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CUTR",
        "relevance_score": "0.036643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2361385/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
    "time_published": "20241031T102007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default41.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999997"
      }
    ],
    "overall_sentiment_score": 0.28471,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.172097",
        "ticker_sentiment_score": "0.268594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.115232",
        "ticker_sentiment_score": "0.06109",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs",
    "url": "https://www.fool.com/investing/2024/10/31/5-dividend-stocks-to-double-up-on-right-now/",
    "time_published": "20241031T093000",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795426%2Fgetty-hiking-outdoors-beard.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999975"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.247253,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.033122",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.02202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "-0.02202",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.209389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.064112",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "O",
        "relevance_score": "0.11123",
        "ticker_sentiment_score": "0.060634",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus",
    "url": "https://www.zacks.com/stock/news/2362882/pharma-stock-roundup-mrk-pfe-abbv-nvs-llys-q3-earnings-in-focus",
    "time_published": "20241101T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.057517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.021907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.300292",
        "ticker_sentiment_score": "0.123993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034185",
        "ticker_sentiment_score": "-0.176359",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.102303",
        "ticker_sentiment_score": "0.03196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus",
    "url": "https://www.zacks.com/stock/news/2362882/pharma-stock-roundup-mrk-pfe-abbv-nvs-llys-q3-earnings-in-focus",
    "time_published": "20241101T190000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.057517,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.235823",
        "ticker_sentiment_score": "-0.021907",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.300292",
        "ticker_sentiment_score": "0.123993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.034185",
        "ticker_sentiment_score": "-0.176359",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.102303",
        "ticker_sentiment_score": "0.03196",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Price Over Earnings Overview: AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/41690485/price-over-earnings-overview-abbvie",
    "time_published": "20241101T161519",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "In the current session, the stock is trading at $201.74, after a 6.49% spike. Over the past month, AbbVie Inc. ABBV stock increased by 4.84%, and in the past year, by 44.26%.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730477716_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.213719,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.049877",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "5 Stocks That Recently Announced Dividend Hikes",
    "url": "https://www.zacks.com/stock/news/2362395/5-stocks-that-recently-announced-dividend-hikes",
    "time_published": "20241101T114400",
    "authors": [
      "Santanu Roy"
    ],
    "summary": "Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/06/2165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99793"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      }
    ],
    "overall_sentiment_score": 0.159974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ASB",
        "relevance_score": "0.286082",
        "ticker_sentiment_score": "0.195837",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HII",
        "relevance_score": "0.417611",
        "ticker_sentiment_score": "0.16102",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.375016",
        "ticker_sentiment_score": "0.215491",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BERY",
        "relevance_score": "0.417611",
        "ticker_sentiment_score": "0.221585",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "COP",
        "relevance_score": "0.331129",
        "ticker_sentiment_score": "0.257068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - Royalty Pharma  ( NASDAQ:RPRX ) , Syndax Pharmaceuticals  ( NASDAQ:SNDX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41727840/royalty-pharma-and-syndax-pharmaceuticals-enter-into-350-million-royalty-funding-agreement-for-nik",
    "time_published": "20241104T211500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.714479"
      }
    ],
    "overall_sentiment_score": 0.053146,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "INCY",
        "relevance_score": "0.089729",
        "ticker_sentiment_score": "0.095223",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNDX",
        "relevance_score": "0.053911",
        "ticker_sentiment_score": "0.063041",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.178328",
        "ticker_sentiment_score": "0.201616",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.017982",
        "ticker_sentiment_score": "0.069864",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.017982",
        "ticker_sentiment_score": "0.107696",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?",
    "url": "https://www.zacks.com/stock/news/2363742/buy-sell-or-hold-pfizer-stock-after-q3-earnings-beat-guidance-boost",
    "time_published": "20241104T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.997874"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.11984,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073659",
        "ticker_sentiment_score": "0.06273",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.56803",
        "ticker_sentiment_score": "0.164389",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BNTX",
        "relevance_score": "0.036869",
        "ticker_sentiment_score": "0.018702",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/11/41721022/heres-how-much-100-invested-in-abbvie-10-years-ago-would-be-worth-today",
    "time_published": "20241104T173019",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.39% on an annualized basis producing an average annual return of 12.18%. Currently, AbbVie has a market capitalization of $360.24 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730741416_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis",
    "url": "https://www.globenewswire.com/news-release/2024/11/04/2973708/0/en/OSE-Immunotherapeutics-Announces-Statistically-Significant-and-Clinically-Meaningful-Results-from-the-Phase-2-Study-of-Anti-IL7R-mAb-Lusvertikimab-for-the-Treatment-of-Ulcerative-C.html",
    "time_published": "20241104T063000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis \u2022 Lusvertikimab met the primary endpoint ( modified Mayo Score improvement ) at each dose tested during the ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.13695,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.077405",
        "ticker_sentiment_score": "0.083668",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41705558/ose-immunotherapeutics-announces-statistically-significant-and-clinically-meaningful-results-from-",
    "time_published": "20241104T063000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Lusvertikimab met the primary endpoint ( modified Mayo Score improvement ) at each dose tested during the 10 week-induction period of treatment in the randomized double-blind CoTikiS Phase 2 study.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.117092,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.066877",
        "ticker_sentiment_score": "-0.037457",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?",
    "url": "https://www.zacks.com/stock/news/2364704/whats-in-store-for-these-5-drug-biotech-stocks-in-q3-earnings",
    "time_published": "20241105T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.165079,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.288408",
        "ticker_sentiment_score": "0.017214",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.327366",
        "ticker_sentiment_score": "0.161772",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.056288",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.125898",
        "ticker_sentiment_score": "-0.034524",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.167322",
        "ticker_sentiment_score": "-0.040624",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.288408",
        "ticker_sentiment_score": "0.065467",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.042122",
        "ticker_sentiment_score": "0.056288",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Most-Watched Stock AbbVie Inc.  ( ABBV )  Worth Betting on Now?",
    "url": "https://www.zacks.com/stock/news/2364192/is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now",
    "time_published": "20241105T140019",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default266.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.221911,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.49407",
        "ticker_sentiment_score": "0.120516",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What the Options Market Tells Us About AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41782029/what-the-options-market-tells-us-about-abbvie",
    "time_published": "20241106T174715",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 11 unusual trades. Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1730915232_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.192192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.081001",
        "ticker_sentiment_score": "0.053084",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.845475",
        "ticker_sentiment_score": "0.252504",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.16117",
        "ticker_sentiment_score": "0.069618",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Genmab Announces Financial Results for the First Nine Months of 2024",
    "url": "https://www.globenewswire.com/news-release/2024/11/06/2975872/0/en/Genmab-Announces-Financial-Results-for-the-First-Nine-Months-of-2024.html",
    "time_published": "20241106T160200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "November 6, 2024 Copenhagen, Denmark. Interim Report for the First Nine Months Ended September ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.129413,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "NVS",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.117678",
        "ticker_sentiment_score": "0.071725",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GMAB",
        "relevance_score": "0.44622",
        "ticker_sentiment_score": "0.106738",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.039353",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Dividend Watch: Three Companies Boosting Quarterly Payouts",
    "url": "https://www.zacks.com/commentary/2366798/dividend-watch-three-companies-boosting-quarterly-payouts",
    "time_published": "20241107T214700",
    "authors": [
      "Derek Lewis"
    ],
    "summary": "Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/50121.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.458286,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FIX",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "0.322757",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.339356",
        "ticker_sentiment_score": "0.333606",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.230235",
        "ticker_sentiment_score": "0.148342",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "RHHBY or ABBV: Which Is the Better Value Stock Right Now?",
    "url": "https://www.zacks.com/stock/news/2366649/rhhby-or-abbv-which-is-the-better-value-stock-right-now",
    "time_published": "20241107T164013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "RHHBY vs. ABBV: Which Stock Is the Better Value Option?",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default86.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.4682,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.616447",
        "ticker_sentiment_score": "0.535074",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema",
    "url": "https://www.globenewswire.com/news-release/2024/11/07/2976768/0/en/Clearside-Biomedical-Partner-Arctic-Vision-Executes-Commercial-Collaboration-Agreement-with-Santen-Pharmaceutical-Co-Ltd-for-ARVN001-Suprachoroidal-Space-Injection-Therapy-for-the-.html",
    "time_published": "20241107T140500",
    "authors": [
      "Clearside Biomedical",
      "Inc."
    ],
    "summary": "- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6eac24f1-af2b-45eb-9777-0ea32dfc73b8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.261713,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CLSD",
        "relevance_score": "0.088909",
        "ticker_sentiment_score": "0.143331",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNPHF",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.141023",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BCRX",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.138123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BLCO",
        "relevance_score": "0.088909",
        "ticker_sentiment_score": "0.169304",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RGNX",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.138123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.138123",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AURA",
        "relevance_score": "0.029691",
        "ticker_sentiment_score": "0.138123",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - Royalty Pharma  ( NASDAQ:RPRX ) , Geron  ( NASDAQ:GERN ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41803153/royalty-pharma-to-acquire-royalty-interest-in-gerons-rytelo-for-125-million",
    "time_published": "20241107T121000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "RYTELO\u2122 ( imetelstat ) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia Transaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.77141"
      }
    ],
    "overall_sentiment_score": 0.136711,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "RPRX",
        "relevance_score": "0.376624",
        "ticker_sentiment_score": "0.250156",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035608",
        "ticker_sentiment_score": "0.077131",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GERN",
        "relevance_score": "0.176631",
        "ticker_sentiment_score": "0.094614",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Novo Nordisk  ( NYSE:NVO ) , Merck & Co  ( NYSE:MRK ) , Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordis",
    "time_published": "20241108T193505",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/08/Wegovy.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.263867,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVO",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "-0.288291",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ALNY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.292055",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GLDAF",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.112666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "-0.186951",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.211306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.318081",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.221481",
        "ticker_sentiment_score": "0.230164",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.148731",
        "ticker_sentiment_score": "0.116145",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down",
    "url": "https://www.zacks.com/stock/news/2367601/ironwoods-q3-earnings-lag-estimates-revenues-top-stock-down",
    "time_published": "20241108T160300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.993781"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.01914,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALPMF",
        "relevance_score": "0.051551",
        "ticker_sentiment_score": "0.142461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.153797",
        "ticker_sentiment_score": "0.102714",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IRWD",
        "relevance_score": "0.253514",
        "ticker_sentiment_score": "0.049307",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.101616",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LSTA",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.087692",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Arcellx  ( ACLX )  Outperforming Other Medical Stocks This Year?",
    "url": "https://www.zacks.com/stock/news/2367446/is-arcellx-aclx-outperforming-other-medical-stocks-this-year",
    "time_published": "20241108T144011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.253974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ACLX",
        "relevance_score": "0.755492",
        "ticker_sentiment_score": "0.460856",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.121331",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street Bulls Look Optimistic About AbbVie  ( ABBV ) : Should You Buy?",
    "url": "https://www.zacks.com/stock/news/2367388/wall-street-bulls-look-optimistic-about-abbvie-abbv-should-you-buy",
    "time_published": "20241108T143011",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_11082024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.329432,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.365294",
        "ticker_sentiment_score": "0.235285",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today",
    "url": "https://www.zacks.com/stock/news/2367250/heres-how-much-a-1000-investment-in-halozyme-therapeutics-made-10-years-ago-would-be-worth-today",
    "time_published": "20241108T133006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      }
    ],
    "overall_sentiment_score": 0.217232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HALO",
        "relevance_score": "0.469253",
        "ticker_sentiment_score": "0.322026",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.071357",
        "ticker_sentiment_score": "0.043195",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Zacks Investment Ideas feature highlights: AbbVie, Visa and Comfort Systems USA",
    "url": "https://www.zacks.com/stock/news/2367165/zacks-investment-ideas-feature-highlights-abbvie-visa-and-comfort-systems-usa",
    "time_published": "20241108T122400",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie, Visa and Comfort Systems USA are part of the Zacks Investment Ideas article.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/af/643.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.46586,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "FIX",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.265063",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "V",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.272726",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167709",
        "ticker_sentiment_score": "0.050213",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 Dividend Kings That Would Have Doubled Your Money in 5 Years",
    "url": "https://www.fool.com/investing/2024/11/08/2-dividend-kings-that-would-have-doubled-your-mone/",
    "time_published": "20241108T100000",
    "authors": [
      "David Jagielski"
    ],
    "summary": "You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796253/investor-calculating-stock-returns-on-a-calculator.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.348232,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VZIO",
        "relevance_score": "0.069495",
        "ticker_sentiment_score": "0.16787",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.373076",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.138464",
        "ticker_sentiment_score": "0.141165",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMT",
        "relevance_score": "0.514619",
        "ticker_sentiment_score": "0.396988",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "My Favorite Dividend King to Buy in November",
    "url": "https://www.fool.com/investing/2024/11/09/abbvie/",
    "time_published": "20241109T104800",
    "authors": [
      "Keith Speights"
    ],
    "summary": "This Dividend King truly wears the crown.",
    "banner_image": "https://g.foolcdn.com/editorial/images/796634/king-chess-piece-held-by-woman.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.335795,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.564693",
        "ticker_sentiment_score": "0.458944",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.05654",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Spectacular High-Yield Dividend Stocks to Buy in November",
    "url": "https://www.fool.com/investing/2024/11/10/spectacular-high-yield-dividend-stocks-to-buy-in/",
    "time_published": "20241110T143000",
    "authors": [
      "David Jagielski",
      "and Prosper Junior Bakiny",
      "Keith Speights"
    ],
    "summary": "High yields aren't a warning indicator with these three stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797003/scientists-in-a-lab-monitor-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999922"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.293865,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.361407",
        "ticker_sentiment_score": "0.434985",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.046816",
        "ticker_sentiment_score": "0.178476",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.402761",
        "ticker_sentiment_score": "0.326656",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.230892",
        "ticker_sentiment_score": "0.281124",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why AbbVie Stock Was Getting Mashed on Monday",
    "url": "https://www.fool.com/investing/2024/11/11/why-abbvie-stock-was-getting-mashed-on-monday/",
    "time_published": "20241111T202246",
    "authors": [
      "Eric Volkman"
    ],
    "summary": "A splashy recent acquisition by the company might not be panning out.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797456/person-in-a-lab-gazing-into-a-microscope.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.026567,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.600602",
        "ticker_sentiment_score": "0.053913",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "What's Going On With Bristol-Myers Squibb Shares Monday? - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/trading-ideas/movers/24/11/41885969/whats-going-on-with-bristol-myers-squibb-shares-monday",
    "time_published": "20241111T184824",
    "authors": [
      "Dylan Berman"
    ],
    "summary": "Bristol-Myers Squibb Co BMY shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc ABBV announced that its Phase 2 EMPOWER trials did not meet their primary endpoints.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/02-LVL-Exterior-Sign-101520-media.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.330251,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.52706",
        "ticker_sentiment_score": "0.210718",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.610896",
        "ticker_sentiment_score": "0.546991",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41885894/this-is-what-whales-are-betting-on-abbvie",
    "time_published": "20241111T184652",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731350809_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.989041"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.189632,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.021212",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.840758",
        "ticker_sentiment_score": "0.292652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.070105",
        "ticker_sentiment_score": "0.021212",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappr",
    "time_published": "20241111T175156",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/Galicia--Spain-June-8--2020--Smart-Phone.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.121284,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.33628",
        "ticker_sentiment_score": "-0.352805",
        "ticker_sentiment_label": "Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.228073",
        "ticker_sentiment_score": "-0.035589",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges",
    "time_published": "20241111T152731",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia. The trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.09307,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.443626",
        "ticker_sentiment_score": "-0.165105",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.275867",
        "ticker_sentiment_score": "0.107884",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday - MARA Holdings  ( NASDAQ:MARA ) ",
    "url": "https://www.benzinga.com/24/11/41880495/mara-holdings-radnet-bit-digital-coinbase-and-other-big-stocks-moving-higher-on-monday",
    "time_published": "20241111T151425",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday. Shares of MARA Holdings, Inc. MARA rose sharply during Monday's session amid strength in Bitcoin. Prices for Bitcoin surged above the $82,000 level on Monday. MARA Holdings shares jumped 17.3% to $22.59 on ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/Bitcoin-WULF-MARA-MSTR-COIN-HUT.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.25"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.392611,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HUM",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CI",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HIMS",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.562626",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HUT",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.356942",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.115455",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CANG",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.562626",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "RXRX",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.175934",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "NNOX",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COIN",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.446058",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.271575",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IREN",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.149077",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAN",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.18965",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RIOT",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BTBT",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.574847",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "HOOD",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.179869",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AFRM",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RDNT",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.403776",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "BTDR",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "0.410124",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.708701",
        "ticker_sentiment_score": "0.594638",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.11983",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio",
    "time_published": "20241112T185244",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.18048,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.4499",
        "ticker_sentiment_score": "-0.174759",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "-0.071461",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NBIX",
        "relevance_score": "0.188928",
        "ticker_sentiment_score": "-0.035889",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock",
    "time_published": "20241112T174839",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy ( a schizophrenia drug ) and milvexian ( anticoagulant ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/02-LVL-Exterior-Sign-101520-media.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.086575,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.04032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "-0.333455",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.31482",
        "ticker_sentiment_score": "0.142037",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
    "url": "https://www.zacks.com/stock/news/2368841/abbvie-stock-declines-as-schizophrenia-studies-fail-bmy-gains",
    "time_published": "20241112T143000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.128822,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALLO",
        "relevance_score": "0.254973",
        "ticker_sentiment_score": "0.123272",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.48457",
        "ticker_sentiment_score": "0.174106",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BIIB",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.075917",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.192694",
        "ticker_sentiment_score": "-0.166421",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer",
    "url": "https://www.benzinga.com/pressreleases/24/11/g41898642/kailera-therapeutics-appoints-scott-m-akamine-as-chief-legal-officer",
    "time_published": "20241112T130014",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "BOSTON and SAN DIEGO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointment of Scott M.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.272582,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.083251",
        "ticker_sentiment_score": "0.060233",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Company News for Nov 12, 2024",
    "url": "https://www.zacks.com/stock/news/2368572/company-news-for-nov-12-2024",
    "time_published": "20241112T121300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Companies In The News Are: ICL, ARMK, ABBV, SPNS.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": -0.00491,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ARMK",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "-0.298045",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.154717",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ICL",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "0.414847",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SPNS",
        "relevance_score": "0.588876",
        "ticker_sentiment_score": "-0.333173",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Smart Money Is Betting Big In ABBV Options - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/41948590/smart-money-is-betting-big-in-abbv-options",
    "time_published": "20241113T174530",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 33% ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1731519926_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.225301,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.686739",
        "ticker_sentiment_score": "0.377712",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "2 Dividend Stocks to Buy Hand Over Fist in November",
    "url": "https://www.fool.com/investing/2024/11/14/2-dividend-stocks-to-buy-hand-over-fist-november/",
    "time_published": "20241114T151500",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "These companies have solid businesses and excellent dividend growth track records.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797409/pharmacist-talking-to-patient.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938793"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.30695,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.528798",
        "ticker_sentiment_score": "0.274951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.399734",
        "ticker_sentiment_score": "0.306577",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.052226",
        "ticker_sentiment_score": "0.023093",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AbbVie  ( NYSE:ABBV ) , Pfizer  ( NYSE:PFE ) ",
    "url": "https://www.benzinga.com/partner/biotech/24/11/41968977/tonix-pharmaceuticals-targets-rapid-migraine-relief-with-non-oral-treatments",
    "time_published": "20241114T123055",
    "authors": [
      "Mangeet Kaur Bouns"
    ],
    "summary": "This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Screenshot-2024-11-13-at-11-54-41PM.png?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": -0.061313,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "-0.031136",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSSMY",
        "relevance_score": "0.021718",
        "ticker_sentiment_score": "-0.109327",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TNXP",
        "relevance_score": "0.086713",
        "ticker_sentiment_score": "0.198335",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.043421",
        "ticker_sentiment_score": "-0.031136",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback",
    "url": "https://www.zacks.com/stock/news/2371249/pharma-stock-roundup-azn-bayrys-earnings-abbvs-pipeline-setback",
    "time_published": "20241115T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.055653,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AKESF",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.044",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.236972",
        "ticker_sentiment_score": "-0.037184",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.348919",
        "ticker_sentiment_score": "0.159153",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SMMT",
        "relevance_score": "0.040078",
        "ticker_sentiment_score": "0.044",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2371100/abbvie-stock-falls-11-in-a-month-should-you-buy-the-dip",
    "time_published": "20241115T150800",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.904684"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.234354,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.082567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.068112",
        "ticker_sentiment_score": "0.082567",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.674346",
        "ticker_sentiment_score": "0.376455",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42009841/tremfyas-promising-debut-boosts-momentum-for-il-23-class-in-ulcerative-colitis-treatment-according",
    "time_published": "20241115T143834",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "EXTON, PA, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- In what has been a transformative year for ulcerative colitis ( UC ) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.285679,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.073905",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.054236",
        "ticker_sentiment_score": "0.073905",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' - Baker Hughes  ( NASDAQ:BKR ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/24/11/42009260/abbvie-bitcoin-and-an-energy-stock-on-cnbcs-final-trades",
    "time_published": "20241115T141840",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "On CNBC's \"Halftime Report Final Trades,\" Jason Snipe of Odyssey Capital Advisors picked AbbVie Inc. ABBV. On Monday, AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/15/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.12762,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BKR",
        "relevance_score": "0.592742",
        "ticker_sentiment_score": "0.31361",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.492659",
        "ticker_sentiment_score": "-0.045156",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "C",
        "relevance_score": "0.131643",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.492659",
        "ticker_sentiment_score": "0.006495",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2370779/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
    "time_published": "20241115T112006",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default33.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.25"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.25"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.25"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.25"
      }
    ],
    "overall_sentiment_score": 0.238152,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MORN",
        "relevance_score": "0.238718",
        "ticker_sentiment_score": "0.205048",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.067941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.067941",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.120733",
        "ticker_sentiment_score": "0.067941",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42003353/protein-therapeutics-market-size-to-be-worth-usd-549-4-billion-by-2031-at-a-cagr-of-6-3-transparen",
    "time_published": "20241115T110000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- The protein therapeutics market ( \ub2e8\ubc31\uc9c8 \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was valued at US$ 318.4 billion in 2022. A CAGR of 6.3% is predicted from 2023 to 2031, reaching more than US$ 549.4 billion by 2031.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ba7b98d3-0c98-4dd7-95c7-ac0441eebbed/protein-therapeutics-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.172406,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "0.052816",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.153487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.153487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.01095",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.153487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.101121",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.068698",
        "ticker_sentiment_score": "-0.075839",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.153487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.034381",
        "ticker_sentiment_score": "-0.153487",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock",
    "url": "https://www.fool.com/investing/2024/11/15/got-1500-to-invest-abbvie-just-proved-the-bull-the/",
    "time_published": "20241115T105000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "The drugmaker has convincingly laid to rest the biggest threat to its top line.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797564/scientists-lab-testing-blood-draw2.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.990893"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.796627"
      }
    ],
    "overall_sentiment_score": 0.164803,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.334008",
        "ticker_sentiment_score": "0.13892",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom - Broadcom  ( NASDAQ:AVGO ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-posit",
    "time_published": "20241115T001326",
    "authors": [
      "Chris Katje"
    ],
    "summary": "A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election. Third Quarter Exits: Viking Fund Management sold out of eight stocks completely in the third quarter, including ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Stuttgart--Germany---08-20-2023-Person-H.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.152826,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ETR",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.395012",
        "ticker_sentiment_score": "0.217509",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "DINO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NTR",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.131969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ES",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "OVV",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NEE",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QSR",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TPL",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "POR",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GTLS",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "KGS",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.192901",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RIO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.410103",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SCCO",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SM",
        "relevance_score": "0.204072",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GE",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.131969",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOREX:USD",
        "relevance_score": "0.102888",
        "ticker_sentiment_score": "0.08133",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe",
    "url": "https://www.zacks.com/stock/news/2371626/abbvies-ovarian-cancer-drug-elahere-gets-approval-in-europe",
    "time_published": "20241118T151700",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.127468,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IMCR",
        "relevance_score": "0.188193",
        "ticker_sentiment_score": "0.029373",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ANIP",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.255574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.308504",
        "ticker_sentiment_score": "0.03441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.249106",
        "ticker_sentiment_score": "0.088962",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/11/18/why-this-beaten-down-dividend-stock-is-no-brainer/",
    "time_published": "20241118T120000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "Last year, pharmaceutical giant AbbVie ( NYSE: ABBV ) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line growth in the second quarter, much earlier than many anticipated.",
    "banner_image": "https://media.ycharts.com/charts/b63c3632776abbc24451d4797e859620.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.097256,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.624578",
        "ticker_sentiment_score": "0.054928",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap",
    "url": "https://www.zacks.com/stock/news/2372244/aldx-up-as-fda-accepts-resubmitted-nda-for-eye-drug-reproxalap",
    "time_published": "20241119T150000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.769861"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.142283,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ALDX",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.157292",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IMCR",
        "relevance_score": "0.174587",
        "ticker_sentiment_score": "0.029381",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.491878",
        "ticker_sentiment_score": "0.406234",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.231332",
        "ticker_sentiment_score": "0.091154",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Where Will AbbVie Be in 5 Years?",
    "url": "https://www.fool.com/investing/2024/11/19/where-will-abbvie-be-in-5-years/",
    "time_published": "20241119T150000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie ( NYSE: ABBV ) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/797891/two-investors-put-sticky-notes-on-glass-wall.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.133862,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.375251",
        "ticker_sentiment_score": "-0.031926",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Unpacking the Latest Options Trading Trends in AbbVie - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42095848/unpacking-the-latest-options-trading-trends-in-abbvie",
    "time_published": "20241120T180037",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732125634_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.413559"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.183212,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.033958",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.682689",
        "ticker_sentiment_score": "0.206552",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.079656",
        "ticker_sentiment_score": "0.025698",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Trending Stock AbbVie Inc.  ( ABBV )  a Buy Now?",
    "url": "https://www.zacks.com/stock/news/2372624/is-trending-stock-abbvie-inc-abbv-a-buy-now",
    "time_published": "20241120T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.202136,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.491255",
        "ticker_sentiment_score": "0.083741",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is Bristol Myers Squibb Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/11/21/is-bristol-myers-squibb-stock-a-buy/",
    "time_published": "20241121T130000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "It's been a challenging past few years for Bristol Myers Squibb ( NYSE: BMY ) . The company's financial results dipped following the loss of patent exclusivity of two important medicines in its arsenal: cancer drugs Revlimid ( its former top-selling product ) and Abraxane.",
    "banner_image": "https://g.foolcdn.com/editorial/images/797903/doctor-with-patient-talking.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.929393"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.360215"
      }
    ],
    "overall_sentiment_score": 0.147036,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.063258",
        "ticker_sentiment_score": "-0.064333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.126119",
        "ticker_sentiment_score": "-0.022871",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View",
    "url": "https://www.zacks.com/stock/news/2374304/pharma-stock-roundup-eu-nod-for-pfes-hympavzi-nvs-ups-sales-view",
    "time_published": "20241122T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.169194,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.17879",
        "ticker_sentiment_score": "0.136826",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "-0.128118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.17879",
        "ticker_sentiment_score": "0.131993",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.045054",
        "ticker_sentiment_score": "-0.128118",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.089965",
        "ticker_sentiment_score": "0.139626",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - AbbVie  ( NYSE:ABBV ) , Elastic  ( NYSE:ESTC ) ",
    "url": "https://www.benzinga.com/24/11/42137270/this-elastic-analyst-turns-bullish-here-are-top-5-upgrades-for-friday",
    "time_published": "20241122T134126",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.392072,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "RBC",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.414187",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.478149",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "SAH",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.367035",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "FLS",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.478149",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ESTC",
        "relevance_score": "0.379051",
        "ticker_sentiment_score": "0.478149",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys",
    "url": "https://www.fool.com/investing/2024/11/23/the-stock-market-is-soaring-but-these-2-stocks-are/",
    "time_published": "20241123T141700",
    "authors": [
      "David Jagielski"
    ],
    "summary": "Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in the index is trading at more than 25 times earnings. However, there are still many deals out ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/798057/investor-at-home-looking-at-multiple-charts.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998663"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.209403,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.445352",
        "ticker_sentiment_score": "0.267213",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "CCZ",
        "relevance_score": "0.25726",
        "ticker_sentiment_score": "0.165724",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "3 Dividend Stocks That Are Screaming Buys in November",
    "url": "https://www.fool.com/investing/2024/11/23/dividend-stocks-that-are-screaming-buys-november/",
    "time_published": "20241123T122000",
    "authors": [
      "Justin Pope"
    ],
    "summary": "Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.",
    "banner_image": "https://g.foolcdn.com/editorial/images/798476/healthcare-consulting.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.972193"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.692272"
      }
    ],
    "overall_sentiment_score": 0.179363,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.329237",
        "ticker_sentiment_score": "0.034308",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.329237",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.28442",
        "ticker_sentiment_score": "0.319877",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
    "url": "https://www.zacks.com/stock/news/2374957/abbvie-stock-rises-after-leerink-partners-upgrades-its-rating",
    "time_published": "20241125T200000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.207105,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.138997",
        "ticker_sentiment_score": "0.092227",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.70655",
        "ticker_sentiment_score": "0.331203",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Market Whales and Their Recent Bets on ABBV Options - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42171031/market-whales-and-their-recent-bets-on-abbv-options",
    "time_published": "20241125T180037",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 38% of traders were bullish, while 53% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732557634_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.221777,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.653656",
        "ticker_sentiment_score": "0.1653",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "url": "https://www.zacks.com/stock/news/2374611/jj-seeks-fda-nod-for-subcutaneous-tremfya-as-induction-regimen-in-uc",
    "time_published": "20241125T140800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.260148,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.243306",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.158519",
        "ticker_sentiment_score": "0.274495",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.200519",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce - Alector  ( NASDAQ:ALEC ) ",
    "url": "https://www.benzinga.com/24/11/42192908/alectorabbvie-partnered-alzheimers-drug-disappoints-in-mid-stage-study-lays-off-17-of-workforce",
    "time_published": "20241126T152905",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/26/Understanding-Alzheimers.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.061995,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GSK",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.246999",
        "ticker_sentiment_score": "0.08399",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.537213",
        "ticker_sentiment_score": "0.013123",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
    "url": "https://www.fool.com/investing/2024/11/26/2-high-yield-dividend-stocks-to-buy-now-for-a-life/",
    "time_published": "20241126T100300",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the ...",
    "banner_image": "https://media.ycharts.com/charts/34d49543d4741856f5330321da34b958.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.220953,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "BHVN",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.098877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.273399",
        "ticker_sentiment_score": "0.08876",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055751",
        "ticker_sentiment_score": "0.102879",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.37552",
        "ticker_sentiment_score": "0.427768",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Upcoming Investor Conferences",
    "url": "https://www.globenewswire.com/news-release/2024/11/27/2988444/0/en/Royalty-Pharma-to-Present-at-Upcoming-Investor-Conferences.html",
    "time_published": "20241127T211500",
    "authors": [
      "Royalty Pharma plc"
    ],
    "summary": "NEW YORK, Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the month of December: ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.142583,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.645516",
        "ticker_sentiment_score": "0.209242",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "0.097661",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma  ( NASDAQ:RPRX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42224599/royalty-pharma-to-present-at-upcoming-investor-conferences",
    "time_published": "20241127T211500",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "NEW YORK, Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the month of December: 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.177417,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EVR",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.587597",
        "ticker_sentiment_score": "0.225785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.091543",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42212288/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference",
    "time_published": "20241127T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc.",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.109565,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.041182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.259267",
        "ticker_sentiment_score": "0.063415",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.041182",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.087824",
        "ticker_sentiment_score": "0.041182",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference",
    "url": "https://www.globenewswire.com/news-release/2024/11/27/2988176/37704/en/CytomX-Therapeutics-to-Present-at-the-36th-Annual-Piper-Sandler-Healthcare-Conference.html",
    "time_published": "20241127T130000",
    "authors": [
      "CytomX Therapeutics Inc."
    ],
    "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.09784,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.047068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.210274",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MRNA",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.047068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.10607",
        "ticker_sentiment_score": "0.047068",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
    "url": "https://www.zacks.com/stock/news/2375772/should-you-invest-in-the-vanguard-health-care-etf-vht",
    "time_published": "20241127T112007",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.261648,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPGI",
        "relevance_score": "0.069094",
        "ticker_sentiment_score": "0.125983",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "UNH",
        "relevance_score": "0.137671",
        "ticker_sentiment_score": "0.065088",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology",
    "url": "https://www.benzinga.com/pressreleases/24/11/g42205102/personalized-medicines-market-to-surpass-valuation-of-usd-1352-81-billion-by-2031-skyquest-technol",
    "time_published": "20241127T003000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Westford, USA, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the global personalized medicines market size will reach a value of USD 1352.81 Billion by 2031, with a CAGR of 11.40% during the forecast period ( 2024-2031 ) .",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.412525,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MOLN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDXH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PSNL",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "EXAS",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIO",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SOPH",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MYGN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "QGEN",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TAK",
        "relevance_score": "0.043979",
        "ticker_sentiment_score": "0.029234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",
    "url": "https://www.zacks.com/stock/news/2377348/pharma-stock-roundup-rhhby-to-buy-pstx-mrk-azn-see-pipeline-success",
    "time_published": "20241129T200000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.131987,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PSTX",
        "relevance_score": "0.191549",
        "ticker_sentiment_score": "0.118333",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.096477",
        "ticker_sentiment_score": "-0.073587",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.144275",
        "ticker_sentiment_score": "0.067967",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.048327",
        "ticker_sentiment_score": "-0.128896",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Spotlight on AbbVie: Analyzing the Surge in Options Activity - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/11/42250104/spotlight-on-abbvie-analyzing-the-surge-in-options-activity",
    "time_published": "20241129T191541",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1732907738_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.195096,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.627711",
        "ticker_sentiment_score": "0.173201",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Why Is AbbVie  ( ABBV )  Down 10.2% Since Last Earnings Report?",
    "url": "https://www.zacks.com/stock/news/2377271/why-is-abbvie-abbv-down-102-since-last-earnings-report",
    "time_published": "20241129T163142",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.998287"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.098416,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.302314",
        "ticker_sentiment_score": "0.185561",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Go Beyond MAGS ETF: Tap Broadening of the Rally With TOPT ETF",
    "url": "https://www.zacks.com/stock/news/2376875/go-beyond-mags-etf-tap-broadening-of-the-rally-with-topt-etf",
    "time_published": "20241129T130000",
    "authors": [
      "Sanghamitra Saha"
    ],
    "summary": "iShares launched TOPT ETF last month. The new ETF offers exposure to Mag-7 stocks while some more U.S. biggies with value focus get a place in TOPT.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/1042.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999326"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.251766,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MSFT",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.143395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.129168",
        "ticker_sentiment_score": "0.143395",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVGO",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.242652",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BRK-A",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.064797",
        "ticker_sentiment_score": "0.034091",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/11/30/want-decades-of-passive-income-3-stocks-to-buy-now/",
    "time_published": "20241130T104100",
    "authors": [
      "Keith Speights"
    ],
    "summary": "What's better than receiving passive income? Enjoying it for decades.Generating long-term passive income is easier than you might think. Here are three stocks to buy now and hold forever for a lifetime of dividends.Let's start with some bona fide dividend royalty.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799307/passive-income.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.650727"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.338842,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MFCSF",
        "relevance_score": "0.061159",
        "ticker_sentiment_score": "0.221149",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.408791",
        "ticker_sentiment_score": "0.341068",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VZ",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.358505",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "O",
        "relevance_score": "0.182047",
        "ticker_sentiment_score": "0.144005",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later",
    "url": "https://www.fool.com/investing/2024/12/01/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/",
    "time_published": "20241201T105200",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.Which dividend stocks are great picks right now? Here's why three Fool.com contributors chose AbbVie ( NYSE: ABBV ) , Johnson & Johnson ( ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/799375/dividends-blackboard-sketch-doodle.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.623304"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.857896"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.221663,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.260652",
        "ticker_sentiment_score": "0.131004",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.382274",
        "ticker_sentiment_score": "0.451133",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.342685",
        "ticker_sentiment_score": "0.199546",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is First Trust Capital Strength ETF  ( FTCS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2377716/is-first-trust-capital-strength-etf-ftcs-a-strong-etf-right-now",
    "time_published": "20241202T181834",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999892"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.310843"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.295914,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "EA",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PKG",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.066792",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "OSE Immunotherapeutics Strengthens Leadership and Executive Committee",
    "url": "https://www.globenewswire.com/news-release/2024/12/02/2989994/0/en/OSE-Immunotherapeutics-Strengthens-Leadership-and-Executive-Committee.html",
    "time_published": "20241202T170000",
    "authors": [
      "OSE Immunotherapeutics"
    ],
    "summary": "NANTES, France, December 2, 2024 - 6:00pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173. Mnemo: OSE ) , today announced that it has strengthened the company's leadership and executive team with two new appointments.",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.312743,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "OMC",
        "relevance_score": "0.027635",
        "ticker_sentiment_score": "0.098708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.027635",
        "ticker_sentiment_score": "0.098708",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.027635",
        "ticker_sentiment_score": "0.098708",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",
    "url": "https://www.zacks.com/stock/news/2377440/the-zacks-analyst-blog-highlights-roche-poseida-therapeutics-merck-astrazeneca-and-novartis",
    "time_published": "20241202T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.119975,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "PSTX",
        "relevance_score": "0.187827",
        "ticker_sentiment_score": "0.097997",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.094576",
        "ticker_sentiment_score": "-0.073236",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.141448",
        "ticker_sentiment_score": "0.032951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.047371",
        "ticker_sentiment_score": "-0.12869",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected",
    "url": "https://www.globenewswire.com/news-release/2024/12/02/2989439/0/en/Nicox-s-Denali-Phase-3-Trial-of-NCX-470-Fully-Enrolled-in-China-Earlier-than-Expected.html",
    "time_published": "20241202T063000",
    "authors": [
      "NICOX SA"
    ],
    "summary": "Attachment ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c4c68e53-e467-4048-b580-d1596c4d6d8e",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.161652,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.054483",
        "ticker_sentiment_score": "-0.039026",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NICXF",
        "relevance_score": "0.215415",
        "ticker_sentiment_score": "0.164846",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
    "url": "https://www.zacks.com/stock/news/2378140/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
    "time_published": "20241203T140018",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default304.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.217351,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.484798",
        "ticker_sentiment_score": "0.107282",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
    "url": "https://www.zacks.com/stock/news/2378129/jj-seeks-fda-approval-for-tremfya-for-psoriasis-in-kids",
    "time_published": "20241203T135800",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.270878,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.221839",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.172527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RXDX",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.036",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.055492",
        "ticker_sentiment_score": "0.109865",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.219312",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.110717",
        "ticker_sentiment_score": "0.088801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/24/12/42287319/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields",
    "time_published": "20241203T123949",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.13736,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.155275",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "-0.052159",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PDCO",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "0.104572",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MS",
        "relevance_score": "0.089129",
        "ticker_sentiment_score": "-0.054715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.17715",
        "ticker_sentiment_score": "-0.189582",
        "ticker_sentiment_label": "Somewhat-Bearish"
      }
    ]
  },
  {
    "title": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
    "url": "https://www.fool.com/investing/2024/12/03/3-high-yield-dividend-growth-stocks-to-buy-in-dece/",
    "time_published": "20241203T092400",
    "authors": [
      "Cory Renauer"
    ],
    "summary": "It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) index rose a whopping 57.1% higher.During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.",
    "banner_image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999701"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.275012,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.156113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "RPRX",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.173649",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.196212",
        "ticker_sentiment_score": "0.163973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.049526",
        "ticker_sentiment_score": "0.149845",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BIPC",
        "relevance_score": "0.380736",
        "ticker_sentiment_score": "0.427828",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42324626/check-out-what-whales-are-doing-with-abbv",
    "time_published": "20241204T194604",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 30% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1733341561_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.2646,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.079921",
        "ticker_sentiment_score": "0.119497",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.684305",
        "ticker_sentiment_score": "0.335951",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Alector  ( NASDAQ:ALEC ) ",
    "url": "https://www.benzinga.com/24/12/42324144/neurology-focused-alector-downgraded-on-failed-alzheimers-study-bofa-securities-highlights-lack-of-catalysts",
    "time_published": "20241204T192042",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program. Alector recently released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/04/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.684621"
      }
    ],
    "overall_sentiment_score": 0.126421,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "BAC",
        "relevance_score": "0.107495",
        "ticker_sentiment_score": "-0.077788",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.213048",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ALEC",
        "relevance_score": "0.500753",
        "ticker_sentiment_score": "0.172942",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
    "url": "https://www.zacks.com/stock/news/2379130/mercks-adc-drug-gets-fda-breakthrough-therapy-tag-in-nsclc",
    "time_published": "20241204T174000",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.108037,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "SKXJF",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.018258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.170075",
        "ticker_sentiment_score": "0.093815",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.113866",
        "ticker_sentiment_score": "0.018258",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.225425",
        "ticker_sentiment_score": "0.102255",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.279653",
        "ticker_sentiment_score": "0.116234",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?",
    "url": "https://www.zacks.com/stock/news/2379380/pfizer-stock-falls-8-in-a-month-should-you-buy-the-dip",
    "time_published": "20241205T133000",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.818451"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.065336,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.146916",
        "ticker_sentiment_score": "-0.074164",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "0.074854",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.098255",
        "ticker_sentiment_score": "-0.061694",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.462953",
        "ticker_sentiment_score": "0.149125",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "FDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/12/05/2992057/0/en/FDA-accepts-supplemental-Biologics-License-Application-for-Roche-s-Columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html",
    "time_published": "20241205T060000",
    "authors": [
      "F. Hoffmann-La Roche Ltd"
    ],
    "summary": "Basel, 5 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) has accepted the company's supplemental Biologics License Application ( sBLA ) for Columvi\u00ae ( glofitamab ) in combination with gemcitabine and oxaliplatin ( GemOx ) for ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.218561,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.02275",
        "ticker_sentiment_score": "0.106267",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.02275",
        "ticker_sentiment_score": "0.057832",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ",
    "url": "https://www.zacks.com/stock/news/2380033/pharma-stock-roundup-llys-zepbound-success-fda-updates-for-mrk-jnj",
    "time_published": "20241206T131100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.155629,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.127699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.130217",
        "ticker_sentiment_score": "0.1242",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.127699",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.043579",
        "ticker_sentiment_score": "-0.122739",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Buy These 3 Healthcare Mutual Funds to Boost Your Portfolio",
    "url": "https://www.zacks.com/stock/news/2379964/buy-these-3-healthcare-mutual-funds-to-boost-your-portfolio",
    "time_published": "20241206T111200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Below, we share with you three top-ranked healthcare mutual funds. Each has earned a Zacks Mutual Fund Rank #1.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/288.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.349553,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "JHG",
        "relevance_score": "0.251247",
        "ticker_sentiment_score": "0.213953",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.056355",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.161412",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "HCSG",
        "relevance_score": "0.085022",
        "ticker_sentiment_score": "0.089904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Five-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/12/08/2993402/0/en/Five-year-results-confirm-Roche-s-Polivy-combination-therapy-as-new-standard-of-care-for-previously-untreated-aggressive-lymphoma.html",
    "time_published": "20241208T173000",
    "authors": [
      "F. Hoffmann-La Roche Ltd"
    ],
    "summary": "Basel, 8 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy\u00ae ( polatuzumab vedotin ) in combination with MabThera\u00ae/Rituxan\u00ae ( rituximab ) , cyclophosphamide, doxorubicin and prednisone ( ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.175979,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.022347",
        "ticker_sentiment_score": "0.106014",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.022347",
        "ticker_sentiment_score": "0.008287",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.022347",
        "ticker_sentiment_score": "0.060492",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investigational Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory  ( R/R )  Chronic Lymphocytic Leukemia  ( CLL )  in Preliminary Analysis",
    "url": "https://www.globenewswire.com/news-release/2024/12/08/2993388/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Monotherapy-Achieves-High-Overall-and-Complete-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Chronic-Lym.html",
    "time_published": "20241208T160000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": -0.014333,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.073154",
        "ticker_sentiment_score": "0.060395",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Investigational Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory  ( R/R )  Follicular Lymphoma  ( FL ) ",
    "url": "https://www.globenewswire.com/news-release/2024/12/08/2993359/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Combination-Therapy-Demonstrates-High-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Follicular-Lymphoma-.html",
    "time_published": "20241208T001200",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.052508,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.106636",
        "ticker_sentiment_score": "0.069201",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
    "url": "https://www.zacks.com/research-daily/2380721/top-stock-reports-for-eli-lilly-abbvie-gilead-sciences",
    "time_published": "20241209T201500",
    "authors": [
      "Sheraz Mian"
    ],
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.216563,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.206166",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.263231",
        "ticker_sentiment_score": "0.206527",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.06697",
        "ticker_sentiment_score": "0.096893",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOSL",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.15323",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.199037",
        "ticker_sentiment_score": "0.316183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRT",
        "relevance_score": "0.13347",
        "ticker_sentiment_score": "0.107017",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/options/24/12/42395060/check-out-what-whales-are-doing-with-abbv",
    "time_published": "20241209T170107",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 10 unusual trades. Delving into the details, we found 70% of traders were bullish, while 10% showed bearish tendencies.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1733763664_0.png",
    "source": "Benzinga",
    "category_within_source": "Markets",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.201855,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MS",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.088904",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.717589",
        "ticker_sentiment_score": "0.254758",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.077845",
        "ticker_sentiment_score": "0.088904",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Two Data Analyses from Clinical Trials Show Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma  ( DLBCL ) ",
    "url": "https://www.globenewswire.com/news-release/2024/12/09/2993970/0/en/Two-Data-Analyses-from-Clinical-Trials-Show-Epcoritamab-DuoBody-CD3xCD20-Induces-Durable-Complete-Responses-as-Monotherapy-and-Combination-Treatment-in-Patients-With-Diffuse-Large-.html",
    "time_published": "20241209T170000",
    "authors": [
      "Genmab A/S"
    ],
    "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.002379,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.080296",
        "ticker_sentiment_score": "0.066048",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/24/12/42393882/abbvies-early-parkinsons-candidate-hits-primary-goal-in-pivotal-late-stage-study",
    "time_published": "20241209T161639",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "On Monday, AbbVie Inc. ABBV revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment ...",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/09/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.127621,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.487546",
        "ticker_sentiment_score": "-0.106768",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis  ( MF )  and Anemia in an Oral Presentation at the 66th American Society of Hematology  ( ASH )  Annual Meeting - Disc Medicine  ( NASDAQ:IRON ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42381718/disc-medicine-presents-positive-updated-results-from-phase-1b-trial-in-patients-with-myelofibrosis",
    "time_published": "20241209T010000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient types WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- ...",
    "banner_image": "https://ml.globenewswire.com/media/ca38ccab-c7d0-43bf-af35-e67b5bc64683/small/disc-med-stacked-logo-one-color-red-1-png.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.495866"
      }
    ],
    "overall_sentiment_score": 0.02657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IRON",
        "relevance_score": "0.1185",
        "ticker_sentiment_score": "0.154601",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.029728",
        "ticker_sentiment_score": "-0.085537",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis  ( MF )  and Anemia in an Oral Presentation at the 66th American Society of Hematology  ( ASH )  Annual Meeting",
    "url": "https://www.globenewswire.com/news-release/2024/12/09/2993429/0/en/Disc-Medicine-Presents-Positive-Updated-Results-from-Phase-1b-Trial-in-Patients-with-Myelofibrosis-MF-and-Anemia-in-an-Oral-Presentation-at-the-66th-American-Society-of-Hematology-.html",
    "time_published": "20241209T010000",
    "authors": [
      "Disc Medicine Inc"
    ],
    "summary": "WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ca38ccab-c7d0-43bf-af35-e67b5bc64683",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.026541,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "IRON",
        "relevance_score": "0.084622",
        "ticker_sentiment_score": "0.140951",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.028254",
        "ticker_sentiment_score": "-0.086971",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal",
    "url": "https://www.zacks.com/stock/news/2381629/abbvies-recently-acquired-parkinsons-drug-meets-third-study-goal",
    "time_published": "20241210T153900",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.174388,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.273399",
        "ticker_sentiment_score": "0.138801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "0.008688",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.166169",
        "ticker_sentiment_score": "0.03811",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.220308",
        "ticker_sentiment_score": "0.126897",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Peripheral Spondyloarthritis Market to Expand at 6.8% CAGR, Reaching US$ 5,220.7 Million by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42410098/peripheral-spondyloarthritis-market-to-expand-at-6-8-cagr-reaching-us-5-220-7-million-by-2034-fact",
    "time_published": "20241210T123000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global peripheral spondyloarthritis market is estimated to reach a valuation of US$ 2,704.0 million in 2024 and is expected to grow at a CAGR of 6.8% during the ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/ad8cd409-69e0-4aa6-b179-3fe6bcdf2b4d/peripheral-spondyloarthritis-market.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.275261,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
    "url": "https://www.zacks.com/stock/news/2381261/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
    "time_published": "20241210T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sector ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.220947,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.196877",
        "ticker_sentiment_score": "0.141519",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.132004",
        "ticker_sentiment_score": "0.070801",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
    "url": "https://www.zacks.com/stock/news/2381245/the-zacks-analyst-blog-highlights-eli-lilly-abbvie-gilead-sciences-air-t-and-fossil-group",
    "time_published": "20241210T100000",
    "authors": [
      "Zacks Investment Research"
    ],
    "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.206635,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.119414",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.250386",
        "ticker_sentiment_score": "0.124977",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FDX",
        "relevance_score": "0.063594",
        "ticker_sentiment_score": "0.096533",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FOSL",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.073565",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.189175",
        "ticker_sentiment_score": "0.223654",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AIRT",
        "relevance_score": "0.126784",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma",
    "url": "https://www.globenewswire.com/news-release/2024/12/10/2994191/0/en/New-and-updated-data-for-Roche-s-fixed-duration-Columvi-and-Lunsumio-at-ASH-2024-reinforce-their-potential-to-improve-outcomes-for-people-with-lymphoma.html",
    "time_published": "20241210T060000",
    "authors": [
      "F. Hoffmann-La Roche Ltd"
    ],
    "summary": "Basel, 10 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology ( ASH ) Annual Meeting & Exposition, 7-10 December ...",
    "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "source": "GlobeNewswire",
    "category_within_source": "n/a",
    "source_domain": "www.globenewswire.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.182751,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHGCF",
        "relevance_score": "0.017483",
        "ticker_sentiment_score": "0.102794",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.017483",
        "ticker_sentiment_score": "-0.037072",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.017483",
        "ticker_sentiment_score": "0.042578",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap - Tesla  ( NASDAQ:TSLA ) ",
    "url": "https://www.benzinga.com/markets/equities/24/12/42435201/elon-musks-net-worth-surpasses-market-cap-of-us-giants-like-bofa-johnson-johnson-salesforce-chev",
    "time_published": "20241211T130825",
    "authors": [
      "Rishabh Mishra"
    ],
    "summary": "Only 25 listed companies have a higher market capitalization than Elon Musk's net worth. Musk has added $155 billion to his wealth this year so far. Elon Musk's net worth is now more than the market capitalization of most of the listed companies in the U.S. and the world.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/Why-It-Matters_0.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.166667"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.166667"
      }
    ],
    "overall_sentiment_score": 0.273488,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "META",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.123133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVDA",
        "relevance_score": "0.147818",
        "ticker_sentiment_score": "0.247127",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CVX",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "KO",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.007105",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HESAF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ASML",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SSNLF",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "-0.077354",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "COST",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.290607",
        "ticker_sentiment_score": "0.286785",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "MA",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.07423",
        "ticker_sentiment_score": "0.107953",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
    "url": "https://www.fool.com/investing/2024/12/12/1-magnificent-sp-500-dividend-stock-down-14-to-buy/",
    "time_published": "20241212T110000",
    "authors": [
      "Bradley Guichard"
    ],
    "summary": "This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made history every five days this year.",
    "banner_image": "https://media.ycharts.com/charts/04690dae5cdf0318f153ec25dd40dcfc.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.214907,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.70826",
        "ticker_sentiment_score": "0.380907",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.076358",
        "ticker_sentiment_score": "0.22722",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2383144/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
    "time_published": "20241213T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.203849,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.353898",
        "ticker_sentiment_score": "0.170702",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.12165",
        "ticker_sentiment_score": "0.068161",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
    "url": "https://www.fool.com/investing/2024/12/15/want-decades-passive-income-stocks-buy-and-hold/",
    "time_published": "20241215T103500",
    "authors": [
      "Justin Pope"
    ],
    "summary": "These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800052/forever-investing.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.243192,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.391158",
        "ticker_sentiment_score": "0.122827",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.051003",
        "ticker_sentiment_score": "-0.028898",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CAH",
        "relevance_score": "0.250902",
        "ticker_sentiment_score": "0.311697",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SYK",
        "relevance_score": "0.29887",
        "ticker_sentiment_score": "0.34943",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Stock Declines While Market Improves: Some Information for Investors",
    "url": "https://www.zacks.com/stock/news/2384199/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors",
    "time_published": "20241216T224516",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.217213,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.538782",
        "ticker_sentiment_score": "0.330087",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?",
    "url": "https://www.zacks.com/stock/news/2384030/abbvs-acquisition-spree-continues-buy-sell-or-hold-the-stock",
    "time_published": "20241216T151700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.962106"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.795202"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.650727"
      }
    ],
    "overall_sentiment_score": 0.252571,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.06785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.073886",
        "ticker_sentiment_score": "0.06785",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.669807",
        "ticker_sentiment_score": "0.39222",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline",
    "url": "https://www.zacks.com/stock/news/2383942/abbv-to-acquire-nimble-therapeutics-to-strengthen-immunology-pipeline",
    "time_published": "20241216T144200",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.928139"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.275853,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.677342",
        "ticker_sentiment_score": "0.544626",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "CTMX",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "0.006632",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SPRO",
        "relevance_score": "0.1568",
        "ticker_sentiment_score": "0.033883",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSTL",
        "relevance_score": "0.208017",
        "ticker_sentiment_score": "0.084645",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now",
    "url": "https://www.zacks.com/stock/news/2383784/if-you-invested-1000-in-halozyme-therapeutics-a-decade-ago-this-is-how-much-itd-be-worth-now",
    "time_published": "20241216T133005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.929393"
      }
    ],
    "overall_sentiment_score": 0.187489,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "HALO",
        "relevance_score": "0.474207",
        "ticker_sentiment_score": "0.324065",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.072217",
        "ticker_sentiment_score": "0.043228",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "url": "https://www.zacks.com/stock/news/2383727/ema-panel-endorses-lillys-omvoh-for-expanded-use-in-crohns-disease",
    "time_published": "20241216T122300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.281043,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.295927",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.279015",
        "ticker_sentiment_score": "0.292425",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.113597",
        "ticker_sentiment_score": "0.129758",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.056943",
        "ticker_sentiment_score": "0.157973",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Enzyme Inhibitor Market to Reach US$ 5.9 Bn by 2034 Amid Rising Demand for Cardiovascular and Oncology Therapies - Transparency Market Research, Inc.",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42504250/enzyme-inhibitor-market-to-reach-us-5-9-bn-by-2034-amid-rising-demand-for-cardiovascular-and-oncol",
    "time_published": "20241216T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research, Inc., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Increasing Use in Disease Management Driving Global Enzyme Inhibitor Industry Growth",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/f7b0f4c1-f2c5-4a4f-a74a-b75ac91fa236/enzyme-inhibitor-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.092836,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.053926",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.112666",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "-0.128033",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.08715",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.143097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "0.051133",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.039483",
        "ticker_sentiment_score": "0.143097",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.118064",
        "ticker_sentiment_score": "-0.025789",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.07887",
        "ticker_sentiment_score": "0.112666",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Epidermal Growth Factors  ( EGFs )  Market to Reach US$ 3.7 Billion by 2034 | Expanding Applications in Regenerative Medicine and Cancer Therapy Drive Growth, Latest Report by TMR",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42503394/epidermal-growth-factors-egfs-market-to-reach-us-3-7-billion-by-2034-expanding-applications-in-reg",
    "time_published": "20241216T103000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Wilmington, Delaware, Transparency Market Research Inc. , Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- The global Epidermal Growth Factors ( EGFs ) market ( March\u00e9 des Facteurs de croissance \u00e9pidermiques ( EGF ) ) was valued at US$ 1.1 Bn in 2023 and is anticipated to expand at a CAGR of 11.3% from 2024 ...",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/27e1d943-6840-4b94-a03f-719fb05a4273/epidermal-growth-factors-egfs-market.jpg",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.180609,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "GOOG",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.053774",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.049244",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAYZF",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.175364",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.136257",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "-0.254204",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.077343",
        "ticker_sentiment_score": "0.096741",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WMGTF",
        "relevance_score": "0.115787",
        "ticker_sentiment_score": "0.058068",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.170484",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.09193",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:NANO",
        "relevance_score": "0.038717",
        "ticker_sentiment_score": "0.031583",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "4 Big Drug Stocks That May Continue to Outperform in 2025",
    "url": "https://www.zacks.com/stock/news/2384649/4-big-drug-stocks-that-may-continue-to-outperform-in-2025",
    "time_published": "20241217T150300",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.996675"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.310843"
      }
    ],
    "overall_sentiment_score": 0.196045,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "LLY",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.083643",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "VRTX",
        "relevance_score": "0.065595",
        "ticker_sentiment_score": "0.057058",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.195025",
        "ticker_sentiment_score": "0.141608",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
    "url": "https://www.benzinga.com/24/12/42528916/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields",
    "time_published": "20241217T131911",
    "authors": [
      "Avi Kapoor"
    ],
    "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
    "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.967645"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.218458,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CVS",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.110518",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.285594",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "C",
        "relevance_score": "0.096283",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.19117",
        "ticker_sentiment_score": "0.165861",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
    "url": "https://www.zacks.com/stock/news/2385145/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
    "time_published": "20241218T140022",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.54554"
      }
    ],
    "overall_sentiment_score": 0.206379,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.490323",
        "ticker_sentiment_score": "0.132523",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study",
    "url": "https://www.zacks.com/stock/news/2385100/sny-teva-stocks-jump-on-encouraging-data-from-ibd-drug-study",
    "time_published": "20241218T132100",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.161647"
      }
    ],
    "overall_sentiment_score": 0.211447,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.222022",
        "ticker_sentiment_score": "0.24879",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "TEVA",
        "relevance_score": "0.178459",
        "ticker_sentiment_score": "0.050537",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.089797",
        "ticker_sentiment_score": "0.121313",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.536492",
        "ticker_sentiment_score": "0.249183",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42551252/neutrolis-expands-senior-leadership-team-to-drive-development-of-growing-pipeline-of-non-immunosup",
    "time_published": "20241218T130000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "CAMBRIDGE, Mass., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps ( NETs ) for the treatment of autoimmune and inflammatory diseases, today announced the expansion of its senior leadership team to support ...",
    "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
    "source": "Benzinga",
    "category_within_source": "News",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.156971,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "CHRS",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.105695",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.170453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.049322",
        "ticker_sentiment_score": "0.170453",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Strength Seen in Sanofi  ( SNY ) : Can Its 6.7% Jump Turn into More Strength?",
    "url": "https://www.zacks.com/stock/news/2385022/strength-seen-in-sanofi-sny-can-its-67-jump-turn-into-more-strength",
    "time_published": "20241218T113300",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.316726"
      }
    ],
    "overall_sentiment_score": 0.170586,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.441698",
        "ticker_sentiment_score": "0.0",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.535653",
        "ticker_sentiment_score": "0.164605",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
    "url": "https://www.zacks.com/stock/news/2385015/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
    "time_published": "20241218T112005",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Smart Beta ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default287.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Energy & Transportation",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.271095,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "MO",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WT",
        "relevance_score": "0.334762",
        "ticker_sentiment_score": "0.240229",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "XOM",
        "relevance_score": "0.114682",
        "ticker_sentiment_score": "0.060978",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/12/42592937/kevin-k-buckbee-executes-sell-order-offloads-310k-in-abbvie-stock",
    "time_published": "20241219T150129",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Buckbee sold 1,800 shares of AbbVie. The total transaction amounted to $310,032.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.99676"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.999346"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      }
    ],
    "overall_sentiment_score": 0.211132,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.352223",
        "ticker_sentiment_score": "0.254053",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
    "url": "https://www.fool.com/investing/2024/12/19/2-top-dividend-stocks-to-buy-and-hold-through-2025/",
    "time_published": "20241219T110000",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800762/nurse-holding-patients-hands.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.214378"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.839681"
      }
    ],
    "overall_sentiment_score": 0.334899,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.448842",
        "ticker_sentiment_score": "0.366317",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.40375",
        "ticker_sentiment_score": "0.40553",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
    "url": "https://www.zacks.com/stock/news/2386138/pharma-stock-roundup-pfes-2025-outlook-mrk-abbvs-ma-deals",
    "time_published": "20241220T122700",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.180271,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.236205",
        "ticker_sentiment_score": "0.121229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.079788",
        "ticker_sentiment_score": "-0.130229",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.311335",
        "ticker_sentiment_score": "0.109548",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.236205",
        "ticker_sentiment_score": "0.126318",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
    "url": "https://www.fool.com/investing/2024/12/21/3-fantastic-stocks-that-could-enjoy-a-santa-claus/",
    "time_published": "20241221T114800",
    "authors": [
      "Keith Speights",
      "and Prosper Junior Bakiny",
      "David Jagielski"
    ],
    "summary": "Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called \"Santa Claus rallies\" can occur near the end of the year.Three Motley Fool contributors think they've identified fantastic stocks that ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801623/santa-claus-buggy-chart.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.614606"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.999186"
      }
    ],
    "overall_sentiment_score": 0.211687,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "VRTX",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "-0.010377",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.327909",
        "ticker_sentiment_score": "0.311137",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.167612",
        "ticker_sentiment_score": "0.140496",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Eli Lilly  ( NYSE:LLY ) ",
    "url": "https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more",
    "time_published": "20241222T195134",
    "authors": [
      "Vandana Singh"
    ],
    "summary": "According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/22/Healthcare--Opioid-Epidemic-And-Drug-Abu.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.744043"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.363138,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ELAN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "VTRS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.345107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.262117",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ZTS",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IDXX",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.195574",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.396574",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "GILD",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.344367",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "REGN",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.217986",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "BMY",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.249624",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "PRGO",
        "relevance_score": "0.175221",
        "ticker_sentiment_score": "0.345107",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "url": "https://www.fool.com/investing/2024/12/22/unstoppable-dividend-stocks-buy-if-sell-off/",
    "time_published": "20241222T115000",
    "authors": [
      "Dan Victor"
    ],
    "summary": "Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid a resilient economy and strong corporate earnings.That being said, it's always prudent to be ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801558%2Fdividend-healthcare-stocks-2025-bullish.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.997405"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.576289"
      }
    ],
    "overall_sentiment_score": 0.384712,
    "overall_sentiment_label": "Bullish",
    "ticker_sentiment": [
      {
        "ticker": "PFE",
        "relevance_score": "0.331765",
        "ticker_sentiment_score": "0.383236",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.432291",
        "ticker_sentiment_score": "0.541209",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Schwab US Dividend Equity ETF Reverses In December: What's Going On? - Schwab US Dividend Equity ETF  ( ARCA:SCHD ) ",
    "url": "https://www.benzinga.com/general/biotech/24/12/42660458/schwab-us-dividend-equity-etf-reverses-in-december-whats-going-on",
    "time_published": "20241223T205355",
    "authors": [
      "Erica Kollmann"
    ],
    "summary": "The Schwab US Dividend Equity ETF SCHD has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund.",
    "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/23/Stock-Exchange-Trading-Data-And-Financia.jpeg?width=1200&height=800&fit=crop",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.682689"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.905476"
      }
    ],
    "overall_sentiment_score": 0.179455,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "AMGN",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.048478",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.211191",
        "ticker_sentiment_score": "-0.167084",
        "ticker_sentiment_label": "Somewhat-Bearish"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.312158",
        "ticker_sentiment_score": "0.048478",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Is AbbVie Stock a Buy?",
    "url": "https://www.fool.com/investing/2024/12/23/is-abbvie-stock-a-buy/",
    "time_published": "20241223T133000",
    "authors": [
      "Alex Carchidi"
    ],
    "summary": "With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie ( NYSE: ABBV ) is a powerhouse big pharma that has a lot of upside to offer to investors.While there's no guarantee the next three years of the company's life will ...",
    "banner_image": "https://g.foolcdn.com/editorial/images/801761/one-investor-explains-something-to-another-at-a-cafe.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.538269"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.459462"
      }
    ],
    "overall_sentiment_score": 0.222893,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.255641",
        "ticker_sentiment_score": "0.243133",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "2 Excellent Dividend Stocks to Buy on the Dip",
    "url": "https://www.fool.com/investing/2024/12/23/2-excellent-dividend-stocks-to-buy-on-the-dip/",
    "time_published": "20241223T093200",
    "authors": [
      "Prosper Junior Bakiny"
    ],
    "summary": "AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...",
    "banner_image": "https://media.ycharts.com/charts/4bcb02efb3ae79099f939b6b71ea724e.png",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.108179"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.26662,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.512596",
        "ticker_sentiment_score": "0.31906",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "ABT",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.085",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMGN",
        "relevance_score": "0.373112",
        "ticker_sentiment_score": "0.395561",
        "ticker_sentiment_label": "Bullish"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.077088",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.055364",
        "ticker_sentiment_score": "0.21904",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Rises Yet Lags Behind Market: Some Facts Worth Knowing",
    "url": "https://www.zacks.com/stock/news/2387728/abbvie-abbv-rises-yet-lags-behind-market-some-facts-worth-knowing",
    "time_published": "20241224T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default204.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.976913"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.204024,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.47379",
        "ticker_sentiment_score": "0.326283",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Introducing the \"Dividend Seven\" Stocks",
    "url": "https://www.fool.com/investing/2024/12/24/introducing-the-dividend-seven-stocks/",
    "time_published": "20241224T205200",
    "authors": [
      "Motley Fool Staff"
    ],
    "summary": "In this podcast, Motley Fool analysts Matt Argersinger and Anthony Schiavone join host Mary Long to discuss:To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our beginner's guide to investing in stocks.",
    "banner_image": "https://g.foolcdn.com/editorial/images/800477/introducing-the-dividend-seven.jpg",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.2"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.2"
      },
      {
        "topic": "Retail & Wholesale",
        "relevance_score": "0.2"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Manufacturing",
        "relevance_score": "0.2"
      },
      {
        "topic": "Earnings",
        "relevance_score": "1.0"
      },
      {
        "topic": "Real Estate & Construction",
        "relevance_score": "0.2"
      }
    ],
    "overall_sentiment_score": 0.184764,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "NVDA",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.12441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSLA",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.12441",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BAC",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.047066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "MDNDF",
        "relevance_score": "0.0854",
        "ticker_sentiment_score": "0.080551",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PLD",
        "relevance_score": "0.106636",
        "ticker_sentiment_score": "0.075523",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PEP",
        "relevance_score": "0.01426",
        "ticker_sentiment_score": "0.025356",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.047279",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GS",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.047066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HD",
        "relevance_score": "0.092486",
        "ticker_sentiment_score": "0.061006",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AMZN",
        "relevance_score": "0.021388",
        "ticker_sentiment_score": "0.104183",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "BNXYF",
        "relevance_score": "0.00713",
        "ticker_sentiment_score": "0.022253",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "HSY",
        "relevance_score": "0.03564",
        "ticker_sentiment_score": "0.148251",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRYPTO:BTC",
        "relevance_score": "0.028515",
        "ticker_sentiment_score": "0.050364",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/news/24/12/42675709/100-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today",
    "time_published": "20241224T204520",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 1.88% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $317.86 billion.",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1735073117_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.108179"
      }
    ],
    "overall_sentiment_score": 0.238974,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.95919",
        "ticker_sentiment_score": "0.384695",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Pharmaceuticals & Medicine Manufacturing Market Set to Surge at 8.9% CAGR, to Reach US$ 2,516.46 Million by 2034 | Fact.MR Report",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42667458/pharmaceuticals-medicine-manufacturing-market-set-to-surge-at-8-9-cagr-to-reach-us-2-516-46-millio",
    "time_published": "20241224T113000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "Rockville, MD , Dec. 24, 2024 ( GLOBE NEWSWIRE ) -- According to the newly released report by Fact.MR, a market research and competitive intelligence provider, the global Pharmaceuticals & Medicine Manufacturing Market is evaluated to reach US$ 1,073.08 billion in 2024.",
    "banner_image": "https://ml.globenewswire.com/Resource/Download/6e48fdb3-4d93-4cfc-ae26-9bd07c9c98f0/pharmaceuticals-medicine-manufacturing-market.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      }
    ],
    "overall_sentiment_score": 0.334998,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "SSNLF",
        "relevance_score": "0.104835",
        "ticker_sentiment_score": "0.018952",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "WUXAY",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TMO",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "FUJIF",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVS",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.070002",
        "ticker_sentiment_score": "0.017274",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "TSOI",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.165496",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.035035",
        "ticker_sentiment_score": "0.070483",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/insights/short-sellers/24/12/42677800/looking-into-abbvies-recent-short-interest",
    "time_published": "20241225T130015",
    "authors": [
      "Benzinga Insights"
    ],
    "summary": "AbbVie's ABBV short percent of float has fallen 3.51% since its last report. The company recently reported that it has 19.32 million shares sold short, which is 1.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their ...",
    "banner_image": "https://www.benzinga.com/files/images/story/2024/1735131612_0.png",
    "source": "Benzinga",
    "category_within_source": "Trading",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.264538,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.212115",
        "ticker_sentiment_score": "0.081887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY",
    "url": "https://www.zacks.com/stock/news/2388207/pharma-stock-roundup-nvos-obesity-study-failure-fda-nod-to-pfe-lly",
    "time_published": "20241226T141100",
    "authors": [
      "Kinjel Shah"
    ],
    "summary": "NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.",
    "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.266143"
      }
    ],
    "overall_sentiment_score": 0.038399,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "AZN",
        "relevance_score": "0.230017",
        "ticker_sentiment_score": "0.05037",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "NVO",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "-0.1171",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "LLY",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.004254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SKXJF",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.027877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.13066",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "DSKYF",
        "relevance_score": "0.139265",
        "ticker_sentiment_score": "0.027877",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "PFE",
        "relevance_score": "0.093108",
        "ticker_sentiment_score": "-0.004254",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "SNY",
        "relevance_score": "0.27432",
        "ticker_sentiment_score": "0.032887",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
    "url": "https://www.benzinga.com/pressreleases/24/12/g42684574/achievements-and-progress-heading-into-2025-for-oncology-treatments-and-therapies-fuel-an-optimist",
    "time_published": "20241226T140000",
    "authors": [
      "Globe Newswire"
    ],
    "summary": "PALM BEACH, Fla., Dec. 26, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios.",
    "banner_image": "https://ml.globenewswire.com/media/f326183f-8829-42af-8851-525b1d7503ed/small/finacialnews-logo-final-01-2-png.png",
    "source": "Benzinga",
    "category_within_source": "General",
    "source_domain": "www.benzinga.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.993856"
      }
    ],
    "overall_sentiment_score": 0.131515,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "-0.022032",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AZN",
        "relevance_score": "0.069819",
        "ticker_sentiment_score": "-0.010213",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CRDF",
        "relevance_score": "0.097626",
        "ticker_sentiment_score": "0.017536",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "GSK",
        "relevance_score": "0.055881",
        "ticker_sentiment_score": "-0.002003",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "The Smartest Dividend Stocks to Buy With $1,000 Right Now",
    "url": "https://www.fool.com/investing/2024/12/26/the-smartest-dividend-stocks-to-buy-with-1000-now/",
    "time_published": "20241226T103500",
    "authors": [
      "Selena Maranjian"
    ],
    "summary": "If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:Here are three dividend stocks to consider for your long-term portfolio.Image source: Getty Images.Continue reading ...",
    "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802040%2Fgetty-pointing-to-cash-fanned-out-in-hand.jpg&op=resize&w=700",
    "source": "Motley Fool",
    "category_within_source": "n/a",
    "source_domain": "www.fool.com",
    "topics": [
      {
        "topic": "Economy - Monetary",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "0.5"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.87644"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.918141"
      },
      {
        "topic": "Mergers & Acquisitions",
        "relevance_score": "0.158519"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.5"
      }
    ],
    "overall_sentiment_score": 0.343141,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "KVUE",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.044521",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "ABBV",
        "relevance_score": "0.257668",
        "ticker_sentiment_score": "0.118563",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "T",
        "relevance_score": "0.130571",
        "ticker_sentiment_score": "0.193745",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "JNJ",
        "relevance_score": "0.194763",
        "ticker_sentiment_score": "0.372067",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
    "url": "https://www.zacks.com/stock/news/2389223/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
    "time_published": "20241230T112008",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Style Box ETF report for ...",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Life Sciences",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "1.0"
      },
      {
        "topic": "Earnings",
        "relevance_score": "0.451494"
      },
      {
        "topic": "Technology",
        "relevance_score": "0.333333"
      },
      {
        "topic": "Finance",
        "relevance_score": "0.333333"
      }
    ],
    "overall_sentiment_score": 0.265939,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "CSCO",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "IVZ",
        "relevance_score": "0.182506",
        "ticker_sentiment_score": "0.179113",
        "ticker_sentiment_label": "Somewhat-Bullish"
      },
      {
        "ticker": "IBM",
        "relevance_score": "0.122269",
        "ticker_sentiment_score": "0.068311",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
    "url": "https://www.zacks.com/stock/news/2390216/abbvie-abbv-gains-as-market-dips-what-you-should-know",
    "time_published": "20241231T224519",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) concluded the recent trading session at $177.70, signifying a +0.85% move from its prior day's close.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default212.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.961735"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.365926"
      }
    ],
    "overall_sentiment_score": 0.135657,
    "overall_sentiment_label": "Neutral",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.624172",
        "ticker_sentiment_score": "0.251917",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie  ( ABBV )  Upgraded to Buy: What Does It Mean for the Stock?",
    "url": "https://www.zacks.com/stock/news/2390172/abbvie-abbv-upgraded-to-buy-what-does-it-mean-for-the-stock",
    "time_published": "20241231T170012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.997845"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.658903"
      }
    ],
    "overall_sentiment_score": 0.305263,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.366961",
        "ticker_sentiment_score": "0.327276",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "Are Medical Stocks Lagging Anavex Life Sciences  ( AVXL )  This Year?",
    "url": "https://www.zacks.com/stock/news/2390053/are-medical-stocks-lagging-anavex-life-sciences-avxl-this-year",
    "time_published": "20241231T144012",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default346.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.714479"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.214378"
      }
    ],
    "overall_sentiment_score": 0.223951,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.370143",
        "ticker_sentiment_score": "0.118248",
        "ticker_sentiment_label": "Neutral"
      },
      {
        "ticker": "AVXL",
        "relevance_score": "0.721785",
        "ticker_sentiment_score": "0.391836",
        "ticker_sentiment_label": "Bullish"
      }
    ]
  },
  {
    "title": "Brokers Suggest Investing in AbbVie  ( ABBV ) : Read This Before Placing a Bet",
    "url": "https://www.zacks.com/stock/news/2390006/brokers-suggest-investing-in-abbvie-abbv-read-this-before-placing-a-bet",
    "time_published": "20241231T143013",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_12312024.png",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.938238"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.503496"
      }
    ],
    "overall_sentiment_score": 0.320651,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.362254",
        "ticker_sentiment_score": "0.199317",
        "ticker_sentiment_label": "Somewhat-Bullish"
      }
    ]
  },
  {
    "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
    "url": "https://www.zacks.com/stock/news/2389939/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "time_published": "20241231T140020",
    "authors": [
      "Zacks Equity Research"
    ],
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
    "source": "Zacks Commentary",
    "category_within_source": "n/a",
    "source_domain": "www.zacks.com",
    "topics": [
      {
        "topic": "Earnings",
        "relevance_score": "0.999999"
      },
      {
        "topic": "Life Sciences",
        "relevance_score": "1.0"
      },
      {
        "topic": "Financial Markets",
        "relevance_score": "0.5855"
      }
    ],
    "overall_sentiment_score": 0.233296,
    "overall_sentiment_label": "Somewhat-Bullish",
    "ticker_sentiment": [
      {
        "ticker": "ABBV",
        "relevance_score": "0.489394",
        "ticker_sentiment_score": "0.141458",
        "ticker_sentiment_label": "Neutral"
      }
    ]
  }
]